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Human population-based studies have shown that cognitive ability and negative emotions are 
associated with later health outcomes. Part of this association might be due to shared genetic 
influences. The present thesis has two main objectives. The first is to examine the shared 
genetic aetiology between cognitive ability and mental and physical health. The second is to 
examine the shared genetic aetiology between the tendency to experience negative emotions 
and mental and physical health.  
Chapter 1 and Chapter 2 provide an introductory overview of the field of individual differences 
in psychology, with the first Chapter focussing on cognitive ability and the second on 
personality (especially neuroticism). Each of these Chapters provide an historical overview of 
the two traits, followed by the associations with health outcomes, and finish by exploring the 
genetic aetiology of both cognitive ability and negative emotions and the potential genetic 
overlap with health outcomes.  
Chapter 3 focusses on the main cohort analysed in this thesis, the UK Biobank. This Chapter 
outlines the study population and its demographics, and provides a detailed account of the 
main variables examined in this thesis.  
Chapters 4 to 7 present the empirical work and are split in two parts; the first part (Chapters 4 
and 5), focusses on cognitive ability. The second part (Chapters 6 and 7) focusses on negative 
emotions.  
Chapter 4 presents two studies, examining the shared genetic aetiology between cognitive 
ability and mental and physical health using linkage disequilibrium score regression and 
polygenic profile analysis; Mendelian Randomization is used to test for direction of effect 
between cognitive ability and physical health. The results indicate a substantially shared 
genetic aetiology between cognitive ability and both physical and mental health. No evidence 
was found for a causal association between cognitive ability and physical health.  
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Chapter 5 examines the genetic aetiology of a test of executive cognitive function, the Trail-
Making test, which has been closely associated with other cognitive abilities. This Chapter 
also examines the shared genetic aetiology between the Trail-Making test, general cognitive 
ability, processing speed, and memory, using a range of molecular genetic techniques. The 
results provide heritability estimates ranging from 7% to 22% for the different Trail-Making 
test measures, and there are new genetic associations with the Trail-Making test. A 
considerable degree of genetic overlap is found between the Trail-Making test and general 
cognitive function and processing speed in particular.  
Chapter 6 explores the shared genetic aetiology between the personality trait of neuroticism 
and mental and physical health using Linkage Disequilibrium Score Regression and polygenic 
profile analysis. The results show significant genetic correlations between neuroticism and 
major depressive disorder, schizophrenia, and anorexia. Polygenic profile scores for multiple 
mental health traits, as well as body mass index, coronary artery disease, and smoking status 
are predictive of neuroticism.  
Chapter 7 examines the genetic contributions to self-reported tiredness, a trait strongly related 
to the tendency to experience negative emotions; it also examines the genetic overlap with 
health outcomes using Linkage Disequilibrium Score Regression and polygenic profile 
analysis. The results demonstrate a significant heritability estimate of 8% for self-reported 
tiredness. Extensive genetic overlap is identified between self-reported tiredness and mental 
and physical health, and particularly with the trait of neuroticism.  
Finally, Chapter 8 summarizes the empirical findings presented in Chapters 4 to 7. This 
Chapter discusses limitations of the methods used in this thesis, and offers suggestions for 
future research in the field of genetic epidemiology, especially as applied to health and 




Some studies have shown that how effectively people think and how they experience negative 
emotions is linked with how healthy they are in later life. People’s thinking skills – referred to 
as cognitive ability, negative emotions, and health are all partly influenced by genes. It is 
therefore possible that the association between cognitive ability, negative emotions, and health 
is partly due to genetic influences. This Thesis will be split in two parts to address the 
possibility of genetic influences on the relation between cognitive ability and health in the first 
part, and between negative emotions and health in the second part. The first study in this Thesis 
showed that genes associated with different health outcomes were also associated with various 
tests of cognitive ability, which supports the idea that better overall health is likely linked to 
higher levels of intelligence. We did not find evidence for a causal link between cognitive 
ability and physical health in any direction. The following study in the cognitive ability part 
of this Thesis examined the genetic background of the Trail Making Test, a measure of mental 
flexibility, and we showed that genes for this test were also genes that are involved in other 
measures of cognitive ability. 
In the second part of the thesis we found that genes for the personality trait of neuroticism, 
which is the tendency to experience negative emotions, are also genes linked to mental health 
diseases. Healthy individuals with more genes for mental health diseases and physical health 
outcomes had higher scores for neuroticism. A second study in this part of the Thesis used a 
measure related to negative emotions, which was self-reported tiredness, and found that 
genetics account for about eight percent of people’s differences in self-reported tiredness; 
which implies that the vast majority of people’s differences in self-reported tiredness are 
environmental in origin. We found that the small genetic contributions to self-reported 
tiredness overlapped with genetic contributions to multiple mental and physical health 
conditions. Overall, the results in this Thesis provide further evidence for genetic links 
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1. Cognitive ability 
The field of differential psychology is a well-established part of psychological science and 
studies how people differ from each other, as well as the potential implications of those 
differences. While this discipline does not have clear boundaries regarding its subject, the term 
‘individual differences’ is generally used to refer to the traits of cognitive ability and 
personality. Research in the past century has led to the development of multiple theories of 
cognitive ability (intelligence) and personality, explanations of what causes differences in both 
traits, and the impact of those differences for example on health outcomes. Evidence in the 
field of individual differences has related both cognitive ability and personality to health 
outcomes (I. J. Deary, Weiss, & Batty, 2010; Lahey, 2009; Watson & Pennebaker, 1989; 
Wraw, Deary, Der, & Gale, 2016; Wraw, Deary, Gale, & Der, 2015). These findings have 
implications for psychologists, epidemiologists, clinicians, and policy makers by providing 
further evidence of the predictive validity of both cognitive ability and personality, as well as 
contributing to the understanding of health inequalities in the population. This Chapter and 
Chapter 2 will present the latest evidence on the phenotypic and genetic associations of 
cognitive ability and personality with health outcomes. Here, cognitive ability (Chapter 1) and 
personality (Chapter 2), in particular negative emotions, will be examined separately. Firstly, 
a brief historical context of the trait will be outlined. Secondly, evidence from the field’s 
empirical work will be presented on the association between cognitive ability or negative 
emotions and health, bringing together both psychology and epidemiology. Finally, empirical 
work on the possible shared genetic aetiology of cognitive ability, negative emotions and 
health, with attention to the methods used to examine a genetic aetiology, will be presented. 
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1.1. History of cognitive ability 
Ever since the Classical Greek times, cognitive ability (also named intelligence) has been 
recognised as one of the most important individual differences. Plato distinguished three 
elements of the human soul; intellect, emotion, and will. He compared intellect to the thinking 
part of the soul. Aristotle then combined the emotion and will elements to ‘oretic’ capacities. 
Finally, Cicero translated the intellectual components of the human soul based on Plato and 
Aristotle to ‘intelligentia’ (H. J. Eysenck, 1979).  
 
Testing differences in intelligence started to take place in the mid-to-late nineteenth century, 
with Sir Francis Galton being one of the pioneers in this area (Galton, 1869). Galton, Charles 
Darwin’s half cousin, believed that the natural selection theory could also be applied to human 
intelligence. He collected data on about 10,000 individuals who visited the ‘Anthropometric 
Laboratory’ at the International Health Exhibition in South Kensington, London, including 
data on several physical measures, reaction times to visual and auditory stimuli, and social 
class (Galton, 1885; Johnson et al., 1985), aiming to measure individual differences in 
cognitive abilities. 
 
1.1.1. Spearman’s construct of general intelligence 
Many theories of intelligence have been developed and the two most common ones are Charles 
Spearman’s construct of ‘general intelligence’ and Horn and Cattell’s theory of fluid and 
crystallized intelligence (Section 1.1.2). In 1904, Charles Spearman (1863 – 1945) proposed 
the construct of ‘general intelligence’, when he was examining the results of children’s school 
exams as well as teacher’s ratings of cognitive ability (Spearman, 1904). Intelligence tests 
generally consist of multiple subdomains, each testing a different cognitive ability. He found 
that both the scores on the different examinations, and teacher’s ratings of cognitive abilities, 
were highly correlated. He concluded that the correlations between the variables could be best 
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explained by a single latent or unobserved factor underlying performance in all of the ability 
measures. Spearman’s theory originally consisted of two factors; one general factor that every 
cognitive task requires (g), as well as skills specific to each cognitive task that are not shared 
between each other (s) (Figure 1-1). Over time, relatively greater importance has been placed 
on the general factor of intelligence (Spearman, 1927). Spearman’s theory of intelligence has 
been criticized numerous times, but till this day it is still one of the most used constructs in 
intelligence research (Carroll, 1993).  
 
 
Figure 1-1. Spearman’s two factor theory; all cognitive abilities have an area 
of overlap (g), but each ability also depends on specific factors (s). 
 
1.1.2. Horn and Cattell’s theory of fluid and crystallized intelligence  
Raymond Cattell first proposed that intelligence is not a unitary construct, but assumes two 
broad types of intelligence, which he named fluid (Gf) and crystallized (Gc) intelligence 
(Cattell, 1940, 1943b). His student John Horn, further developed this construct (Horn & 
Cattell, 1966). Gf represents the ability to perform well on non-verbal tasks that involve 
reasoning, working memory, and processing speed, while Gc represents the ability to do well 
on verbal tasks which involve knowledge and abilities acquired via experience. Many 
cognitive domains, in particular domains related to Gf, show an age-related decline over time, 
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and this is frequently referred to as healthy cognitive ageing. There is, however, great 
widespread variation in the onset and rate of this so called ‘cognitive ageing’ (Hedden & 
Gabrieli, 2004; Salthouse, 2009). As shown in Figure 1-2, the measures displaying an age-
related decline, involve Gf and measures that are part of Gf. Gc displays an increase up to age 
60 and declines thereafter. 
 
 
Figure 1-2. Age relations on composite cognitive scores. These are formed 
by averaging the z-scores for the variables contributing to each factor. Gc, 
crystallized cognitive ability; Gf, fluid cognitive ability; WM, working memory; 
ViMem, visual memory; VbMem, verbal memory. Reprinted with permission 
from Salthouse (2009). Copyright 2009 by Cambridge University Press. 
 
The theory of fluid and crystallized intelligence is widely accepted among psychologists and 
to quote John Carroll it “appears to offer the most well founded and reasonable approach to an 
acceptable theory of the structure of cognitive abilities” (Carroll, 1993, p. 62). However, the 
theory of fluid and crystallized intelligence does not provide a third order factor to account for 
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the correlations between fluid and crystallized intelligence, which has been addressed by John 
Carroll, as discussed in Section 1.1.3.  
 
1.1.3. Carroll’s three-stratum model 
In a further attempt to resolve the phenotypic structure of human cognitive abilities, John 
Carroll proposed the three-stratum model of intelligence (Carroll, 1993). According to Carroll 
the fluid and crystallized model by Cattell and Horn did not accept a general factor of 
intelligence as an explanation for the correlations between the fluid and crystallized abilities. 
He based his model on the analyses of more than 460 sets of intelligence test scores. His three-
stratum model supports the positive manifold of correlations between intelligence domains, 
acknowledging the general factor of intelligence. Carroll’s model includes three strata with in 
the third stratum a general factor of intelligence, multiple broad abilities in the second stratum 
and many specific or narrow abilities in the first stratum (Figure 1-3). The second stratum is 
very similar to the abilities of the crystalized and fluid abilities in the Horn and Cattell model, 
but also includes memory, visual and auditory perception, retrieval ability, cognitive speed 
and processing speed. Other models might include abilities such as processing speed as part 
of fluid cognitive ability. The narrow abilities in the first stratum are based on specific 





Figure 1-3. The structure of human cognitive abilities according to the three-
stratum model. Adapted with permission from Carroll (1993). Copyright 1993 
by Cambridge University Press.  
 
1.2. Cognitive epidemiology 
Cognitive epidemiology is part of the field of individual differences that seeks to understand 
the associations between cognitive ability and health (I. J. Deary, 2010; I. J. Deary & Batty, 
2007; I. J. Deary et al., 2010). In general, cognitive epidemiology has been particularly 
concerned with childhood ability and its association with health in later life. In the late 1980s 
the first peer reviewed studies examining the association between intelligence and mortality 
appeared (O'Toole, Adena, & Jones, 1988; O'Toole & Stankov, 1992). O'Toole et al. (1988) 
found that in Australian servicemen those with lower scores on the army intelligence test had 
higher risks of mortality. Participation in post-secondary education was associated with lower 
risk of early death and was more important than years of education or degree attainment, which 
indicated that participation itself rather than the time spend in education is important in the 
association between education and mortality (O'Toole et al., 1988). The first study to examine 
the association between childhood cognitive ability and all-cause mortality was a longitudinal 
population-wide study including 80% (N = 2230) of children born in Aberdeen in 1921, as 
part of the Scottish Mental Survey 1932, with a follow-up time of 65 years (Whalley & Deary, 
2001). The results showed that one SD increase in childhood cognitive ability was associated 
with a hazard ratio of 0.79 (95% CI 0.75 to 0.84) for mortality risk at age 76 years. This study 
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brought the association between childhood cognitive ability and mortality a wider readership, 
leading the area of individual differences into the field of public health. 
 
1.2.1. Mortality 
Many cognitive epidemiology studies examine the association between cognitive ability and 
mortality. A large cohort study of just under 1 million Swedish men found a stepwise negative 
association between intelligence and mortality, each one-point decrease on a nine-point 
intelligence scale was associated with an increase in mortality rate (HR = 1.15, 95% CI = 1.14 
– 1.16) (Batty et al., 2009), as shown in Figure 1-4. This association remained the same when 
correcting for physical measures (height, BMI, and blood pressure) or parental social class, 
but did decrease when educational attainment was controlled for. One could argue that it is not 
appropriate to control for educational attainment in studies of cognitive ability, as recent 
studies have shown educational attainment to be a good proxy measure for cognitive ability 
(I. J. Deary & Johnson, 2010; Hill, Davies, Liewald, McIntosh, & Deary, 2016; Rietveld et al., 
2014). Similar findings between cognitive ability and mortality were found in a large meta-
analysis that also included the Batty et al. (2009) study, where one SD increase in childhood 
intelligence was associated with a 24% lower mortality risk (HR = 0.76, 95% CI = 0.75 – 0.77) 
(Calvin et al., 2011). A cohort study including 728,160 men from the Danish Conscription 
Database, showed a 28% higher risk of dying for all-cause mortality for each SD decrease in 
cognitive ability (HR = 1.28, 95% CI = 1.27 – 1.29) (G. T. Christensen, Mortensen, 
Christensen, & Osler, 2016). 
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Figure 1-4. Hazard ratios for the relation of IQ score with total mortality (N = 
994,262). Basic adjustment: age, year of birth, and conscription testing center 
(grey bars); full adjustment (age, year of birth, conscription testing center, 
parental social class, height, BMI, blood pressure, and illness) without 
education (black); full adjustments with education (white). The referent is the 
highest scoring IQ group (category 9). Reprinted with permission from Batty 
et al. (2009). Copyright 2009 by Wolters Kluwer Health.  
 
Studies examining cause-specific mortality have found consistent results for the negative 
association between childhood cognitive ability and one of the world’s major causes of death; 
coronary artery disease. For example, a study of 680,000 Swedish men who had their cognitive 
ability tested around age 18 found an inverse association between general cognitive ability and 
specific cognitive abilities, and death due to coronary artery disease (HR = 0.82, 95% CI = 
0.79 – 0.85). This association was independent of childhood or adult socio-economic status 
(Silventoinen, Modig-Wennerstad, Tynelius, & Rasmussen, 2007). As shown in Figure 1-5, 
using the Danish Conscription Database, each SD decrease in cognitive ability was associated 
with an 36% higher risk of dying due to cardiovascular (HR = 1.36, 95% CI = 1.34 – 1.38) (G. 
T. Christensen et al., 2016).  Results for one of the other major causes of death, cancer, have 
been inconsistent (Batty, Deary, & Gottfredson, 2007; Batty et al., 2009; G. T. Christensen et 
al., 2016; Wraw et al., 2015), and will not be discussed further in this thesis.  
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Figure 1-5. Age-adjusted hazard ratios for the associations between cognitive 
ability test score (Børge Prien Prøve (BPP)-score) in nine equal sized groups 
and cause-specific mortality in 662,185 men. Reprinted with permission from 
G. T. Christensen et al. (2016). Copyright by Elsevier.  
 
1.2.2. Physical health 
To better understand the underlying aetiology of the well-established link between cognitive 
ability and mortality, it is important to examine the association between cognitive ability and 
morbidity. This could strengthen the results of the mortality studies, due to the relatively 
uninformative nature of all-cause mortality studies with regards to the aetiology of the 
association, as well as the lack in power due to small numbers of deaths for cause-specific 
mortality. A study by Wraw et al. (2015), based on the National Longitudinal Study of Youth 
1979 (NLSY-79), found that higher cognitive ability in youth is associated with better physical 
health at age 50 (OR = 1.70, 95% CI = 1.55 – 1.86). Most studies examining the association 
between cognitive ability and health outcomes focus on cardiovascular traits (Hart et al., 2004; 
Hemmingsson, Essen, Melin, Allebeck, & Lundberg, 2007) and mental health disorders 
(Dickson, Laurens, Cullen, & Hodgins, 2011; Zammit, Allebeck, David, & et al., 2004). The 




1.2.2.1. Cardiovascular disease 
Higher cognitive ability has been linked to lower risk of cardiovascular disease and its risk 
factors. Batty, Mortensen, Nybo Andersen, and Osler (2005a) found a negative association 
between childhood cognitive ability and coronary artery disease (HR = 2.70, 95% CI = 1.60 – 
4.57) in a sample of about 7000 Danish men. This association was not attenuated when 
controlling for childhood socioeconomic status. B. A. Roberts et al. (2013) examined the 
association between childhood cognitive ability and a subclinical precursor for coronary artery 
disease, i.e. intima-media thickness, in 1142 children from the Newcastle Thousand Families 
Study. Intima-media thickness is a measure for arterial wall thickness and when increased it is 
a form of atherosclerosis, and is associated with increased risk of coronary artery disease 
(Polak  et al., 2011). The study by B. A. Roberts et al. (2013) found that higher general 
cognitive ability in childhood and better performance on specific tests for English and 
mathematics was associated with lower intima-media thickness (IMT) at age 50, a one SD 
increase in childhood cognitive ability was associated with a 0.039 mm lower IMT (95% CI -
0.080 to -0.002) in females and a 0.053 mm (95% CI -0.102 to -0.004)  lower IMT in males. 
In a study of 5793 individuals based on the NLSY-79, higher childhood cognitive ability was 
associated with lower risk for cardiovascular disease (OR = 0.59, 95% CI = 0.48 – 0.73) (Wraw 
et al., 2015). The negative association between cognitive ability and cardiovascular disease 
supports the idea that vascular processes mediate the pathway between childhood cognitive 
ability and cognitive decline in late life.  
 
Rostamian, Mahinrad, Stijnen, Sabayan, and de Craen (2014) examined the association 
between cognitive performance and risk of stroke in a meta-analysis of 12 studies including a 
total of 83,000 participants (3043 cases of stroke) and found an association between lower 
performance on tests of general cognitive ability, executive functioning, memory, and 
language, and higher risk of stroke. A smaller study by Batty et al. (2005a) in 7000 Danish 
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men (93 cases of stroke), did not find such association between childhood cognitive ability 
and risk of stroke, however this could be due to the lower number of stroke cases. Results from 
the NLSY-79 showed an inverse association between childhood cognitive ability and stroke 
(OR = 0.65, 95% CI = 0.52 – 0.81) (Wraw et al., 2015), supporting the findings by Rostamian 
et al. (2014).  
 
The previous paragraph provided evidence for an association between lower childhood 
cognitive ability and higher risk for cardiovascular disease. However, it could also be possible 
that cardiovascular disease is a risk factor for cognitive decline in later life. Neuroimaging and 
autopsy studies have shown that vascular changes in the brain are associated with dementia 
(F. E. Matthews et al., 2009; Schneider, Arvanitakis, Leurgans, & Bennett, 2009). The 
Whitehall II study showed an association between prior coronary artery disease events and 
later cognitive ability, with lower scores on domains of reasoning, fluency and vocabulary that 
were independent of socio-economic status and medication (Singh-Manoux et al., 2008). A 
systematic review examining cognitive function in patients with coronary artery disease 
concluded that coronary artery disease is a risk factor for decline in general cognitive ability 
(Eggermont et al., 2012). These findings are supported by other epidemiological studies, as 
discussed by Qiu and Fratiglioni (2015), who suggested that cardiovascular disease and its risk 
factors potentially share pathological processes with cognitive ageing. Figure 1-6 shows the 
possible association between cardiovascular disease and cognitive decline. The association 
between childhood cognitive ability and later life cardiovascular disease has not been 
discussed in this paper, and it is possible that lifestyle cardiovascular risk factors in young 




Figure 1-6. The heart–brain connection in ageing and cognitive decline. The 
schematic shows aetiological factors, pathophysiological mechanisms, and 
the sequence of events over the life-course of an individual. BBB, blood–
brain barrier; MCI, mild cognitive impairment. Reprinted with permission from 
Qiu and Fratiglioni (2015). Copyright by Springer Nature 2015. 
 
1.2.2.2. Cardiovascular risk factors 
Two important risk factors for cardiovascular disease are type 2 diabetes (Shah et al., 2015) 
and high blood pressure (Kannel, 1996) and these are both also associated with cognitive 
ability. Cukierman, Gerstein, and Williamson (2005) examined the association between type 
2 diabetes and cognitive ability in a systematic review including 25 longitudinal studies with 
a total of 8656 participants. They showed both a higher risk of cognitive decline as well as a 
greater rate of cognitive decline in type 2 diabetes patients. This supports the general consensus 
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that cognitive decline is a chronic complication of type 2 diabetes (Biessels, Deary, & Ryan, 
2008; Biessels, Staekenborg, Brunner, Brayne, & Scheltens, 2006). The association between 
cognitive ability and subsequent diabetes is less clear. A longitudinal study, using data from 
the Lothian Birth Cohort 1936, examined the association between childhood cognitive ability 
and subsequent type 2 diabetes (Mõttus, Luciano, Starr, & Deary, 2013). The Lothian Birth 
Cohort 1936 (LBC1936) is a longitudinal study with the aim to identify determinants in normal 
cognitive ageing using data from the Scottish Mental Survey of 1947 (I. J. Deary et al., 2007). 
The Survey tested nearly all Scottish children (93.2%) born in 1936 using a validated test of 
general cognitive ability (Moray House Test, Number 12). Survivors of the study living in the 
Lothian area of Scotland were recruited for cognitive testing 60 years later at age 70 years, 
which provides the opportunity to assess change in cognitive ability over nearly a lifetime’s 
duration. The study by Mõttus et al. (2013) showed that participants with a diagnosis of type 
2 diabetes, diagnosed using average plasma glucose levels measured by glycated haemoglobin 
(HbA1c), had lower performance on test of general cognitive ability in both childhood (OR = 
0.76, 95% CI = 0.64 – 0.92) and older age (OR = 0.78, 95% CI = 0.66 – 0.93) (Mõttus et al., 
2013). Very similar results were found based a self-report measure of type 2 diabetes. This 
suggests that instead of cognitive decline being a chronic complication of type 2 diabetes, 
cognitive ability might contribute to the onset of type 2 diabetes, supporting the hypothesis of 
reverse causation. A large study of almost 6000 individuals supported this reverse causality 
hypothesis by showing that higher childhood cognitive ability (measured between age 14 and 
21) was associated with lower risk of type 2 diabetes (OR = 0.85, 95% CI = 0.77 – 0.93), but 
this result became non-significant when adjusted for childhood and adult socio-economic 
status (Wraw et al., 2015). Twig et al. (2014) showed, in a sample of 35,500 young men from 
the Metabolic, Lifestyle and Nutrition Assessment in Young Adults (MELANY) cohort, that 
each point decrease on a 9-point cognitive ability scale was associated with a 10% increase in 
risk for diabetes (HR = 1.10, 95% CI = 1.04 – 1.17), after adjusting for age, BMI, fasting 
plasma glucose levels, white blood cell count, socio-economic status, and lifestyle risk factors. 
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Both high and low blood pressure have been associated with a decline in cognitive ability, 
especially in combination with other cardiovascular risk factors (Novak & Hajjar, 2010). Wolf 
et al. (2007) showed that lower cognitive performance on the domains of executive functioning 
and visual-motor skills in participants suffering from both hypertension and obesity. Similar 
results were found in the  Atherosclerosis Risk in Communities (ARIC) study (Knopman, 
Mosley, Catellier, & Coker, 2009) and in the third National Health and Nutrition Examination 
Survey (NHANES III) study (Pavlik, Hyman, & Doody, 2005), showing lower cognitive 
ability in individuals with hypertension and other cardiovascular risk factors (such as diabetes 
and stroke). Wraw et al. (2015) found an association between lower levels of childhood 
cognitive ability and hypertension (OR = 0.80, 95% CI = 0.75 – 0.86), independent of both 
childhood and adult socio-economic status. The findings for hypotension are inconsistent, with 
some studies finding lower cognitive ability in participants with hypotension, while others find 
no effect (Novak & Hajjar, 2010). 
 
To summarize, studies have indicated a relationship between cardiovascular disease, including 
cardiovascular risk factors, and cognitive ability, with both lower cognitive ability being 
associated with higher risk for cardiovascular diseases, as well as cardiovascular diseases as a 
risk factor for later life cognitive decline. No consistent evidence has been found so far to 
indicate a direction of effect for this association, it is therefore important that studies examine 
the potential direction of effect between cognitive ability and cardiovascular disease. 
 
1.2.2.3. Dementia 
A decline in cognitive ability is part of non-pathological cognitive ageing, but it can also be a 
symptom of pathological cognitive decline. Whalley et al. (2000) examined the association 
between childhood cognitive ability and dementia using data from the Scottish Mental Survey 
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1932, and found that participants with late-onset dementia had lower childhood cognitive 
ability (p < 0.03). A large follow-up, using the same sample, reported that lower childhood 
cognitive ability was a risk factor for late-onset vascular dementia (OR = 0.62, 95% CI = 0.41 
– 0.94), but not for Alzheimer’s type dementia (OR = 0.97, 95% CI = 0.79 – 1.19) (McGurn, 
Deary, & Starr, 2008). These findings indicate vascular processes potentially mediate the 
association between childhood cognitive ability and cognitive decline in later life. The findings 
also provide support for the idea of reverse causation, which suggests that pathological disease 
leads to cognitive decline.  
 
1.2.3. Mental health 
The other highly relevant link between cognitive ability and health is the one with mental 
health. Mental health problems are an important cause of disability in the world, with one in 
six English adults suffering from a common mental disorder, which are more common in 
females (one in five) than in males (one in eight) (McManus, Bebbington, Jenkins, & Brugha, 
2016). 
 
Mood disorders, such as major depressive disorder and bipolar disorder, are commonly 
associated with cognitive impairment on the domains of memory, executive functioning and 
processing speed, however the direction of the association is not clear. A large cohort study of 
around 50,000 Swedish men showed that lower performance on tests of premorbid general 
intelligence was associated with higher risk of developing schizophrenia and depression, but 
not bipolar disorder (Zammit et al., 2004). Wraw et al. (2016) showed a potential protective 
effect of intelligence on mental health in middle age. They found that higher childhood 
intelligence was associated with fewer depressive symptoms [β, = -0.16, 95% CI = -0.19 – (-
0.12)] measured by the 7-item Center for Epidemiological Studies Depression Scale, and better 
overall mental health state at age 50 (OR = 0.78, 95% CI = 0.72 – 0.85), but also with a higher 
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lifetime self-reported diagnosis of depression (OR = 1.11, 95% CI = 1.01 – 1.22). Various 
longitudinal studies have found an association between lower childhood cognitive ability and 
increased risk of mental health disorders (Batty, Mortensen, & Osler, 2005b; Gale, Batty, 
Tynelius, Deary, & Rasmussen, 2010; Gale et al., 2008; Gale, Hatch, Batty, & Deary, 2009; 
Koenen et al., 2009; Walker, McConville, Hunter, Deary, & Whalley, 2002). The largest study, 
including over 1 million men from the Swedish Conscript Study, showed an association 
between lower childhood cognitive ability and greater hospitalization risk for eight different 
mental health disorders (Gale et al., 2010). Each SD decrease in cognitive ability was 
associated with a 60 % (HR = 1.60, 95% CI = 1.55 – 1.65) increased risk of being admitted 
for schizophrenia, as well as a 50 % (HR = 1.50, 95% CI = 1.47 – 1.51) increased risk for 
mood disorders. Figure 1-7 shows the hazard ratios for hospital admission for both 
schizophrenia and mood disorders, as well as other mental health disorders, according to a 
nine-point scale for cognitive ability. 
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Figure 1-7. Hazard ratios for admission for different categories of mental 
health disorders, according to nine-point scale of cognitive ability (IQ scale). 
Reprinted with permission from Gale et al. (2010). Copyright by Lippincott, 
Williams and Wilkins. 
 
Lower cognitive ability was also associated with increased risk of multiple diagnoses, for a 1 
SD decrease in cognitive ability, the OR for receiving multiple diagnoses ranged from 1.71 
(95% CI = 1.68 – 1.73) for two or more diagnoses, to 2.06 (95% CI = 1.91 – 2.22) for six or 
more diagnoses (Gale et al., 2010). 
A meta-analysis of 29 longitudinal studies, including 121,749 individuals, showed that the 
correlation between higher cognitive ability and lower risk of subsequent major depressive 
disorder was attenuated from -0.09 [95% CI = -0.13 – (-0.05)] to -0.03 (95% CI = -0.08 – 0.01) 
35
after adjusting for baseline depression symptoms (Scult et al., 2017), which indicates that 
symptoms of major depressive disorder have an effect on cognitive performance at the time of 
measurement, rather than cognitive ability being a risk factor for subsequent major depressive 
disorder. 
 
Multiple studies have shown the impact of schizophrenia on cognitive performance, as well as 
an association between lower childhood cognitive abilities and increased risk of schizophrenia 
(Dickson et al., 2011; McIntosh, Harrison, Forrester, Lawrie, & Johnstone, 2005; Osler, 
Lawlor, & Nordentoft, 2007). The neurodevelopmental theory of schizophrenia hypothesizes 
that cognitive deficits in schizophrenia arise prior to the onset of the disease. McIntosh et al. 
(2005) showed an impairment in both general, verbal and premorbid intelligence in 74 
schizophrenia patients and their unaffected relatives. A meta-analysis of 23 studies including 
youths under 16 years old, who later developed schizophrenia, examined the association 
between different cognitive abilities and later schizophrenia diagnosis (Dickson et al., 2011). 
This study showed lower cognitive ability scores and impaired motor skills in youths who later 
developed schizophrenia, compared to healthy controls. No difference was found between 
schizophrenia patients and healthy controls in general academic achievement and 
mathematical achievement. A study by Kendler, Ohlsson, Mezuk, Sundquist, and Sundquist 
(2016) found that lower cognitive performance is not a strong risk factor for schizophrenia, 
but that the deviation in cognitive performance from family cognitive performance, measured 
by both general intelligence and academic achievement, is a stronger risk factor for 
schizophrenia.   
 
Bipolar disorder has been linked to cognitive decline, but findings on this association have 
been non-specific, with great heterogeneity in effect sizes (Bourne et al., 2013).  
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Similar to the association between physical health and cognitive ability, mental health has been 
linked to cognitive ability. Several studies have shown mental health disorders to be a risk 
factor for cognitive decline, as well as lower childhood cognitive ability as a risk factor for 
mental health disorders in later life. In order to better understand pathways between mental 
health and cognitive disorders, it is important to examine the direction of effect for this 
association. 
 
1.2.4. Cognitive ability and health mechanisms 
All cognitive epidemiology studies to date have contributed to the progress in understanding 
the aetiology between cognitive ability and health. The exact mechanisms, however, remain 
unclear. There are multiple mechanisms that could underlie this association, for example the 
theory of system integrity (I. J. Deary, 2012), the disease management hypothesis, and the 
disease prevention hypothesis (Whalley & Deary, 2001). These and other potential pathways 
between premorbid cognitive ability and mortality are displayed in Figure 1-8 (Batty et al., 
2007). Batty et al. (2007) suggest that genetic analyses will provide further insight in to the 
pathways between premorbid cognitive ability and mortality. Findings from genetic analysis 





Figure 1-8. Simplified model of influences on pre-morbid IQ and potential 
pathways linking pre-morbid IQ with later mortality. a Although psychiatric 
disease is shown as a mediating variable between IQ and mortality, it might 
also be an antecedent variable if, for example, suboptimal neurodevelopment 
were the prior cause of both psychiatric disease and early mortality. Both of 
these possibilities are captured in the text. b Note that system integrity is 
shown as antecedent to both IQ and mortality. In this pathway, lower IQ is not 
a cause of mortality, but both IQ and mortality are influenced by this more 
fundamental physiological integrity. Adapted with permission from Batty et 
al. (2007). Copyright by Elsevier 2007. 
 
The theory of bodily system integrity suggests that the negative association between cognitive 
ability and health may be explained by an individual’s physiological make-up (I. J. Deary, 
2012). Higher childhood cognitive ability might be a characteristic of a ‘well-wired’ body that 
is better at handling environmental challenges, and might therefore covary with disease risk 
instead of being a causal risk factor for disease. This association also works the other way 
around; lower childhood cognitive ability could reflect a body that is less adapted to handle 
environmental challenges.  
 
The disease management hypothesis provides an explanation for the lower disease rates in 
individuals with better cognitive abilities, suggesting that these individuals are better at 
managing their existent diseases. As written by Gottfredson (2004), health self-care is a 
cognitive competence. Individuals with better cognitive ability are likely to better understand 
and remember medical advice, as well as recognizing symptoms that require further medical 
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attention. This hypothesis has been supported by multiple studies finding an association 
between better cognitive ability and treatment adherence (I. J. Deary et al., 2009; Stilley, 
Bender, Dunbar-Jacob, Sereika, & Ryan, 2010). Using data from the Aspirin for 
Asymptomatic Atherosclerosis (AAA) study, a randomized controlled trial including 1993 
individuals, I. J. Deary et al. (2009) examined the association between cognitive ability and 
treatment adherence. The study showed that individuals with higher cognitive ability were 
more likely to continue treatment during a two-year observational period, one SD advantage 
in cognitive ability was associated with a 25% lower risk of stopping medication (HR = 0.75, 
95% CI = 0.64 – 0.75). Similar results have been found in a study showing that better cognitive 
performance on tests of memory, attention and executive function was associated with better 
medication adherence (Stilley et al., 2010).  
 
The disease prevention hypothesis suggests an association between higher cognitive ability 
and better health outcomes due to the association with better social status and healthier lifestyle 
choices. For example, studies have shown that children with better cognitive ability were less 
likely to start smoking (Martin, Fitzmaurice, Kindlon, & Buka, 2004) and more likely to stop 
smoking in adulthood (Taylor et al., 2003). This is relevant in the association between 
cognitive ability and physical health, as smoking is a risk factor for cardiovascular diseases 
(US Department of Health and Human Services, 2014). 
 
Childhood socioeconomic status can be seen as a possible confounder of the association 
between cognitive ability and health. However, most studies discussed in the previous Section 
show little or no attenuation when adjusting for childhood socioeconomic status, measures by 
parental income or social class (Calvin et al., 2011; Wraw et al., 2015). This suggests that the 
individual differences in childhood cognitive ability act independently from the individual 
differences in childhood social class to predict health outcomes.  
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Individual differences in adult socioeconomic status may explain more of the association 
between childhood cognitive ability and health then childhood socioeconomic status. It is 
hypothesized that cognitive ability has an effect on adult socioeconomic status, measured by 
education, income and adult social class, with adult socioeconomic status being a mediator of 
the cognitive ability and health association (Batty et al., 2007). Previously discussed studies 
have shown an attenuation of the cognitive ability and health association when adjusting for 
adult socioeconomic status (Calvin et al., 2011; Wraw et al., 2015), supporting the hypothesis 
that adult socioeconomic status is a mediator of the association between cognitive ability and 
health. One explanation for this is that the protective effects of higher childhood cognitive 
ability build up during the lifetime. Higher childhood cognitive ability potentially leads to 
more educational success, better social status and thus better access to healthcare, which in 




1.3. Cognitive ability and health: genetics  
Section 1.2.4 of this Chapter described different mechanisms potentially underlying the 
association between cognitive ability and health. Many studies have shown a familial aspect 
indicating that genetics could also play an important role in the aetiology of cognitive ability 
and its associations with health outcomes (Plomin, DeFries, Knopik, & Neiderhiser, 2016). In 
order to better understand the associations between cognitive ability and health, it is central to 
first understand the genetic aetiology of cognitive ability. This Section of Chapter 1 will 
therefore start by describing common techniques to test for a shared genetic aetiology, 
followed by empirical work examining the genetic aetiology of cognitive ability using both 
behavioural genetic as well as molecular genetic studies.  This Chapter will finish with the 
shared genetic aetiology between cognitive ability and health outcomes. 
 
1.3.1. Genetic methodologies 
1.3.1.1. Behavioural genetics 
The study of the biological basis of individual differences is known as behavioural genetics. 
This area assesses the effect of genetic and environmental factors on different traits, such as 
cognitive ability, using for example family, adoption, and twin studies. Family studies are 
generally unable to distinguish genetic effects from shared environmental effects, unless the 
study consists of large families with different degrees of relatedness (Falconer & Mackay, 
1996). Adoption and twin studies can be used to disentangle the genetic aetiology of traits, by 
identifying and separating genetic and shared and non-shared environmental effects (Falconer 
& Mackay, 1996). Francis Galton was a pioneer in the field of behavioural genetics; he 
conducted one of the first studies showing a familial resemblance in cognitive ability (Galton, 
1869). The field of behaviour genetics, specifically Eric Turkheimer, has come up with three 
‘laws’ of behaviour genetics (Turkheimer, 2000), which are: 
1. All human behavioural traits are heritable. 
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2. The effect of being raised in the same family is smaller than the effect of genes. 
3. A substantial portion of the variation in complex human behavioural traits is not 
accounted for by the effects of genes or families. 
The first and third ‘law’ have been shown to be accurate, in particular by a large meta-analysis 
of all human twin studies over the past fifty years (Polderman et al., 2015). The second ‘law’ 
might not be accurate in traits with low heritability estimates, in which case the effect of being 
raised in the same family could be higher than effect of genes. (Polderman et al., 2015) 
 
The familial aspect of traits such as cognitive ability can be studied using the adoption design. 
Non-adoptive families consist of individuals who are genetically related and have a shared 
environment, while adoptive families also have a shared environment, but are not genetically 
related. This creates the opportunity to study the genetic and environmental sources of a trait. 
Similarities between the adopted child and its biological parents are due to genetic reasons 
only, whereas the similarities between the adopted child and its adopting parents are due to 
shared environment only (Plomin & Daniels, 2011). Early adoption studies showed that the 
correlations for cognitive ability were stronger in non-adoptive families than in adoptive 
families, which indicates a genetic effect (Burks, 1928; Leahy, 1935). 
 
As mentioned at the beginning of this Section, another behavioural genetics design to 
disentangle the genetic aetiology of a trait is a twin study. Twin studies examine the 
resemblance of monozygotic (MZ) twins, who are genetically identical, with same-sex 
dizygotic (DZ) twins, who share, on average, 50 % of their genetic information. A classic twin 
study splits the phenotypic variance in three components; the additive genetic (A) component, 
the common or shared environmental component (C), and the unique or non-shared 
environmental (E) component. As MZ twins are genetically identical, both A and C are 
assumed to have a correlation of 1, whereas DZ twins only shared around 50% of their genes, 
which means that C is assumed to correlate at one, and A only at 0.5. E is assumed to be 
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uncorrelated between twins and contributes to the differences within pairs. If a trait is 
influenced by genetic factors, it is expected that the correlation between MZ twins is stronger 
than the correlations between DZ twins. An important part of twin studies is the ‘equal 
environments assumption’, which assumes that twins raised in the same family share the same 
environment (Plomin & Daniels, 2011). A violation of this assumption would inflate the 
genetic influence estimates, but it has been shown that this assumption is valid for most traits 
(Derks, Dolan, & Boomsma, 2006).  
 
1.3.1.2. Heritability 
Twin and adoption studies use familial resemblance to estimate the genetic influence on traits, 
but molecular genetic methods enable scientists to estimate identify specific genes affecting a 
trait by using DNA instead of familial resemblance. Molecular genetic methods can also be 
used to estimate the heritability across many genetic variants, using DNA in unrelated 
individuals; this method is referred to as Genome-wide Complex Trait Analysis (GCTA-
GREML) (Yang, Lee, Goddard, & Visscher, 2011). GCTA-GREML uses the genetic 
similarity between each pair of, say, thousands of unrelated individuals to predict phenotypic 
similarity (Jian Yang et al., 2010; Yang et al., 2011). The genetic similarity between pairs is 
based on the similarity across hundreds of thousands of single nucleotide polymorphisms 
(SNPs) across the genome, leading to millions of pair comparisons. These polymorphisms are 
single base pair substitutions and are the most common form of genetic variation in individuals 
(The 1000 Genomes Project Consortium, 2010). Pairs of individuals with a genetic similarity 
greater than the level of fifth degree relatives are removed from the analysis to ensure that all 
pairs are effectively unrelated. Heritability estimates derived using GCTA-GREML to date are 
limited by the fact that they have used only common SNPs, with allele frequencies above 1%, 
instead of all genetic variants such as in twin studies, and as such they provide the lower bound 
heritability estimate.   
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1.3.1.3. Linkage analysis and candidate gene studies 
Linkage analysis can be used to identify regions of a chromosome that are associated with a 
disorder or trait, by analysing how genetic markers segregate with a trait in a family. This 
approach has been successful in identifying genetic variants involved in rare disorders such as 
cystic fibrosis (Kerem et al., 1989) or Huntington disease (MacDonald et al., 1992). When 
applying this method to complex traits such as cognitive ability, linkage analysis has been less 
successful due to the number of genetic variants each with small effects involved. 
 
While linkage analysis is unable to detect linkage for genes of small effect, candidate gene 
studies are able to detect these small effects. Candidate gene studies focus on associations 
between genetic variation within pre-specified genes. These genes are selected based on a prior 
hypothesis, for example in the case of cognitive ability, candidate genes were selected based 
on neurotransmitter genes involved in disease, or based on developmental and metabolic 
processes. 
 
1.3.1.4. Genome-wide association studies 
Genome-wide association studies (GWAS) test for an association between single SNPs and 
traits by evaluating the correlation between a trait and the allele frequency of a SNP (Bush & 
Moore, 2012). GWAS are based on the principle of linkage disequilibrium (LD) in the 
population. LD measures the non-random assortment of alleles at two loci. If allele A at locus 
1 and allele B at locus 2, with a population frequency of pA and pB respectively, are independent 
of each other, the allele frequency for the haplotype AB would be pApB (Pritchard & 
Przeworski, 2001). These two alleles would be in LD when the population frequency is higher 
or lower than the expected population frequency. Ancestrally older populations (such as the 
African population) have smaller regions of LD, due to the accumulation of more 
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recombination events, than ‘younger’ populations such as European or Asian populations 
(Bush & Moore, 2012).  
 
GWAS have been very successful in identifying associations between traits and genetic 
variants, such as height (Wood et al., 2014), BMI (Locke et al., 2015), schizophrenia 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014), and 
educational attainment (Okbay et al., 2016b). The effect size of the association between a 
particular SNP and the trait is generally very small, both in terms of the amount of variance 
explained and the beta effect. As shown in Figure 1-9, in a GWAS of educational attainment 
(as measured by years of education), the amount of variance explained by the 74 genome-wide 
significant SNPs (p < 5 × 10−8) ranged between 0.01 % and 0.04 % with effect sizes ranging 
from 0.01 to 0.05 SD per allele (Okbay et al., 2016b). At the other end of the spectrum, the 







Figure 1-9 . a, SNPs ordered by absolute value of the standardized effect of 
one more copy of the education-increasing allele, with 95% confidence 
intervals. b, SNPs ordered by R2. Effects on EduYears are benchmarked 
against the top 74 genome-wide significant hits identified in the largest 
GWAS conducted to date of height and body mass index (BMI), and the 48 
associations reported for waist-to-hip ratio adjusted for BMI (WHR). These 
results are based on the GIANT consortium’s publicly available results for 
pooled analyses restricted to European-ancestry individuals:  
https://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consort
ium. Reprinted with permission from Okbay et al. (2016b). Copyright 2016 by 
Springer Nature.  
 
The possible shared genetic aetiology between cognitive ability and health can be assessed 
using both behavioural genetic and molecular genetic techniques, the main molecular genetic 
techniques that will be discussed in the next Sections are linkage disequilibrium score 
regression (LDSR), polygenic risk score analysis (PRS), and Mendelian randomization 




The previous Section described different techniques to examine the genetic aetiology of traits. 
The main focus on this thesis is, however, the shared genetic aetiology between cognitive 
ability and health, and between negative emotions and health. The phenotypic link between 
these traits is possibly caused by pleiotropic genetic variants. Pleiotropy described the 
phenomenon that one genes contributes to multiple phenotypic traits, and it consist of different 
subtypes, as shown in Figure 1-10. The work in this Thesis will mainly focus on biological 
and mediated pleiotropy. Biological pleiotropy is the result of the same genetic variants being 
involved in two traits, while mediated pleiotropy describes the situation of two traits causally 
associated with each other where a genetic variant affects the first trait, which then causally 
affects the second trait.  
47
 
Figure 1-10. In each scenario, the observed genetic variant (S) is associated 
with phenotypes 1 and 2 (P1 and P2). We assume that the observed genetic 
variant is in linkage disequilibrium (LD) with a causal variant (red star) that 
affects one or more phenotypes. In some cases, the causal variant may be 
identified directly and the figures can be simplified accordingly. The various 
figures correspond to the unobserved underlying pleiotropic structure. a | 
Biological pleiotropy at the allelic level: the causal variant affects both 
phenotypes. b | Colocalizing association (biological pleiotropy): the observed 
genetic variant is in strong LD with two causal variants in the same gene that 
affect different phenotypes. c | Biological pleiotropy at the genic level: two 
independent causal variants in the same gene affect different phenotypes. d 
| Mediated pleiotropy: the causal variant affects P1, which lies on the causal 
path to P2, and thus an association occurs between the observed variant and 
both phenotypes. e | Spurious pleiotropy: the causal variant affects only P1, 
but P2 is enriched for P1 owing to misclassification or ascertainment bias, and 
a spurious association occurs between the observed variant and the 
phenotype 2. f | Spurious pleiotropy: the observed variant is in LD with two 
causal variants in different genes that affect different phenotypes. GWAS, 
genome-wide association study. Reprinted with permission from Solovieff, 





1.3.1.6. Linkage disequilibrium score regression 
LDSR is used to test for genetic overlap between traits, by using information from GWAS 
summary statistics (Brendan K. Bulik-Sullivan et al., 2015b). It relies on the fact that the 
effect-size estimate from the GWAS for a certain SNP incorporates the effects of all SNPs that 
are in LD with that SNP, and uses this to compute a genetic correlation between two traits of 
interest. For polygenic traits, SNPs in regions of high LD will be able to measure a greater 
proportion of the genome than SNPs in low LD regions, and will therefore have a higher χ2 
statistics than the SNPs in low LD regions. SNPs in higher LD with causal variants will also 
have a higher probability to tag the causal variant. LDSR uses the LD pattern in known 
populations to compute the genetic correlations from separate GWAS of different traits by 
using the standardized effect size (z-score) of the association between each SNP and a trait. 
By regressing the product of z-scores onto the LD score, the genetic covariance can be 
estimated (Brendan K. Bulik-Sullivan et al., 2015b). Genetic correlations reflect the 
correlation in additive genetic components. Using these correlations, one can calculate the co-
heritability of two traits, i.e. the covariance between two traits on the same scale as the 
heritability, using the following formula: rg * √(h2x * h2y), where rg is the genetic correlation, 
and h2x/y represents the heritability estimate of the two traits the genetic correlation is based on 
(Falconer & Mackay, 1996). Genetic correlations, as with any correlations, can be explained 
in multiple (and not mutually exclusive) ways: it might be that the genes cause both traits, 
biological pleiotropy, or it might be that there is mediated pleiotropy, where the gene affects 
one trait which then affects others. Some traits are more likely to be mediated pleiotropy (such 
as education, which is not measured biologically), whereas some are more likely—though, not 
certain—to be biological pleiotropy. While pleiotropy is one of the explanations for the 
existence of genetic correlations; genetic correlations are also possible in the absence of 




1.3.1.7. Polygenic risk score analysis 
The theory of polygenic inheritance states that most complex traits are affected by multiple 
loci, all of which contribute a small amount to the variation in the trait, previously described 
by Chabris, Lee, Cesarini, Benjamin, and Laibson (2015) as the fourth law of behavioural 
genetics. When performing a traditional GWAS the many loci with small effects will be 
indistinguishable from noise, but together these loci can account for a substantial proportion 
of the variation in the risk for a disease. This can be identified by PRS, by summarizing the 
variation across all loci into polygenic risk scores and examining the association between the 
polygenic risk score and the outcome variable in an independent sample (Purcell et al., 2009). 
In order to create PRS, several steps have to be performed. First, independent SNPs, based on 
the summary results from an independent GWAS, are identified by performing linkage 
disequilibrium clumping. This process forms ‘clumps’ of SNPs that are in LD with an ‘index’ 
SNP. The index SNP is the SNP with the lowest p-value in a predefined region (for example 
250kb). All SNPs in LD with the index SNP, e.g. SNPs with an r2 above a certain value, are 
then assigned to the clump. The next index SNP will be the following SNP with the lowest p-
value that is not in LD with the previous index SNP. Secondly, all independent SNPs below 
different thresholds of p-values (e.g. 0.01, 0.05, 0.1, 0.5 and all SNPs) are identified. PRS are 
then created for each individual representing the net predictive effect of all reference alleles at 
each different threshold that an individual possesses from the discovery results. PRS are based 
on common SNPs that have been genotyped and therefore do not necessarily accurately tag 
causal variants. The associations between the SNPs and the outcome measure will be estimated 
with sampling error as the association is based on a finite sample. Due to this the amount of 
variance explained by PRS is usually relatively small and will never correspond to the 
heritability estimate for a trait, but it should be considered the minimum amount of variance 
explained. It is important to note that independence of the two samples (GWAS and prediction) 
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is crucial, as PRS are created based on SNPs in approximate linkage equilibrium based on 
arbitrary thresholds, which can also bias the amount of variance explained (Wray et al., 2013).  
In this Thesis, the term polygenic risk scores will be used for disorders, while polygenic profile 
score will be used for non-disorder-based traits (such as cognitive ability or negative 
emotions). 
 
1.3.1.8. Mendelian randomisation 
LDSR and PRS identify possible shared genetic aetiology between traits, however these 
techniques do not inform on possible causality between traits. Identifying the underlying 
causes of the associations between cognitive ability and health is one of the fundamental aims 
of the field of cognitive epidemiology. Mendelian randomization (MR) is a technique that can 
be used to identify causal associations. MR utilizes genetic variants as instrumental variables 
for a modifiable exposure (e.g. BMI) in order to estimate the causal effect of that exposure on 
an outcome (e.g. cognitive ability). The instrumental variables should predict the exposure and 
the outcome only through the exposure. Biological pleiotropy (as described in Section 1.3.1.5) 
violates these assumptions, while mediated pleiotropy does not violate these assumptions due 
to the idea that the genetic variant is associated with a trait, which is then associated with a 
second trait. GWAS summary statistics can be used to perform MR analysis, for example by 
using inverse variance weighted regression (IVW). IVW estimates the causal effect of the 
exposure on the outcome using the ratio of two “vectors”. These so-called vectors are based 
on the GWAS summary statistics of the gene variant – outcome association estimate (β) and 
the gene variant – exposure association estimate (β). The study in the current Thesis (Section 
4.3) will use multiple SNPs for each instrumental variable, which means that the two vectors 
consists of a “list” of SNPs for the exposure with their respective effect estimates for the 
association and a list of those same SNPs with the effect estimate based on the association 
with the outcome. These two vectors are then regressed on each other, corrected for minor 
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allele frequency, by weighing the association by the standard error of the genetic variant – 
outcome association.  
 
1.3.2. Genetic aetiology of cognitive ability 
1.3.2.1. Adoption and twin studies 
Adoption, twin, and family studies have estimated the heritability of cognitive ability, the 
amount of variance accounted for by genetic factors, to be between 40-80% with most 
evidence based on twin studies (Davis, Haworth, & Plomin, 2009; Haworth et al., 2010; 
Plomin et al., 2016; Plomin, Fulker, Corley, & DeFries, 1997; Polderman et al., 2015). A meta-
analysis of all published twin studies in the past 50 years, which included almost 450,000 twin 
pairs for general cognitive ability, showed a heritability estimate of 47% for cognitive ability 
(Polderman et al., 2015). Haworth et al. (2010) showed, in a cross-sectional study of 11,000 
twins, that the heritability of general cognitive ability increases significantly from 41% in 
childhood, to 55% in adolescence to 66% in young adulthood. Lyons et al. (2009) examined 
the heritability of cognitive ability in a longitudinal twin study of adult men and showed that 
the heritability increased from 49% at age 20 to 57% at age 55. The phenotypic correlation 
between cognitive ability at age 20 and at age 55 was 0.74, and 71% of this phenotypic 
correlation was due to additive genetic effects, 22% was due to shared environmental 
influences, and 6% was due to non-shared environmental influences. The study also reported 
a genetic correlation of 1 between the two measures of cognitive ability, which suggests that 
the same genetic variants influence cognitive ability both at age 20 and at age 55. A small twin 
study of 110 MZ twins and 130 DZ twins aged 80 years or older estimated the heritability of 
cognitive ability to be 62% while shared and non-shared environment account for 15% and 
22% of the variance respectively (McClearn et al., 1997). A large meta-analysis, including 15 
samples of longitudinal twin and adoption studies, replicated these findings by showing a low 
genetic stability in very early life, with strong increases over childhood, stabilizing in 
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adulthood (Tucker-Drob & Briley, 2014). In very early childhood, the greatest proportion to 
the phenotypic stability of cognitive ability is the shared environment (C), but with age, this 




Figure 1-11. Proportional genetic, shared environmental, and nonshared 
environmental contributions to stability across the life span. Estimates are 
based on expectations from the best fitting continuous models. Reprinted 
with permission from Tucker-Drob and Briley (2014). Copyright by American 
Psychological Association 2014. 
 
1.3.2.2. Molecular genetics 
Multiple studies have estimated the SNP-based heritability (h2SNP) of cognitive ability in both 
childhood and adulthood (Benyamin et al., 2014; G. Davies et al., 2015a; G. Davies et al., 
2016b). Benyamin et al. (2014) reported the h2SNP for childhood cognitive ability in three 
different cohorts, the Avon Longitudinal Study of Parents and Children (ALSPAC, N = 5517), 
the Twins Early Development Study (TEDS, N = 2794), and the University of Minnesota study 
(UMN, N = 1736). Common SNPs accounted for 46% (SE 6%), 22% (SE 10%), and 40% (SE 
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21%) of the variance in childhood cognitive ability in the ALSPAC, TEDS, and UMN cohorts 
respectively. Both TEDS and UMN are likely to be underpowered to provide a valid h2SNP 
estimate due to the smaller sample sizes compared to ALSPAC, as indicated by the size of the 
SEs. GCTA requires very large sample sizes (at least several thousand individuals) to be able 
to extract a small signal of genetic similarity from the noise of hundreds of thousands of SNPs 
(Visscher et al., 2014). G. Davies et al. (2015a) reported the h2SNP of general cognitive ability 
in later life to be 29% (SE 5%) and 28% (SE 7%) in the Atherosclerosis Risk in Communities 
Study (ARIC, N = 6617) and Health and Retirement Study (HRS, N = 5976) cohorts. These 
estimates have been replicated in the UK Biobank, showing a h2SNP of 31% (SE 2%) for a 
measure of general cognitive ability in a sample of 36,035 individuals (G. Davies et al., 
2016b).  
 
1.3.2.3. Linkage analysis and candidate gene studies 
Linkage analysis of cognitive ability identified linkage with regions implicated in reading 
disability and autism (Dick et al., 2006; Doyle et al., 2008; Luciano et al., 2006; Posthuma et 
al., 2005), however these results have not been replicated. Many candidate genes have been 
identified for cognitive ability, as discussed in detail by Payton (2009), but most have not been 
replicated (Chabris et al., 2012; Houlihan et al., 2009; Mandelman & Grigorenko, 2012). 
APOE is the only candidate gene that has been replicated in a meta-analysis of 77 studies 
including 40,942 individuals (Wisdom, Callahan, & Hawkins, 2011). This meta-analysis 
showed that carriers of APOE ε4 performed significantly poorer on measures of general 
cognitive ability, memory, processing speed, and executive function, compared to APOE ε4 
non-carriers. The results also indicated that the difference between ε4 carriers and non-carriers 
on measures of general cognitive ability and memory increased with age (Wisdom et al., 2011). 
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Due to the limitations of both linkage analysis and candidate gene studies, as well as the 
availability and affordability of genome-wide association studies, linkage analysis and 
candidate gene studies will not be further discussed in this Thesis. 
 
1.3.2.4. Genome-wide association studies 
GWAS of general cognitive ability found similar small effect estimates as discussed in Section 
1.3.1.4, the largest GWAS to date by G. Davies et al. (2015a) showed that, in a sample of 
nearly 54,000 individuals, the most significant SNP had an effect size of 0.03 SD change in 
general cognitive ability per allele. The small effect sizes detected by GWAS have led to the 
‘fourth law of behavioural genetics’, stating: “A typical human behavioural trait is associated 
with very many genetic variants, each of which accounts for a very small percentage of the 
behavioural variability” (Chabris et al., 2015, p. 305). Traits influenced by many genes of 
small effects are also called ‘polygenic traits’, as discussed in Section 1.3.1.6.  
 
1.3.2.5. General cognitive ability 
Several GWAS of general cognitive ability, as well as specific cognitive abilities, have been 
performed in the past ten years (Benyamin et al., 2014; G. Davies et al., 2015a; G. Davies et 
al., 2016b; G. Davies et al., 2011; De Jager et al., 2012; Debette et al., 2015a; Ibrahim-Verbaas 
et al., 2016; Kirkpatrick, McGue, Iacono, Miller, & Basu, 2014; Need et al., 2009; Okbay et 
al., 2016b; Rietveld et al., 2014; Trampush et al., 2017). Earlier studies were unable to detect 
any genome-wide significant SNPs for general cognitive ability in both childhood and 
adulthood in samples of 750 individuals (Need et al., 2009), 3500 individuals (G. Davies et 
al., 2011), 7100 individuals (Kirkpatrick et al., 2014) or 17,989 individuals (Benyamin et al., 
2014), except for the GWAS by De Jager et al. (2012), who reported genome-wide significant 
results in the APOE region on chromosome 19. The APOE gene is a major genetic risk factor 
for Alzheimer’s disease (Corder et al., 1993; Genin et al., 2011), but has also been associated 
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with cognitive phenotypes in older age (I. J. Deary et al., 2002; Small, Rosnick, Fratiglioni, & 
Bäckman, 2004; Wisdom et al., 2011) and non-pathological cognitive ageing (G. Davies et al., 
2014; Zhang & Pierce, 2014). Whereas GWAS of cognitive ability generally exclude 
individuals with dementia to ensure that all individuals are cognitive healthy, the study by De 
Jager et al. (2012) included 152 individuals with dementia and 151 individuals with mild 
cognitive impairment, meaning that just under 60% of the sample was cognitively healthy. It 
is therefore possible that this small GWAS picked up the APOE locus due to its association 
with Alzheimer’s disease rather than with cognitive ability.  
 
The first genome-wide significant hits for general cognitive ability were found on chromosome 
6 (MIR2113), chromosome 14 (AKAP6 and NPAS3), and chromosome 19 (APOE and 
TOMM40) in a meta-analysis of 53,949 individuals from the Cohorts for Heart and Aging 
Research in Genomic Epidemiology (CHARGE) consortium (G. Davies et al., 2015a). Some 
of the hits have previously been associated with educational attainment (MIR2113) (Rietveld 
et al., 2013), brain development (NPAS3) (Kamm, Pisciottano, Kliger, & Franchini, 2013; Sha 
et al., 2012), and cognitive ability or Alzheimer’s disease (APOE and TOMM40) (G. Davies 
et al., 2014; Lambert et al., 2013). More recently, a smaller GWAS meta-analysis of general 
cognitive ability, in a sample of 35,298 individuals from the Cognitive Genomics Consortium 
(COGENT), identified two genome-wide significant loci on chromosome 1 (LOC105378853) 
and chromosome 2 (CENPO) (Trampush et al., 2017). The hit on chromosome 1 fell within a 
large intergenic non-coding RNA and the hit on chromosome 2 has previously been associated 
with height (Wood et al., 2014). Trampush et al. (2017) meta-analysed nominally significant 
SNPs (p < 0.05) from the COGENT GWAS with the suggestive SNPs (p < 1 × 10−5) from the 
CHARGE GWAS (G. Davies et al., 2015a). The findings from this meta-analysis supported 
the previously identified loci from the CHARGE GWAS (G. Davies et al., 2015a) on 
chromosome 6 and chromosome 14, and also identified a novel locus on chromosome 3. It is 
important to note that the COGENT study had a mean age (SD) of 45.6 (8.6) years, whereas 
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the CHARGE study only included individuals aged 45 years or older, this might explain the 
discrepancy in results between the two studies. Three loci were identified in a GWAS of 
general cognitive ability on 36,035 individuals on chromosome 7, chromosome 14 and 
chromosome 22 (G. Davies et al., 2016b). The strongest association was on chromosome 22 
and involved a region that included genes involved in mitochondrial function (NDUFA6) 
(Emahazion & Brookes, 1998), drug metabolism (CYP2D6) (Gaedigk, Blum, Gaedigk, 
Eichelbaum, & Meyer, 1991), and Alzheimer’s disease (SEPT3) (Takehashi et al., 2004).  The 
region on chromosome 7 included the PDE1C gene, involved in the calcium-calmodulin 
complex (Repaske, Swinnen, Jin, Van Wyk, & Conti, 1992), and the region on chromosome 
14 included the FUT8 gene. 
 
The studies discussed in this section all examined genetic contributions to cognitive ability 
directly; an alternative approach to identify genetic variants for cognitive ability is the proxy-
phenotype method (Rietveld et al., 2014), in which a GWAS is performed to identify SNPs 
associated with a proxy phenotype, this is followed by a test of association between the 
identified SNPs (P < 1 × 10-5) and the phenotype of interest in an independent sample. Rietveld 
et al. (2014) adopted this method using educational attainment as a proxy phenotype for 
cognitive ability, based on the findings of previous studies showing that educational attainment 
is a good proxy for cognitive ability (Calvin et al., 2012; I. J. Deary & Johnson, 2010; Marioni 
et al., 2014b; Wainwright, Wright, Geffen, Luciano, & Martin, 2005). The first stage of the 
method identified 69 independent SNPs that were associated with educational attainment (P < 
1 × 10-5), of which three were significantly associated with cognitive ability after correction 
for multiple testing. Each of the three SNPs was associated with ~0.02 SD increase in cognitive 
performance. PRS based on the 69 educational attainment SNPs explained between 0.2 and 
0.4% of the variance in cognitive performance in four cohorts with a total sample size of 4463 
individuals. The most recent GWAS for educational attainment found a genetic correlation of 
0.75 (SE = 0.05) with cognitive ability, indicating that a large proportion of the phenotypic 
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correlation between educational attainment and cognitive ability is due to genetic factors 
(Okbay et al., 2016b). Based on these findings, supporting the idea that educational attainment 
is a good proxy for cognitive ability, this thesis will include educational attainment as a proxy 
measure of cognitive ability, particularly when examining the overlap between cognitive 
ability and health. 
 
1.3.2.6. Specific cognitive abilities 
In addition to general cognitive ability, the genetic aetiology of performance on specific 
measures of cognitive ability has also been analysed. Although many specific cognitive 
abilities exist (Tucker-Drob, 2009), only a few, including memory, executive function and 
processing speed, have been subject to GWAS (G. Davies et al., 2016b; Debette et al., 2015a; 
Ibrahim-Verbaas et al., 2016). The GWAS for memory (Debette et al., 2015a), and executive 
function and processing speed (Ibrahim-Verbaas et al., 2016) were performed using data from 
the CHARGE consortium and included 29,076 individuals for memory, 32,070 individuals for 
processing speed, and between 5429 and 13,454 individuals for executive function. Two 
genome-wide significant loci were associated with memory, one of which was in LD with the 
APOE gene, previously associated with Alzheimer’s disease (Lambert et al., 2013). One 
genome-wide significant locus (CADM2) on chromosome 3 was identified for processing 
speed and has previously been associated with both educational attainment (G. Davies et al., 
2016b) and BMI (Speliotes et al., 2010). This might indicate a shared genetic aetiology 
between cognitive ability and health. No genome-wide significant loci were identified for 
executive functioning, which could possibly be due to the relatively small samples sizes (< 
14,000 individuals). A substantially larger GWAS of 112,151 individuals in UK Biobank 
identified two genome-wide significant loci (SPATS2L on chromosome 2 and SH2B3 on 
chromosome 12) associated with processing speed (G. Davies et al., 2016b), SH2B3 has 
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previously been associated with neurodegenerative diseases and longevity (Auburger et al., 
2014). No genome-wide significant loci were identified for memory. 
 
To sum up, individual differences in cognitive ability are partly due to genetic variation. 
Common genetic variants account for approximately 30 % of the variance in cognitive ability. 
GWAS have shown that cognitive ability is influenced by many common genetic variants 
(SNPs), each with a very small effect size. 
 
1.4. Shared genetic aetiology with health 
The previous Sections of this Chapter have discussed the genetic aetiology of cognitive ability 
and showed some associations with health outcomes. Polderman et al. (2015) and Pickrell et 
al. (2016) provided a comprehensive analysis of genetic contributions to a large range of health 
traits. The phenotypic associations between cognitive ability and health may therefore, in part, 
be due to a shared genetic aetiology. Understanding the genetics of cognitive ability and its 
overlap with the genetics of health outcomes will help elucidate common pathways of disease 
outcomes. This Section of the introduction will discuss the potential shared genetic aetiology 
between cognitive ability and health. Studies assessing the shared genetic aetiology between 
cognitive ability and health using a quantitative design (such as twin studies) have been 
relatively sparse, but the availability of genotype data has led to an increase in the 
investigations into the shared genetic aetiology between cognitive ability and health.  
 
1.4.1. Mortality 
The phenotypic association between cognitive ability and mortality has been well-replicated 
(Calvin et al., 2011) and recent studies have reported this association to be partly due to genetic 
factors (Arden et al., 2016; Marioni et al., 2016a). A behavioural genetics meta-analysis 
including 1312 twin pairs from America, Sweden and Denmark, showed that the genetic 
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contribution to the small phenotypic correlation between cognitive ability and mortality was 
95% (Arden et al., 2016). This finding was supported by a study of over 130,000 individuals 
examining the association between PRS for educational attainment (a proxy for cognitive 
ability) and parental longevity, which showed that a 1 SD increase in PRS for educational 
attainment was associated with ~2.5% lower risk of parental mortality (Marioni et al., 2016a). 
 
1.4.2. Physical health 
Wraw et al. (2015) showed a phenotypic association between childhood cognitive ability and 
better physical health at age 50. A recent study (Harris et al., 2016a) examined the genetic 
overlap between self-rated health, a powerful predictor of future health, and among other traits, 
cognitive ability. They showed a genetic correlation, using LDSR, of 0.4 (SE = 0.05) and 0.6 
(SE = 0.03) with cognitive ability and educational attainment, respectively. PRS analysis 
indicated that polygenic profiles for general cognitive ability explained 0.12 % (p = 1.29 × 
10−30) of the variance in self-rated health. These results indicate that the same generic variants 
possibly influence both cognitive ability and self-rated health. 
 
When assessing more specific health outcomes, similar results have been reported. Luciano et 
al. (2010) showed, in an extended behavioural genetic pedigree based study of 6118 
individuals from 1983 families, that the association between behavioural risk factors for 
cardiovascular disease, such as physical activity, psychological distress, and lung capacity, 
and cognitive ability is largely due to genes (30 – 94 %). Using a PRS approach, Hagenaars et 
al. (2016a) examined the association between coronary artery disease polygenic risk and 
cognitive ability in 11,387 older adults and found that a higher genetic risk for coronary artery 
disease was associated with lower general cognitive ability, verbal intelligence and memory 
performance. This was finding was supported by a study performing LDSR on a large range 
of health outcomes, who reported a negative genetic correlation between coronary artery 
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disease and educational attainment (rg = -0.28, SE = 0.07) (Brendan K. Bulik-Sullivan et al., 
2015a), but did not find a significant genetic correlation between childhood cognitive ability 
and coronary artery disease. 
 
With regards to cardiovascular risk factors such as stroke, type 2 diabetes and BMI, several 
studies have shown a shared genetic aetiology between these risk factors and cognitive ability 
(Brendan K. Bulik-Sullivan et al., 2015a; Harris et al., 2016b; Luciano et al., 2014; Marioni et 
al., 2016b). Harris et al. (2016b) found a negative correlation between polygenic risk for stroke 
and general cognitive ability (r = -0.07), indicating that individuals with a higher genetic risk 
for stroke have poorer cognitive performance.  Marioni et al. (2016b) reported that, in a sample 
of 6815 unrelated individuals, polygenic profile scores for general cognitive ability explained 
0.08 % of the variance in BMI, while polygenic profile scores for BMI explained 0.42 % of 
the variance in cognitive ability. A smaller study including 3152 individuals did not support 
these findings (Krapohl et al., 2016), the discrepancy in results is likely due to the difference 
in sample size between the two studies. Marioni et al. (2016b) also showed a moderate genetic 
correlation between general cognitive ability and BMI (rg between -0.10 and -0.51), using both 
LDSR and a bivariate GCTA-GREML study. Both BMI and different classes of obesity have 
been found to be genetically correlated with childhood cognitive ability and educational 
attainment (rg between -0.17 and -0.29) using LDSR (Brendan K. Bulik-Sullivan et al., 2015a). 
Similar to its inconsistent phenotypic association, as discussed in Section 1.2.2.2, the shared 
genetic aetiology between cognitive ability and type 2 diabetes is less clear. Whereas Luciano 
et al. (2014) reported a counterintuitive positive association between polygenic risk for type 2 
diabetes and cognitive ability, two studies using a small number of SNPs to create a polygenic 
risk score for type 2 diabetes did not find an association with cognitive ability (Bonilla et al., 
2012; De Jager et al., 2012). Brendan K. Bulik-Sullivan et al. (2015a) reported no significant 
genetic correlation between childhood cognitive ability and measures of type 2 diabetes 
(including HbA1c, glucose and insulin measures), but did report significant negative genetic 
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correlations between educational attainment and measures of type 2 diabetes (rg between -
0.11 and -0.30). 
 
1.4.3. Mental health 
This Section will focus on the shared genetic aetiology between cognitive ability and mental 
health (Brendan K. Bulik-Sullivan et al., 2015a; Clarke et al., 2016; Georgiades et al., 2016; 
Harris et al., 2014; Hill et al., 2016; Kendler, Ohlsson, Sundquist, & Sundquist, 2015; Krapohl 
et al., 2016; Kuntsi et al., 2004; McIntosh et al., 2013; Toulopoulou et al., 2007). In a 
behavioural genetic study of 267 twins a genetic correlation of -0.61 (95% CI -0.71 to -0.48) 
was found between general cognitive ability and schizophrenia, 92% of the phenotypic 
variation between the two traits was due to genes (Toulopoulou et al., 2007). This was 
supported by Kendler et al. (2015) who, using a behavioural genetic study, showed that high 
general cognitive ability attenuated the influence of genetic risk for schizophrenia, as well as 
by Hill et al. (2016), who reported a genetic correlation, using the molecular genetic method 
LDSR, of -0.23 (SE = 0.03). A shared genetic aetiology between general cognitive ability and 
schizophrenia was also indicated using the PRS approach in a sample of 937 individuals, 
where genetic risk for schizophrenia explained between 0.6 and 0.8% of the variance in general 
cognitive ability (McIntosh et al., 2013). Hill et al. (2016) also found, using LDSR, significant 
genetic correlations between childhood cognitive ability and Alzheimer’s disease (rg = -0.34, 
SE = 0.11), and autism (rg = 0.36, SE = 0.11), between general cognitive ability and 
Alzheimer’s disease (rg = -0.32, SE = 0.08), and between educational attainment and bipolar 
disorder (rg = 0.26, SE = 0.06), autism (rg = 0.32, SE = 0.07), and Alzheimer’s disease (rg = 
-0.32, SE = 0.07). The positive genetic correlation between cognitive ability, in both childhood 
and adulthood, and autism, has been also been reported using the PRS approach by Clarke et 
al. (2016) in a meta-analysis of 15,885 individuals. Harris et al. (2014) did not report a 
significant association between polygenic risk for Alzheimer’s disease and cognitive ability in 
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a sample of 3500 individuals, however this polygenic risk score was based on a GWAS of 
Alzheimer’s disease that only included 3,941 Alzheimer’s disease cases and 7,848 controls. A 
more recent GWAS has been released including 17,008 Alzheimer’s disease cases and 37,154 
controls (Lambert et al., 2013).  
 
Twin and family studies have shown that the phenotypic association between cognitive ability 
and health is partly due to genes, and using molecular genetic methods such as LDSR and PRS 
it has been shown that some of the same genes are associated with both cognitive ability and 
health. Several studies discussed in this Section lack power due to small sample sizes, 
particularly the PRS studies. It is therefore of high importance to attempt to replicate and 
extend these findings in large samples to be able to further dissect the shared genetic aetiology 
between cognitive ability and health. 
 
1.5. Summary 
This Chapter provided an introduction to one of the key fields reported in this thesis; cognitive 
ability, phenotypic and genetic associations of cognitive ability with health, and relevant 
genetics concepts, methods and results. The empirical work in this thesis focussed on cognitive 
ability will address the key question: 
 
1) Do cognitive ability and health have some shared genetic aetiology? 
 
Empirical evidence for this question will be provided in Chapters 4 and 5, relating to: shared 
genetic aetiology of cognitive ability with mental and physical health in UK Biobank; and the 
genetic aetiology of executive function and its shared genetic aetiology with general cognitive 
ability. The next Chapter will provide a comprehensive introduction to the association between 





2. Negative emotions 
2.1. Unfolding the relation between emotions and disease 
Today’s science is in the process of understanding the relationship between emotions and 
health. Long before modern science started, philosophers and physicians already 
acknowledged an association between the way people feel (their mental health) and their 
physical health. One of the personality traits that is of great importance to public health is 
neuroticism, which is characterized by the tendency to experience negative emotions. 
Neuroticism is important to the public health, because it has been associated with a range of 
mental and physical health outcomes. These associations might contribute to the understanding 
of health inequalities in the population and this part of the introduction will therefore focus on 
the personality trait of neuroticism. First, a brief historical context will be presented on the 
different theories of personality, starting with Hippocrates’ and Galen’s theory of the four 
bodily humours and ending with Costa and McCrae’s Five Factor Model of personality. This 
will be followed by a brief discussion of the stability of the personality trait of neuroticism. 
Third, empirical work examining the association between neuroticism and health outcomes 
will be presented in the following order: cardiovascular disease, cardiovascular disease risk 
factors, mental health, and fatigue. The final part of this Section will discuss one of the 
proposed mechanisms underlying the associations between neuroticism and health; a shared 
genetic aetiology.  
 
2.2. A brief history 
2.2.1. The four bodily humours 
In the ancient Greek times, Hippocrates (460 – 370 BC) hypothesized that the four bodily 
fluids, blood, yellow bile, black bile, and phlegm, are the basis of human health. He proposed 
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that these four fluids, also called humours, produce perfect health when balanced. If 
unbalanced, for example, because of an excess of one of the fluids, it could lead do diseases 
and disabilities (Chadwick, 1983). Galen (130 – ~216 AD), a well-known philosopher and 
physician, continued the work five hundred years after Hippocrates and added the idea of 
temperament to the theory of bodily humours. Similar to Hippocrates, Galen hypothesized that 
excess of one of the bodily humours would not only lead to physical illness, but also to a 
certain type of personality. In Galen’s work ‘De Temperamentis’, he suggests that the four 
main personality types are sanguine, choleric, melancholic, and phlegmatic (Allport, 1961). 
The sanguine personality type is based on the humour of blood, with the heart being its main 
organ. People with this temperament tend to be lively, optimistic and carefree. An excess of 
yellow bile is associated with the choleric temperament, with the liver and gall bladder being 
its main organs. These people tend to be egocentric, analytical and passionate. The 
melancholic temperament is associated with an excess of black bile and the tendency of a 
lonely, introverted, and depressed personality. The main organ of this temperament is the 
spleen. The fourth temperament, phlegmatic, is associated with an excess of phlegm and forms 
the calm, reasonable and apathetic character. The brain is its main organ, which could reflect 
the lack of emotions in this temperament. Figure 2-1 displays the four bodily humours and the 
main personality types.  
 
Figure 2-1. Hippocrates and Galen’s theory of the four bodily humours. 
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The theory of the four bodily humours remained popular during the Renaissance, as shown in 
Burton’s ‘The Anatomy of Melancholy’ (Burton, 1621). The theory, however, was already in 
jeopardy during the time Burton wrote his book. Galen based his theory on anatomical 
assumptions, but he had never dissected a human body. His assumptions started to receive 
criticism in the 16th century due to the advances in anatomy by for example Andreas Vesalius. 
Vesalius’s book ‘De Humani Corporis Fabrica’ exposed a large range of mistakes in Galen’s 
anatomical assumptions. Due to the emergence of these new findings and the development of 
new medical techniques, emotions became more separate from diseases. This lead to the theory 
being rejected due to the lack of empirical support and it now only exists as a descriptive 
metaphor. 
 
2.2.2. Psychosomatic medicine 
The development of psychosomatic medicine expanded the theory that an individual’s 
personality could have an effect on the development of disease. Helen Flanders Dunbar (1943) 
suggested that different personality profiles were associated with different diseases. One 
example is the cardiac type of personality, which represents relentlessly ambitious and 
aggressive males with a tendency towards depression, that was associated with the 
development of coronary insufficiency. Dunbar acknowledged that many individuals who 
have traits that are part of Dunbar’s personality profiles, such as the cardiac type, are free of 
any illness. She argued that the diagnostic value of her personality profiles would be in the co-
occurrence of traits, meaning that one trait will likely not lead to cardiovascular disease, but 
multiple traits together might.  Franz Alexander (1950) focussed more on the emotional states 
and adjustments to the environment instead of the more superficial personality types suggested 
by Dunbar. He stated that “the true correlation may not be between personality make-up and 
coronary disease, but between the mode of living and disease” (Alexander, 1950, p. 73). 
Disturbance of the personality make-up, for example by mode of living, could lead to 
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disturbance of a bodily organ, which is somewhat similar to the theory of the four humours 
described in an earlier part of this Chapter. Asthma would, for example, be linked to an 
unconscious desire to be protected by a mother, also named separation anxiety, while ulcers 
would be caused by the unconscious desire to have infantile needs satisfied.  Following this 
idea, Alexander (1950) and Dunbar (1943) identified the Holy Seven Psychosomatic Diseases, 
which included bronchial asthma, hypertension, thyrotoxicosis, peptic ulcer, neurodermatitis, 
bronchial asthma and rheumatoid arthritis. The discovery of the Helicobacter pylori bacteria 
by Marshall and Warren (1984) was one of the findings that contributed to the theory of the 
psychosomatic illnesses being abandoned, as this bacterium was found to be an important 
factor in the development of ulcers. It is important to note, though, that the presence of the 
Helicobacter pylori bacteria does not necessarily lead to ulcers. Individuals differ in the way 
they experience symptoms and in the effects of stress on the body. Instead of ulcers being 
caused purely by psychosomatic factors, it is more likely that interplay of both psychosocial 
and physical factors could lead to the development of ulcers.  
 
2.2.3. Friedman & Rosenman: The A, B, and C personality types 
Two cardiologists, Meyer Friedman and Ray Rosenman, further explored the relationship 
between cardiovascular disease and personality in the 1950s. In their paper (Friedman & 
Rosenman, 1959), they selected three groups of males according to three specific overt 
behaviour patterns. The first pattern, Type A, was characterised by a drive for achievement, 
sense of urgency and an eagerness to compete. Type B, the second pattern, was the opposite 
of Type A and characterised by a lack of ambition, competitiveness, and drive. The third 
behaviour pattern, Type C, was very similar to Type B, but also included a chronic state of 
anxiety. Friedman and Rosenman examined if there was an association between the three types 
of behaviour and measures of cardiovascular disease, which included clotting time, serum 
cholesterol and clinical diagnoses of cardiovascular disease, diagnosed using an 
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electrocardiogram. All males in the study were aged between 30 and 60 years. They found that 
males in the Type A group had significantly higher cholesterol levels (253 mg/100 ml) 
compared to males in the Type B group (215 mg/100 ml) and the Type C group (220 mg/100 
ml). Fully developed, showing a complete behavioural pattern, Type A males had a 
significantly faster clotting time (6.8 minutes) compared to fully developed males in the Type 
B (7.2 minutes) or Type C (7.4 minutes) groups. Similarly, 28% of males in the Type A group 
showed signs of cardiovascular disease, while only 4% of males in the Type B and C group 
showed signs of cardiovascular disease. These results did not attenuate when adjusting for 
confounding factors such as diet, alcohol intake, smoking or exercise. Similar to Dunbar, 
Friedman and Rosenman concluded that males with Type A personality were prone to 
cardiovascular disease.  While these studies did show an association between type A 
personality and cardiovascular disease, later studies have failed to replicate these findings 
(Gallacher, Sweetnam, Yarnell, Elwood, & Stansfeld, 2003; Myrtek, 2001; Ragland & Brand, 
1988; Šmigelskas, Žemaitienė, Julkunen, & Kauhanen, 2015). A large meta-analysis (Myrtek, 
2001), including over 74,000 individuals, reported a correlation of 0.003 and concluded that 
the effect of the association between type A personality and cardiovascular mortality is 
negligible. A more recent study (Šmigelskas et al., 2015) supported these findings and showed 
inconsistent results between different measures of type A personality and cardiovascular 
mortality, some measures showed a decreased risk, while others showed an increased risk of 
cardiovascular mortality. The authors conclude that there is no clear association between type 
A personality and cardiovascular mortality, and if there were to be an association this would 
likely be due to sample and study specific factors. 
 
2.3. Trait theories 
The next Section of this Chapter will discuss trait theories of personality. According to these 
trait theories, personality is formed by the combination and interaction of different traits. The 
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personality trait theories have two important underlying assumptions; traits are stable over 
time, and traits directly influence behaviour (Matthews, Deary, & Whiteman, 2009). 
 
2.3.1. Eysenck’s three-factor theory 
A biological theory of personality was developed by H. J. Eysenck (1967), he used factor 
analysis (H. J. Eysenck, 1947), to identify two personality factors; extraversion and 
neuroticism. Extraversion is characterised by the tendency to enjoy positive events, while 
neuroticism is characterised by the tendency to experience negative emotions. Later Eysenck 
added a third trait to his model, psychoticism. Individuals who score high on this trait are 
characterised by “cold, impersonal, lacking in sympathy, unfriendly, untrustful, odd, 
unemotional, unhelpful, antisocial, lacking in insight, strange, with paranoid ideas that people 
were against him” (H. J. Eysenck & Eysenck, 1976, p. 47). 
 
Eysenck hypothesised that the individual differences in personality are caused by biological 
factors, specifically by differences in the levels of arousal of two brain systems, i.e. the 
reticulo-cortical and the reticulo-limbic system (H. J. Eysenck, 1967; H. J. Eysenck & 
Eysenck, 1985). The reticulo-cortical system determines the levels of emotion, motivation and 
conditioning, depending on the arousal of the cerebral cortex. Eysenck argued that changes in 
this system are associated with individual differences in extraversion, while changes in the 
reticulo-limbic system are associated with individual differences in neuroticism. The arousal 
of the reticulo-limbic system could lead to the experience of intense emotions, such as anxiety. 
Eysenck suggested that the dopamine neurotransmitter, responsible for the regulation and 
experience of emotions, might cause individuals differences in psychoticism. Eysenck’s 
theory has greatly influenced the study of individual differences, but due to, among other 
things, its biological complexity, the theory has not been able to withstand the scientific 
empirical examinations (M. W. Eysenck, 2016; Matthews, 2016). 
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2.3.2. Five-factor model 
While Eysenck’s three-factor model focussed on the broad personality traits, Raymond Cattell 
focussed on narrower, supposedly underlying traits. His work was based on Allport and 
Odbert’s list of English trait names (Allport & Odbert, 1936). They found over 19,000 words 
to describe psychological aspects of differences in individuals. Cattell argued that different 
words often describe the same trait, he reduced this list to 4500 words and identified 16 so-
called primary personality factors (Cattell, 1943a, 1946). These 16 factors can be reduced to 
fewer broader dimensions, i.e. extraversion, anxiety/neuroticism, tough poise, independence, 
and control, with the first two lining up with Eysenck’s extraversion and neuroticism 
personality factors (Krug & Johns, 1986). The main criticism of Cattell’s theory is that is too 
complex and a total of five factors can be used to describe much of personality variation (Fiske, 
1949; Norman, 1963). 
 
The most-used model of personality today is the five-factor model, first developed by Tupes 
and Christal (1961) and followed up by Norman (1963). This model is, as is Cattell’s sixteen 
personality factor model, based on the lexical hypothesis. Tupes and Christal (1961) showed 
five factors that underlie the personality structure, based on eight different samples, which also 
included Cattell’s original samples. They named the personality factors surgency/extroversion, 
agreeableness, dependability, emotional stability, and culture. A later study by Norman (1963) 
showed similar results, but he renamed the dependability factor to conscientiousness. The most 
commonly used names for the five personality factors, as proposed by Costa and McCrae 
(1992), are neuroticism, extraversion, openness to experience, agreeableness, and 
conscientiousness. Costa and McCrae (1976) first identified the factors of neuroticism and 
extraversion based on cluster analysis of Cattell’s 16 personality factors, as well as a third 
factor that, after adding more items to the analysis, was named openness to experience (Costa 
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& McCrae, 1978). They decided that each factor should be represented by six behavioural 
traits, called facets, as shown in Table 2-1. Later they also added the factors of agreeableness 
and conscientiousness, which completed the five factor model. The factors of neuroticism and 
extraversion were based on the personality model of Cattell, but they can be traced back even 
further, particularly neuroticism, to 1925, where it has been used in different personality scales 
(I. J. Deary & Bedford, 2011; Guilford & Guilford, 1939; Laird, 1925; Thurstone & Thurstone, 
1930). Neuroticism can be described as the tendency to experience negative emotions, with at 
the high end of the dimension, a greater likelihood of experiencing feelings of anxiety and 
depression, and on the low-end emotional stability. The dimension of extraversion describes 
the experience of sociability and impulsiveness on the high end, whilst the low end, also called 
introversion, is characterised by shy and quiet behaviour. The third dimension, openness to 
experience, is the tendency to engage in intellectual activities and new experiences on the high 
end, in contrast to conservative behaviour on the low end. Agreeableness is characterised by 
trusting and compliant behaviour on the high end of the dimension, versus stubbornness and 
independence on the low end. The high end of the final dimension of the five-factor model, 
conscientiousness, is characterised by being well-organized and responsible, compared to the 
low end, which is characterised by a tendency to be disorganised and careless. Table 2-1 shows 










Table 2-1. Trait facets associated with five personality traits as proposed by 
Costa and McCrae’s Five Factor model 
Trait Trait facets 
Openness to experience Fantasy, aesthetics, feelings, actions, 
ideas, values 
Conscientiousness Competence, order, dutifulness, 
achievement striving, self-discipline, 
deliberation 
Extraversion Warmth, gregarious, assertive, activity, 
excitement seeking, positive emotion 
Agreeableness Trust, straightforward, altruism, 
compliant, modesty, tenderminded 
Neuroticism Anxiety, angry hostility, depression, self-
conscious, impulsive, vulnerable 
 
2.4. Stability, age and sex differences 
Many studies have examined the longitudinal stability of neuroticism, and have shown that its 
stability increases with age (B. W. Roberts & Delvecchio, 2000). However, mean neuroticism 
scores increase from adolescence into adulthood, peaking in late adolescence, and show a 
steady decline through midlife (Donnellan & Lucas, 2008; Lucas & Donnellan, 2009; B. W. 
Roberts & Mroczek, 2008; Soto, John, Gosling, & Potter, 2011; Terracciano, McCrae, Brant, 
& Costa, 2005). Figure 2-2 shows the age and sex distribution of neuroticism scores in a study 
of approximately 1.2 million individuals aged between 10 and 60 years (Soto et al., 2011). 
Soto et al. (2011) used T-scores to quantify the differences between males and females, which 
are standardized scores with a mean of 50 and a SD of 10. A 5 T-score point difference between 
males and females was found in mid-adolescence, which indicates a medium effect based on 
Cohen’s guidelines for interpreting effect sizes (J. Cohen, 1988). This effect attenuated to a 2 
T-score point difference, a small effect, in later life. Females have consistently been reported 
to score higher on neuroticism than males (Costa, Terracciano, & McCrae, 2001; Soto et al., 
2011), which is in line with the idea that females are diagnosed more often with disorders 
related to negative emotions, such as major depressive disorder, anxiety disorder, and panic 
disorder (N. R. Eaton et al., 2012). Costa et al. (2001) showed that sex differences in 
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neuroticism are strongest in European and American cultures, with differences in z-scores 
between males and females ranging from 0.42 to 0.75, and weakest in Asian and African 
cultures where the z-scores ranged from -0.02 to 0.40. They argued that the differences in 
neuroticism are seen in all cultures, but that these differences could be attributed to gender 
roles instead of personality traits in traditional cultures, such as the African and Asian cultures. 
 
Figure 2-2. Means for overall Neuroticism by age and gender, based on T-
scores with a mean of 50 and a SD of 10. Single lines show the means for 
males, and double lines show the means for females. Reprinted with 
permission from Soto et al. (2011). Copyright 2011 by American 
Psychological Association.  
 
One of the key assumptions of personality trait theories is that personality traits directly 
influence behaviour (G. Matthews et al., 2009). It is therefore conceivable that personality 
traits are associated with morbidity and mortality. As mentioned earlier, due to the public 
health significance of neuroticism, the main aim of this part of the Thesis is the association 
between negative emotions, specifically neuroticism, and health; therefore, the next part of 
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this Thesis will provide an overview of the associations between the personality trait of 
neuroticism and health, and discuss potential mechanisms underlying these associations. 
 
2.5. Negative emotions and health 
2.5.1. Cardiovascular disease 
Negative emotions and health have been linked together since Hippocrates and Galen’s theory 
of the four bodily humours; one of the most studied associations between personality and 
health is the association with cardiovascular disease. Multiple studies have examined the 
association between negative emotions (including anger, anxiety, and depression) and 
cardiovascular disease, and found consistent evidence between higher levels of negative 
emotions and a higher risk of cardiovascular disease (Booth-Kewley & Friedman, 1987; 
Kubzansky & Kawachi, 2000). When focussing on the more specific personality trait of 
neuroticism, similar results were found, but with an important distinction. Paul Costa (1987) 
for example, examined the association between neuroticism, angina and coronary artery 
disease, in a sample of approximately 7000 individuals who had received a detailed medical 
examination as part of the National Health and Nutrition Examination Survey (NHANES1) 
Epidemiologic Follow-up Study. He found that individuals who reported more chest pain had 
higher levels of neuroticism, but he did not find an association between increased mortality 
due to myocardial infarction and neuroticism levels. Similar results were found by Watson and 
Pennebaker (1989), who showed consistent correlations between higher levels of neuroticism 
and more health complaints, but no association with coronary artery diseases, and suggested 
neuroticism to be “a more general trait of somatopsychic distress” (Watson & Pennebaker, 
1989, p. 248). More recent studies have, however, shown associations between neuroticism 
and cardiovascular disease (Jokela, Pulkki-Råback, Elovainio, & Kivimäki, 2014b; Shipley, 
Weiss, Der, Taylor, & Deary, 2007). For example, Jokela et al. (2014b) found, in an individual-
participant meta-analysis of just under 25,000 individuals, that higher neuroticism was 
75
associated with coronary artery disease mortality, 1 SD change in neuroticism was associated 
with a 16% risk increase for coronary artery disease mortality (HR 1.16, 95% CI = 1.04 – 
1.29). They suggested that neuroticism and coronary artery disease might be linked via 
physiological pathways, for example by activation of the hypothalamic-pituitary-
adrenocortical (HPA) axis, which has been linked to risk factors for cardiovascular disease, 
including the metabolic syndrome, decreased heart rate variability, and atherosclerosis. Čukić 
and Bates (2015) showed that higher neuroticism was associated with decreased heart rate 
variability, which was independent of cardiovascular disease diagnosis. This supports the 
hypothesis that neuroticism and cardiovascular disease might be linked via physiological 
pathways. 
 
2.5.2. Cardiovascular risk factors 
2.5.2.1. Type 2 diabetes 
Type 2 diabetes, obesity, hypertension, and smoking are major risk factors for cardiovascular 
disease and have also been linked to neuroticism. Personality traits could play an important 
role in the development of type 2 diabetes, but the results for an association between 
neuroticism and type 2 diabetes have been inconsistent. Goodwin, Cox, and Clara (2006) 
found an association between higher levels of neuroticism (1 SD above the mean) and 
increased likelihood of diabetes in a sample of around 6000 individuals, which remained 
significant after adjusting for both sociodemographic factors and psychiatric disorders. 
Individuals with high neuroticism had a three times higher risk of a diabetes diagnosis (OR = 
3.00, 95% CI = 1.62 – 5.58), when the model was unadjusted. After adjusting for 
sociodemographic factors and psychiatric disorders, this increased to a 3.33 times higher risk 
for diabetes diagnosis (OR = 3.33, 95% CI = 1.57 – 7.04). In the same year, another study was 
published by Goodwin and Friedman (2006), which examined the association between 
neuroticism and diabetes in the Midlife Development in the United States (MIDUS) survey, 
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including a total of 3032 individuals. This study did not find any association between diabetes 
and neuroticism. It is important to note that in both studies the type of diabetes was not 
specified and diabetes diagnosis was based on self-report. A pooled analysis of five cohort 
studies, including 34,913 diabetes-free individuals (Jokela et al., 2014a), did not provide 
consistent evidence for an association between self-reported diabetes and neuroticism; only 
one of five cohorts showed that higher neuroticism was associated with diabetes diagnosis. 
More recently, Čukić, Mõttus, Realo, and Allik (2016) examined the association between 
diabetes, measured using a combination of self-report and medical records confirming 
diagnosis, and neuroticism, measured by both self-report based ratings and informant-based 
ratings. Significant associations were found between higher levels of neuroticism and 
diagnosis of diabetes using the self-report based personality ratings (OR = 1.20, 95% CI = 
1.01 – 1.42), but not when using the informant based personality ratings (OR = 1.13, 95% CI 
= 0.95 – 1.35). Eriksson et al. (2008) examined the association between psychological distress 
and type 2 diabetes. Psychological distress was measured by a Likert-scale questionnaire 
asking about the prevalence of symptoms of fatigue, anxiety, apathy, insomnia, and depression 
in the past year. The answers were summed and divided in quartiles, the two median quartiles 
were combined leading to three different groups of psychological distress (low, middle, and 
high). The results showed that high psychological distress was associated with both pre-
diabetes (OR = 1.90, 95% CI = 1.20 – 2.80) and type 2 diabetes (OR = 2.20, 95% CI = 1.20 – 
4.10) in males, and middle psychological distress with pre-diabetes only (OR = 1.80, 95% CI 
= 1.10 – 3.00) in females, after adjusting for age, BMI, family history of diabetes, smoking 
status, physical activity and socio-economic status. Pre-diabetes was defined as impaired 
fasting glucose and impaired glucose tolerance using an oral glucose tolerance test. In males, 
symptoms of fatigue were on its own also associated with both pre-diabetes and type 2 diabetes 
(OR = 1.80, 95% CI = 1.10 – 2.90). A study of just under a 1000 non-diabetic individuals 
found that neuroticism interacts with BMI to predict both insulin levels and insulin resistance 
(Tsenkova, Carr, Coe, & Ryff, 2012). This indicates that psychological distress, acting 
77
together with BMI, could have an effect on the progression to disease. While some of the 
studies discussed in this Section did report an association between neuroticism and diabetes, 
others did not find such an association. 
 
2.5.2.2. BMI 
A second major risk factor for cardiovascular disease is obesity, and a growing body of 
evidence is showing an association between neuroticism and body weight (Armon, Melamed, 
Shirom, Shapira, & Berliner, 2013; Gerlach, Herpertz, & Loeber, 2015; Magee & Heaven, 
2011; Sutin & Terracciano, 2016). Magee and Heaven (2011) examined this association in 
about 5200 Australian individuals and found that neuroticism was positively correlated with 
BMI. Regression models showed that neuroticism and obesity were positively associated (OR 
= 1.13, 95% CI = 1.03 – 1.24). They did not find an association between neuroticism and 
changes in body weight over a two-year period. A large cross-sectional individual-participant 
meta-analysis of 78,931 individuals did show an association between neuroticism and BMI in 
the European and Australian cohorts, but not in the American cohorts (Jokela et al., 2013). 
The overall association was non-significant. Armon et al. (2013) found significant associations 
between neuroticism and three measures of body weight, i.e. BMI (β = 0.05), waist-hip ratio 
(β = 0.05), and waist circumference (β = 0.06), at baseline. They also found an association 
between neuroticism and weight increase over a four-year period, one that was stronger in 
females compared to males. In females, all three measures showed a significant association 
between neuroticism and weight increase, with β’s between 0.06 – 0.12. In males, only change 
in waist-hip ratio showed a significant association with neuroticism, with a β of 0.06. This 
finding could explain some of the inconsistencies of the associations between neuroticism and 
body weight. Several studies have indicated that the effects of the association between 
neuroticism and body weight could be moderated by gender. Faith, Flint, Fairburn, Goodwin, 
and Allison (2001) showed that increased neuroticism was associated with increased BMI in 
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females only (β = 0.08). These results were supported by the University of North Carolina 
Alumni Heart Study (UNCAHS), which showed positive correlations between neuroticism 
and BMI in females, but not in males (Brummett et al., 2006). Females in the upper half of the 
neuroticism distribution weighed approximately 5 kg (1.9 kg/m2) more than females in the 
lower half of the neuroticism distribution. Brummett et al. (2006) suggested that the greater 
stigma of obesity could be causing the sex differences, with higher levels of neuroticism 
leading to poorer health choices, such as overeating and physical inactivity. This is supported 
by Sutin and Terracciano (2016) who suggest that higher levels of neuroticism in females 
might lead to emotional eating that contributes to excess weight. Taken together, all these 
studies show that higher neuroticism is associated with higher BMI. 
 
2.5.2.3. Blood pressure 
Hypertension is a third major risk factor for cardiovascular disease, and multiple studies have 
examined the association of hypertension with neuroticism (Cheng, Montgomery, Treglown, 
& Furnham, 2016; Goodwin et al., 2006; Turiano et al., 2012). Goodwin et al. (2006) used 
data from the National Comorbidity Survey and showed a positive association between 
individuals with high neuroticism levels and self-reported hypertension status. This 
association remained significant after adjusting for sociodemographic measures, including 
age, sex, socio-economic status, race and marital status, after adjusting for psychiatric 
disorders the association became non-significant. This was supported by Turiano et al. (2012) 
who examined the association between neuroticism and self-reported blood pressure, which 
was measured by asking participants if their blood pressure was low, normal, slightly raised 
or high at their last doctor’s visit. They found that higher neuroticism levels predicted higher 
blood pressure status (β = 0.05). Results from the National Child Development Study also 
showed positive associations between neuroticism and self-reported hypertension status, 1 SD 
increase in neuroticism was associated with a 15 % higher risk of hypertension (OR = 1.15, 
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95% CI = 1.09 – 1.23) (Cheng et al., 2016). It is important to note that the three previously 
discussed studies used self-report measures for blood pressure and hypertension, which could 
cause a bias towards the null hypothesis, due to misclassification of the diagnosis (Tenkorang, 
Sedziafa, Sano, Kuuire, & Banchani, 2015). Bibbey, Carroll, Roseboom, Phillips, and de Rooij 
(2013) measured blood pressure at baseline and after three acute psychological stress tasks, to 
examine the association between neuroticism and blood pressure stress reactivity. Blood 
pressure stress reactivity was defined as the difference between blood pressure after the stress 
tasks and blood pressure at baseline. The results showed that higher neuroticism was 
associated with lower blood pressure stress reactivity (β between -0.12 and -0.16). This 
supports the findings using the self-report measures of blood pressure and hypertension, 
indicating that higher neuroticism is associated with higher blood pressure. Overall, studies 
using both self-reported measures and physical measures indicate a positive association 
between neuroticism and blood pressure. 
 
2.5.2.4. Smoking 
The final cardiovascular risk factor to be discussed in this Section is smoking. The harmful 
effects of smoking are well known and previous research has identified multiple psychological 
and social risk factors for smoking, including individual differences in neuroticism (Hakulinen 
et al., 2015b; Munafò, Zetteler, & Clark, 2007; Terracciano & Costa, 2004; Zvolensky, Taha, 
Bono, & Goodwin, 2015). A study of 1638 individuals, who were part of the Baltimore 
Longitudinal Study on Aging (BLSA), found that current smokers had higher levels of 
neuroticism than individuals who had never smoked (F (2,1635) = 17.77) (Terracciano & 
Costa, 2004). This finding has been replicated by both longitudinal and cross-sectional studies. 
A meta-analysis of 25 studies including over 47,000 individuals reported that increased 
neuroticism was associated with an increased likelihood of being a smoker compared to not 
smoking (Cohen’s d = 0.12, 95% CI = 0.04 – 0.20) (Munafò et al., 2007). Zvolensky et al. 
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(2015)  examined the association between neuroticism and different smoking outcomes over 
a period of 10 years in a sample of 2101 individuals from the MIDUS survey. They found an 
association between neuroticism and lifetime cigarette use (OR = 1.20, 95% CI = 1.10 – 1.40), 
progression to daily smoking (OR = 1.30, 95% CI = 1.10 – 1.50), and persistence of daily 
smoking (OR = 1.30, 95% CI = 1.10 – 1.60). The most recent and largest study to date 
examining the association between smoking and neuroticism was a cross-sectional and 
longitudinal individual-participant meta-analysis including 79,757 individuals with a mean 
follow-up time of 5.2 years (Hakulinen et al., 2015b). Using the cross-sectional data, the study 
showed that higher neuroticism was associated with higher risk of smoking (OR = 1.19, 95% 
CI = 1.13 – 1.26) and an increased likelihood of being an ex-smoker (OR = 1.13, 95% CI = 
1.07 – 1.19). Longitudinal analyses indicated that higher neuroticism was associated with 
higher odds of smoking relapse among ex-smokers (OR = 1.16, 95% CI = 1.04 – 1.30) as well 
as lower odds of quitting smoking among baseline smokers (OR = 0.91, 95% CI = 0.87 – 0.96). 
The authors suggest that smoking might be a strategy to reduce tension and anxiety among 
individuals with high neuroticism (Hakulinen et al., 2015b). While the effects in the above 
discussed studies might be relatively small, the consistently reported association between 
neuroticism and smoking is of great importance, due to the large number of people that smoke 
(Orchard, 2016). These findings highlight the importance of neuroticism in smoking behaviour 
and may help to enhance knowledge about smoking behaviour and improve smoking 
prevention and cessation programs.  
 
2.5.3. Mental health 
There is strong evidence that neuroticism and different mental disorders are associated across 
the lifespan. A meta-analysis, including 33 studies, showed strong associations between 
neuroticism and different mental disorders (Malouff, Thorsteinsson, & Schutte, 2005). The 
strongest association was found between neuroticism and mood disorders, with a Cohen’s d 
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of 1.54. These results were supported by a larger meta-analysis, including 175 studies, 
showing that mood disorders, anxiety disorders, and substance use disorders were all 
characterized by high neuroticism levels (Kotov, Gamez, Schmidt, & Watson, 2010). The 
meta-analysis by Malouff et al. (2005) found that the strongest association was between 
neuroticism and mood disorders in general (Cohen’s d = 1.54, 95% CI = 1.21 – 1.86), whilst 
Kotov et al. (2010) showed stronger effects for the association between neuroticism and 
dysthymia (Cohen’s d = 1.93, 80% credibility interval = 1.01 – 2.84), compared to the 
association between neuroticism and major depressive disorder (Cohen’s d = 1.33, 80% 
credibility interval = 0.44 – 2.23). Dysthymia is a chronic form of depression, while major 
depressive disorder could include individuals who have only been diagnosed with a single 
episode of depression (W. W. Eaton et al., 2008). The finding that the association with a more 
chronic form of depression is stronger than major depressive disorder, could implicate that the 
chronic nature of a disorder is associated with the extremity of neuroticism levels. 
 
Elovainio et al. (2015) examined the longitudinal association between negative affect, as 
measured by the Emotionality-Activity-Sociability (EAS) Temperament Survey, and 
depressive symptoms in a sample of 1739 individuals who were part of the Cardiovascular 
Risk in Young Finns Study with a follow-up time of 15 years. The negative affect part of the 
EAS has been shown to be highly similar to the personality trait of neuroticism (Braithwaite, 
Duncan-Jones, Bosly-Craft, & Goodchild, 1984). Negative affect at baseline significantly 
predicted depressive symptoms at follow-up (β = 0.34, 95% CI = 0.29 – 0.40). However, this 
effect was attenuated to 0.04 (95% CI = -0.03 – 0.10) after adjusting for depressive symptoms 
at baseline. Baseline depressive symptoms were also predictive of negative affect at follow-
up (β = 0.41, 95% CI = 0.36 -0.45), and this association was robust to adjustment for baseline 
negative affect (β = 0.11, 95% CI = 0.05 – 0.17). These findings were supported by Hakulinen 
et al. (2015a) who performed similar analysis in an individual-participant meta-analysis of 10 
studies including a total of 117,899 individuals with a follow-up time of 5 years. Cross-
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sectional analysis showed an association between neuroticism and depressive symptoms (β = 
0.39, 95% CI = 0.32 – 0.45). Longitudinal analysis indicated that higher neuroticism was 
associated with depressive symptoms at follow-up (β = 0.12, 95% CI = 0.10 – 0.13). To test 
for reverse causality, the association between baseline depressive symptoms and neuroticism 
at follow-up was examined, and the results showed that depressive symptoms at baseline were 
associated with higher neuroticism at follow-up (β = 0.23, 95% CI = 0.09 – 0.36). Both 
longitudinal models were adjusted for either depressive symptoms at baseline, or neuroticism 
at baseline. Together with the findings from Elovainio et al. (2015), this large meta-analysis 
suggests a reciprocal relationship between neuroticism and depressive symptoms, where both 
traits affect each other, leading to a negative spiral of increased risk for depressive symptoms 
and psychological vulnerability to depressive symptoms.  
 
A longitudinal study, using data from the Finnish Hospital Discharge Register, examined the 
association between premorbid personality and later risk of schizophrenia or bipolar disorder 
(Lönnqvist et al., 2009). The results showed that each standard deviation increase in 
neuroticism was associated with a 26% increase in risk for schizophrenia (OR = 1.26, 95% CI 
= 1.19 – 1.34), after adjusting for birth year, test year, age at testing, and intelligence. No 
significant associations were found between neuroticism and bipolar disorder. The authors 
note that individuals who are hospitalized with a bipolar disorder diagnosis represent the most 
severe cases of the disorder. Many patients with bipolar disorder are unlikely to be 
hospitalized. Other studies have shown inconsistent results when examining the association 
between neuroticism and bipolar disorder (Akiskal et al., 2006; M. V. Christensen & Kessing, 
2006; Jylhä et al., 2010). M. V. Christensen and Kessing (2006) showed that there was no 
association between neuroticism and bipolar disorder, while Akiskal et al. (2006) showed that 
individuals with bipolar disorder have significantly higher neuroticism scores compared to 
controls. This is supported by the findings from Jylhä et al. (2010), who showed that both 
individuals diagnosed with bipolar disorder or major depressive disorder had significantly 
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higher neuroticism scores than the general population. No differences in neuroticism scores 
were found between individuals diagnosed with bipolar disorder or major depressive disorder. 
This suggests that neuroticism might indicate vulnerability for mood disorders in general, 
including both bipolar disorder and major depressive disorder. 
 
Kotov et al. (2010) argued that individual differences in neuroticism might be the key to 
understanding comorbidity amongst mental disorders, as neuroticism has been shown to be 
associated with different mental disorders (Malouff et al., 2005). Khan, Jacobson, Gardner, 
Prescott, and Kendler (2005) showed that neuroticism accounted for an average of 26% of the 
pair-wise comorbidity between mental disorders (range between 12 – 88%), which included 
major depressive disorder, anxiety disorder, panic disorder, substance use disorder, and 
personality disorders. Similar results were found when examining comorbidity for both mental 
and physical disorders, where neuroticism accounted for a substantial proportion of the 
comorbidity within mental disorders and within physical disorders (Neeleman, Ormel, Bijl, 
Neeleman, & Ormel, 2001). 
 
2.5.4. Fatigue 
Watson and Pennebaker (1989) have suggested that neuroticism is a measure of psychological 
distress, and several studies have shown that individuals who report more psychological 
distress, are more likely to experience medically unexplained symptoms and disorders (I. J. 
Deary, 1999; I. J. Deary, Scott, & Wilson, 1997), such as fatigue (De Gucht, Fischler, & 
Heiser, 2004; Henningsen, Zimmermann, & Sattel, 2003). For example, De Gucht et al. (2004) 
showed that negative affect is the strongest determinant of symptom evolution and persistence 
in patients who reported medically unexplained symptoms, including fatigue. A meta-analytic 
review showed that chronic fatigue syndrome was characterised by two measures of 
psychological distress, i.e. depressive symptoms and anxiety (Henningsen et al., 2003). 
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Buckley et al. (1999) examined personality in a small study including 30 patients with chronic 
fatigue, 20 patients with major depressive disorder, and 15 healthy controls, and found 
increased levels of neuroticism in both patients with major depressive disorders and chronic 
fatigue syndrome, compared to the healthy controls. A study examining the association 
between personality and fatigue symptoms found that neuroticism and fatigue are strongly 
related, individuals who scored higher on neuroticism reported more fatigue symptoms (De 
Vries & Van Heck, 2002). These findings are supported by other studies examining the 
association between neuroticism and fatigue, reporting higher levels of neuroticism in 
individuals with fatigue symptoms (V. Deary & Chalder, 2010; Taillefer, Kirmayer, Robbins, 
& Lasry, 2003; Tobback et al., 2016). All these studies indicate that psychological distress, as 
measured by neuroticism, is associated with fatigue. As shown by Henningsen et al. (2003), 
depression is also a common factor associated with fatigue, and some of the symptoms in 
chronic fatigue syndrome are similar to major depressive disorder symptoms (van Geelen, 
Sinnema, Hermans, & Kuis, 2007). Valero, Sáez-Francàs, Calvo, Alegre, and Casas (2013) 
examined the associations between neuroticism, depressive symptoms, and fatigue using 
structural equation modelling. They found that the effect of neuroticism on fatigue was 
mediated by depressive symptoms. Most studies examining the association between 
neuroticism and fatigue have a cross-sectional design, which means that their ability to unravel 
the direction of association between neuroticism and fatigue is limited. Two longitudinal 
studies using the Swedish Twin Registry Study, which comprises all twin births in Sweden 
since 1886 (Lichtenstein et al., 2002), showed that higher premorbid neuroticism levels were 
associated with both reporting more fatigue symptoms (Charles, Gatz, Kato, & Pedersen, 
2008) and higher risk of chronic fatigue syndrome (Kato, Sullivan, Evengård, & Pedersen, 
2006) after a follow-up time of 25 years. Each standard deviation increase in neuroticism was 
association with 55 – 72%  increase in risk of chronic fatigue syndrome in an unselected 
population. This effect was slightly attenuated when analysing monozygotic and dizygotic 
twins, but remained significant, the effect became non-significant when analysing 
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monozygotic twins only. The authors suggest that this implicates that the associations between 
neuroticism and fatigue could be due to a shared genetic background. 
 
2.5.5. Neuroticism and health mechanisms 
Given the robust association between neuroticism and health outcomes, it is important to 
understand and discover potential mechanisms underlying this association. While multiple 
different mechanisms have been proposed (Figure 2-3), this Section will focus on health 
behaviours, physiological responses, and a shared biological background, as indicated by the 
second and third causal models in Figure 2-3.  
 
 
Figure 2-3. Four causal models for associations between neuroticism and 
health. Adapted with permission from G. Matthews et al. (2009). Copyright by 
Cambridge University Press (2009). 
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As personality traits are directly linked to behaviour (G. Matthews et al., 2009), it is possible 
that certain health-promoting or health-harming behaviours associated with prior personality 
dispositions thereafter directly affect health, thereby mediating the association between 
neuroticism and health. Previous research has indicated that individuals with higher 
neuroticism are more likely to smoke (Hakulinen et al., 2015b) or suffer from substance use 
disorders (Larkins & Sher, 2006), which could lead to increased risk of developing 
cardiovascular risk factors, cardio-metabolic diseases, or cancer (Lahey, 2009). High 
neuroticism has also been linked to a lack of physical activity (Wilson & Dishman, 2015). As 
discussed in Section 2.5.3, high neuroticism predisposes individuals to increased risk of 
developing mental health disorders, which could be improved by physical activity. Individuals 
with higher neuroticism are more likely to engage in unhealthy eating habits (T. W. Smith & 
MacKenzie, 2006), which increases risk for higher body weight (Torres & Nowson, 2007), in 
itself a strong risk factor for cardio-metabolic diseases. This indicated that health behaviours 
could potentially mediate the association between neuroticism and health. Formal tests have 
shown that mediation by health behaviours only explains a small part of the association 
between neuroticism and health (Chapman, Fiscella, Kawachi, & Duberstein, 2010; Mroczek, 
Spiro, & Turiano, 2009; Weiss, Gale, Batty, & Deary, 2009), suggesting that other processes 
might underlie the association between neuroticism and health 
 
The experience of psychological stress has been linked to the activation of the HPA axis (S. 
Cohen, Janicki-Deverts, & Miller, 2007). Previous research has provided some evidence that 
the physiological responses to stress are moderated by neuroticism (Evans et al., 2016; Norris, 
Larsen, & Cacioppo, 2007). Activation of the HPA axis leads to the release of classical stress 
hormones such as adrenaline, noradrenaline, and cortisol. Chronic stress exposure could have 
damaging effects on the HPA axis, as cortisol regulates various physiological processes, 
including anti-inflammatory responses, metabolism of carbohydrates, fats, and proteins, and 
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gluconeogenesis. Stress could therefore lead to an increase in body fat and insulin resistance 
(Kyrou, Chrousos, & Tsigos, 2006). 
 
Health behaviours and physiological responses to stress might partly explain the associations 
between neuroticism and health outcomes. The spectrum model, used in depression research, 
hypothesized that high neuroticism and depression cover similar constructs with different 
names, also called a ‘jangle’ fallacy (Kelley, 1927). The robust association of neuroticism, not 
just with depression, but also with other indicators of negative emotions such as fatigue and 
anxiety, suggests that all these traits represent a general state of psychological distress, which 
could partly be influenced by an underlying biological background. The next Section will 
discuss the potential shared genetic aetiology of neuroticism and health. 
 
2.6. Negative emotions and health: genetics 
Several mechanisms have been proposed to explain the relationship between neuroticism and 
health outcomes, as discussed in Section 2.5.5 of this Chapter. This thesis will focus on the 
shared genetic aetiology between negative emotions and health, to better understand the 
pathways between health and disease. But before we can discuss the shared genetic aetiology 
it is important to understand the genetic aetiology of neuroticism itself. This Section of Chapter 
2 will therefore start by discussing the genetic aetiology of neuroticism using twin studies, 
SNP based studies, and association analyses. This will be followed by the shared genetic 
aetiology between neuroticism and health outcomes. The theoretical background of the 
different techniques used in these studies was outlined in Section 1.3. 
 
2.6.1. Genetic aetiology of neuroticism 
The field of behavioural genetics has produced many studies on the heritability of neuroticism 
(Birley et al., 2006; Bouchard & Loehlin, 2001; Hahn, Johnson, & Spinath, 2013; Keller, 
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Coventry, Heath, & Martin, 2005; Vukasović & Bratko, 2015; Wray, Birley, Sullivan, 
Visscher, & Martin, 2007) and has shown the heritability to be around 40%. A large meta-
analysis of 113,452 individuals from 62 independent studies showed that 39% of the variance 
in neuroticism was due to genetic effects, using both the Five Factor Model and Eysenck’s 
personality framework (Vukasović & Bratko, 2015). No evidence was found for differential 
heritability based on the personality model that was used, nor did sex have a moderating effect 
on the heritability estimates. This supports earlier findings, using 4731 twins from the 
Netherlands Twin Register, by Wray et al. (2007) who did not find any sex differences in the 
genetic aetiology of neuroticism. The same study also showed strong genetic correlations (> 
0.9) between four measures of neuroticism taken over a period of 22 years in more than 20,000 
individuals from 4999 families, indicating that the effects of age on the genetic contributions 
to neuroticism are likely to be small. It is important to note that the meta-analysis by Vukasović 
and Bratko (2015) showed that the heritability estimates from family and adoption studies (h2 
~ 22%) were lower than the estimates from adoption studies (h2 ~ 47%). This could indicate 
the importance of non-additive genetic effects, as heritability estimates from twin studies 
include both additive and non-additive genetic effects, whereas family and adoption studies 
only include additive genetic effects. The contribution of non-additive genetic effects for 
neuroticism have been estimated to be up to half of the genetic variance (Hahn et al., 2013; 
Keller et al., 2005; Plomin, Corley, Caspi, Fulker, & DeFries, 1998). 
 
The heritability of neuroticism based on common genetic variants, using both GCTA-GREML 
and linkage disequilibrium score regression (LDSR), has been estimated to be around 15% 
(Genetics of Personality Consortium, 2015; Lo et al., 2017; Power & Pluess, 2015; Realo et 
al., 2016; D. J. Smith et al., 2016). The largest study to date (D. J. Smith et al., 2016) included 
91,370 individuals from UK Biobank and reported the heritability of neuroticism to be 13.6% 
(SE = 1.5%) using LDSR, and 15.6% (SE = 0.7%) using GCTA-GREML. This study also 
showed similar heritability estimates for both males (h2 = 13.5%, SE = 2.4%) and females (h2 
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= 14.9%, SE = 1.7%), as well as a genetic correlation of 0.91 (SE = 0.07) between the two 
sexes. This suggest that the sex difference in neuroticism scores, as discussed in Section 2.4, 
is not due to common genetic variants, but more likely to environmental factors, gene-gene 
interactions, gene-environment interactions, or rare genetic variants for example.  
 
2.6.2. Genome-wide association studies 
Early molecular genetic research into genetics variants’ effect on neuroticism, using candidate 
gene studies, focussed on genes potentially involved in the HPA-axis, such as dopamine, 
serotonin, and oxytocin; however, these studies did not find consistent evidence for an 
association with neuroticism, possibly due to underpowered studies, differences in personality 
questionnaires, or gene-environment interactions (Montag & Reuter, 2014). GWAS have been 
a little more successful in identifying genetic variants associated with neuroticism. A GWAS 
meta-analysis of 63,611 individuals from the Genetics of Personality Consortium (GPC) 
identified one SNP in the MAGI1 gene to be associated with neuroticism at a genome-wide 
significance level, but did not replicate in independent cohorts (Genetics of Personality 
Consortium, 2015). MAGI1 is primarily expressed in neuronal tissue in the hippocampus (Ito 
et al., 2012) and has previously been associated with several psychiatric disorders, such as 
schizophrenia, bipolar disorder, and major depressive disorder (Etain et al., 2006; Ferentinos 
et al., 2014; Karlsson et al., 2012). One GWAS has analysed the X-chromosome in 2168 
individuals, but did not find any genome-wide significant findings (Calboli et al., 2010). 
 
D. J. Smith et al. (2016), using the UK Biobank sample, reported nine genome-wide significant 
loci in genes which for example have been implicated in the HPA axis (CRHR1) and the 
glutamate system (GRIK3). Both pathways are involved in the body’s stress response and the 
two genes have been linked to major depressive disorder, anxiety, and panic disorder (Gray, 
Hyde, Deep-Soboslay, Kleinman, & Sodhi, 2015; P. H. Lee et al., 2012; Stetler & Miller, 
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2011; Weber et al., 2016). The largest GWAS to date for neuroticism combines the participants 
from both the GPC and UK Biobank, leading to a total sample size of 170,911 individuals 
(Okbay et al., 2016a). This GWAS identified 11 genome-wide significant loci of which four 
were also nominally significant in a GWAS of major depressive disorder and subjective well-
being. The effect sizes of the genome-wide significant SNPs in these GWAS were all very 
small, therefore supporting a polygenic architecture of neuroticism. The findings discussed in 
this paragraph indicate a shared genetic aetiology between neuroticism and psychiatric 
disorders. 
 
2.6.3. Shared genetic aetiology neuroticism and health 
2.6.3.1. Physical health 
Evidence of a shared genetic aetiology between neuroticism and physical health is relatively 
sparse. A family study including 6148 individuals from Sardinia did not any evidence for a 
shared genetic aetiology between neuroticism and a range of cardiovascular traits (Pilia et al., 
2006). Similarly, a twin study of 3752 twins examining the genetic association between 
neuroticism and mortality did not find an association between the two. Where twin and family 
studies have been unable to capture a possible shared genetic aetiology between neuroticism 
and physical health, molecular genetic methods have had more success. Okbay et al. (2016a) 
used LDSR to examine the genetic association between neuroticism and physical health and 
reported significant genetic correlations between neuroticism and coronary artery disease (rg 
= 0.13, SE = 0.04), smoking (rg = 0.13, SE = 0.04), and triglycerides (rg = 0.07, SE = 0.03), as 
shown in Figure 2-4C. The genetic correlation between neuroticism and these traits is 
relatively small and the traits themselves have a low heritability (h2 < 0.12) (J. Zheng et al., 
2016). This means that the co-heritability is likely to be low as well (see Section 1.3.1.6), 
indicating that the proportion of the variation in neuroticism accounted for by the additive 
genetic components to the physical health traits is likely also to be small. This is supported by 
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the findings of Harris et al. (2016a), who showed that polygenic profile scores for neuroticism 
explained 0.03% of the variance in self-rated health, which itself shows great genetic overlap 
with physical health traits, as well as a genetic correlation of -0.38 (SE = 0.07) between 
neuroticism and self-rated health. A small study of 837 individuals from the Lothian Birth 
Cohort 1936 did not find an association between polygenic risk for type 2 diabetes and 
neuroticism (Čukić et al., 2015). 
 
 
Figure 2-4. Correlations were estimated using bivariate LD Score (LDSC) 
regression. (a) Genetic correlations between subjective well-being, 
depressive symptoms, and neuroticism ('our three phenotypes'), as well as 
between our three phenotypes and height. (b) Genetic correlations between 
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our three phenotypes and selected neuropsychiatric phenotypes. (c) 
Genetic correlations between our three phenotypes and selected physical 
health phenotypes. In b and c, we report the negative of the estimated 
correlation with depressive symptoms and neuroticism (but not subjective 
well-being). Error bars represent 95% confidence intervals. Reprinted with 
permission from Okbay et al. (2016a). Copyright 2016 by Springer Nature.  
 
2.6.3.2. Mental health 
As discussed in Section 2.5.3 neuroticism is strongly associated with low mood, anxiety and 
psychological distress, and all these traits possibly cover the same general trait of negative 
emotions. It is therefore not surprising that a wide range of studies have explored the shared 
genetic aetiology between neuroticism and mental health. Twin studies reported genetic 
correlations between neuroticism and major depressive disorder of 0.43 in 542 twins (Kendler 
& Myers, 2010), 0.46 in 7831 twin pairs (Kendler, Gatz, Gardner, & Pedersen, 2006), and 0.60 
in 9270 twins (Hettema, Neale, Myers, Prescott, & Kendler, 2006). Molecular genetic studies 
have also reported a shared genetic aetiology between neuroticism and major depressive 
disorder; polygenic profiles for neuroticism explained 0.1% of the variance in major 
depressive disorder (Middeldorp et al., 2011). The polygenic profiles in this study were based 
on GWAS of neuroticism including 13,835 individuals and predicted in to 8921 individuals, 
which might limit the predictive power of this analysis. Using a much larger GWAS, based on 
63,661 individuals, polygenic profiles for neuroticism explained 1.05% of the variance in 
major depressive disorder (Genetics of Personality Consortium, 2015). While the amount of 
variance explained is small, it should be considered the minimum amount of variance 
explained, as per Section 1.3.1.7. These results support the findings by Okbay et al. (2016a), 
who reported a genetic correlation of 0.75 (SE = 0.03) between neuroticism and depressive 
symptoms (Figure 2-4A). Major depressive disorder and anxiety are highly comorbid and it is 
therefore likely that anxiety disorders also show a shared genetic aetiology with neuroticism. 
Hettema et al. (2006) showed a genetic correlation of 0.77 between neuroticism and anxiety 
disorders, and of 0.69 between neuroticism and panic disorder in 9270 twins. In a behavioural 
93
genetics study of 23,280 twins, neuroticism accounted for approximately 25% of the genetic 
correlation between major depressive disorder and anxiety, which indicated that all these traits 
are genetically related to each other (Kendler, Gardner, Gatz, & Pedersen, 2007). No 
differences have been found in the genetic correlations between neuroticism and anxiety 
disorder between males and females (Hettema, Prescott, & Kendler, 2004), which is in line 
with the finding that the heritability for neuroticism for males and females is similar (D. J. 
Smith et al., 2016).  
 
With major depressive disorder and anxiety on the negative end of the scale, it could be said 
that subjective well-being can be found on the positive end of the scale. In line with that, 
Okbay et al. (2016a) found a significant negative genetic correlation between neuroticism and 
subjective well-being (rg = -0.75, SE = 0.03), which is higher than the genetic correlation 
reported by Weiss et al. (2016) between neuroticism and positive affect (rg = -0.55, SE = 0.09), 
and between neuroticism and life satisfaction (rg = -0.49, SE = 0.07). This discrepancy in 
results for traits that are strongly associated is potentially due to the different methods being 
used (GCTA-GREML in the study of Weiss et al. (2016) compared to LDSR by Okbay et al. 
(2016a)), as well as the difference in sample size. The genetic correlation reported by Okbay 
et al. (2016a) was based on a GWAS for neuroticism which included 170,911 individuals and 
a GWAS for subjective well-being which included 298,420 individuals, while the genetic 
correlation reported by Weiss et al. (2016) was based on a total sample of 30,367 individuals. 
 
Limited evidence is available to indicate a genetic overlap between neuroticism and bipolar 
disorder or schizophrenia. Middeldorp et al. (2011) did not find a significant association 
between polygenic profiles for neuroticism and bipolar disorder in 6329 individuals, but a 
significant genetic correlation was found between neuroticism and bipolar disorder (rg = 0.11, 
SE = 0.04) using LDSR. As can be seen in Figure 2-4B, the same study also reported a 
significant genetic correlation between neuroticism and schizophrenia (rg = 0.22, SE = 0.04), 
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which supports results by Macare, Bates, Heath, Martin, and Ettinger (2012) who reported that 
51 % of the phenotypic correlation between schizotypy, defined as attenuated schizophrenia-
like traits, and neuroticism is explained by genetic factors. 
 
2.7. Summary 
This Chapter provided an introduction to the second part of this thesis; negative emotions, and 
its associations with health outcomes, both on a phenotypic and genetic level. The empirical 
work in the second part of this thesis will address the following key question: 
 
1) Do the tendency to experience negative emotions and health have some shared 
genetic aetiology? 
 
Empirical evidence for this key question will be provided in Chapters 6 and 7 relating to: the 
shared genetic aetiology between neuroticism and physical and mental health; and the shared 
genetic aetiology between self-reported tiredness and physical and mental health, with a focus 
on neuroticism. First, however, Chapter 3 will next provide background on the main cohort 




3. UK Biobank 
3.1. Introduction 
This Chapter describes the methodology used by the UK Biobank, a health resource for 
researchers that aims to improve the prevention, diagnosis, and treatment of a range of illnesses 
(http://www.ukbiobank.ac.uk). It will include information about the study population, 
recruitment procedures and ethical approval. In addition, it will provide an in-depth discussion 
of the cognitive testing, measurements of negative emotions and the genetic data.  
 
3.2. Baseline data 
The UK Biobank is a population-based prospective study, set up as a resource for identifying 
determinants of disease in middle aged and older people. Between the years 2006 and 2010, 
about 500,000 individuals aged from middle age to older age were recruited throughout the 
United Kingdom, covering 22 assessment centres. This provided a spread in socioeconomic 
status and ethnicity, as well as an urban and rural mix. Data were collected on cognitive 
functions, physical and mental health, lifestyle, socio-demographic information, food intake, 
and family medical history. Data collection also involved collecting biological samples. 
 
3.2.1. Study population 
UK Biobank sent out invitations to around 9.2 million individuals aged between 40 and 69, 
who were registered with the National Health Service and were living up to 25 miles away 
from one of the 22 assessment centres. With a response rate of 5.47%, a total of 503,325 
participants were recruited. At the first visit to the assessment centre (2006 – 2010) all 
participants completed multiple questionnaires covering the following topics: socio-
demographics, family history and early life exposures, psychosocial factors, environmental 
factors, lifestyle, health status, hearing threshold, and cognitive function. Physical 
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measurements included blood pressure, heart rate, hand grip strength, anthropometry, 
spirometry, bone density, arterial stiffness, a fitness test, and an eye examination. Blood, urine 
and saliva were collected for DNA extraction and biomarker measurement (Allen et al., 2012). 
Between 2014 and 2015 around 120,000 participants completed additional tests, including 
questionnaires on cognitive ability and work environment, diet by 24-hour recall, and physical 
measurement activity. In June 2015 UK Biobank released an interim dataset of the genetic 
data including 152,729 individuals, and this sample will be used throughout this Thesis. 
 
3.2.2. Ethical approval 
UK Biobank received ethical approval from the National Health Service National Research 
Ethics Committee (REC), under the reference 11/NW/0382. All participants provided written 
consent prior to assessment, which will apply throughout the lifetime of UK Biobank unless 
the participant withdraws.  
 
3.2.3. Demographics 
In total, 121,151 individuals (of 152,729 individuals) remained after quality control of the data 
(see Section 3.5.2 for details). The mean (SD) age was 56.91 (7.93) years with a range between 
40 and 73 years. The dataset consisted of 58,914 females and 53,237 males. The age-sex 
distribution can be found in Figure 3-1. Table 3-1 displays the distribution of qualifications in 
UK Biobank, in which 30.2% of all participants had a college or university degree. All 
participants were asked at what age they completed continuous full time education; however, 
this excluded individuals who indicated they had a college or university degree. The mean 





Table 3-1. Distribution of qualifications in UK Biobank based on data from the 
first release of genetic data. 
Qualification Number of individuals % Females 
College/University degree 33,852 50.57 
A/AS levels 12,560 56.18 
0 levels/GCSEs 24,802 58.21 
CSEs 6064 52.03 
NVQ/HND/HNC 7788 34.17 
Other professional qualifications 5776 58.89 
None of the above 20,272 52.67 
Prefer not to answer 953 51.10 
 
Socioeconomic status has been measured in UK Biobank using the Townsend deprivation 
index, a measure of material deprivation (Townsend, Phillimore, & Beattie, 1988). The 
Townsend deprivation index is calculated from Census data and is a standardised composite 
score based on non-home ownership, unemployment over the age of 16, non-car ownership, 
and the number of individuals in each home. A greater Townsend score indicates a greater 
degree of deprivation. The mean (SD) Townsend deprivation index in UK Biobank was -1.49 
(2.98), ranging between -6.26 and 10.78. The distribution by sex is displayed in Figure 3-1. 
Figure 3-2 shows the comparison between UK Biobank and the general population based on 
the Census data. The age distribution shows that UK Biobank is oversampled for older 
individuals compared with the 2011 Census. The Townsend deprivation index distribution 
shows that UK Biobank is a little more posh than the general population based on the 2001 
Census, with more individuals in the lower Townsend score group and less in the higher 
groups. It is important to note that for the Townsend deprivation index the most updated 
Census data was from 2001, which at the time of writing is more than 15 years old. It is 





Figure 3-1. Left, age by sex distribution in UK Biobank; right, Townsend 
deprivation index by sex distribution in UK Biobank. 
 
 
Figure 3-2. Left, comparison of age distribution in UK Biobank and in the 
United Kingdom based on the 2011 Census; right, comparison of the 
Townsend deprivation index in UK Biobank and in the United Kingdom based 
on the 2001 Census. 
 
3.3. Cognitive testing 
3.3.1. Reaction time 
Reaction time was measured by a computerized ‘snap’ game during baseline testing (Figure 
3-3). In this game, participants are shown two cards with simple symbols (e.g. an equal sign 
or square) at the same time, and are asked to press a button, with their dominant hand, as 
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quickly as possible when the two cards on the screen match. This game consisted of 12 trials 
(each with one pair of cards); the first four trials were regarded as ‘exercise’, resulting in eight 
experimental trials. From these eight experimental trials, four trials had matching cards and 
thus required the button to be pressed. 
 
 
Figure 3-3. Reaction time test in UK Biobank. Participants were asked to press 
a button as quickly as possible when the symbols on the cards matched. 
Adapted with permission from UK Biobank (2013b). Copyright by UK Biobank 
2013. 
 
Each participant’s reaction time (in ms) was calculated as the mean time to press the button 
for the four experimental trials with matching cards. A general test of reaction time would 
normally include at least 20 trials (I. J. Deary, Der, & Ford, 2001; Der & Deary, 2006). Times 
over 2000 ms were disregarded before calculating the means, as the cards had disappeared 
from the screen by then. The mean (SD) reaction time was 555.1 (112.7) ms, with a range 
between 63 and 1905 ms. One participant was removed from all analysis because of an 
outlying reaction time (1905 ms, 12 standard deviations above the mean reaction time). Owing 
to a positively skewed distribution, all mean scores were log-transformed before further 
analysis. Figure 3-4 shows the distribution of reaction time before and after the logarithmic 




Figure 3-4. Distribution of reaction time; left, untransformed; right log 
transformed and outliers excluded. 
 
The Cronbach alpha coefficient showed an internal consistency of 0.85 (Hagenaars et al., 
2016b). Reaction time showed moderate stability over time, with an intraclass correlation of 
0.57 (95% CI = 0.56 to 0.58) over a period ranging from two to seven years (Lyall et al., 2016). 
Reaction time scores are flipped for the ease of interpretation; a higher score indicates better 
reaction time. Figure 3-5 shows a linear decline in this reaction time measure between the ages 
of 40 and 70 years, with longer reaction times in older age, as well as a linear decline for the 
Townsend deprivation index with longer reaction times for individuals with higher Townsend 
scores (lower socio-economic status). Figure 3-6 shows that the average reaction time is worse 
for individuals with lower qualifications. Overall, males have better reaction times than 




Figure 3-5. Age and Townsend deprivation index distribution for reaction time 
separated by sex. Error bars represent +/- one standard error of the mean. 
Higher scores indicate better performance on the reaction time test. 
 
 
Figure 3-6. Qualifications distribution for reaction time separated by sex. 
Error bars represent +/- one standard error of the mean. 
  
3.3.2. Memory 
Memory was measured by a computerized ‘pairs matching’ game during baseline testing 
(Figure 3-7). The participant was shown a set of picture cards on a screen with matching pairs 
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and was asked to memorize the positions of as many pairs as possible. The picture cards were 
then turned over and no longer visible. The participant was asked to identify the matching 
pairs of cards, in the fewest number of attempts. Pairs were identified by touching the cards 
on the screen consecutively. The first round of the game included six cards (three pairs) that 
were shown for three seconds in a 2x3 grid. The second round of the game included 12 cards 
(six pairs) that were shown for five seconds in a 3x4 grid. To utilise the most information 
possible, this thesis will only use the 3x4 grid.  
 
           
 
Figure 3-7. Pairs matching game in 3 x 4 gird in UK Biobank. Left, the cards 
turned down. Right, six pairs of matching cards are displayed to participants 
for five seconds. Adapted with permission from UK Biobank (2013a). 
Copyright by UK Biobank 2013.  
 
Each participant’s memory score was calculated as the number of errors made until all pairs 
of cards were correctly identified consecutively. The layout of the cards on the screen was at 
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random in each round. This game did not have a time restriction, i.e. the participants were able 
to identify pairs of cards until all matching pairs had been identified or they pressed the 
‘abandon’ button. If the ‘abandon’ button was pressed, the participant was asked ‘Are you 
sure?’, when selecting ‘no’ they were returned to the current entry screen, when selecting ‘yes’, 
they continued with the next test. Figure 3-8 shows the distribution of the memory scores based 
on the smaller 2x3 grid, this grid has a clear ceiling effect, with 70% of the sample having no 
errors in the memory test. The 3x4 grid was more difficult and has less of a ceiling effect 
(Figure 3-9), this grid was therefore used in any further analysis. Twenty-nine individuals who 
made more than 30 errors had their number of errors set to 30 (winsorising). The distribution 
before and after winsorising are shown in Figure 3-9.  
 
 




Figure 3-9. Distributions of memory scores based on the 3 x 4 grid; left, 
untransformed; right, winsorised. 
 
This memory test showed low stability over a period of two to seven years, with an intraclass 
correlation of 0.16 (95% CI = 0.15 to 0.17) (Lyall et al., 2016). Memory scores are flipped for 
the ease of interpretation; a higher memory score indicates better performance on the test. 
Figure 3-10 shows a linear decline between the ages of 40 and 70 years, with more errors in 
older age, and very little differences across the Townsend deprivation index distribution. 
Figure 3-11 shows that individuals with lower qualifications make more errors compared to 
individuals with higher qualifications. Males and females have very similar performance on 
the test for memory across the differences distributions. A total of 112,067 individuals with 




Figure 3-10. Age (left) and Townsend deprivation index (right) distribution for 
memory separated by sex. Error bars represent +/- one standard error of the 
mean. Higher scores indicate better memory performance. 
 
Figure 3-11. Qualifications distribution for memory separated by sex. Error 
bars represent +/- one standard error of the mean. 
 
3.3.3. Verbal-numerical reasoning 
To test each participant’s ability to solve problems requiring reasoning ability and logic, a so-
called ‘fluid-intelligence’ test was performed. This test was introduced at a later stage during 
baseline testing and only a subset of individuals therefore completed the verbal-numerical 
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reasoning questionnaire. This test comprised of thirteen multiple choice questions, which had 
to be answered within a two-minute time limit. The test included six verbal items and seven 
numerical items. All questions and the possible answers are shown in Table 3-2. 
 
Table 3-2. Verbal-numerical reasoning questions and possible answers in UK 
Biobank. 
Question Possible answers 
1. Add the following numbers together: 
1 2 3 4 5 – is the answer? 
13/14/15/16/17/Do not know/Prefer not 
to answer 
2. Which number is the largest? 642/308/987/714/253/Do not 
know/Prefer not to answer 
3. Bud is to flower as child is to? Grow/Develop/Improve/Adult/Old/Do 
not know/Prefer not to answer 
4. 11 12 13 14 15 16 17 18 Divide the 
sixth number to the right of twelve by 
three. Is the answer? 
5/6/7/8/Do not know/Prefer not to 
answer 
5. If Truda’s mother’s brother is Tim’s 
sister’s father, what relation is Truda 
to Tim? 
Aunt/Sister/Niece/Cousin/No 
relation/Do not know/Prefer not to 
answer 
6. If sixty is more than half of seventy-
five, multiply twenty-three by three. If 
not subtract 15 from eighty-five. Is 
the answer? 
68/69/70/71/72/Do not know/Prefer not 
to answer 
7. Stop means the same as? Pause/Close/Cease/Break/Rest/Do not 
know/Prefer not to answer 
8. If David is twenty-one and Owen is 
nineteen and Daniel is nine years 
younger than David, what is half their 
combined age? 
25 /26 /27 /28 /29 /Do not know /Prefer 
not to answer 
9. Age is to years as height is to? Long /Deep /Top /Metres /Tall /Do not 
know /Prefer not to answer 
10. 150…137…125…114…104… What 
comes next? 
96 /95 /94 /93 /92 /Do not know /Prefer 
not to answer 
11. Relaxed means the opposite of? Calm /Anxious /Cool /Worried /Tense 
/Do not know /Prefer not to answer 
12. 100…99…95…86…70… What 
comes next? 
50 /49 /48 /47 /46 /45 /Do not know 
/Prefer not to answer 
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13. If some flinks are plinks and some 
plinks are stinks then some flinks are 
definitely stinks? 
False True /Neither true nor false /Not 
sure /Do not know /Prefer not to answer 
 
Each participant’s score on the test was calculated as the overall score of the thirteen items in 
the test. The Cronbach alpha coefficient showed an internal consistency of 0.62. The intraclass 
correlation coefficient was 0.65 (95% CI = 0.63 – 0.67), indicating good stability of the test 
over a period of two to seven years (Lyall et al., 2016). Figure 3-12 shows the distribution of 
the scores. UK Biobank named this test the ‘fluid-intelligence’ test, comparable to the concept 
of fluid cognitive ability as proposed by Horn and Cattell (1966). One would, therefore, expect 
to see a steady age-related decline in the scores (Salthouse, 2010; Tucker-Drob, 2009). As can 
be seen in Figure 3-13, this test shows stable mean scores between the ages of 40 and 60 years, 
followed by a linear decline in mean scores between the age of 60 and 70 years. This pattern 
is somewhat similar to that of vocabulary tests, which are used to assess crystalized cognitive 
ability (Salthouse, 2004). Therefore, this test will be referred to by its contents, i.e. the verbal-
numerical reasoning test.  
 
 
Figure 3-12. Distribution of the verbal-numerical reasoning scores. 
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Figure 3-13 shows a positive linear decline in mean scores for the Townsend deprivation 
index, indicating that individuals with a lower socio-economic status score lower on the 
verbal-numerical reasoning test. A similar pattern of decline can be seen in Figure 3-14, 
showing that individuals with higher educational attainment had better verbal-numerical 
reasoning performance. Males generally scored higher on the test of verbal-numerical 
reasoning than females. A total of 36,035 individuals with genetic data completed the verbal-
numerical reasoning questionnaire. 
 
 
Figure 3-13. Age (left) and Townsend deprivation index (right) distribution for 
verbal-numerical reasoning separated by sex. Error bars represent +/- one 
standard error of the mean. Individuals with a Townsend deprivation index > 




Figure 3-14. Qualifications distribution for verbal-numerical reasoning 
separated by sex. Error bars represent +/- one standard error of the mean. 
 
3.3.4. Educational attainment 
All participants completed a sociodemographic questionnaire during baseline testing, which 
included questions about educational attainment (UK Biobank, 2012). This thesis will use the 
question, ‘Which of the following qualifications do you have? (You can select more than one)’ 
(answers included: ‘College or University Degree/A levels or AS levels or equivalent/O levels 
or GCSE or equivalent/CSEs or equivalent/NVQ or HND or HNC or equivalent/Other 
professional qualifications e.g. nursing, teaching/None of the above/Prefer not to Answer’). 
The age and Townsend deprivations index distributions for all qualifications are shown in 
Figure 3-15. In order to indicate whether or not a participant had a college or university degree, 
a binary educational attainment variable was created. Educational attainment has shown to be 
a good proxy phenotype for cognitive ability as has been discussed in Section 1.3.2.5 (Rietveld 
et al., 2014), and college degree attainment will be used as such in this Section 4.2. A total of 





Figure 3-15. Age (left) and Townsend deprivation index (right) distribution for 
each type of qualifications. Individuals with a Townsend deprivation index > 
9 are not displayed in the graph due to the low N. 
 
3.3.5. Trail making test 
Processing speed and executive functioning were assessed during the additional web-based 
follow up between 2014 and 2015, by the trail making test, part A (TMT A) and B (TMT B), 
among other tests. As this assessment was completed remotely, it is possible that participants 
used different technologies (for example using a tablet, touchpad or mouse) to complete the 
test. UK Biobank did not provide information on this. For TMT A, participants have to 
consecutively connect numbers (1 – 25) randomly distributed on the screen as quickly as 
possible by clicking on the next number (Figure 3-16). TMT B is similar, but in this case, 
letters (A – L) and numbers (1 – 13) have to be connected in ascending order, e.g. 1 A 2 B 3 
C etc. (Figure 3-16). 
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Figure 3-16. Trail Making Test Part A (left) and Trail Making Test Part B (right). 
Adapted with permission from UK Biobank (2015d). Copyright by UK Biobank 
2015.      
 
The intervals between touching two points was timed in seconds using a Javascript timer. The 
time (in seconds) to complete the trail making test (part A or B) was derived by summing the 
interval values between two points. Individuals who scored above 250 seconds for TMT B 
were excluded (N = 9). Owing to a positively skewed distribution, both TMT A and TMT B 
scores were log-transformed before further analysis (Figure 3-17). The differences between 
the scores for TMT A and TMT B was calculated by subtracting the untransformed scores for 
TMT A from TMT B (TMT B – A). Individuals who scored <-50 or >150 seconds were 




Figure 3-17. Distributions of Trail Making Part A (top) and Trail Making Part B 
(bottom) scores; left, untransformed; right, transformed and outliers 
excluded. 
 
Both TMT measures showed a stable decline with age, with little difference between males 
and females, as shown in Figure 3-18. The Townsend deprivation index distribution is shown 
in Figure 3-19, and shows no difference in TMT performance between males and females 
across the distribution of the Townsend deprivation index scores. Figure 3-20 shows that 
individuals with more qualifications have better TMT performance. A total of 23,822 
individuals with genetic data completed the TMT A task, and 23,812 individuals with genetic 




Figure 3-18. Age distribution for TMT A (left) and TMT B (right) separated by 
sex. Error bars represent +/- one standard error of the mean. 
 
 
Figure 3-19. Townsend deprivation index distribution for TMT A (left) and TMT 
B (right) separated by sex. Error bars represent +/- one standard error of the 
mean. Individuals with a Townsend deprivation index > 8 are not displayed in 




Figure 3-20. Qualifications distribution for TMT A (left) and TMT B (right) 
separated by sex. Error bars represent +/- one standard error of the mean. 
 
3.4. Negative emotions 
3.4.1. Neuroticism 
Neuroticism is the personality trait that assesses individual differences in the tendency to 
experience negative emotions. This trait was measured, at baseline, by the Neuroticism scale 
of the Eysenck Personality Questionnaire Short Form-Revised (S. B. G. Eysenck, Eysenck, & 
Barrett, 1985), consisting of the following 12 yes (scored as 1) or no (scored as 0) items; "Does 
your mood often go up and down?"; "Do you ever feel 'just miserable' for no reason?"; "Are 
you an irritable person?”; "Are your feelings easily hurt?"; "Do you often feel 'fed-up'?"; 
"Would you call yourself a nervous person?"; "Are you a worrier?"; "Would you call yourself 
tense or 'highly strung'?"; "Do you worry too long after an embarrassing experience?"; "Do 
you suffer from 'nerves'?"; "Do you often feel lonely?"; "Are you often troubled by feelings of 
guilt?". The neuroticism score was calculated as the total of the twelve items, thus ranging 
from 0 – 12 (Gale et al., 2016; D. J. Smith et al., 2013). The neuroticism scores are not normally 
distributed, and show a zero-inflation, as shown in Figure 3-21. No transformation was 




Figure 3-21. Distribution of neuroticism scores in UK Biobank. 
 
The neuroticism scale shows a reliability of above 0.8 (S. B. G. Eysenck et al., 1985) and has 
been validated in older individuals, showing a correlation of -0.84 with the International 
Personality Item Pool (IPIP) – Emotional Stability scale and of 0.85 with the NEO-Five Factor 
Inventory (NEO-FFI) – Neuroticism Scale, two of the most widely used neuroticism scales 
(Gow, Whiteman, Pattie, & Deary, 2005). Figure 3-22 shows that neuroticism declines with 
both older age and better socio-economic status (lower Townsend deprivation index). Females 
score consistently higher than males on neuroticism, as previously shown by Soto et al. (2011). 
Individuals with higher educational attainment score lower on neuroticism (Figure 3-23). A 
total of 108,038 individuals with genetic data completed the neuroticism questionnaire. 
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Figure 3-22. Age (left) and Townsend deprivation index (right) mean and 
standard error scores for neuroticism separated by sex. Error bars represent 
+/- one standard error of the mean. Individuals with a Townsend deprivation 
index > 8 are not displayed in the graph due to the low N. 
 
 
Figure 3-23. Qualifications distribution for neuroticism separated by sex. 




3.4.2. Self-reported tiredness 
At baseline, participants were asked the question, "Over the past two weeks, how often have 
you felt tired or had little energy?" Possible answers were: “Not at all/Several days/More than 
half the day/Nearly every day/Do not know/Prefer not to answer”. This question was asked as 
part of the Mental Health Questionnaire, which consists of items from the Patient Health 
Questionnaire (Spitzer, Kroenke, & Williams, 1999). Participants answering with “Do not 
know” or “Prefer not to answer” were excluded, resulting in a four-category variable for 
tiredness ranging from “Not at all” to “Nearly every day”. A total of 108,976 individuals with 
genetic data answered the tiredness question. Table 3-3 shows the number of individuals in 
each category of tiredness. 
 
Table 3-3. Distribution of self-reported tiredness in UK Biobank. 
 Number of individuals (%) 
Not at all 51 416 (47.2) 
Several days 44 208 (40.6) 
More than half the days 6404 (5.9) 
Nearly every day 6948 (6.4) 
 
Figure 3-24 shows that tiredness, when treated as a continuous trait, decreases with age, and 
that females reported to be more tired than males. As shown in Figure 3-25 the percentage of 
individuals reporting they were not tired at all increases with age, whereas increasing 
Townsend deprivation index, i.e. lower socioeconomic status, was associated with individuals 
reporting they were more tired. Very little differences is shown for different categories of 




Figure 3-24. Age- and sex distribution of self-reported tiredness as a 
continuous variable. Error bars represent +/- one standard error of the mean. 
 
 
Figure 3-25. Age (left) and Townsend deprivation index (right) distribution for 
self-reported tiredness. Individuals with a Townsend deprivation index > 9 are 




Figure 3-26. Distribution of each category of tiredness for each category of 
educational attainment, shown as percentage of individuals in each group. 
 
3.5. Genotypic data 
3.5.1.  DNA extraction and genotyping 
DNA was extracted from blood samples of 152,279 UK Biobank participants and genotyped 
for the interim release of the data, using either the UK BiLEVE array (N = 49,979) (Wain et 
al., 2015) or the UK Biobank Axiom array (N = 102,750). The UK BiLEVE array was 
designed for optimal imputation of markers associated with lung health and disease. This array 
formed the basis of the UK Biobank Axiom array, for which markers associated with a wide 
range of phenotypes have been added. The two arrays have an overlap of more than 95% and 
are very similar in processing stages.  
 
DNA extraction took place at the UK Biobank facility in Stockport. Due to the large sample 
size, a sample selection algorithm ensured an equal distribution of assessment centres in each 
plate (UK Biobank, 2015c). Several quality checks were performed to ensure the quality of 
the extracted DNA (UK Biobank, 2014 ). All samples (UK BiLEVE array and UK Biobank 
Axiom array) were genotyped at the Affymetrix Research Services Laboratory in Santa Clara, 
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California, USA. Two controls from the 1000 Genomes were added to each plate containing 
94 UK Biobank samples, to check for both control concordance with 1000 Genomes, as well 
as sample reproducibility. Genotypes were called in batches of around 4800 samples using the 
Affymetrix Power Tools Software and the Affymetrix Best Practices Workflow (Affymetrix, 
2014). Quality control was performed by Affymetrix for each batch separately after genotype 
calling (Affymetrix, 2014, 2015). SNPs that did not meet the quality control thresholds set by 
Affymetrix were set to missing in all samples in that batch. 
 
3.5.2.  Quality control (QC) 
Further sample quality control was performed (Hagenaars et al., 2016b). Samples were set to 
missing in all batches when the SNPs showed less reliable genotyping results, e.g. batch 
effects, Hardy-Weinberg equilibrium or SNPs that did not pass QC thresholds, based on 
Affymetrix recommendations, in all batches of the interim release (UK Biobank, 2015b). 
Samples were excluded in the order as displayed in Table 3-4, if they did not pass the following 
criteria: 
 
Table 3-4. Sample quality control in UK Biobank. 
 Quality control criteria Number of individuals removed 
1 Non-White British ancestry (self-report) 32,484 
2 Missingness 0 
3 Relatedness (KING estimated kinship 
coefficient > 0.0442) 
7948 
4 QC failure in UK BiLEVE sample 187 
5 Gender mismatch 0 
 
Non-autosomal variants and SNPs with a minor allele frequency < 1% across all batches were 
removed prior to analysis. This resulted in a total sample of 112,151 individuals of the interim 
release for further analysis. 
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3.5.3.  Imputation 
UK Biobank performed genotype imputation on the genotype data in two steps; pre-phasing 
and imputation (UK Biobank, 2015a). Pre-phasing was done using a new version of 
SHAPEIT2 to allow for the large sample size of UK Biobank in chunks of 5000 SNPS with a 
250 SNP overlap between chunks. The 1000 Genomes phase 3 and UK10K haplotype 
reference panels were merged in IMPUTE2 to get a large number of British and European 
ancestry haplotypes, as well as a set of various worldwide ancestry haplotypes, leading to a 
reference panel with 87,696,88 bi-allelic variants and 12,570 haplotypes. Whole genome 
imputation was carried out in 2Mb chunks with a 250 Kb buffer region, using IMPUTE2. 




This Chapter has described the recruitment procedures and measurements of UK Biobank. 
After quality control, a total sample of 112,151 individuals remained for further analysis, the 
actual numbers for each analysis will differ for each phenotype as displayed in Table 3-5. 
Participants were assessed on different cognitive abilities and filled in questionnaires about 

































































































































































































































































































































































































































































































4. Genetic overlap between cognitive ability and health 
4.1. Introduction 
Chapter 1 described the associations between general cognitive ability and health. Higher 
childhood cognitive ability is predictive of later mortality and less morbidity in later life, but 
morbidities, such as cardiovascular- and mental health diseases, are linked to a decline in 
cognitive ability. This indicates that cognitive ability and health are inextricably linked 
throughout life. Both cognitive ability and health outcomes are influenced by genetic factors 
to some extent, as shown by both behavioural and molecular genetic studies, discussed in 
Section 1.3.2.4 (G. Davies et al., 2016b; Ge, Chen, Neale, Sabuncu, & Smoller, 2016; Pickrell 
et al., 2016; Polderman et al., 2015). The genetic association between cognitive ability and 
health is not as well established, but some studies have indicated a shared genetic aetiology 
between cognitive ability and health outcomes (Arden et al., 2016; Brendan K. Bulik-Sullivan 
et al., 2015a; Hagenaars et al., 2016a; Harris et al., 2016a). In order to better understand the 
shared genetic aetiology between cognitive ability and health, it is important to also examine 
the causality of this correlation. The main limitation of previous molecular genetic studies, 
particularly when using a polygenic profile score approach, is a lack of power due to small 
sample sizes. The large sample size of UK Biobank overcomes this limitation and has enough 
statistical power to detect the usually small effects of polygenic associations. This Chapter 
first examines the shared genetic aetiology of verbal-numerical reasoning, reaction time, 
memory, and educational attainment with vascular-metabolic disease, psychiatric disorders, 
brain measures, physical and physiological measures, and life course cognitive traits and 
proxies. This study has been published in Molecular Psychiatry and this paper is included in 
full in Section 4.2. A more detailed description of the methodology used in this paper can be 
found in Section 1.3. The second part of this Chapter will use Mendelian randomization 
analysis to better understand the direction of effect between cognitive ability, educational 
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attainment, and physical health measures. This study has been accepted for publication in 
Scientific Reports and is included in full in Section 4.3. 
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4.2. Shared genetic aetiology between cognitive functions and physical and 





Shared genetic aetiology between cognitive functions and
physical and mental health in UK Biobank (N= 112151) and
24 GWAS consortia
SP Hagenaars1,2,3,13, SE Harris1,4,13, G Davies1,2, WD Hill1,2, DCM Liewald1,2, SJ Ritchie1,2, RE Marioni1,4,5, C Fawns-Ritchie1,2,
B Cullen6, R Malik7, METASTROKE Consortium, International Consortium for Blood Pressure GWAS, SpiroMeta Consortium,
CHARGE Consortium Pulmonary Group, CHARGE Consortium Aging and Longevity Group, BB Worrall8,9, CLM Sudlow1,4,10,
JM Wardlaw1,10, J Gallacher11, J Pell6, AM McIntosh3, DJ Smith6, CR Gale1,2,12,14 and IJ Deary1,2,14
Causes of the well-documented association between low levels of cognitive functioning and many adverse neuropsychiatric
outcomes, poorer physical health and earlier death remain unknown. We used linkage disequilibrium regression and polygenic
profile scoring to test for shared genetic aetiology between cognitive functions and neuropsychiatric disorders and physical health.
Using information provided by many published genome-wide association study consortia, we created polygenic profile scores for
24 vascular–metabolic, neuropsychiatric, physiological–anthropometric and cognitive traits in the participants of UK Biobank, a very
large population-based sample (N= 112 151). Pleiotropy between cognitive and health traits was quantified by deriving genetic
correlations using summary genome-wide association study statistics and to the method of linkage disequilibrium score regression.
Substantial and significant genetic correlations were observed between cognitive test scores in the UK Biobank sample and many
of the mental and physical health-related traits and disorders assessed here. In addition, highly significant associations were
observed between the cognitive test scores in the UK Biobank sample and many polygenic profile scores, including coronary artery
disease, stroke, Alzheimer’s disease, schizophrenia, autism, major depressive disorder, body mass index, intracranial volume, infant
head circumference and childhood cognitive ability. Where disease diagnosis was available for UK Biobank participants, we were
able to show that these results were not confounded by those who had the relevant disease. These findings indicate that a
substantial level of pleiotropy exists between cognitive abilities and many human mental and physical health disorders and traits
and that it can be used to predict phenotypic variance across samples.
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INTRODUCTION
Cognitive functioning is positively associated with greater long-
evity and less physical and psychiatric morbidity, and negatively
associated with many quantitative disease risk factors and
indices.1 Some specific associations between cognitive functions
and health appear to arise because an illness has lowered prior
levels of cognitive function.2,3 For others, the direction of
causation appears to be the reverse: there are many examples
of associations between lower cognitive functions in youth, even
childhood, and higher risk of later mental and physical illness and
earlier death.4–8 In some cases, it is not clear whether illness
affects cognitive functioning or vice versa, or whether both are
influenced by some common factors. Many examples of these
phenotypic and cognitive–illness associations are shown in
Supplementary Table 1. Overall, the causes of these cognitive–
health associations remain unknown and warrant further investi-
gation. It is also well recognized that lower educational attainment
is associated with adverse health outcomes,9 and educational
attainment has been used as a successful proxy for cognitive
ability in genetic research.10,11 A study that included three cohorts
of twins indicated that the association between higher cognitive
function and increased lifespan was mostly owing to common
genetic effects.12
The associations between cognitive and health and illness
variables may, in part, reflect shared genetic influences. Cognitive
functions show moderate heritability,13 and so do many physical
and mental illnesses and health-associated anthropometric
measures.14 Therefore, researchers have begun to examine
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pleiotropy between scores on tests of cognitive ability and health-
related variables.15,16 Pleiotropy is the overlap between the
genetic architecture of two or more traits, perhaps owing to a
variety of shared causal pathways.17 Originally, the possibility of
pleiotropy in cognitive–health associations was tested using
family- and twin-based designs.18 However, now data from
single-nucleotide polymorphism (SNP) genotyping can assess
pleiotropy, opening the possibility for larger-scale, population-
generalizable studies.
Multiple methods can be used to test for pleiotropy using
SNP-based genetic data. Calculating genetic correlations between
health measures using the summary results of previous genome-
wide association studies (GWAS) has become possible using the
method of linkage disequilibrium (LD) score regression.19
In addition, the method of polygenic profile scoring20 also uses
summary GWAS data to test whether genetic liability to a given
illness or health-related anthropometric measurement is associated
with phenotypes such as cognitive test scores in a second
independent data set. For example, lower cognitive functioning
was associated significantly in healthy older people with higher
polygenic risk for schizophrenia21 and stroke,22 but not for
dementia.23 However, most polygenic profile studies to date have
been limited in the information they provide on this important topic:
they have reported on single health outcomes, and have used
relatively small cohorts with available cognitive data. Two recent
papers, using polygenic profile scoring and/or LD score regression,
have identified pleiotropy between a number of health-related traits
and diseases, and educational attainment15 and between a number
of psychiatric disorders and cognitive traits, and behavioural traits.16
We aimed to discover whether cognitive functioning is
associated with many physical and mental health and health-
related anthropometric measurements, in part, because of their
shared genetic aetiology using the recently released UK Biobank
genetic data (http://www.ukbiobank.ac.uk).24 We curated GWAS
meta-analyses for 24 health-related measures, and used them in
two complementary methods to test for cognitive–health
pleiotropy. First, we used LD score regression to derive genetic
correlations between cognitive function and educational attain-
ment traits measured in UK Biobank, and 24 health-related
measures from the GWAS meta-analyses. Second, to provide a
measure of the phenotypic variance that these genetic correla-
tions account for, the summary data from GWAS meta-analyses
were used to calculate polygenic profile scores in UK Biobank,
which includes cognitive, educational and genome-wide SNP data
on over 110 000 individuals. We calculated the associations
between polygenic profile scores for the 24 health-related
measures and the cognitive domains of memory, processing
speed and verbal-numerical reasoning, and educational attain-
ment in UK Biobank participants. These new data and results
provide a substantial advance in understanding the aetiology of
cognitive–health associations.
MATERIALS AND METHODS
Study design and participants
This study includes baseline data from the UK Biobank Study (http://www.
ukbiobank.ac.uk).24 UK Biobank received ethical approval from the
Research Ethics Committee. The Research Ethics Committee reference for
UK Biobank is 11/NW/0382. UK Biobank is a health resource for researchers
that aims to improve the prevention, diagnosis and treatment of a range of
illnesses. A total 502 655 community-dwelling participants aged between
37 and 73 years were recruited between 2006 and 2010 in the United
Kingdom. They underwent cognitive and physical assessments, provided
blood, urine and saliva samples for future analysis, gave detailed
information about their backgrounds and lifestyles, and agreed to have
their health followed longitudinally. For the present study, genome-wide
genotyping data were available on 112 151 individuals (58 914 females)
aged 40–73 years (mean age= 56.9 years, s.d. = 7.9) after the quality control
process (see below).
Procedures
Cognitive phenotypes. Three cognitive tests were used in the present
study. These tests, which cover three important cognitive domains, were
reaction time (n=496 891; of whom 111 484 also had genotyping data),
memory (n=498 486; 112 067 with genotyping) and verbal-numerical
reasoning (n=180 919; 36 035 with genotyping). The reaction time test
was a computerized ‘Snap’ game, in which participants were to press a
button as quickly as possible when two ‘cards’ on screen were matching.
There were eight experimental trials, with a Cronbach α reliability of 0.85.
In the memory test, participants were shown a set of 12 cards (six pairs) on
a computer screen for 5 s, and had to recall which were matching after the
cards had been obscured. We used the number of errors in this task as the
(inverse) measure of memory ability. The verbal-numerical reasoning task
involved a series of 13 items assessing verbal and arithmetical deduction
(Cronbach α reliability = 0.62). A total 492 513 participants also reported
whether or not they had a college or university degree (henceforth
referred to as ‘educational attainment’), 111 114 of whom had genotyping
data. Full details on the content and administration of each test (and the
educational attainment question) are provided in the Supplementary
Materials. Supplementary Figure 1 shows that the broad age distribution of
the cognitive tests did not differ between the full and genotyped samples.
Genotyping and quality control. A total 152 729 UK Biobank blood
samples were genotyped using either the UK BiLEVE array (N= 49 979)25
or the UK Biobank axiom array (N= 102 750). Details of the array design,
genotyping, quality control and imputation are available in a publication25
and in the Supplementary Materials. Quality control was performed by
Affymetrix, the Wellcome Trust Centre for Human Genetics, and by the
present authors; this included removal of participants based on missing-
ness, relatedness, gender mismatch, non-British ancestry and other criteria,
and is described in the Supplementary Materials.
GWAS analyses in the UK Biobank sample. GWAS analyses were performed
on the three UK Biobank cognitive test scores and on the Educational
Attainment data to use the summary results for LD score regression. Details
of the GWAS procedures are provided in the Supplementary Materials.
Curation of summary results from GWAS consortia on health-related
variables. To conduct LD score regression and polygenic profile score
analyses between the UK Biobank cognitive data and the genetic
predisposition to a large number of health-related variables, selected
because of previous associations with cognitive functions (Supplementary
Table 1), we gathered 24 sets of summary results from international GWAS
consortia. Details of the health-related variables, the consortia’s websites,
key references and number of subjects included in each consortia’s GWAS
are given in Supplementary Table 2.
Statistical analysis
Computing genetic associations between health and cognitive variables. We
used two methods to compute genetic associations between health
variables from 24 GWAS consortia, and cognitive and educational
attainment variables measured in UK Biobank: LD score regression and
polygenic profile scoring. Each provides a different metric to infer the
existence of pleiotropy between pairs of traits. LD score regression was
used to derive genetic correlations to determine the degree to which the
polygenic architecture of a trait overlaps with that of another. Next, the
polygenic profile score method was used to test the extent to which these
genetic correlations are predictive of phenotypic variance across samples.
Both LD score regression and polygenic profile scores are dependent on
the traits analysed being highly polygenic in nature, that is, where a large
number of variants of small effect contribute toward phenotypic
variation.19,20 This was tested for each trait before running the LD score
regression and polygenic profile analyses.
LD score regression. To quantify the level of pleiotropy between the traits
assessed here, LD score regression was used.15,19 LD score regression is a
class of techniques that exploits the correlational structure of the SNPs
found across the genome. In the Supplementary Materials, we provide
more details of LD score regression. Here, we use LD score regression to
derive genetic correlations between health-related and cognitive traits
using 24 large GWAS consortia data sets that enable pleiotropy of their
health-related traits to be quantified with the cognitive traits in UK Biobank.
We followed the data processing pipeline devised by Bulik-Sullivan et al.,19
described in more detail in the Supplementary Materials. To ensure that the
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genetic correlation for the Alzheimer’s disease phenotype was not driven
by a single locus or biased the fit of the regression model, a 500 kb region
centred on the APOE locus was removed and this phenotype was re-run.
This additional model is referred to in the tables and figures below as
‘Alzheimer’s disease (500 kb)’.
Polygenic profiling. The UK Biobank genotyping data required recoding
from numeric (1, 2) allele coding to standard ACGT format before being
used in polygenic profile scoring analyses. This was achieved using a
bespoke programme developed by one of the present authors (DCML),
details of which are provided in the Supplementary Materials.
Polygenic profiles were created for 24 health-related phenotypes (see
Table 3, and Supplementary Table 1) in all genotyped participants using
PRSice.26 PRSice calculates the sum of alleles associated with the
phenotype of interest across many genetic loci, weighted by their effect
sizes estimated from a GWAS of that phenotype in an independent sample.
Before creating the scores, SNPs with a minor allele frequency o0.01 were
removed and clumping was used to obtain SNPs in linkage equilibrium
with an r2o0.25 within a 200 bp window. Multiple scores were then
created for each phenotype containing SNPs selected according to the
significance of their association with the phenotype. The GWAS summary
data for each of the 24 health-related phenotypes were used to create five
polygenic profiles in the UK Biobank participants, at thresholds of Po0.01,
Po0.05, Po0.1, Po0.5 and all SNPs.
Correlation coefficients were calculated between each of the UK Biobank
cognitive phenotypes. The associations between the polygenic profiles
and the target phenotype were examined in regression models (linear
regression for the continuous cognitive traits and logistic regression for the
binary education variable), adjusting for age at measurement, sex,
genotyping batch and array, assessment centre and the first 10 genetic
principal components to adjust for population stratification. We corrected
for multiple testing across all polygenic profile scores at all significance
thresholds for associations with all cognitive phenotypes (470 tests) using
the false discovery rate method.27 We conducted sensitivity analyses as
follows. Where the original findings were false discovery rate significant,
UK Biobank participants with cardiovascular disease (N=5300) were then
removed from analyses of coronary artery disease, those with diabetes
(N= 5800) were removed from type 2 diabetes analyses, and those with
hypertension (N= 26 912) were removed from systolic blood pressure
analyses. See Supplementary Materials for further details of these
sensitivity analysis. Four multivariate regression models were then
performed, including all 24 polygenic profile scores and the covariates
described above.
RESULTS
Phenotypic and genetic associations among the UK Biobank’s
cognitive traits
In addition to descriptive statistics, Table 1 shows phenotypic
correlations and genetic correlations (calculated using LD score
regression) among the cognitive traits in UK Biobank. There were
modest correlations between the three cognitive test scores; those
who did well on one test tended to do well on the other two.
Verbal-numerical reasoning showed the highest phenotypic
correlation with educational attainment (r= 0.30). The strongest
genetic correlation was also between verbal-numerical reasoning
and educational attainment (rg = 0.79). All but one of the other
genetic correlations were statistically significant: there was a
nonsignificant genetic correlation between educational attain-
ment and reaction time. These results show that different
cognitive traits and educational attainment correlate, in part,
due to overlapping genetic architecture.
Cognitive–health pleiotropy: overview
To test for pleiotropy between cognitive and health traits, we
present the LD score regression (Table 2, Figure 1) and polygenic
profile score (Table 3, Supplementary Tables 4a and d) results for
the four UK Biobank cognitive function and educational attainment
traits, and the 24 health-related traits from GWAS consortia. Results
are false discovery rate-corrected for multiple comparisons.
In overview, using LD score regression results, educational
attainment showed significant genetic correlations with 14 of the
22 health-related traits, verbal-numerical reasoning had significant
genetic correlations with 10 of the 24, and memory and reaction
time both correlated significantly with 3 of the 24 (Table 2,
Figure 1).
In the polygenic profile score results, using the best SNP
threshold of the five that were created, summary GWAS data
from 19 of 22 consortia predicted significant phenotypic variation
in educational attainment in the UK Biobank sample (Table 3). For
verbal-numerical reasoning, results from 15 of the 24 consortia
predicted significant phenotypic variation. The numbers for
memory and reaction time were seven and six, respectively.
The numbers of SNPs included in each polygenic threshold
score for each of the 24 health-related traits are shown in
Supplementary Table 3. The fuller results relating all five of the
SNP thresholds for all the 24 health-associated variables with the
UK Biobank cognitive phenotypes are shown in Supplementary
Tables 4a–d.
Cognitive–health pleiotropy: brain-cognitive traits
Cognitive and brain traits provided a first check before moving to
more mainstream health measures whose phenotypes appear
more distant from cognitive function. In LD score regression
analyses, we expected significant genetic correlations between
GWAS consortia results from cognitive- and brain-related traits
and the UK Biobank GWAS results for cognitive variables. In
polygenic risk score analyses, we expected the polygenic scores
based on the health-related GWAS consortia’s results to predict
phenotypic variation in UK Biobank’s cognitive traits.
Using LD score regression, genetic correlations of greater than
0.9 were found between UK Biobank’s Education Attainment
variable and GWAS consortia results from childhood cognitive
Table 1. Descriptive statistics and phenotypic (below diagonal) and genetic (above diagonal) correlations for the UK Biobank cognitive and
educational variables in all genotyped participants
Variable Mean (s.d.) Genetic/phenotypic correlation




Reaction time (ms) 555.08 (112.69) — 0.179 (0.06)* 0.206 (0.05)* 0.066 (0.04)
Memory (errors) 4.06 (3.23) 0.116 (0.003)* — 0.437 (0.06)* 0.126 (0.05)†
Verbal-numerical reasoning (max. score 13) 6.16 (2.10) 0.156 (0.005)* 0.176 (0.005)* — 0.729 (0.04)*
Educational attainment 30.5% with degree 0.099 (0.003)* 0.052 (0.003)* 0.338 (0.005)* —
Genetic correlations are based on the results of genome-wide association studies of the UK Biobank variables. Standard errors for the correlations are shown in
parentheses. For the phenotypic variables, Pearson correlations used for continuous–continuous correlations and point–biserial correlations for continuous–
categorical correlations. All variables are coded such that higher scores indicate better performance. *P-value o0.0001; †P-value o0.05.
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ability, college degree attainment and years of education (Table 2,
Figure 1). The genetic correlation between UK Biobank’s Educa-
tional Attainment variable and ENIGMA’s intracranial volume was
0.44 and with Early Growth Genetics Consortium’s infant head
circumference was 0.25. Verbal-numerical reasoning in UK Biobank
had a genetic correlation of 0.81 with childhood cognitive ability,
of 0.75 with attaining a college degree (Social Science Genetic
Association Consortium), 0.72 with years of education (Social
Science Genetic Association Consortium), and 0.25 with intracranial
volume. These results demonstrate substantial shared genetic
aetiology between brain size, cognitive ability and educational
attainment. Reaction time and memory did not have significant
genetic correlations with the brain, cognitive or educational
variables.
In summarizing polygenic profile analyses’ results in the text, we
shall use standardized betas (β). Polygenic profiles for higher
childhood cognitive ability and a higher level of educational
attainment (Social Science Genetic Association Consortium) were
significantly associated with increased likelihood of a college
degree (β between 0.12 and 0.28), higher scores on verbal-
numerical reasoning (β between 0.08 and 0.11), and faster
reaction time (β about 0.001). Only childhood cognitive ability
was significantly associated with memory (β= 0.01). Polygenic
profiles for greater intracranial volume and greater infant head
circumference were significantly associated with increased
likelihood of a college degree (β= 0.04 and 0.05, respectively),
and higher scores on verbal-numerical reasoning (both β= 0.02).
Cognitive–health pleiotropy: neuropsychiatric disorders
Using LD score regression, there were negative genetic correla-
tions between Alzheimer’s disease and UK Biobank’s educational
attainment variable and verbal-numerical reasoning (rg between
− 0.27 and − 0.39; Table 2, Figure 1). Autism had positive genetic
correlations with the same two Biobank variables: 0.34 for
educational attainment and 0.19 for verbal-numerical reasoning.
Bipolar disorder and schizophrenia showed a pattern of having a
positive genetic correlation with educational attainment (0.22 and
0.13, respectively) and a negative genetic correlation with verbal-
numerical reasoning (−0.11 and − 0.30, respectively). Schizophre-
nia was genetically associated with slower reaction time (−0.24)
and poorer memory (−0.34). Bipolar disorder was also genetically
associated with poorer memory (−0.24). Major depressive disorder
was genetically associated with slower reaction time (−0.25).
Table 2. Genetic correlations between the cognitive and education phenotypes documented in the UK Biobank data set and the health-related
variables collected from GWAS consortia






Memory (n= 112 067) Educational attainment
(n=111 114)
rg s.e. P rg s.e. P rg s.e. P rg s.e. P
Vascular–metabolic diseases
Coronary artery disease − 0.086 0.062 0.163 0.058 0.066 0.378 0.058 0.074 0.430 − 0.262 0.048 5.6 ×10−8
Stroke: ischaemic − 0.231 0.092 0.012 − 0.007 0.088 0.935 0.035 0.095 0.711 − 0.168 0.066 0.011
Stroke: cardioembolic − 0.037 0.133 0.781 − 0.104 0.125 0.405 − 0.056 0.134 0.679 − 0.027 0.092 0.771
Stroke: large vessel disease − 0.408 0.187 0.029 − 0.061 0.156 0.695 0.010 0.172 0.953 − 0.336 0.145 0.020
Stroke: small vessel disease — — — — — — — — — — — —
Type 2 diabetes − 0.023 0.064 0.725 0.034 0.064 0.590 0.059 0.077 0.444 − 0.090 0.050 0.074
Neuropsychiatric disorders
ADHD − 0.334 0.147 0.023 − 0.072 0.138 0.599 − 0.043 0.159 0.788 − 0.305 0.141 0.030
Alzheimer's disease − 0.394 0.124 0.002 0.042 0.085 0.622 − 0.131 0.116 0.256 − 0.266 0.082 0.001
Alzheimer's disease (500 kb) − 0.325 0.081 6.0 ×10−5 0.036 0.070 0.603 − 0.117 0.097 0.229 − 0.223 0.057 1.0 ×10−4
Autism 0.187 0.066 0.005 − 0.160 0.067 0.016 − 0.092 0.081 0.258 0.344 0.053 6.7 ×10−11
Bipolar disorder − 0.107 0.063 0.091 − 0.131 0.066 0.048 − 0.237 0.073 0.001 0.219 0.047 4.0 ×10−6
Major depressive disorder − 0.108 0.093 0.248 − 0.248 0.087 0.004 − 0.217 0.106 0.042 − 0.103 0.082 0.213
Schizophrenia − 0.295 0.045 3.5 ×10−11 − 0.240 0.040 2.1 × 10−9 − 0.339 0.041 1.1× 10−16 0.128 0.034 1.1 ×10−16
Brain measures
Hippocampal volume − 0.040 0.107 0.710 0.222 0.124 0.073 0.014 0.132 0.916 − 0.076 0.086 0.380
Intracranial volume 0.245 0.101 0.015 − 0.175 0.098 0.073 0.084 0.114 0.463 0.442 0.084 2.0 ×10−4
Infant head circumference 0.193 0.093 0.038 − 0.048 0.080 0.547 0.103 0.097 0.287 0.248 0.069 3.0 ×10−4
Physical and physiological measures
Blood pressure: diastolic − 0.071 0.057 0.213 − 0.074 0.054 0.172 − 0.050 0.065 0.442 − 0.071 0.039 0.067
Blood pressure: systolic − 0.061 0.058 0.297 − 0.027 0.052 0.600 − 0.010 0.063 0.873 − 0.082 0.037 0.026
BMI − 0.119 0.033 2.0 ×10−4 − 0.028 0.028 0.317 0.154 0.035 1.0× 10−5 − 0.233 0.024 3.6 ×10−22
Height 0.056 0.029 0.054 0.067 0.027 0.014 − 0.017 0.033 0.609 0.120 0.024 5.0 ×10−7
Longevity 0.111 0.092 0.226 − 0.067 0.086 0.437 0.130 0.114 0.254 NA NA NA
Forced expiratory volume in 1 s
(FEV1)
0.109 0.054 0.044 − 0.061 0.048 0.209 − 0.023 0.066 0.722 NA NA NA
Life-course cognitive traits and proxies
Childhood cognitive ability 0.812 0.094 6.2 ×10−18 0.067 0.089 0.451 0.100 0.112 0.370 0.906 0.082 4.2 ×10−28
College degree 0.749 0.055 3.3 ×10−42 0.046 0.053 0.388 − 0.050 0.060 0.404 0.984 0.041 3.8 ×10−130
Years of education 0.720 0.056 2.0 ×10−38 0.031 0.048 0.523 − 0.050 0.059 0.403 0.948 0.041 1.4 ×10−115
Abbreviations: ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GWAS, genome-wide association study; NA, not available; rg, genetic
correlation. Statistically significant P-values (after false discovery rate correction; threshold: Po0.016) are shown in bold. There was no evidence for a sufficient
polygenic signal in the small vessel disease data set and so no genetic correlation could be derived as shown in Supplementary Table 3.
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Polygenic profile scoring replicated the directions of association
found with LD score regression-estimated genetic correlations
(Table 3). Higher polygenic risk for Alzheimer’s disease was
associated with lower educational attainment and a lower score
on verbal-numerical reasoning and memory (β between − 0.01
and − 0.05). Higher polygenic risk for ADHD was associated with
lower educational attainment (β=−0.03). Higher polygenic risk for
autism was associated with higher educational attainment and
better verbal-numerical reasoning (β= 0.07 and 0.02, respectively).
Higher polygenic risk for bipolar disorder and schizophrenia had a
positive association with educational attainment (β= 0.06 and
0.03, respectively), and the genetic risk for schizophrenia and
major depressive disorder had a negative association with verbal-
numerical reasoning (β=− 0.06 and − 0.02, respectively).
Cognitive–health pleiotropy: vascular–metabolic diseases
There were significant negative genetic correlations between UK
Biobank’s educational attainment variable and coronary artery
disease (−0.26), ischaemic stroke (−0.17) and large vessel disease
stroke (−0.34; Table 2, Figure 1). There was a significant negative
genetic correlation between ischaemic stroke and verbal-
numerical reasoning (−0.23).
Greater polygenic risk for coronary artery disease, type 2
diabetes, and ischaemic, and large and small vessel disease
stroke were all associated with lower educational attainment
(β between − 0.02 and − 0.05). Greater polygenic risk for coronary
artery disease, and ischaemic and large vessel disease stroke
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Figure 1. Heat map of genetic correlations calculated using LD regression between cognitive phenotypes in UK Biobank and health-related
variables from GWAS consortia. Hues and colours depict, respectively, the strength and direction of the genetic correlation between the
cognitive phenotypes in UK Biobank and the health-related variables. Red and blue indicate positive and negative correlations, respectively.
Correlations with the darker shade associated with a stronger association. Based on results in Table 2. ADHD, attention deficit hyperactivity
disorder; FEV1, forced expiratory volume in 1 s; GWAS, genome-wide association study; LD, linkage disequilibrium; NA, not available.
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(β between − 0.01 and − 0.02). Greater polygenic risk for large
vessel disease stroke was associated with more errors in the
memory task (β=− 0.01). There was little change to the results for
coronary artery disease when individuals diagnosed with cardio-
vascular disease were removed from the analyses, and little
change for type 2 diabetes results when individuals with diabetes
were removed (Table 3).
Cognitive–health pleiotropy: physical, physiological and
anthropometric measures
There were significant genetic correlations between UK Biobank’s
educational attainment variable and body mass index (−0.23), and
height (0.12), both obtained from the GIANT Consortium. There
was a significant negative genetic correlation between body mass
index and verbal-numerical reasoning (−0.12) and a significant
positive genetic correlation with memory (0.15).
Greater polygenic risk for diastolic and systolic blood pressure
(obtained from International Consortium for Blood Pressure), and
body mass index were all associated with lower educational
attainment (β of − 0.02, − 0.04 and − 0.09, respectively). A
polygenic profile for greater height was associated with higher
educational attainment (β= 0.07). Higher verbal-numerical reason-
ing scores were associated with lower polygenic risk for body
mass index (β=− 0.03), and a polygenic profile for greater height
(β= 0.02) and higher systolic blood pressure (β= 0.01). Results for
systolic blood pressure changed little when individuals with
hypertension were removed from the analysis (Table 3).
Multivariate models predicting cognitive variance using many
polygenic profile scores
We next ran four multivariate regression models that included all
24 polygenic profile scores alongside the same covariates as were
described above. This tested whether there was redundancy
among the polygenic profile scores, and the extent to which
including them all together in a multivariate model would
improve the prediction of the cognitive phenotype. We compared
the R2 value of models including all the profile scores to models
including only the covariates. The polygenic profile scores alone
accounted for 3.33% of the variance in educational attainment of
a college or university degree, 2.26% of the variance in verbal-
numerical reasoning scores, 0.12% in reaction time and 0.16% in
memory scores. See Supplementary Table 5 for full results.
DISCUSSION
The present study has combined the power of UK Biobank’s very
large genotyped and cognitively tested sample with the summary
results of 24 large international GWAS consortia of physical and
mental disorders and health-related traits. Two methods—LD
score regression and polygenic profile scoring based on previous
GWAS findings—discovered extensive cognitive–health pleiotropy
and showed that it can be used to predict phenotypic variance
between GWAS data sets. Our results provide comprehensive new
findings on the overlaps between phenotypic cognitive ability
levels, genetic bases for health-related characteristics such as
height and blood pressure, and liabilities to physical and
psychiatric disorders even in mostly healthy, non-diagnosed
individuals. They make important steps toward understanding
the specific patterns of overlap between biological influences on
health and their consequences for key cognitive abilities. For
example, some of the association between educational attainment
—often used as a social background indicator—and health
appears to have a genetic aetiology. These results should
stimulate further research that will be informative about the
specific genetic mechanisms of the associations found here, which
likely involves both protective and detrimental effects of different
genetic variants.
Findings for polygenic risk for coronary artery disease were not
confounded by individuals with a diagnosis of cardiovascular
disease, findings for type 2 diabetes were not confounded by
individuals with a diagnosis of diabetes and findings for systolic
blood pressure were not confounded by individuals with a
diagnosis of hypertension. These results indicate that even in
healthy individuals, being at high polygenic risk for coronary
artery disease, type 2 diabetes or high blood pressure is associated
with lower cognitive function and lower educational attainment.
Using LD score regression, we quantified for the genetic
correlations from molecular genetic evidence between tests of
cognitive ability and a wealth of health and anthropometric traits
in over 100 000 individuals. As shown in Table 2, verbal-numerical
reasoning and educational attainment showed a greater degree of
pleiotropy than reaction time and memory, with many of the
health and anthropometric variables studied here. Novel genetic
correlations were quantified between cognitive function, using
verbal-numerical reasoning, and schizophrenia, Alzheimer’s dis-
ease and ischaemic stroke. It has not escaped our notice that there
are multiple possible interpretations of these genetic correlations.
Not only might particular genes contribute both to cognitive and
health-related traits, but genetic variants relating to health
conditions could have indirect effects on cognitive ability (for
example, via medications used to treat disorders), and vice versa
(for example, via cognitively associated lifestyle choices). See
Solovieff et al.17 for discussion of these issues of causality and
pleiotropy.
Perhaps counter-intuitively, our results indicated that the
genetic variants associated with obtaining a college degree were
also related to higher genetic risk of schizophrenia, bipolar
disorder and autism, which for bipolar disorder and autism
support the findings from a previous study.15 For the cognitive
tests, only polygenic risk for autism was related with higher
cognitive ability, in agreement with a previous study.28 Genes
related to bipolar disorder were negatively related to all of the
cognitive tests, and genes related to schizophrenia even more so.
Previous epidemiological studies indicate that both very high and
very low educational achievement is associated with an increased
risk of bipolar disorder29 and high polygenic risk of schizophrenia
and bipolar disorder were recently associated with higher levels of
creativity.30 The discrepancy between the cognitive and educa-
tional results may be explained by the age of the participants: if
schizophrenia genes are detrimental to cognitive functioning only
later in life, they may have differential effects on educational
attainment, which tends to peak before age 30, and the cognitive
tests, which were taken in UK Biobank at an average age of 56.9
years. It should also be noted the UK Biobank sample consists of
individuals who are, on average, older than those in most
schizophrenia genetic studies, have a higher level of education
and are of a higher social class. It is also likely to have been the
case that individuals in middle age with a history of serious mental
illness will have been less likely than those without such a history
to volunteer as UK Biobank participants. These demographic and
clinical factors might have contributed to apparently contradictory
findings with respect to cognitive function and previous educa-
tional attainment.
The educational attainment variable demonstrated pleiotropy
with 20 of the 24 health-related variables, indicating that the
genetic variants that collectively act to facilitate an individual’s
progress through the educational system to degree level make
important contributions to many important health outcomes. One
explanation for this is that the educational attainment variable
shows the greatest degree of pleiotropy with general cognitive
ability in childhood with a genetic correlation of 0.906. This could
indicate that it is genes related to cognitive ability early in life that
are responsible for the pleiotropy with health variables: educa-
tional attainment, therefore, might act as a proxy phenotype for
general cognitive ability, as others have demonstrated.8
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The significant genetic correlations across traits enabled the use
of polygenic profile scores to predict phenotypic cognitive
variance in the UK Biobank sample. The amount of variance
explained by the polygenic profile scores for each UK Biobank
cognitive phenotype is small, as would be expected by the fact
that not all SNPs were genotyped, and those that were do not
necessarily accurately tag the causal genetic variants. The multi-
variate polygenic risk score analyses showed that additional
variance can be accounted for when the polygenic liabilities of
multiple disorders and traits are combined; this implies that there
are risk alleles unique to each disorder and trait that affect
cognitive and educational traits.
The results of the present study are supported by a previous
study examining the genetic associations between polygenic
profile scores for psychiatric and cognitive traits, and many
phenotypic traits, showing comparable directions of effect.16
However, owing to the much smaller sample size (3000 versus
112 000 in the present study), the previous study yields
insufficient power to detect several of the associations found in
the present study. The same previous study also supported the
results of the LD regression analyses of the present study between
several psychiatric and cognitive traits, but the following traits
show novel associations with cognitive ability and educational
attainment in the present study: ischaemic stroke, infant head
circumference and years of education.
The polygenic profile analysis replicated previous, smaller studies
that showed associations between higher cognitive function and
higher polygenic risk for autism28 and lower polygenic risk for
schizophrenia21 and stroke.22 We did not replicate the previous
finding that higher cognitive function is associated with higher type
2 diabetes genetic risk,31 but we did find that higher type 2
diabetes genetic risk is associated with decreased likelihood of
obtaining a college degree. Unlike a previous small, underpowered,
study23 we found that higher polygenic risk for Alzheimer’s disease
is associated with lower cognitive function.
To the extent that these genetic associations between cognitive
and health measures are explained by shared genetic influences,
they support the theoretical construct of bodily system integrity.32
System integrity was formulated as a latent trait which is manifest
as individual differences in how effectively people meet cognitive
and health challenges from the environment, and which has some
genetic aetiology. Although it is recognized that some illnesses
will cause changes in cognitive functions, system integrity
suggests, in addition, that there is shared variance in how well
different complex bodily systems operate and that this underlies
correlations between higher cognitive functioning and good
health and longevity.
The present study has a number of strengths. First, the large
sample size of UK Biobank (N4100 000) affords powerful, robust
tests of genetic association. Second, the participants took identical
cognitive tests, which were always administered in the same
computerized fashion, reducing any potential bias owing to
heterogeneity in test content and administration. Third, all of the
UK Biobank genetic data were processed in a consistent matter,
on the same platform and at the same location. Fourth, our use of
summary data from a large number of international GWAS studies
allowed a comprehensive and detailed examination of shared
genetic aetiology with cognitive ability across a wide range of
health-related phenotypes, producing many of the first estimates
of the genetic correlation between traits.
The present study has some limitations. The three cognitive
tests were brief, bespoke measures. However, they covered three
major cognitive domains (reasoning, processing speed and
memory), showed acceptable internal consistency and had validity
in that they showed the expected correlations with one another
and with age and educational attainment.33,34 The verbal-
numerical reasoning test has types of item that are the same as
those found in tests of general cognitive ability. In addition,
verbal-numerical reasoning and educational attainment showed
strong genetic correlations (0.812 and 0.906, respectively) with
childhood general cognitive function. This suggests that the
variance in these traits is largely the product of the same genetic
variants that underpin general cognitive function. The GWAS
studies we curated to perform LD score regression and extract the
polygenic profile scores were often consortia studies, involving
meta-analyses across data sets with substantial heterogeneity in
sample size, genome-wide imputation quality and phenotypic
measurement. We expect that, with larger and more consistent
independent data sets, we would be able to use the polygenic
profile scores to predict more variance in cognitive test
performance. Some of the GWAS consortia studies did not have
ethical approval to be used for genetic correlation and polygenic
profile scoring analyses associated with education, meaning that
we were unable to estimate a few correlations. Clustering in
genetic population structure meant that we restricted the
genotyped samples to individuals of white British ancestry. Our
results thus need to be replicated in large samples of different
genetic backgrounds; the sample sizes available in UK Biobank
were not large enough for us to model, with adequate power, data
from UK Biobank individuals of other ancestries.
The best method for showing pleiotropy using GWAS data
would be to obtain the genome-wide significant hits from two
GWAS and correlate the effect sizes. However, there are two
reasons why this is suboptimal at present. The first reason is that
many significant SNP hits are needed in multiple GWAS data sets,
which is currently not possible. The second reason is that GCTA
has shown that many true associations do not reach statistical
significance owing to low power, therefore, SNPs that do not
attain statistical significance should also be considered. Both LD
regression and polygenic profile score analyses provide the
opportunity to use the full GWAS output to examine pleiotropy.
Because the optimum number of SNPs used to generate a
particular polygenic profile can differ between traits, we created
five profile scores per physical and mental health trait and tested
each in a regression against each of the UK Biobank cognitive
traits to determine the score that explained the greatest variance
in each cognitive trait. We found that these did differ between
different trait combinations, suggesting that the amount of shared
genetic aetiology differs between different pairs of traits.
However, as pleiotropy was quantified using LD score regression
to perform a single test for each pair of phenotypes, the multiple
testing problems associated with the polygenic profile score
method did not confound the estimates of pleiotropy shown here.
Although the estimate of phenotypic variance explained by the
polygenic profile method was small, this should be considered as
the minimum estimate of the variance explained. Owing to
pruning SNPs in LD, the PGRS method makes the assumption of a
single causal variant being tagged in each LD block considered. If
this assumption is not true for the phenotypes considered, the
proportion of variance explained will be underestimated here.
CONCLUSION
It is notable that, a short while ago, a single result from several of
the findings reported here would have been considered a major
novel finding and reported as a study in itself.20 With so many
findings, it has not been possible fully to discuss their implications.
For example, the genetic associations between infant head
circumference and intracranial volume with educational
attainment and verbal-numerical reasoning are important in
themselves, as are many other cognitive–mental health and
cognitive–physical health associations. Taken all together, these
results provide a resource that advances the study of aetiology in
cognitive epidemiology substantially.
Pleiotropy between cognitive ability and health
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The results in Section 4.2 show, using two molecular genetic techniques—LDSR and PRS—
that the association between cognitive ability and health is partly due to shared genetic 
influences. Whereas this Section did provide support for a shared genetic aetiology, the 
potential causality of the association was not investigated. The next Section of this Chapter 
will, therefore, assess whether cognitive ability causally affects physical health, or if physical 
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Causes of the association between cognitive ability and health remain unknown, but may 
reflect a shared genetic aetiology. This study examines the causal genetic associations between 
cognitive ability and physical health. We carried out two-sample Mendelian randomization 
analyses using the inverse-variance weighted method to test for causality between later life 
cognitive ability, educational attainment (as a proxy for cognitive ability in youth), BMI, 
height, systolic blood pressure, coronary artery disease, and type 2 diabetes using data from 
six independent GWAS consortia and the UK Biobank sample (N = 112 151). BMI, systolic 
blood pressure, coronary artery disease and type 2 diabetes showed negative associations with 
cognitive ability; height was positively associated with cognitive ability. The analyses 
provided no evidence for casual associations from health to cognitive ability. In the other 
direction, higher educational attainment predicted lower BMI, systolic blood pressure, 
coronary artery disease, type 2 diabetes, and taller stature. The analyses indicated no causal 
association from educational attainment to physical health. The lack of evidence for causal 
associations between cognitive ability, educational attainment, and physical health could be 





Lower cognitive ability, lower educational attainment and greater cognitive decline are all 
associated with poorer health outcomes (Calvin et al., 2011; I. J. Deary et al., 2010; Wraw et 
al., 2015). Some of these associations possibly arise because of the effect of lower cognitive 
ability in childhood on later life health, others because illnesses may lower cognitive ability in 
later life. The causes of these associations are unclear, but some may reflect, in part, a shared 
genetic aetiology. Recent papers have reported genetic associations between cognitive ability 
and educational attainment, and a number of physical and mental health traits and diseases 
(Brendan K. Bulik-Sullivan et al., 2015a; Hagenaars et al., 2016b; Hill et al., 2016). These 
(Hagenaars et al., 2016b; Hill et al., 2016), and other papers (Banks & Mazzonna, 2012; 
Rietveld et al., 2014; Trampush et al., 2015), have shown successful use of educational 
attainment as a proxy for cognitive ability, showing phenotypic correlations between 
educational attainment and general cognitive ability around 0.50 (Banks & Mazzonna, 2012) 
and a genetic correlation of 0.72 (Hagenaars et al., 2016b). 
 
Some of the reciprocal phenotypic associations between cognitive and physical health 
variables, and their genetic correlations, are as follows. Short stature has been consistently 
linked with lower cognitive ability (Keller et al., 2013; Silventoinen, Posthuma, Van 
Beijsterveldt, Bartels, & Boomsma, 2006). Molecular genetic studies have indicated positive 
genetic correlations between height and cognitive ability (Hagenaars et al., 2016b; Marioni et 
al., 2014a), as well as between height and educational attainment (Brendan K. Bulik-Sullivan 
et al., 2015a; Hagenaars et al., 2016b). Higher polygenic scores for height have been associated 
with better cognitive ability in adulthood (Hagenaars et al., 2016b). A causal association was 
reported between taller stature and educational attainment (not including individuals with a 
degree) in UK Biobank using a Mendelian randomization analysis (Tyrrell et al., 2016). 
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Multiple studies have shown associations between cognitive ability and cardiovascular risk 
factors. For example, lower childhood cognitive ability is associated with subsequent high 
blood pressure (Starr et al., 2004) and obesity (Belsky et al., 2013). However, higher BMI in 
mid-life (Dahl et al., 2010) and both hypertension and hypotension (Novak & Hajjar, 2010) 
are associated with lower cognitive ability and greater cognitive decline in later life. A negative 
genetic correlation has been identified between BMI, but not blood pressure, and educational 
attainment and cognitive ability in mid to late life (Brendan K. Bulik-Sullivan et al., 2015a; 
Hagenaars et al., 2016b) and a polygenic score for higher BMI is associated with lower 
cognitive ability in mid to late life and lower educational attainment (Hagenaars et al., 2016b), 
however, a polygenic score for higher systolic blood pressure is associated with lower 
educational attainment, but higher cognitive ability in mid to late life (Hagenaars et al., 2016b).  
 
Similarly, associations have been identified between cognitive ability and cardio metabolic 
diseases. Childhood cognitive ability has been associated with developing diabetes (Mõttus et 
al., 2013) and coronary artery disease (Lawlor, David Batty, Clark, McIntyre, & Leon, 2008) 
later in life. Diabetes (Rawlings et al., 2014) and coronary artery disease (Eggermont et al., 
2012; Kovacic, Castellano, & Fuster, 2012) in midlife have been associated with greater 
cognitive decline later in life. A polygenic risk score for type 2 diabetes is associated with 
lower educational attainment, but not with cognitive ability in mid to late life (Hagenaars et 
al., 2016b), although one has been associated with reduced cognitive decline (Luciano et al., 
2014). To date, no significant genetic correlation between diabetes and cognitive ability has 
been identified (Brendan K. Bulik-Sullivan et al., 2015a; Hagenaars et al., 2016b). A polygenic 
risk score for coronary artery disease is associated with lower educational attainment and 
lower mid to late life cognitive ability (Hagenaars et al., 2016b), and a negative genetic 
correlation was identified between coronary artery disease and educational attainment 
(Brendan K. Bulik-Sullivan et al., 2015a; Hagenaars et al., 2016b), but not cognitive ability in 
mid to late life (Hagenaars et al., 2016b). 
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The question arises as to whether the genetic cognitive-health associations caused by:  1) genes 
influencing health traits/diseases, and then those health traits/diseases subsequently 
influencing cognitive ability; 2) genes influencing cognitive ability, and then cognitive ability 
subsequently influencing health traits/diseases; 3) genes influencing general bodily system 
integrity(I. J. Deary, 2012) that influences both cognitive ability and health traits/diseases?  
 
To try to make some progress in understanding causality of the correlation between cognitive 
ability and a number of physical and mental health traits, in the present report we used a bi-
directional, two-sample Mendelian randomization (MR) approach (Bowden, Davey Smith, & 
Burgess, 2015). MR uses genetic variants as proxies for environmental exposures and is 
subject to the following assumptions: 1) the genetic variants are associated with the exposure; 
2) the genetic variants are only associated with the outcome of interest via their effect on the 
exposure [i.e., there is no biological pleiotropy (the phenomenon whereby one SNP 
independently influences multiple traits), also called the exclusion restriction]; and 3) the 
genetic variants are independent of confounders. Figure 4-1 shows the Mendelian 
randomization study model; the instrumental variable, based on genome-wide significant 
SNPs from independent studies for the exposure, is used to estimate if the exposure (e.g. BMI) 
causally influences the outcome (e.g. cognitive ability).  
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Figure 4-1. Model for Mendelian randomization study. The instrumental 
variable, based on genome-wide significant SNPs from independent studies 
for the exposure, is used to estimate if the exposure (e.g. BMI) causally 
influences the outcome (e.g. cognitive ability). The instrumental variable 
should be unrelated to potential confounders of the exposure-outcome 
association and should only affect the outcome via the exposure. 
 
Individual single nucleotide polymorphisms (SNPs) are often found to be weak instruments 
for investigating causality because they often have small effect sizes. Using multiple SNPs can 
increase the strength of the instrument. However, this increases the chance of violating the MR 
assumptions, specifically violation of the assumption that the genetic variants affect the 
outcome only via the exposure. We used multiple genetic variants for a number of health-
related traits and diseases, previously identified in genome-wide association studies, as 
instrumental variables to see if they predicted cognitive ability (verbal-numerical reasoning) 
in mid to later life in the UK Biobank. We then used genome-wide significant educational 
attainment SNPs as an instrumental variable to test whether genetic differences associated with 
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educational attainment (a proxy measure of cognitive ability in early life (Hill et al., 2016; 




This study uses baseline data from the UK Biobank Study, a large resource for identifying 
determinants of human diseases in middle aged and older individuals (Sudlow et al., 2015). 
Around 500,000 community-dwelling participants aged between 37 and 73 years were 
recruited and underwent assessments between 2006 and 2010 in the United Kingdom. This 
included cognitive and physical assessments, providing blood, urine and saliva samples for 
future analysis, and giving detailed information about their backgrounds and lifestyles, and 
agreeing to have their health followed longitudinally. For the present study, genome-wide 
genotyping data were available on 112,151 individuals (58,914 females) aged 40–70 years 
(mean age=56.9 years, s.d.=7.9) after the quality control process which is described in more 
detail elsewhere (Hagenaars et al., 2016b). This study has been approved by the National 
Health Service (NHS) Research Ethics Service (approval letter dated 17th June 2011, 
reference: 11/NW/0382). This study has been completed under UK Biobank application 
10279. All experiments were performed in accordance with guidelines and regulations from 
these committees. Written informed consent was obtained from each subject. 
 
4.3.2.2. Measures 
Body mass index 
Body mass index (BMI) was calculated as weight(kg)/height(m)2, and measured using an 
impedance measure, i.e. a Tanita BC418MA body composition analyser, to estimate body 
composition. We used the average of the two methods when both measures were available (r 
= 0.99); if only one measure was available, that measure was used (N = 1629). 291 individuals 
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did not have information on BMI. One outlier was excluded based on visual inspection of the 
BMI distribution (BMI > 50). 111,712 individuals had valid BMI and genetic data.  
 
Height 
Standing and sitting height (cm) were measured using a Seca 202 device. We used standing 
height and excluded one individual based on the visual inspection of the height distribution 
with a standing height < 125 cm and a sitting/standing height ratio < 0.75. 111,959 had valid 
height and genetic data. 
 
Systolic blood pressure  
Systolic blood pressure was measured twice, a few moments apart, using the Omron Digital 
blood pressure monitor. A manual sphygmomanometer was used if the digital blood pressure 
monitor could not be employed (N = 6652). Systolic blood pressure was calculated as the 
average of measures at the two time points (for either automated or manual readings). 
Individuals with a history of coronary artery disease were excluded from the analysis (N = 
2513). Following the recommendation by Tobin, Sheehan, Scurrah, and Burton (2005), 15 
mmHg was added to the average systolic blood pressure of individuals taking antihypertensive 
medication (N = 10,988). Individuals with a systolic blood pressure (after correcting for 
medication) more than 4 SD from the mean were excluded from future analyses (N = 75). 
After all exclusions, 106,759 individuals remained with valid blood pressure and genetic data. 
 
Coronary artery disease 
UK Biobank participants completed a touch screen questionnaire on past and current health, 
which included the question “Has a doctor ever told you that you have had any of the following 
conditions? heart attack/angina/stroke/high blood pressure/none of the above/prefer not to 
answer”. This was followed by a verbal interview with a trained nurse who was made aware 
if the participant had a history of certain illnesses and confirmed these diagnoses with the 
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participant. For the present study, coronary artery disease was defined as a diagnosis of 
myocardial infarct or angina, reported during both the touchscreen and the verbal interview in 
individuals with genetic data (N = 5288). The control group (N = 104,784) consisted of 
participants who reported none of the following diseases (based on the non-cancer illness code 
provided by UK Biobank): myocardial infarction, angina, heart failure, cerebrovascular 
disease, stroke, transient ischaemic attack, subdural haemorrhage, cerebral aneurysm, 
peripheral vascular disease, leg claudication/intermittent claudication, arterial embolism. 
 
Type 2 diabetes 
Type 2 diabetes case-control status was created using the same method as described by Wood 
et al. (2014), for all individuals with genetic data based on the interim release of UK Biobank. 
Cases included participants who reported type 2 diabetes or generic diabetes during the nurse 
interview, started insulin treatment at least one year after diagnosis, were older than 35 years 
at the time of diagnosis, and did not receive a diagnosis one year prior to baseline testing (N = 
3764). The control group consisted of participants who did not fulfil these criteria, and did not 
report a diagnosis of type 1 diabetes, diabetes insipidus and gestational diabetes (N = 108,015). 
 
Years of education 
As part of the sociodemographic questionnaire in the study, participants were asked, “Which 
of the following qualifications do you have? (You can select more than one)”. Possible 
answers were: “College or University Degree/A levels or AS levels or equivalent/O levels or 
GCSE or equivalent/CSEs or equivalent/NVQ or HND or HNC or equivalent/Other 
professional qualifications e.g. nursing, teaching/None of the above/Prefer not to answer”. For 
the present study, a new continuous variable was created measuring ‘years of education 
completed’. This was based on the ISCED coding, using the 1997 International Standard 
Classification of Education (ISCED) of the United Nations Educational, Scientific and 
Cultural Organization (UNESCO, 2006). See the Table 4-1 for further details. Individuals who 
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reported that they had a NVQ or HND or HNC degree, individuals who reported other 
qualifications, and individuals who preferred not to answer were excluded from analyses. The 
reason for these exclusions was as follows: the first two categories would correspond to 15 
and 19 years of education according to the ISCED coding; regarding their mean scores on 
cognitive ability tests, this might not be the right place for these two degree levels in the 
ordered hierarchy of educational attainments (Supplementary Figure 1). For the current study, 
years of education was used a proxy phenotype for cognitive ability (Hagenaars et al., 2016b; 
Hill et al., 2016; Rietveld et al., 2014). A total of 97,550 individuals had valid data for the 
years of education variable. 
 
Table 4-1. Coding for years of education in UK Biobank based on the ISCED 
coding. ISCED, 1997 International Standard Classification of Education of the 
United Nations Educational, Scientific and Cultural Organization. 










College or university 
degree 1 5 20 (19 +1) 33,852 
A levels/AS levels or 
equivalent 2 3 13 12,560 
O levels/GCSEs or 
equivalent 3 2 10 24,802 
CSEs or equivalent 4 2 10 6064 
NVQ or HND or HNC or 
equivalent 5 NA NA 7788 
Other professional 
qualification eg: nursing, 
teaching 
6 NA NA 5776 
None of the above -7 1 7 20,272 
Prefer not to answer -3 NA NA 953 
 
 
Cognitive ability  
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Cognitive ability was measured using a 13-item touchscreen computerized verbal-numerical 
reasoning test. The test included six verbal and seven numerical questions, all with multiple-
choice answers, with a two-minute time limit. An example verbal item is: ‘If some flinks are 
plinks and some plinks are stinks then some flinks are definitely stinks?’ (possible answers: 
‘True/False/Neither-true-nor-false/do not know/prefer not to answer’). An example numerical 
item is: ‘If sixty is more than half of seventy-five, multiply twenty-three by three. If not 
subtract 15 from eighty-five. Is the answer?’ (possible answers: ‘68/69/70/71/72/do not 
know/prefer not to answer’). The cognitive ability score was the total score out of 13 (further 
detail can be found in Hagenaars et al. (2016b)). This test was introduced at a later stage during 
baseline assessment and only a subset of individuals therefore completed this test. A total of 
36,035 had valid cognitive ability and genetic data. 
 
4.3.2.3. Covariates 
All analyses were adjusted for the following covariates: age when attending assessment centre, 
sex, genetic batch and array, and the first ten genetic principal components for population 
stratification. 
 
4.3.2.4. Instrumental variables 
SNPs used in the instrumental variables were extracted from the imputed UK Biobank 
genotypes interim release including 112,151 individuals after quality control. Details on the 
quality control process have been published previously (Hagenaars et al., 2016b). All 
instrumental variables were created based on SNPs that reached genome-wide significance in 
the largest available GWAS in European samples for the variables of interest (BMI (Locke et 
al., 2015), height (Wood et al., 2014), systolic blood pressure (The International Consortium 
for Blood Pressure Genome-Wide Association Studies, 2011), coronary artery disease 
(Schunkert et al., 2011), type 2 diabetes (Morris et al., 2012) and educational attainment 
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(Okbay et al., 2016b)). For educational attainment, we downloaded the summary statistics 
based on the discovery GWAS only, which did not include the UK Biobank sample. 
Corresponding SNPs used in the instrumental variables were then extracted from the imputed 
UK Biobank’s interim release of genotypes, which amounted to 112,151 individuals of self-
reported White British ancestry after quality control. Details on the quality control process 
have been published previously (Hagenaars et al., 2016b). SNPs out of Hardy-Weinberg 
equilibrium (HWE, p < 1×10-6), with an imputation quality below 0.9, or individual genotypes 
with a genotype probability below 0.9 and strand ambiguous SNPs were excluded from the 
instrumental variables. The individual variants were recoded as 0, 1 or 2 according to the 
number of trait increasing alleles. Table 4-2 includes information on the number of SNPs 
included, the reference paper, and the amount of variance explained by the instrumental 
variables for the corresponding variable of interest. Supplementary Table 3a-f provides details 


























































































































































































































































































































































































































































4.3.2.5. Statistical analysis 
Phenotypic associations 
We performed linear regression analysis using BMI, height, systolic blood pressure, coronary 
artery disease, and type 2 diabetes to predict cognitive ability. We regressed BMI, height, and 
systolic blood pressure against educational attainment in a linear regression model; coronary 
artery disease and type 2 diabetes were regressed against educational attainment in logistic 
regression models.  
 
Mendelian randomization analysis 
The Mendelian randomization analysis was performed using inverse variance weighted 
regression analysis based on SNP level data, with each instrumental variable (IV) consisting 
of multiple SNPs (Bowden et al., 2015). The inverse variance weighted method is based on a 
regression of two vectors with the intercept constrained to zero; the genetic variant with the 
exposure association, and the genetic variant with the outcome association (Figure 4-1). By 
constraining the intercept to zero, this method assumes that all variants are valid instrumental 
variables. We performed an association analysis between each SNP in the instrumental 
variable for the exposure and the exposure itself (IV - exposure), as well as between the 
instrumental variable for the exposure and the outcome (IV - outcome). We then used the 
vector of the instrumental variable-outcome association analyses against the vector of the 
instrumental variable-exposure analyses. This association (vector IV - outcome ~ vector IV - 
exposure) was weighted by the standard error of the original IV-outcome association, to 
correct for minor allele frequency, as described by Bowden et al. (2015). Power calculations 
for the MR analyses can be found in Supplementary Table 1. No sensitivity analyses were 
performed due to the lack of significant causal associations. 
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4.3.3. Results 
4.3.3.1. Health outcomes predicting cognitive ability 
BMI, height, systolic blood pressure, and coronary artery disease predicted performance on 
the verbal-numerical reasoning test of cognitive ability (Table 4-3). A 1 SD higher BMI was 
associated with a 0.05 SD lower score for cognitive ability [β = -0.05, 95% CI = -0.06 – (-
0.04)]. A 1 SD greater height was associated with a 0.18 SD higher score for cognitive ability 
[β = 0.18, 95% CI = 0.17 – 0.20]. A 1 SD higher systolic blood pressure was associated with 
a 0.05 SD lower score for cognitive ability [β = -0.05, 95% CI = -0.06 – (-0.04)]. Individuals 
with coronary artery disease had, on average, a 0.27 SD lower score for cognitive ability [β = 
-0.27, 95% CI = -0.32 – (-0.21)]. Individuals with type 2 diabetes had, on average, a 0.06 SD 
lower score for cognitive ability [β = -0.06, 95% CI = - 0.12 – 0.01]. The Mendelian 
randomization inverse variance weighted analyses, with the five health outcomes as the 
exposures, and cognitive ability as the outcome, did not provide any causal evidence for any 





































































































































































































































































































































































































































































4.3.3.2. Education predicting health outcomes 
Educational attainment, as measured by years of education, predicted BMI, height, systolic 
blood pressure, type 2 diabetes and coronary artery disease (Table 4, Figure 2). The difference 
between 7 and 20 years of education was associated with a 0.37 SD lower BMI [β = -0.37, 
95% CI = -0.39 – (-0.35)], 0.31 SD taller stature [β = 0.31, 95% CI = 0.30 – 0.32], 0.20 lower 
SBP [β = -0.20, 95% CI = -0.22 – (-0.19)], 0.58 lower odds of type 2 diabetes [OR = 0.58, 
95% CI = 0.52 – 0.64], and 0.40 lower odds of coronary artery disease [OR = 0.40, 95% CI 
0.37 – 0.43]. The differences between the other groups (7 versus 10 and 13 years of education) 
can be found in Supplementary Table 2. In every case, the Mendelian randomization inverse 
variance weighted method did not show a causal effect of educational attainment on the health 







































































































































































































































































































































































































































































This study was designed to investigate causes of the well replicated finding that lower 
cognitive ability is associated with poorer health outcomes (Calvin et al., 2011; I. J. Deary et 
al., 2010; Wraw et al., 2015). It used a bidirectional two-sample MR approach to investigate 
this. We found no evidence for causal association between several health outcomes and 
cognitive ability, in middle and older age, or between educational attainment and physical 
health. 
 
Tyrrell et al. (2016) showed a significant causal association between taller stature and time 
spent in full time education in UK Biobank. They did not find a causal association between 
taller stature and degree level. The measure of time spent in full time education in UK Biobank 
excluded individuals who reported having a college degree, which could explain the 
discrepancy in results. The current study did include individuals who reported having a college 
degree, however used a categorical measure of four categories, whereas (Tyrrell et al., 2016) 
used a continuous measure of time spent in full time education. In a non-peer-reviewed (at the 
time of writing) study, Tillmann et al. (2017) did report a causal association from educational 
attainment to coronary artery disease and BMI using a two-sample MR approach based on two 
independent consortia. They used data from two independent GWAS consortia, including 
349,306 individuals for educational attainment, 194,427 (63,746 cases) individuals for 
coronary artery disease, and 339,224 individuals for BMI. The current study used the same 
data for educational attainment on a subset of individuals (N = 293,723), and 111,712 
individuals with BMI data; however, coronary artery disease was based on self-report 
diagnosis in UK Biobank, which included 110,072 (5288 cases) individuals. The summary 
level data for coronary artery disease in the Tillmann et al. (2017) report included both 
European and East-Asian individuals, whereas the current study only includes individuals of 
White British ancestry. They (Tillmann et al., 2017) excluded overlapping cohorts between 
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educational attainment and coronary artery disease data; however, it is unclear if overlapping 
cohorts were excluded for BMI. 
 
Another explanation for the lack of causal associations in the present study could be the high 
polygenic aetiology of the traits analysed in this study. Instrumental variables for 
cardiovascular disease, type 2 diabetes, blood pressure, and educational attainment explain a 
small amount of the variance in the exposure. A better instrumental variable would be expected 
to explain a substantial amount of the variance of the exposure. As shown by the power 
calculations (Supplementary Table 1), all instrumental variables (except BMI and systolic 
blood pressure) had sufficient power to detect the same magnitude of association as the 
observational estimates. The low power for BMI and systolic blood pressure potentially 
explains the lack of association with cognitive ability. A previous study by the current authors 
indicated a degree of genetic overlap between cognitive ability and health across the genome 
(Hagenaars et al., 2016b). The idea of pleiotropy between health and cognitive ability is 
consistent with the theoretical construct of bodily system integrity (I. J. Deary, 2012), whereby 
a latent trait is manifest as individual differences in how effectively people meet cognitive and 
health challenges from the environment, and which has some genetic aetiology.  
 
Strengths of this study include the large sample size of UK Biobank, the participants of which 
all took the same cognitive tests, completed the same questionnaires and answered the same 
interview questions, in contrast to most genetic studies, where assessments across different 
cohorts often vary. A further strength is the fact that all of the UK Biobank genetic data were 
processed in a consistent matter, on the same platform and at the same location. The genetic 
variants on which the instrumental variables originated used the largest available GWAS at 
moment of testing.  
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Limitations of this study include the fact that cognitive ability was only measured on a subset 
of the UK Biobank participants and that it was a bespoke test. A second major limitation was 
that there is no published large genome-wide association study of cognitive ability in early life 
from which we could obtain genetic variants to use as an instrumental variable. Therefore, we 
used genome-wide significant SNPs associated with educational attainment as our early life 
cognitive ability instrument. A further limitation is the case-control ascertainment in UK 
Biobank, as the current study based case-control status on self-report measures. This may have 
led to misclassification of disease status, causing a likely bias towards the null hypothesis (L. 
Zheng et al., 2012). 
 
Overall, this study found phenotypic cognitive-physical health associations, but did not find 
evidence for causal associations between cognitive ability and physical health. This may be 
due to weak instrumental variables, poorly measured outcomes, or the small numbers of 
disease cases.  Future work should therefore focus on stronger instrumental variables, as well 
as better measurement of the outcome variables. 
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As discussed by Hagenaars et al. (2016b) in Section 4.2, the finding that the association 
between different measures of cognitive ability and health is partly due to shared genetic 
influences, represents a first step in advancing the understanding of the mechanisms that 
underlie the association between cognitive ability and health. A further step has been made to 
untangle the potential causal pathways between cognitive ability and health in Section 4.3; 
however, no evidence of such pathways was found. Identifying bidirectional causal processes 
between cognitive ability and health, remains a challenge for future work to address. A recent 
study did show a causal association between educational attainment and coronary artery 
disease using a Mendelian randomization approach, this will be discussed in more detail in 
Section 8.1.1. The next Chapter will examine the genetic architecture of an executive function 




5. Genetic contributions to trail making test performance in 
UK Biobank 
5.1. Introduction  
The two studies in Chapter 4 examined the genetic association between different measures of 
cognitive ability and health, and the potential causal pathways between those measures of 
cognitive ability and physical health. The verbal-numerical reasoning, reaction time, and 
memory tests in UK Biobank are non-standardized bespoke measures of cognitive ability. It 
is therefore more difficult to generalize findings across other measures of cognitive ability. 
UK Biobank introduced follow-up tests, which included a web-based assessment of cognitive 
ability. The Trail Making Test was part of this web-based assessment, and is a widely used, 
standardized measure of executive function. Phenotypic studies have indicated that both fluid 
cognitive ability and processing speed are involved in the Trail Making Test (Salthouse, 
2011a, 2011b). This Chapter will therefore explore the genetic architecture of the Trail making 
test and the potential shared genetic aetiology with other cognitive abilities, both within UK 
Biobank and in independent samples. This paper has been submitted for publication at 




5.2. Genetic contributions to trail making test performance in UK Biobank 
(submitted).  
Saskia P Hagenaars1,2,3, Simon R Cox1,2, W David Hill1,2, Gail Davies1,2, David CM Liewald1,2, 
CHARGE consortium Cognitive Working Group, Sarah E Harris1,4, Andrew M McIntosh1,3, 
Catharine R Gale1,2,5*, Ian J Deary1,2*# 
 
1 Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7 
George Square, Edinburgh EH8 9JZ, UK 
2 Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, 
UK 
3 Division of Psychiatry, University of Edinburgh, Edinburgh, EH10 5HF, UK 
4 Medical Genetics Section, University of Edinburgh Centre for Genomic and Experimental 
Medicine and MRC Institute of Genetics and Molecular Medicine, Western General Hospital, 
Crewe Road, Edinburgh EH4 2XU, UK 
5 MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, SO16 6YD, 
UK 
*These authors contributed equally to the work. 
 
# Corresponding author, 
Ian J. Deary   
Centre for Cognitive Ageing and Cognitive Epidemiology 
Department of Psychology 
University of Edinburgh 
7 George Square 
Edinburgh, EH8 9JZ 
Scotland, UK 
Telephone: +44 131 650 3452 






The Trail Making Test is a widely used test of executive function and has been thought to be 
strongly associated with general cognitive function. We examined the genetic architecture of 
the trail making test and its shared genetic aetiology with other tests of cognitive function in 
23 821 participants from UK Biobank. The SNP-based heritability estimates for trail-making 
measures were 7.9 % (part A), 22.4 % (part B), and 17.6 % (part B – part A). Significant 
genetic correlations were identified between trail-making measures and verbal-numerical 
reasoning (rg > 0.6), general cognitive function (rg > 0.6), processing speed (rg > 0.7), and 
memory (rg > 0.3). Polygenic profile analysis indicated considerable shared genetic aetiology 
between trail making, general cognitive function, processing speed, and memory (standardized 
β between 0.03 and 0.08). These results suggest that trail making is both phenotypically and 





The Trail Making Test (TMT) is widely used in both research and clinical settings as a test of 
some aspects of executive function (Delis, Kaplan, & Kramer, 2001; Lezak, Howieson, & 
Loring, 2004; Reitan & Wolfson, 1985). The TMT is usually given as two parts, from which 
three measures are derived. In Part A (TMT-A), participants are required to connect an array 
of numbers in ascending order, by drawing a continuous line (trail) between them as quickly 
and accurately as possible. Part B (TMT-B) requires participants to connect an array of both 
numbers and letters in alternating ascending order (1, A, 2, B, 3, C, etc.) with the same 
emphasis on speed and accuracy (Supplementary Figure 1). Subtracting TMT-A completion 
time from that of TMT-B (TMT B minus A) is thought to allow the relative contributions of 
visual search and psychomotor speed to be parsed from the more complex executive functions 
(such as cognitive flexibility) required to alternate between numbers and letters (Arbuthnott & 
Frank, 2000; Bowie & Harvey, 2006; Gläscher et al., 2012; Kortte, Horner, & Windham, 2002; 
Strauss, Sherman, & Spreen, 2006). 
 
TMT performance has been ascribed to a number of cognitive processes, “including attention, 
visual search and scanning, sequencing and shifting, psychomotor speed, abstraction, 
flexibility, ability to execute and modify a plan of action, and ability to maintain two trains of 
thought simultaneously” (Salthouse, 2011b, p. 222). It is considered a useful tool in research 
and clinical practice due to the sensitivity of the task (particularly TMT B and B-A) to frontal 
lobe damage (in some, but not other studies; see MacPherson, Della Sala, Cox, Girardi, and 
Iveson (2015)) and dementia (Amieva et al., 1998; Ferman et al., 2006; Rasmusson, 
Zonderman, Kawas, & Resnick, 1998). There are declines in both TMT A and B performance 
in ageing (Giovagnoli et al., 1996; Hamdan & Hamdan, 2009; Hashimoto et al., 2006; Hester, 
Kinsella, Ong, & McGregor, 2005; MacPherson et al., 2015; Periáñez et al., 2007; Salthouse, 
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2011a; Seo et al., 2006). There is also evidence for performance deficits on TMT B in mood 
disorders (Marvel & Paradiso, 2004), and in patients with schizophrenia and their relatives 
(Aleman, Hijman, Haan, & Kahn, 1999; Gilvarry, Russell, Hemsley, & Murray, 2000; 
Heinrichs & Zakzanis, 1998; Periáñez et al., 2007; Sitskoorn, Aleman, Ebisch, Appels, & 
Kahn, 2004; Wölwer & Gaebel, 2002; Zalla et al., 2004)  
 
Family-based and twin-based studies have provided evidence for a genetic contribution to 
individual differences in trail making, estimating the heritability for trail making part A 
between 0.23 and 0.38, and between 0.39 and 0.65 for trail making part B (Buyske et al., 2005; 
Knowles et al., 2014; Vasilopoulos et al., 2012). A recent genome-wide association study 
(GWAS) of trail making part A and part B in a sample of around 6000 individuals did not find 
any genome-wide significant hits (Ibrahim-Verbaas et al., 2016); however, GWAS of other 
cognitive phenotypes have demonstrated that much larger sample sizes are required to reliably 
identify significant genetic loci (G. Davies et al., 2015a; G. Davies et al., 2016b). Trail making 
is thought to have genetic influences that are shared with other cognitive abilities, with a twin-
based genetic correlation of 0.48 reported between trail making, measured as the ratio between 
trail making part A and trail making part B, and general cognitive function, and 0.52 with 
working memory (T. Lee et al., 2012). 
 
In addition to a relatively poor understanding of the molecular genetic underpinnings of TMT, 
its cognitive and psychometric architecture merits further research. Specifically, it is unclear 
whether the cognitive abilities required for TMT-B performance are distinct from other 
cognitive domains, because TMT A and B scores correlate with measures of general cognitive 
function and processing speed (correlation coefficient estimates range from ~0.3 to ~0.7; 
(Salthouse, 2011a, 2011b)) (Corrigan & Hinkeldey, 1987; Goul & Brown, 1970; Steinberg, 
Bieliauskas, Smith, & Ivnik, 2005; Vasilopoulos et al., 2012; Waldmann, Dickson, Monahan, 
& Kazelskis, 1992). Evidence from cognitive-ageing studies further suggests a strong overlap 
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between TMT performance and other cognitive domains, because age-related decline in 
processing speed and working memory account for much of the age effects on TMT-B 
(Oosterman et al., 2010; Salthouse, 2011a, 2011b; Sanchez-Cubillo, Perianez, Adrover-Roig, 
& Rodriguez-Sanchez, 2009). However, reliably identifying the cognitive processes that 
underpin cognitive test performance using phenotypic correlational analyses alone is sub-
optimal, (e.g. Cox et al., 2014; Delis, Jacobson, Bondi, Hamilton, & Salmon, 2003; Rabbitt, 
2011). Rather, the interpretation of relationships between TMT performance and other 
cognitive abilities such as general cognitive function, may be enhanced by considering and 
comparing their respective shared and unshared causes, including their genetic architecture. 
By examining the shared genetic architecture of TMT and other measures of cognitive ability, 
the current study will aid a better understanding of potential biological pathways involved in 
cognitive ability. 
 
The aim of the present study is to: 1) add to the understanding of the genetic architecture of 
trail making; and 2) to explore the overlap between genetic architecture of TMT performance 
and other cognitive abilities, including general cognitive function. Although several studies 
have examined the genetic architecture of the trail making test and its overlap with other 
cognitive abilities, they had relatively low power. The largest TMT GWAS (N ~ 6000) to date 
used a variety of assessments across multiple cohorts across multiple countries, potentially 
leading to heterogeneity in both sample composition and in the cognitive measures (Ibrahim-
Verbaas et al., 2016). The current study design, using >23,000 UK Biobank participants, 
mitigates such confounds: the almost four-fold increase in sample size yields greater statistical 
power, and the single sample reduces heterogeneity in genetic testing and in phenotype, 
because all participants had white British ancestry and took the same TMT test with the same 
instructions. In addition, we add to this significantly larger GWAS than has previously been 
conducted with: (1) estimates of the SNP-based heritability of TMT performance, and (2) an 
examination of genetic overlap among the different TMT test measures and with other 
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5.2.2. Materials and methods 
5.2.2.1. Participants 
UK Biobank is a large resource which aims to identify determinants of human diseases in 
middle aged and older individuals (http://www.ukbiobank.ac.uk) (Sudlow et al., 2015). A total 
of 502,655 community-dwelling individuals aged between 37 and 73 years were recruited in 
the United Kingdom between 2006 and 2010. Baseline assessment included cognitive testing, 
personality self-report, and physical and mental health measures. For the present study, 
genome-wide genotyping data were available for 112,151 participants (58,914 females, 53,237 
males) after quality control (see below). They had a mean (SD) age of 56.9 (7.9) years (range 
40 to 73 years). UK Biobank received ethical approval from the Research Ethics Committee 
(REC reference for UK Biobank is 11/NW/0382). This study was completed under UK 




Figure 5-1. Flow diagram of participant selection. 
 
5.2.2.2. Measures  
The trail making test parts A (TMT A) and B (TMT B) were introduced at a follow up testing 
wave in UK Biobank, between 2014 and 2015. For TMT A, participants were instructed to 
connect numbers (1 – 25) consecutively (which were quasi-randomly distributed on the 
touchscreen) as quickly as possible in ascending order by selecting the next number. TMT B 
is similar, but letters (A – L) and numbers (1 – 13) had to be selected in alternating ascending 
order, e.g. 1 A 2 B 3 C etc. The intervals between touching two points was timed in seconds 
169
using a Javascript timer. The total time (in seconds) to complete the trail making test (part A 
or B) was derived by summing the interval values between two points. Nine out of 23,821 
individuals who scored >250 seconds for TMT B were excluded. Owing to positively skewed 
distributions, both TMT A and TMT B scores were log-transformed prior to further analyses. 
The difference between the raw scores for TMT A and TMT B was computed as TMT B minus 
TMT A (TMT B-A). 52 out of 23,821 individuals with scores <-50 or >150 were removed 
from TMT B-A. After exclusions, 23,822 individuals with genetic data completed TMT A, 
23,812 individuals with genetic data completed TMT B, and 23,769 individuals had complete 
information for TMT B-A. The three trail making measures have been scored such that a 
higher score indicates better performance. This study also used the verbal-numerical reasoning 
test from UK Biobank (VNR, N = 36,035), which consisted of a 13-item questionnaire 
assessing verbal and arithmetical deduction (Chronbach α reliability = 0.62) as described by 
Hagenaars et al. (2016b). 
 
5.2.2.3. Genotyping and quality control 
The interim release of UK Biobank included genotype data for 152,729 individuals, of whom 
49,979 were genotyped using the UK BiLEVE array and 102,750 using the UK Biobank axiom 
array. These arrays have over 95% content in common. Details of the array design, genotyping 
procedures and quality control details have been published elsewhere (Hagenaars et al., 2016b; 
Wain et al., 2015). UK Biobank released an imputed dataset as part of the interim data release. 
More details can be found at the following URL: 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020. A minor allele frequency cut-off of 
1 % was used for all autosomal variants, as well as an imputation quality score above 0.3 (N 
~ 9.7M SNPs). 
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5.2.2.4. Genome-wide association analysis (GWAS) 
Genotype-phenotype association analyses were conducted using SNPTEST v2.5.1 (Marchini, 
Howie, Myers, McVean, & Donnelly, 2007). The ‘frequentist 1’ option was used to specify 
an additive model, and genotype dosages were analysed to account for genotype uncertainty. 
All phenotypes were adjusted for the following covariates prior to analysis; age, gender, 
assessment centre, genotyping array and batch and the first 10 genetic principal components 
for population stratification. The GWAS of VNR has been performed previously (G. Davies 
et al., 2016b). 
 
5.2.2.5. SNP-based heritability and genetic correlations 
Univariate GCTA-GREML (J. Yang et al., 2010) analysis was performed to estimate the 
proportion of variance explained by all genotyped common SNPs for TMT A, TMT B and 
TMT B-A. To include only unrelated individuals, a relatedness cut-off of 0.025 was used in 
the generation of the genetic relationship matrix. Given the likely difference in reliability 
between the raw (TMT-A and TMT-B) and difference (TMT B-A) scores (Crocker & Algina, 
1986), we undertook a supplementary analysis to compare reliability-weighted heritability 
estimates (see Supplementary Methods) to provide a clearer comparison of h2 differences 
between elements of the TMT. Bivariate GCTA-GREML (J. Yang et al., 2010) and LD score 
regression (B. K. Bulik-Sullivan et al., 2015) were used to derive genetic correlations between 
TMT measures and VNR in UK Biobank (G. Davies et al., 2016a). LD score regression was 
also used to estimate genetic correlations between trail making measures in UK Biobank and 
trail making part A, trail making part B, general cognitive function, processing speed, and 
memory from the CHARGE consortium (participants aged 45 years or older) meta-analyses 
of these cognitive phenotypes (G. Davies et al., 2015b; Debette et al., 2015b; Ibrahim-Verbaas 
et al., 2016). 
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5.2.2.6. Gene-based association analysis 
MAGMA (de Leeuw, Mooij, Heskes, & Posthuma, 2015) was used to derive gene-based 
associations using the summary results of the three GWAS for trail making. 18 062 genes were 
analysed after the SNPs were assigned a gene based on their position using the NCBI 37.3 
build, without additional boundaries placed around the genes. To account for linkage 
disequilibrium, the European 1000 Genomes data panel (phase 1, release 3) was used as a 
reference. A Bonferroni correction was used to control for 18 062 tests (α= 0.05/18 345; P < 
2.73 x 10-6). The gene-based associations for trail making were compared with gene-based 
associations for VNR, and with the gene-based associations for trail making, general cognitive 
function, processing speed, and memory from the CHARGE consortium, based on the GWAS 
summary results (G. Davies et al., 2015a; Debette et al., 2015a; Ibrahim-Verbaas et al., 2016). 
The CHARGE summary results were converted from HapMap2 to 1000G format to ensure the 
maximum overlap between the two samples. This was achieved using the LiftOver program, 
which converts coordinate ranges between genome assemblies. 
 
5.2.2.7. Partitioned heritability 
Partitioned heritability analyses were performed on the trail making SNP-based association 
results to determine if SNPs group together according to a specific biological function or role 
and thereby making an enriched contribution to the total proportion of heritability of the trail 
making phenotypes. These analyses were performed using the data processing pipeline as 
suggested by Finucane et al. (Finucane et al., 2015). 
 
5.2.2.8. Polygenic profile analyses 
Polygenic profile analyses were performed to predict trail making test performance into UK 
Biobank and to predict cognitive function scores in two independent cohorts, Generation 
Scotland’s Scottish Family Health Study (GS) and the Lothian Birth Cohort of 1936 
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(LBC1936). Prediction from the CHARGE consortium meta-analysis of trail making, general 
cognitive function, processing speed, and memory into UK Biobank was performed to test the 
extent to which individual differences in trail making tests in UK Biobank could be predicted 
by the polygenic architecture of these four traits. 
 
Polygenic prediction into UK Biobank.  
The UK Biobank genotyping data were recoded from numeric (1,2) allele coding to standard 
ACGT coding using a bespoke programme developed by one of the present authors (DCL) 
(Hagenaars et al., 2016b). Polygenic profile scores were created for trail making part A, trail 
making part B, general cognitive function, processing speed, and memory based on the results 
from the CHARGE consortium meta-analysis in all genotyped participants using PRSice 
(Euesden, Lewis, & O'Reilly, 2015). SNPs with a minor allele frequency < 0.01 were removed 
prior to creating the scores. Clumping was used to obtain SNPs in linkage disequilibrium with 
an r2 < 0.25 within a 250kb window. Five polygenic profiles were created for each of the three 
phenotypes according to the significance of the association with the trail making phenotype, 
at p-value thresholds of 0.01, 0.05, 0.1, 0.5 and 1 (all LD pruned SNPs). Regression models 
were used to examine the association between the polygenic profiles and TMT A, TMT B and 
TMT B-A phenotype scores in UK Biobank, adjusting for age at measurement, sex, 
genotyping batch and array, assessment centre, and the first ten genetic principal components 
for population stratification. All associations were corrected for multiple testing using the false 
discovery rate (FDR) method (Benjamini & Hochberg, 1995). 
 
Polygenic prediction into GS and LBC1936.  
Polygenic profile scores were created in PRSice (Euesden et al., 2015), using the UK Biobank 
trail making SNP-based association results, for genotyped participants of GS (n = 19 994, 
mean (SD) age = 47.18 (15.10) years) and LBC1936 (n = 1005, mean (SD) age of 72.55 (0.7) 
years for all tests except trail making part B which was tested at a mean (SD) age of 76.30 
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(0.68) years). Individuals were removed from GS if they had contributed to both UK Biobank 
and GS (n = 174). Polygenic profile scores were created based on the significance of the 
association in UK Biobank with the trail making phenotype, at p-value thresholds of 0.01, 
0.05, 0.1, 0.5 and 1 (all SNPs). Linear regression models were created to test the association 
between the polygenic profiles for trail making and the target phenotypes in:  GS (Wechsler 
digit-symbol substitution (Wechsler, 1997a), phonemic verbal fluency (Lezak et al., 2004), 
Wechsler logical memory (Wechsler, 1997b), the Mill Hill vocabulary test (Raven & Court, 
1993), a fluid cognitive function component, and a general cognitive function component); 
and LBC1936 (trail making part B, a fluid cognitive function component, vocabulary, 
memory, processing speed, change in fluid cognitive function between age 11 and age 70, 
Moray House Test score at age 11, and Moray House Test score at age 70). Further details 
about the cognitive tests can be found in the Supplementary Materials. All models were 
adjusted for age, sex and the first five (GS) or four (LBC1936) principal components for 
population stratification. The GS models were also adjusted for family structure by fitting a 
univariate linear mixed model which estimates the genetic and environmental variance, using 
the ASReml program (Gilmour, Gogel, Cullis, Thompson, & Butler, 2009). All associations 
were corrected for multiple testing using the FDR method (Benjamini & Hochberg, 1995). 
 
5.2.2.9. Meta-analysis 
Inverse variance-weighted meta-analysis of UK Biobank trail making and CHARGE trail 
making GWAS was performed using the METAL package 
(http://www.sph.umich.edu/csg/abecasis/Metal). The meta-analysis was restricted to SNPs 
that were available in both samples (N SNPs TMT A = 2,332,746; N SNPs TMT B = 
2,466,810), and the samples did not include any overlapping individuals. The total sample in 




5.2.3.1. Phenotypic correlations 
23,822 individuals with genetic data completed TMT A, 23,812 individuals with genetic data 
completed TMT B, and 23,769 individuals with genetic data had complete information for 
TMT B-A. Table 5-1 shows the phenotypic correlations between the TMT phenotypes, as well 
as with verbal-numerical reasoning in UK Biobank. Correlations indicated that individuals 
who took more time to complete the trail making tests had lower performance on the verbal-
numerical reasoning test. The strongest correlation between VNR and TMT was found for 
TMT B (0.36). Supplementary Figure 2 shows the age and sex distribution of the different trail 
making measures. 
 
Table 5-1. Phenotypic correlations for the UK Biobank cognitive tests in all 
genotyped participants. Standard errors for the correlations are shown in 
parentheses. Pearson correlations were used for continuous-continuous 
correlations for the phenotypic correlations. 
 TMT A TMT B TMT B-A VNR 
TMT A -    
TMT B 0.62 (0.004) -   
TMT B-A 0.04 (0.006) 0.80 (0.002) -  
VNR 0.20 (0.010) 0.36 (0.009) 0.32 (0.010) - 
TMT A, trail making part A; TMT B, trail making part B; TMT B-A, trail making part B – part A; 
VNR, verbal-numerical reasoning. 
 
5.2.3.2. Genome-wide association study 
The results of the GWAS analyses are presented in Figure 5-2; for each trail making phenotype 
a Manhattan and a QQ plot is shown. 
 
Trail making test part A 
For TMT A no SNPs reached genome-wide significance. Gene based analyses identified three 
genes that were significantly associated with TMT A (Table 5-2 and Supplementary Table 1a); 
CRNKL1, a protein necessary for pre-mRNA splicing on chromosome 20 (Chung et al., 2002); 
caspase 5 (CASP5), which plays a role in the execution phase of cell apoptosis on chromosome 
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11 (Earnshaw, Martins, & Kaufmann, 1999); and NAA20, a component of the N-
acetyltransferase complex B on chromosome 20 (Starheim et al., 2008). All three of these 
genes were also nominally significant (p < 0.05) in the GWAS of TMT B, and CASP5 was 
also nominally significant in the analyses for CHARGE general cognitive function and 
processing speed (Table 5-2). 
 
The proportion of variance in TMT A explained by all common genetic variants using GCTA-
GREML was 0.079 (SE 0.024). 
 
Trail making test part B 
One SNP exhibited genome-wide significance for TMT B, on chromosome 1 (rs34804445, p 
= 4.18 x 10-8, MAF = 0.0253). This SNP was not located within a gene. Gene based analyses 
identified one gene (PUM1 on chromosome 1) associated with TMT B (Table 5-2 and 
Supplementary Table 1b); this gene regulates ATAXIN1, and is associated with 
neurodegeneration (Gennarino et al., 2015). This gene was also nominally significant (p < 
0.05) in the gene-based analysis for the other trail making variables measured in UK Biobank. 
Results for this gene were not available for the CHARGE consortium phenotypes (Table 5-2). 
 
The proportion of variance in TMT B explained by all common genetic variants using GCTA-
GREML was 0.224 (SE 0.026). 
 
Trail making test part B – part A 
No SNPs reached genome-wide significance for TMT B-A. Gene-based analyses did not 
identify any significant associations for TMT B-A (Supplementary Table 1c). 
 
The proportion of variance in TMT B-A explained by all common genetic variants using 
GCTA-GREML was 0.176 (SE 0.025). Heritability estimates and standard errors of all three 
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TMT measures, weighted according to estimates of their reliabilities, are reported in 
Supplementary Table 2. They indicate that the ostensible difference in h2 between TMT-B 

























































































































































































































































































































































































































































































































































































































































































5.2.3.3. Partitioned heritability 
Significant enrichment was found for TMT B in evolutionary conserved regions with a 500bp 
boundary, where 33% of the SNPs accounted for 95% of the heritability (enrichment metric = 
2.85, SE = 0.44, p = 2.42 × 10−5). TMT A and TMT B-A were unsuitable for this analysis, due 
to low heritability Z-scores, which were 2.6 and 5.4 respectively (Finucane et al., 2015).  
5.2.3.4. Genetic correlations 
The results of the bivariate GCTA-GREML and LD score regression analyses within UK 
Biobank are shown in Table 5-3. The LD score regression analyses with the cognitive 
phenotypes from the CHARGE consortium are shown in Table 5-4. Strong positive genetic 
correlations, using GCTA-GREML, were observed between all three measures derived from 
the trail making test in UK Biobank (rg between 0.64 and 0.96). Large genetic correlations 
were found between the three trail making tests and verbal-numerical reasoning (rg between 
0.59 and 0.64). Similar results were found when calculating the genetic correlations using LD 
score regression (Table 5-3). Positive genetic correlations were observed between trail making 
in UK Biobank and the following GWAS meta-analyses from the CHARGE consortium: 
general cognitive function (rg between 0.61 and 0.70), processing speed (rg between 0.69 and 
0.76), and memory (rg between 0.29 and 0.35) (Table 5-4). The confidence interval for the 
associations between TMT and general cognitive function, and between TMT and processing 
speed did not overlap with the confidence interval for the association between TMT and 
memory. 
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Table 5-3. Genetic correlations (standard errors) using GCTA-GREML (under 
diagonal) and LD score regression (above diagonal) for the trail making tests 
and verbal-numerical reasoning in UK Biobank. TMT A, trail making part A; TMT 
B, trail making part B; TMT B-A, trail making part B minus trail making part A; 
VNR, verbal-numerical reasoning. 
 TMT A TMT B TMT B-A VNR 
TMT A - 0.921 (0.07) 0.827 (0.17) 0.558 (0.11) 
TMT B 0.840 (0.09) - 0.981 (0.03) 0.767 (0.07) 
TMT B-A 0.640 (0.19) 0.958 (0.03) - 0.793 (0.10) 







































































































































































































































































































































































5.2.3.5. Polygenic prediction 
Polygenic profiles based on the TMT A summary results from the CHARGE consortium 
significantly predicted all three trail making tests in UK Biobank (β between 0.016 and 0.029, 
Table 5-5). Polygenic profiles based on the TMT B summary results from the CHARGE 
consortium significantly predicted all three trail making tests in UK Biobank (β between 0.024 
and 0.036, Table 5-5). The strongest associations for the other cognitive test polygenic profiles 
(general cognitive function, processing speed, and memory) were found for general cognitive 
function polygenic profiles predicting TMT B in UK Biobank, explaining 0.67% of the 










































































































































































































































































































































































































































































































The GWAS results for the three trail making phenotypes in UK Biobank were used to create 
polygenic profile scores in two independent cohorts; Generation Scotland (GS), and the 
Lothian Birth Cohort of 1936 (LBC1936) (Figure 5-3 and Supplementary Tables 3b and 3c). 
The polygenic profiles for TMT A significantly predicted digit-symbol substitution, verbal 
fluency, Mill Hill vocabulary, fluid cognitive function, and general cognitive function in GS 
(β between 0.018 and 0.039). In the LBC1936, the polygenic profiles for TMT A significantly 
predicted trail making part B (β = 0.102), fluid cognitive function, memory and change in fluid 
cognitive function (β between 0.079 and 0.094). Significant predictions were observed across 
almost all thresholds for TMT B and TMT B-A for the cognitive phenotypes measured in GS. 
In LBC1936, polygenic profiles for TMT B and TMT B-A were both significantly associated 
with fluid cognitive function, processing speed, cognitive function at age 11 and cognitive 
function at age 70. TMT B was also significantly associated with trail making part B, memory 
and change in fluid cognitive function between age 11 and age 70. The strongest association 
in GS was found between the polygenic profile for TMT B and Wechsler digit symbol 
substitution; this association explained 0.53% of the variance, at a SNP inclusion threshold of 
all SNPs from the GWAS. The largest proportion of variance explained in LBC1936 was 
1.75% for trail making part B using the TMT B polygenic score with a SNP inclusion threshold 





Figure 5-3. Heat map of associations between the polygenic profile scores for 
trail making in UK Biobank and cognitive function in Generation Scotland and 
the Lothian Birth Cohort 1936 (LBC 1936). * indicates FDR corrected 
significant associations (FDR corrected p-value <= 0.029 (Generation 
Scotland) or 0.025 (LBC 1936)).  Further information can be found in 
Supplementary Tables 2b and 2c. 
 
5.2.3.6. Meta-analysis 
In the meta-analysis of the combined dataset (UK Biobank and CHARGE, combined N TMT 
A = 29,251, combined N TMT B = 30,022), no genome-wide significant SNPs were observed 
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for TMT A or TMT B (Supplementary Figure 3). The one genome-wide significant hit 
identified in this study for TMT B was not available in CHARGE.  
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5.2.4. Discussion 
This study finds one genome-wide significant variant associated with trail making test part B 
performance in UK Biobank, and provides the first SNP-based heritability estimates for the 
three widely-used TMT measures. We identified high genetic correlations between trail 
making, verbal-numerical reasoning, general cognitive function, and processing speed, and 
somewhat lower genetic correlations with memory. Using only common SNPs to create a 
polygenic score for TMT B, we were able, at best, to predict ~2% of the variance in trail 
making part B in LBC1936. Taken together, these analyses point to a considerable degree of 
shared polygenic architecture for TMT performance with general cognitive function and 
processing speed measures, in particular. The results are consistent with the hypothesis that 
trail making is genetically and phenotypically similar to general fluid cognitive function (T. 
Lee et al., 2012; Salthouse, 2011a, 2011b). 
 
Univariate GCTA-GREML analyses suggested SNP-based heritability estimates for TMT A, 
TMT B and TMT B-A of 8%, 22% and 18% respectively. These provide a first estimate of the 
contribution of common SNPs to the phenotype of trail making and suggest that common SNPs 
account for around half of the additive genetic variation for trail making, based on twin and 
family studies (Vasilopoulos et al., 2012). SNP-based heritability studies for other complex 
traits also report similar differences between SNP based and pedigree based heritability (G. 
Davies et al., 2011; Jian Yang et al., 2010).  Twin and family studies estimate heritability based 
on all causal variants, both common and rare, whereas SNP-based studies estimate heritability 
only on genotyped SNPs in LD with causal variants. It is possible that causal variants have 
lower minor allele frequencies than the genotyped SNPs, leading to incomplete LD between 
unknown causal variants and genotyped SNPs (Visscher, Yang, & Goddard, 2010).  
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Previous studies of the genetic overlap between trail making and other cognitive abilities have 
shown genetic overlap between trail making and general cognitive function using a twin design 
(T. Lee et al., 2012; Vasilopoulos et al., 2012). Our results add to this by using a molecular 
genetic design and showing shared genetic aetiology between trail making and verbal 
numerical reasoning in UK Biobank, as well as with general cognitive function, processing 
speed, and memory from the CHARGE consortium. The estimates of the genetic correlations 
within UK Biobank were similar for both GCTA-GREML and LDS regression, suggesting 
that these results are unlikely to constitute false positives.  
 
We also used polygenic profile scores to estimate the genetic overlap between TMT and other 
cognitive abilities. First we created polygenic profiles based on the CHARGE consortium 
summary GWAS data (including trail making, general cognitive function, processing speed, 
and memory) and found that the polygenic profile for general cognitive function was the best 
predictor of all TMT scores in UK Biobank compared to either of the other polygenic profiles. 
All estimates were small (< 1% of variance was accounted for), but should be considered the 
minimum estimate of the variance explained. The polygenic profile method prunes SNPs in 
LD and assumes that a single causal variant is tagged in each LD block. If that assumption is 
violated, the proportion of variance explained will be underestimated. Nevertheless, the 
unequal sample sizes from which the polygenic profile scores were derived (TMT ~ 6000; 
general cognitive function ~54,000; processing speed ~ 32,000, memory ~ 29,000) may have 
led to an underestimation of the ability of CHARGE TMT score to predict UK Biobank TMT 
test performance.  
 
The genetic association between TMT and other cognitive measures could be due to an overall 
halo-effect of general cognitive ability. While the current study does not allow us to test this 
empirically, we note that the respective polygenic associations between TMT and fluid 
cognitive ability in GS and LBC1936, as well as the genetic correlations between TMT and 
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verbal-numerical reasoning, do point to this halo-effect. Future studies could expand these 
findings by removing the variance specific to a latent measure of general cognitive ability 
(measured using ≥3 tests from different cognitive domains) from the associations between 
TMT and other measures of cognitive ability. 
 
Our combined meta-analysis of UK Biobank and CHARGE trail making did not yield any 
significant SNPs. This could be ascribed to the following factors. The SNPs for the CHARGE 
consortium are imputed to the HAPMAP 2 reference panel (N ~ 2M SNPs) whereas the UK 
Biobank sample is imputed to a combination of the UK10 haplotype and the 1000G reference 
panel (N ~ 17M SNPs). For TMT A, 2 332 746 SNPs overlapped between UK Biobank and 
CHARGE, and for TMT B, 2 466 810 SNPs overlapped between the two samples. The SNP 
that reached genome-wide significance in the UK Biobank GWAS was not available in 
CHARGE. 
 
In addition to those discussed above, our study has other limitations. There are currently no 
reliability data available for the TMT version administered in UK Biobank. Though the 
computer-based version was based upon standard administration protocols, the current 
absence of such data necessitates that these results be interpreted with appropriate caution. The 
measure of fluid cognitive function provided by UK Biobank (which we have called verbal-
numerical reasoning) showed a relatively modest age-related trajectory, in contrast to the 
steeper and well-replicated age-related decline that would be expected for this construct 
(Salthouse, 2004; Tucker-Drob, 2009) (Supplementary Figure 4). This may partly explain the 
relatively modest correlation of verbal-numerical reasoning with TMT performance, when 
compared to those previously reported (Salthouse, 2011b) and may have also had a bearing on 
our analyses of genetic overlap within UK Biobank. In addition, the UK Biobank sample did 
not have sufficient breadth of contemporaneously-administered standardised/validated 
cognitive tests to be able to construct a robust measure of general cognitive function (such as 
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in other large samples(Ritchie et al., 2016; Salthouse, 2011a, 2011b)). This limited our ability 
to perform a more detailed analysis of the phenotypic or genetic overlap between trail making 
and general cognitive function in UK Biobank itself.  
 
This study has several strengths. It has the largest single sample size to date of a GWAS for 
trail making, offering greater statistical power while excluding bias caused by sample or 
phenotypic heterogeneity. Population stratification was minimized by only using individuals 
of white British ancestry. This study shows the first estimates of the heritability for TMT using 
molecular genetic data, uses a comprehensive battery of techniques to examine genetic 
architecture of TMT, and used the same trail making test and administration protocol across 
the whole sample. The use of both GWAS summary data from the CHARGE consortium, and 
the prediction of the UK Biobank TMT GWAS into GS and LBC1936 cognitive phenotypes 
allowed a detailed examination of the shared genetic aetiology between TMT and cognitive 
phenotypes.  
 
These strengths have enabled a detailed characterisation of the shared genetic aetiology 
between performance on TMT and other cognitive abilities. Our results, spanning 
methodologies and cohorts, provide strong evidence for a shared genetic aetiology between 
TMT performance and general cognitive function and processing speed, which are themselves 
strongly phenotypically and genetically correlated. When the full genetic data from UK 
Biobank on half a million individuals becomes available, it would enable robust replication 
and extensions of the current findings. More detailed cognitive testing is planned for UK 
Biobank, and these data can be used in future studies to further examine the genetic overlap 
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This Chapter set out to investigate the genetic architecture of the Trail Making Test and its 
overlap with other domains of cognitive ability. Up to 22% of the variance in the Trail Making 
Test is explained by common genetic influences. Of the modest phenotypic association 
between TMT and verbal-numerical reasoning in UK Biobank, around 70% is due to common 
genetic influences. Similar estimates were found for the genetic correlation between TMT and 
general cognitive ability and processing speed. PRS analysis also indicated extensive shared 
genetic aetiology between TMT, general cognitive ability and processing speed. Some overlap 
was found with memory; however, these estimates were much smaller. More broadly, these 
results highlight the complex pathways with cognitive ability, and might in, future research, 
aid to the understanding of association between cognitive ability and health. Together with 
Chapter 4, the current Chapter focussed on cognitive ability and its overlap with health 
outcomes. As described in Chapter 2, personality is a second important trait in the field of 
individual differences. The following two Chapters will therefore focus on negative emotions 
and its association with health outcomes, starting with the association between neuroticism 
and health in Chapter 6, followed by the associations between self-reported tiredness and 




6. Genetic overlap between neuroticism and health 
6.1. Introduction 
The second Section of this thesis, including this Chapter and the next (Chapter 7), will examine 
the shared genetic aetiology between negative emotions and health. The current Chapter will 
focus on the personality trait of neuroticism. Neuroticism is partly influenced by genetic 
factors; behavioural genetic studies have indicated a heritability of around 40% (Vukasović & 
Bratko, 2015), whereas molecular genetic studies have shown that around 15% of the variance 
in neuroticism is due to genetic factors (D. J. Smith et al., 2016). Both behavioural and 
molecular genetic studies have identified some shared genetic aetiology between neuroticism 
and health, in particular mental health (Kendler & Myers, 2010; Okbay et al., 2016a). 
Relatively little research has been performed to quantify the extent of the genetic association 
between neuroticism and health traits using molecular genetic techniques. This Chapter will 
examine the shared genetic aetiology between neuroticism and mental and physical health in 
UK Biobank. This study has been published in Translational Psychiatry and is included in full 
in Section 6.2. 
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6.2. Pleiotropy between neuroticism and physical and mental health: 





Pleiotropy between neuroticism and physical and mental
health: findings from 108038 men and women in UK Biobank
CR Gale1,2,3,9, SP Hagenaars1,2,4,9, G Davies1,2, WD Hill1,2, DCM Liewald1,2, B Cullen5, BW Penninx6, International Consortium for Blood
Pressure GWAS, CHARGE Consortium Aging and Longevity Group, DI Boomsma7, J Pell5, AM McIntosh4, DJ Smith5, IJ Deary1,2,10 and
SE Harris1,8,10
People with higher levels of neuroticism have an increased risk of several types of mental disorder. Higher neuroticism has also
been associated, less consistently, with increased risk of various physical health outcomes. We hypothesised that these associations
may, in part, be due to shared genetic influences. We tested for pleiotropy between neuroticism and 17 mental and physical
diseases or health traits using linkage disequilibrium regression and polygenic profile scoring. Genetic correlations were derived
between neuroticism scores in 108 038 people in the UK Biobank and health-related measures from 14 large genome-wide
association studies (GWASs). Summary information for the 17 GWASs was used to create polygenic risk scores for the health-related
measures in the UK Biobank participants. Associations between the health-related polygenic scores and neuroticism were
examined using regression, adjusting for age, sex, genotyping batch, genotyping array, assessment centre and population
stratification. Genetic correlations were identified between neuroticism and anorexia nervosa (rg = 0.17), major depressive disorder
(rg = 0.66) and schizophrenia (rg = 0.21). Polygenic risk for several health-related measures were associated with neuroticism, in a
positive direction in the case of bipolar disorder, borderline personality, major depressive disorder, negative affect, neuroticism
(Genetics of Personality Consortium), schizophrenia, coronary artery disease, and smoking (β between 0.009–0.043), and in a
negative direction in the case of body mass index (β=− 0.0095). A high level of pleiotropy exists between neuroticism and
some measures of mental and physical health, particularly major depressive disorder and schizophrenia.
Translational Psychiatry (2016) 6, e791; doi:10.1038/tp.2016.56; published online 26 April 2016
INTRODUCTION
There is considerable evidence that the personality trait of
neuroticism1—which describes stable individual differences in
the tendency to experience negative emotions—has profound
significance for public health.2 People who are higher in neuro-
ticism have an increased risk of developing Axis I psychopathol-
ogy, especially the common mental disorders such as mood,
anxiety, somatoform and substance use disorders, and also
schizophrenia, bipolar disorder and attention-deficit hyperactivity
disorder (ADHD).3–6 Higher neuroticism is associated with
increased likelihood of diagnosis with Axis II personality disorders7
and with greater comorbidity between internalising disorders
(such as major depression, generalised anxiety, panic disorders
and phobias) and externalising disorders (such as alcohol and
drug dependence, antisocial personality and conduct disorders).8
There is evidence that higher neuroticism is linked with risk of
developing Alzheimer’s disease.9 People who are higher in
neuroticism tend to make greater use of mental health services,
regardless of whether they have a mental disorder,10 perhaps
because they are more likely to perceive a need for care.11 The
estimated economic costs of neuroticism in terms of health-care
use and absenteeism are massive.12 Much of these costs relate
to reported chronic somatic conditions.12 Higher neuroticism has
been linked with increased somatic complaints,13,14 with percep-
tion of poorer health,15,16 with future somatic multi-morbidity, as
assessed by a count of reported chronic conditions,17 and with
increased likelihood of reporting a range of physical health
problems.18
Evidence that neuroticism is predictive of objectively assessed
physical health is still relatively sparse and findings to date are
often mixed. For example, whereas some prospective studies have
found that higher neuroticism increases mortality from all
causes19 or coronary heart disease,20 and is predictive of raised
blood pressure21 or body mass index (BMI),22 others have found
no such association.23–26 In a pooled analysis of data from five
cohorts, there was no consistent association between neuroticism
and incidence of type 2 diabetes: higher neuroticism was linked
with increased risk in one cohort, but not in others.27
Part of the explanation for associations between neuroticism
and these various mental and physical health outcomes may be
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due to shared genetic influences. Twin and adoption studies
suggest that genetic influences account for between a third and a
half of individual differences in neuroticism.1 Many physical and
mental illnesses and health-related measures also show moderate
heritability.28 Twin studies have shown that there is considerable
overlap between the genetic factors that influence variations in
neuroticism and those that determine risk of depression and other
internalising disorders.29,30 It is now possible to test for such
pleiotropy in associations between neuroticism and health
outcomes using data from single nucleotide polymorphism
(SNP) genotyping in unrelated individuals, making it possible to
carry out much larger studies without the assumptions made by
twin-study methods. A recent genome-wide association meta-
analysis based on data from over 70 000 individuals found that
neuroticism is influenced by many genetic variants of small effect,
that is, a polygenic effect, that also influence the risk of major
depressive disorder.31 Whether there is pleiotropy between
neuroticism and other mental disorders or with physical health
outcomes is unclear.
Testing for pleiotropy using SNP-based genetic data can be
carried out in several ways. Linkage disequilibrium (LD) regression
calculates genetic correlations between health measures using the
summary results of genome-wide association studies (GWASs).32 It
determines how much of the genetic influence on two traits/
diseases is common to both. Polygenic risk scoring33 uses summary
GWAS data for a given illness or health trait to test whether
polygenic liability to that illness/trait is associated with phenotypes
for that illness/trait (for example, neuroticism scores) or others
measured in an independent sample. It allows the amount of
variance in one trait/disease attributed to the polygenic score for a
second trait/disease to be calculated. Polygenic risk of neuroticism
was recently associated with major depressive disorder.31
In the present study we aimed to discover whether shared
genetic aetiology explains part of the associations between
neuroticism and various physical and mental health outcomes,
all of which have been shown to be phenotypically correlated with
neuroticism in at least one study. We used data on over 108 000
UK Biobank participants who completed a questionnaire on
neuroticism and provided DNA for genome-wide genotyping.
Using summary data from GWAS meta-analyses on 17 health-
related measures, we tested for neuroticism-health pleiotropy
using two complementary methods. First, we used LD score
regression to derive genetic correlations between health-related
measures and neuroticism. Second, we calculated the associations
between polygenic risk scores for health-related measures and the
neuroticism phenotype in UK Biobank participants.
MATERIALS AND METHODS
Participants
The participants in this study took part in the baseline survey of UK
Biobank.34 (http://www.ukbiobank.ac.uk). UK Biobank was set up as a
resource for identifying determinants of disease in middle-aged and older
people. Between 2006 and 2010, 502 655 community-dwelling people
aged between 37 and 73 years and living in the United Kingdom were
recruited to the study. They underwent assessments of cognitive and
physical functions, mood and personality. They provided blood, urine and
saliva samples for future analysis, completed questionnaires about their
social backgrounds and lifestyle and agreed to have their health followed
longitudinally. UK Biobank received ethical approval from the Research
Ethics Committee (REC reference 11/NW/0382).
For the present study, genome-wide genotyping data were available on
112 151 individuals (58 914 female) aged 40–73 years (mean age= 56.9
years, s.d. = 7.9) after the quality control process (see below).
Procedures
Neuroticism. Participants completed the Neuroticism scale of the Eysenck
Personality Questionnaire-Revised (EPQ-R) Short Form.35 This scale has
been concurrently validated in older people against two of the most
widely used measures of neuroticism, taken from the International
Personality Item Pool (IPIP) and the NEO-Five Factor Inventory (NEO-FFI);
it correlated − 0.84 with the IPIP-Emotional Stability scale and 0.85 with the
NEO-FFI Neuroticism scale.36 A previous study found a high genetic
correlation (0.91) between the EPQ-R Short Form Neuroticism scale and
psychological distress assessed in a non-psychiatric population using the
30-item General Health Questionnaire.37
Genotyping and quality control. In all, 152 729 UK Biobank blood samples
were genotyped using either the UK BiLEVE38 array (N=49 979) or the UK
Biobank axiom array (N=102 750). A full description of the genotyping
process is available in the Supplementary Materials. Quality control was
performed by Affymetrix (Santa Clara, CA, USA), the Wellcome Trust Centre
for Human Genetics and by the present authors; this included removal of
participants based on missingness, relatedness, gender mismatch, non-
British ancestry and other criteria, and is described in the Supplementary
Materials.
Genome-wide association analyses in the UK Biobank sample. Genome-
wide association analyses were performed on the neuroticism measure in
order to use the summary results for LD regression. Details of the GWAS
procedures are provided in the Supplementary Materials. Results from the
GWAS are published elsewhere.39
Curation of summary results from GWAS consortia on health-related
variables. In order to conduct LD score regression and polygenic profile
score analyses between the UK Biobank neuroticism data and the genetic
predisposition to mental and physical health outcomes, we gathered
summary data from published meta-analyses on 17 health-related
measures: 9 relating to mental health (ADHD, Alzheimer’s disease, anorexia
nervosa, bipolar disorder, borderline personality, major depressive
disorder, negative affect, neuroticism (from the Genetics of Personality
Consortium (GPC)) and schizophrenia) and 8 relating to physical health
(systolic and diastolic blood pressure, BMI, coronary artery disease,
longevity, rheumatoid arthritis, smoking status and type 2 diabetes).
Details of these health-related variables, the consortia’s websites, key
references and number of subjects included in each consortium’s GWAS
are given in Supplementary Table 1.
Statistical analysis
Computing genetic associations between neuroticism and health-related
variables. We use two methods to compute genetic associations between
neuroticism and the health-related variables, LD score regression and
polygenic profile/risk scoring. Each provides a different metric to infer the
existence of pleiotropy between pairs of traits. LD score regression was
used to derive genetic correlations to determine the degree to which the
polygenic architecture of a trait overlaps with that of another. Genetic
correlations were also derived between the different physical and mental
health measures, and neuroticism based on the results of the GWAS from
the GPC by de Moor et al.31 A genetic correlation between the two
neuroticism GWAS (UK Biobank and GPC) was also calculated. The
polygenic risk score method was used to test the extent to which the
polygenic information from GWASs of health-related variables could
predict neuroticism in the UK Biobank participants. Both LD score
regression and polygenic risk scores are dependent on the traits analysed
being highly polygenic in nature, that is, where a large number of variants
of small effect contribute towards phenotypic variation.32,40 LD score
regression was performed between the 14 health-related traits from GWAS
consortia, as some measures did not pass thresholds to be included in LD
score analysis, while the polygenic profile score analyses were performed
on the complete set of 17 health-related traits from GWAS consortia.
LD score regression. In order to quantify the extent of pleiotropy between
neuroticism, measured in UK Biobank, and the collated health traits, we
used LD score regression.32,41 This is a class of techniques that exploits the
correlational structure of the SNPs found across the genome (we provide
more details of LD score regression in the Supplementary Materials). Here
we use LD score regression to derive genetic correlations between
neuroticism and health-related measures using 14 large GWAS consortia
data sets that enable pleiotropy of their health-related traits to be
quantified with the neuroticism trait in UK Biobank. We followed the data-
processing pipeline devised by Bulik-Sullivan et al.32,41 described in more
detail in the Supplementary Materials. In order to ensure that the genetic
correlation for the Alzheimer’s disease phenotype was not driven by a
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single locus or biased the fit of the regression model, a 500-kb region
centred on the APOE locus was removed and this phenotype was re-run.
This additional model is referred to in Table 1 as ‘Alzheimer’s disease
(500 kb)’.
Polygenic profiling. The UK Biobank genotyping data required recoding
from numeric (1, 2) allele coding to standard ACGT format before being
used in polygenic profile scoring analyses. This was achieved using a
bespoke programme developed by one of the present authors (DCML),
details of which are provided in the Supplementary Materials.
Polygenic profiles were created for 17 health-related phenotypes
(Table 2 and Supplementary Table 2) in all genotyped participants using
PRSice.42 This software calculates the sum of alleles associated with the
phenotype of interest across many genetic loci, weighted by their effect
sizes estimated from a GWAS of that phenotype in an independent sample.
Before creating the scores, SNPs with a minor allele frequency o0.01 were
removed, and clumping was used to obtain SNPs in linkage equilibrium
with an r2o0.25 within a 200-bp window. Multiple scores were then
created for each phenotype containing SNPs selected according to the
significance of their association with the phenotype. The GWAS summary
data for the 12 health-related phenotypes were used to create five
polygenic profiles for each in the UK Biobank participants, at thresholds of
Po0.01, Po0.05, Po0.1, Po0.5 and all SNPs. The most predictive
threshold will be presented in the main tables of this paper. The full results,
including all five thresholds, can be found in Supplementary Table 2.
Associations between the polygenic profiles and neuroticism were
examined in linear regression models, adjusting for age at measurement,
sex, genotyping batch and array, assessment centre and the first 10
genetic principal components to adjust for population stratification. We
corrected for multiple testing across all polygenic profile scores at all
significance thresholds for associations with neuroticism using the false
discovery rate method.43 As neuroticism on average is higher in females
and likely declines with age,2 age- (under and over 60 years old) and
gender-stratified models were examined.
RESULTS
Within UK Biobank, 108 038 individuals with genotype data
completed the Neuroticism scale of the EPQ-R Short Form. Their
mean (s.d.) score for neuroticism was 4.02 (3.17).
The genetic correlation between neuroticism measured in
the UK Biobank and neuroticism measured in the GPC is 1.0
(s.e. = 0.11).
Table 1 shows the genetic correlations obtained using LD score
regression between neuroticism in UK Biobank and neuroticism
from the GPC, and the published GWAS results on the health-
related traits. Neuroticism in UK Biobank showed significant
positive genetic correlations with three traits, all related to mental
health, namely major depressive disorder (rg = 0.66), schizophrenia
(rg = 0.21) and anorexia nervosa (rg = 0.17). The findings replicated
when using Neuroticism from the GPC. There were no significant
genetic correlations between neuroticism and either the other
mental health-related traits (ADHD, Alzheimer’s disease and
bipolar disorder) or any of the physical health-related traits
(systolic and diastolic blood pressure, BMI, coronary artery disease,
type 2 diabetes, smoking status, rheumatoid arthritis or longevity).
These results are shown graphically in Figure 1.
Table 2 shows the results of the polygenic risk scoring, using the
most predictive threshold of the five that were created. Higher
polygenic risk for six mental health-related traits, bipolar disorder,
borderline personality, major depressive disorder, negative affect,
neuroticism (calculated using summary data from the GPC) and
schizophrenia, was significantly associated with higher levels of
neuroticism in UK Biobank (standardised β between 0.017 and
0.043). There were no significant associations between neuroti-
cism and polygenic risk for the other mental health-related traits
examined, namely ADHD, Alzheimer’s disease and anorexia
nervosa. Polygenic risk scores for three physical health-related
traits were significantly associated with neuroticism: higher
polygenic risk for BMI was associated with lower levels of
neuroticism (β=− 0.0095, P= 0.0015), higher polygenic risk for
coronary artery disease was associated with higher levels of
neuroticism (β= 0.011, P= 0.0003) and higher polygenic profile
scores for smoking were associated with higher levels of
neuroticism (β= 0.17, P= 2.48 × 10− 7). No significant associations
were found between polygenic risk for the other physical health-
related traits (systolic and diastolic blood pressure, type 2
diabetes, rheumatoid arthritis or longevity) and neuroticism. To
test whether the false discovery rate significant association
between polygenic risk for coronary artery disease and neuroti-
cism was confounded by individuals diagnosed with cardiovas-
cular disease, 2717 individuals who had had a heart attack and
2468 individuals with angina were removed from the regression
analysis. Our estimate of the association between polygenic risk of
coronary artery disease and neuroticism was unchanged by this
exclusion. The same applied for major depressive disorder
(excluding 7494 individuals with a probable diagnosis of major
Table 1. Genetic correlations between neuroticism documented in UK Biobank and mental and physical health-related traits curated from GWAS
consortia
Trait Category Traits from GWAS consortia Neuroticism (UKB) (n= 108 038) Neuroticism (GPC) (n=63 661)
rg s.e. P rg s.e. P
Mental health ADHD 0.060 0.082 0.4681 0.090 0.191 0.6371
Alzheimer’s disease 0.118 0.080 0.1378 0.089 0.177 0.6147
Alzheimer’s disease (500 kb) 0.091 0.063 0.1514 0.051 0.145 0.7262
Anorexia nervosa 0.174 0.04 2.36× 10−5 0.319 0.082 9.56× 10−5
Bipolar disorder 0.083 0.052 0.1096 0.162 0.101 0.1091
Major depressive disorder 0.659 0.087 2.75× 10−14 1.073 0.199 7.15× 10−8
Schizophrenia 0.212 0.050 2.39× 10−5 0.198 0.068 0.0033
Physical health Blood pressure: diastolic − 0.011 0.078 0.887 − 0.108 0.091 0.2363
Blood pressure: systolic − 0.051 0.060 0.3959 –0.008 0.083 0.925
BMI − 0.036 0.028 0.1921 0.046 0.055 0.4077
Coronary artery disease 0.104 0.053 0.0489 0.221 0.104 0.0331
Longevity − 0.083 0.081 0.3011 0.002 0.163 0.9888
Rheumatoid arthritis − 0.0816 0.05 0.103 − 0.093 0.123 0.4463
Smoking status 0.113 0.05 0.0205 0.124 0.090 0.1657
Type 2 diabetes − 0.145 0.07 0.0389 0.044 0.107 0.6837
Abbreviations: ADHD, attention-deficit hyperactivity disorder; BMI, body mass index; GPC, Genetics of Personality Consortium; GWAS, genome-wide
association study; UKB, UK Biobank. Statistically significant P-values (after false discovery rate correction—Po0.0033) are shown in bold.
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depression or bipolar disorder44), where the estimate of the
association showed little change. The complete polygenic risk
score results, including all five thresholds, are shown in
Supplementary Table 2.
Age- and gender-stratified analyses indicated there were no
substantial differences by age or gender for 13 out of 17 traits.
Four traits did show a potential age or gender effect. Polygenic
risk for anorexia nervosa predicts neuroticism in males, but not in
females. Polygenic risk for diastolic blood pressure predicts
neuroticism only in females over 60 years of age. The strongest
associations between polygenic risk for negative affect and
smoking status, and neuroticism, are in females under 60 years
of age. The full results for these stratified analyses can be found in
Supplementary Table 3.
DISCUSSION
In this study of 108 038 men and women from UK Biobank who
had been genotyped and assessed for neuroticism, we exploited
the summary results of 17 large international GWAS consortia to
Table 2. Associations between polygenic risk scores for mental and physical health-related traits created from GWAS consortia summary data and
neuroticism in UK Biobank participants, adjusted for age, sex, assessment centre, genotyping batch and array, and 10 principal components for
population stratification
Trait category Traits from GWAS consortia Neuroticism (n= 108 038)
Threshold β R2 P
Mental health ADHD 0.05 0.0045 2.06× 10− 5 0.1292
Alzheimer’s disease 0.05 − 0.0065 4.16× 10− 5 0.0312
Anorexia nervosa 0.1 0.0054 2.87× 10− 5 0.0735
Bipolar disorder 0.5 0.0171 0.0003 1.71× 10−8
Borderline personality 1 0.0150 0.0002 5.43× 10−7
Major depressive disorder 1 0.0357 0.0012 1.23× 10−31
Negative affect (anxiety) 1 0.00949 8.99× 10− 5 1.55× 10−3
Neuroticism (GPC) 0.5 0.0433 0.0020 1.77× 10−47
Schizophrenia 0.1 0.0359 0.0012 7.88× 10−32
Physical health Blood pressure: diastolic 0.1 − 0.0047 2.20× 10− 5 0.1167
Blood pressure: systolic 0.05 − 0.0016 2.51× 10− 6 0.5969
BMI 0.01 − 0.0095 9.00× 10− 5 0.0015
Coronary artery disease 0.1 0.0109 0.00012 0.0003
Longevity 0.05 − 0.0051 2.55× 10− 5 0.0917
Rheumatoid arthritis 0.5 − 0.0007 5.09× 10− 5 0.8266
Smoking status 0.5 0.0167 0.0002 2.48× 10−7
Type 2 diabetes 0.01 − 0.0031 9.67× 10−6 0.2989
Abbreviations: ADHD, attention-deficit hyperactivity disorder; BMI, body mass index; GPC, Genetics of Personality Consortium; GWAS, genome-wide
association study. The associations between the polygenic risk scores and neuroticism with the largest effect size (threshold) are presented. Statistically
significant P-values (after false discovery rate correction—Po0.0065) are shown in bold.
Figure 1. Barplot of genetic correlations (s.e.) calculated using linkage disequilibrium score regression between neuroticism in UK Biobank
(UKB) and the Genetics of Personality Consortium (GPC), and mental and physical health measures from genome-wide association study
consortia. *Po0.0033. ADHD, attention-deficit hyperactivity disorder; BMI, body mass index.
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examine whether there is pleiotropy between neuroticism and a
range of physical and mental health outcomes using two
methods, LD score regression and polygenic profile scoring.
Summary results from two separate GWASs of neuroticism
showed a genetic correlation of 1.0. Using summary data from
both of these studies of neuroticism, the genetic correlations that
were calculated with physical and mental health were very similar.
As regards the six mental health outcomes that were investigated
using both LD score regression and polygenic profile scoring, we
found consistent evidence of pleiotropy between neuroticism and
both major depression and schizophrenia with these methods,
showing that, to a significant degree, the same genetic variants
are responsible for the heritability of each pair of phenotypes and
that genetic variants associated with major depression or
schizophrenia in GWAS consortia are significantly predictive of
variation in neuroticism in UK Biobank. There was some evidence
for pleiotropy between neuroticism, and bipolar disorder, border-
line personality, anorexia nervosa and negative affect on the basis
of results from polygenic profile scoring or LD score regression,
respectively, but the extent of these associations varied according
to the method used. In all cases where there was a significant
finding using one method but not the other, the direction of effect
was the same using both methods. We found no evidence of
pleiotropy between neuroticism and the other mental health
outcomes examined—ADHD and Alzheimer’s disease. Of the eight
physical health outcomes studied, none showed evidence of
pleiotropy with neuroticism on the basis of the genetic correla-
tions obtained from LD score regression, but there was some
indication of genetic overlap between neuroticism and coronary
artery disease, smoking status and BMI. Higher polygenic risk for
coronary artery disease and smoking status was significantly
associated with higher levels of neuroticism, and polygenic risk for
higher BMI was associated with lower levels of neuroticism.
No associations were found between polygenic risk for the
other physical health-related traits (systolic and diastolic blood
pressure, rheumatoid arthritis, type 2 diabetes or longevity) and
neuroticism.
Previous investigations into pleiotropy between neuroticism
and mental health outcomes using polygenic risk profiling have
found evidence of substantial shared genetic aetiology between
neuroticism and major depression.31,45,46 Our observations in the
present, much larger, sample confirm those findings and for, we
believe, the first time quantify the extent to which the same
genetic variants are responsible for the heritability in these two
phenotypes, using an additional metric, LD score regression.32 The
relatively high genetic correlation between neuroticism and major
depression (rg = 0.66), identified in our study, is similar to the
genetic correlation identified in a previous twin study (rg = 0.43).
30
Our results also provide the first evidence, to our knowledge, that
the phenotypic correlations found between neuroticism and
schizophrenia47,48 are due at least in part to genetic overlap.
The extent of pleiotropy between anorexia nervosa or bipolar
disorder and neuroticism has been unclear, though there is some,
though limited, evidence to link both disorders phenotypically
with neuroticism.5,49 A previous study found no significant
association between polygenic risk scores for neuroticism and
bipolar disorder, but the sample size was small.46 In this much
larger sample, higher polygenic risk scores for bipolar disorder
were significantly predictive of higher neuroticism, but results of
LD score regression showed little indication of genetic correlation
between neuroticism and this disorder. We found a small but
highly significant genetic correlation between neuroticism and
anorexia (rg = 0.17), but there was no association between
polygenic risk scores for this condition and neuroticism. Although
there is now considerable evidence that neuroticism is a risk factor
for the development of Alzheimer’s disease,9 there was no
indication in our analyses that shared genes account for this link.
So far as we are aware, there have been no previous
investigations of the extent of pleiotropy between neuroticism
and physical health outcomes. This may be because, whereas
there is considerable evidence for phenotypic associations
between higher neuroticism and poorer self-rated health or
greater somatic complaints,13–18 fewer studies have examined
neuroticism as a predictor of objectively measured physical health
outcomes, and findings on such outcomes as coronary heart
disease, blood pressure, BMI and all-cause mortality have been
inconsistent.19–26 Of the eight objectively measured physical
health outcomes included in the current study, three showed
evidence of a degree of genetic pleiotropy with neuroticism:
coronary artery disease, smoking status and BMI. Neither
demonstrated any measurable genetic correlation with neuroti-
cism, but higher polygenic risk score for coronary artery disease
was associated with higher neuroticism. This is consistent with the
finding in pooled data from three cohorts that higher neuroticism
was associated with increased mortality from coronary heart
disease.20 Higher polygenic risk for BMI was associated with lower
neuroticism. The direction of this association was unexpected.
Findings on the phenotypic relationships between neuroticism
and BMI have produced inconsistent results: one study showed
higher neuroticism was associated with higher BMI,22 but another
found no association.25
The chief strength of our study is the large sample size that
permits powerful, robust tests of genetic association. Second, all
the UK Biobank genetic data were processed at the same location
and on the same platform. Finally, use of summary data from 17
large international GWAS consortia studies allowed us to perform
a comprehensive examination of the degree of pleiotropy
between neuroticism and a range of physical and mental
health-related phenotypes, and to produce many of the first
estimates of the genetic correlation between neuroticism and
these phenotypes.
Our study also has some limitations. First, the GWAS studies we
curated to carry out LD score regression and extract polygenic risk
scores often involved meta-analyses of results from data sets with
considerable heterogeneity in sample size, genome-wide imputa-
tion quality and measurement of phenotypes. With larger and
more consistent independent data sets, it should be possible to
use the polygenic risk scores to predict more variance in
neuroticism. Second, we restricted the genotyped samples to
individuals of white British ancestry in order to minimise any
influence of population structure. Our results therefore need to be
replicated in large samples with different genetic backgrounds as
we did not have the power to model data from UK Biobank
individuals of other ancestries. In the stratified analysis 13 out of
17 traits did not indicate a gender or age effect. These stratified
results need to be interpreted with caution; they were mostly null,
and no multiple testing correction was applied due to the high
correlations between the different models. The four traits that did
indicate potential gender or age effects need to be replicated in
an independent sample, before any conclusions can be drawn
from them.
We note that genetic correlations reflect the amount of the
genetic influence on two traits that is common to both. This is
independent of the heritability of either trait. Therefore, it is
entirely possible for a trait to have a small proportion of variance
accounted for by genetic variants, but to have a high genetic
correlation with another trait. The amount of variance explained
by each polygenic profile score is small, as would be expected by
the fact that not all SNPs were genotyped, and those that were do
not necessarily accurately tag the causal genetic variants. The
polygenic risk score most predictive threshold varied between
health traits, suggesting that the amount of shared genetic
aetiology between neuroticism and each of the health traits
differs. Although testing multiple thresholds may be deemed to
increase the multiple testing problem, it should be noted that the
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SNPs included in each threshold are not independent. Also, at
least for major depressive disorder and schizophrenia, pleiotropy
was quantified using LD score regression, which involved only a
single test per pair of phenotypes. The estimate of neuroticism
variance explained by each polygenic profile should be consid-
ered as the minimum estimate of the variance explained. Owing
to pruning SNPs in LD, the polygenic risk score method makes the
assumption of a single causal variant being tagged in each LD
block considered. If this assumption is not true for the phenotypes
considered, the proportion of variance explained will be
underestimated here.
In this large sample from UK Biobank, we aimed to discover
whether shared genetic aetiology explained part of the associa-
tions between neuroticism and various physical and mental health
outcomes. Our findings suggest that associations between
neuroticism and several mental health outcomes including major
depression, schizophrenia, bipolar disorder and anorexia nervosa
are in part due to shared genetic influences. We found that
polygenic risk scores for coronary artery disease, smoking and BMI
were predictive of neuroticism scores. This large-scale mapping of
the extent of pleiotropy between neuroticism and physical and
mental health outcomes adds to our understanding of the cause
of links between this important personality trait and later health.
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As discussed by Gale et al. (2016) in Section 6.2, neuroticism was genetically associated with 
multiple mental health traits. Significant genetic correlations identified between neuroticism 
and anorexia nervosa, major depressive disorder and schizophrenia in UK Biobank were 
replicated using neuroticism summary statistics from the Genetics of Personality Consortium. 
Some evidence was found for a shared genetic aetiology between neuroticism and physical 
health using PRS analysis; however, LDSR did not find any association between neuroticism 
and the physical health variables studied here. Overall, these results aid to a better 
understanding of the relationship between neuroticism and health. This Chapter examined the 
associations between one measure of negative emotions, i.e. neuroticism, and health; the next 
Chapter will examine the associations between self-reported tiredness, as a measure related to 
negative emotions, and health. 
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7. Genetic contributions to self-reported tiredness 
7.1. Introduction 
Fatigue is common in the general population and has been linked to higher levels of 
neuroticism and psychological distress, but also to poorer physical health. Both behavioural 
and molecular genetic studies have indicated genetic contributions to fatigue (Schlauch et al., 
2016; Schur, Afari, Goldberg, Buchwald, & Sullivan, 2007) and behavioural genetic studies 
suggested that the associations between neuroticism and fatigue could be due to a shared 
genetic aetiology (Charles et al., 2008; Kato et al., 2006). The molecular genetic studies 
examining the genetic contributions to people’s differences in fatigue are limited by the small 
sample sizes. This Chapter will examine the genetic contributions to fatigue, measured by self-
reported tiredness in the large UK Biobank sample, and will also examine the shared genetic 
aetiology between self-reported tiredness and physical and mental health. This study has been 
published in Molecular Psychiatry and is included in full in Section 7.2. 
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Genetic contributions to self-reported tiredness
V Deary1,7, SP Hagenaars2,3,4,7, SE Harris2,5, WD Hill2,3, G Davies2,3, DCM Liewald1,2, International Consortium for Blood Pressure GWAS,
CHARGE Consortium Aging and Longevity Group, CHARGE Consortium Inflammation Group, AM McIntosh4, CR Gale2,3,6,7 and
IJ Deary2,3,7
Self-reported tiredness and low energy, often called fatigue, are associated with poorer physical and mental health. Twin studies
have indicated that this has a heritability between 6 and 50%. In the UK Biobank sample (N= 108 976), we carried out a genome-
wide association study (GWAS) of responses to the question, ‘Over the last two weeks, how often have you felt tired or had little
energy?’ Univariate GCTA-GREML found that the proportion of variance explained by all common single-nucleotide polymorphisms
for this tiredness question was 8.4% (s.e. = 0.6%). GWAS identified one genome-wide significant hit (Affymetrix id 1:64178756_C_T;
P= 1.36 × 10− 11). Linkage disequilibrium score regression and polygenic profile score analyses were used to test for shared genetic
aetiology between tiredness and up to 29 physical and mental health traits from GWAS consortia. Significant genetic correlations
were identified between tiredness and body mass index (BMI), C-reactive protein, high-density lipoprotein (HDL) cholesterol, forced
expiratory volume, grip strength, HbA1c, longevity, obesity, self-rated health, smoking status, triglycerides, type 2 diabetes,
waist–hip ratio, attention deficit hyperactivity disorder, bipolar disorder, major depressive disorder, neuroticism, schizophrenia
and verbal-numerical reasoning (absolute rg effect sizes between 0.02 and 0.78). Significant associations were identified between
tiredness phenotypic scores and polygenic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary
artery disease, C-reactive protein, HbA1c, height, obesity, smoking status, triglycerides, type 2 diabetes, waist–hip ratio, childhood
cognitive ability, neuroticism, bipolar disorder, major depressive disorder and schizophrenia (standardised β’s had absolute
valueso0.03). These results suggest that tiredness is a partly heritable, heterogeneous and complex phenomenon that is
phenotypically and genetically associated with affective, cognitive, personality and physiological processes.
Molecular Psychiatry advance online publication, 14 February 2017; doi:10.1038/mp.2017.5
INTRODUCTION
‘Hech, sirs! But I’m wabbit, I’m back frae the toon; I ha’ena
dune pechin’—jist let me sit doon.’
From Glesca’ By William Dixon Cocker (1882–1970)
The present study examines genetic contributions to how the UK
Biobank’s participants answered the question, ‘Over the last two
weeks, how often have you felt tired or had little energy?’ Ideal
questionnaire items do not have conjunctions, but the ‘or’ is
understandable here, and it may even allow capture of both
peripheral and central fatigue. The first and last authors of the
present study grew up in South Lanarkshire in Scotland, where
fatigue was often self-reported in terms of feeling ‘wabbit’. The
Scots word wabbit encompasses both peripheral fatigue,
the muscle weakness after a long walk, and central fatigue, the
reduced ability to initiate and/or sustain mental and physical
activity, such as we might experience while having flu. Through-
out the paper, we refer mainly to the single English words ‘fatigue’
and/or ‘tiredness’ as the construct captured by the question, but
the Scottish vernacular word is a good reminder of the subjective
‘feel’ of fatigue.
Fatigue is a common complaint. In a Dutch adult, general
population survey with 9375 respondents, 4.9% reported short-
term fatigue (o6 months duration), 30.5% chronic fatigue
(46 months duration) and 1% fulfilled diagnostic criteria for
chronic fatigue syndrome (CFS).1 These findings are similar to a
London-based survey of general practice patients in England,
aged 18–45 years, with 15 283 respondents, where 36.7% reported
substantial fatigue, 18.3% substantial fatigue of 46 months
duration and 1% fulfilled the diagnostic criteria for CFS.2 Two
other large surveys of US workers and community-dwelling adults
aged 51 years and over report fatigue rates of 37.9% (2-week
period prevalence) and 31.2% (1-week period prevalence)
respectively.3,4 In an early review of fatigue epidemiology, Lewis
and Wessely5 argue that fatigue ‘is best viewed on a continuum’,
and the continuous distribution of fatigue in the general popula-
tion is supported by the Pawlikowska et al.2 study. Fatigue is also a
common presentation in primary care. In a survey of 1428 consul-
tations to 89 general practitioners in Ireland, fatigue prevalence
was 25% and the main reason for attendance in 6.5%.6
Demographically, higher levels of self-reported fatigue are
associated with female sex, lower socioeconomic status1 and
poorer self-rated health status.7 There are less clear associations
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between age and fatigue, with some studies reporting a small but
significant positive correlation between age and fatigue,2 whereas
others report no association6 or a negative association.1,7 There is
a clearer link with the Fried phenotype of frailty in older adults,8
which has significant associations with mortality. The frailty
phenotype comprises weakness (as measured by grip strength),
weight loss, reduced mobility, reduced walking speed and
fatigue.9
Fatigue is associated with a number of lifestyle-related factors
and conditions. Smoking is a risk factor for fatigue10 and fatigue
has strong cross-sectional associations with type 2 diabetes11 and
increased body mass index (BMI).12 Fatigue is consistently
associated with poorer physical and mental health status. It is
one of the most common symptom complaints of cancer patients.
For those undergoing treatment, prevalence estimates vary
between 25 and 99%, and 25 and 30% of survivors report long-
term fatigue.13 Fatigue is also a significant symptom of, to name
just a few conditions, primary biliary cirrhosis,14 multiple
sclerosis,15 rheumatoid arthritis,16 primary Sjogren’s syndrome17
and Parkinson’s disease.18 It is associated with chronic disease in
general, and there is a linear relationship between number of
chronic diseases and self-reported fatigue.19 Fatigue is also
associated with depression,20 with self-reported psychological
distress,2,21 and with the personality trait of neuroticism.22,23
Research into the biological mechanisms of fatigue has
focussed on a few key areas. Fatigue is associated with the
cytokine-mediated inflammatory response, particularly interl-
eukin-1beta and interleukin-6. These latter have been shown, for
instance, to be elevated in cancer patients,24 and administration of
interferon-alpha produces depression and/or fatigue in the
majority of patients receiving it as a treatment.25 Hypothalamic-
pituitary-adrenal axis dysregulation in the form of hypocortisolae-
mia, blunted diurnal variation and blunted stress reactivity have
been found in the cross-sectional studies of CFS patients (see
Tomas et al.26 for a recent review). Other popular candidate aetio-
pathological mechanisms for fatigue include serotonin pathways,
circadian dysregulation, autonomic dysfunction,17 5HT neuro-
transmitter dysregulation, alterations in ATP metabolism and vagal
afferent activation.24 Some authors have suggested that, rather
than being located with one biological system, fatigue represents
a systemic dysregulation of the interaction between these
systems.27
At the other end of the biopsychosocial spectrum, psychosocial
models of fatigue focus on the role that the individual’s response
to their symptom may serve in perpetuating it. For instance, in a
cross-sectional study of 149 patients with multiple sclerosis,
illness-related cognitions and behaviours were associated with a
higher level of fatigue independent of neurological impairment.28
More integrative models are predicated on the notion of allostatic
load, the psychophysiological work done to adjust to stress and its
impact upon the body’s self-regulatory systems. As such, these
models complement biological accounts of fatigue and provide
potential pathways for integrating psychosocial and biological
findings.29 Multifactorial accounts and models of fatigue exist in
multiple sclerosis,30 primary biliary cirrhosis,14 obesity,31 diabetes,32
frailty33 and cancer.13 These multifactorial models postulate that
fatigue is likely to be the product of physiological factors (generic,
such as inflammation and/or disease specific such as hypergly-
caemia in diabetes), psychosocial factors (for example, emotional
distress), lifestyle and behavioural factors (for example, reduced
activity), illness consequences (for example, sleep disturbance and
weakness) and the interaction of these contributors.
Research into the genetics and epigenetics of fatigue has
tended to focus on genes associated with the biological
mechanisms described above, and done so usually within
fatiguing illnesses such as those listed above. Candidate gene
studies have suggested several genes to be involved in CFS,
particularly genes involved in the immune system and
Hypothalamic-pituitary-adrenal axis. Reviewing this literature,
Landmark-Høyvik et al.34 suggest that findings are inconclusive,
and are hampered by phenotypic heterogeneity, lack of power
and poor study design. For example, the candidate gene studies
included in the Landmark-Høyvik paper had sample sizes between
2 and 248 individuals, and the results have not been replicated.
Twin studies have shown the heritability of fatigue to be between
6 and 50% with a higher concordance in monozygotic twins than
dizygotic twins.35,36 One of these studies36 did not show any sex-
specific patterns of genetic influences in a Swedish sample,
whereas the other one35 showed differences in the amount of
variance explained by the genetic effect for males and females.
Around half the variance in males was explained by the genetic
effects compared to only a fifth of the variance in females. In a
study of fatigue, insomnia and depression in 3758 twins (893
monozygotic pairs and 884 dizygotic pairs), the best model was a
common pathway model, suggesting that the high association
between the symptoms (correlations of 0.35–0.44) was mediated
by an underlying common factor whose variation was 49%
genetic and 51% unique environmental.37 This study showed that
unique specific variance in fatigue was 38% genetic and 62%
unique environmental, which supports a previous study, suggest-
ing that fatigue is largely attributable to additive genetic factors.38
Genome-wide association studies (GWAS) have shown an
association between single-nucleotide polymorphisms (SNPs) in
genes associated with impaired cognitive abilities (GRIK2,
P= 1.26 × 10− 11)39,40 and the circadian clock (NPAS2, not
genome-wide significant)40 and CFS, but this was in a sample of
just 42 cases of CFS and 38 controls, lacking statistical power to
detect genome-wide findings.
To sum up in the words of Landmark-Høyvik et al.:41 ‘fatigue can
be conceptualised as a final common end point for psychological
and biological processes. Fatigue is therefore both heterogeneous
(occurring across different conditions) and multifactorial’. Given
that, it could be argued that it is futile to search for a shared
genetic contribution to tiredness, as it may not exist. However, in
line with other fatigue research programmes42 and the research
cited above, we judge that the best way to approach this
complexity is to conduct large, well-designed studies focussing on
specific areas of the biopsychosocial spectrum, and that to date no
large study has done this at the genetic level.
Tiredness can be the result of external factors—such as poor
sleep—or inherent factors—such as personality traits or poor
health. It is therefore important that we clarify the scope of the
present study in terms of what questions we can ask, and how
definitively we can answer them. By averaging tiredness across a
large sample and performing a GWAS, the present study will
primarily pick upon the genetic links between tiredness and
inherent factors. These are likely to be various, so we will seek to
bring some clarity to what we consider to be the likely genetic
heterogeneity of tiredness by posing the following questions:
1. Is there a direct genetic contribution to self-reported tiredness
per se, not accounted for the factors in questions 2–4 below?
2. Is tiredness genetically linked to proneness to health-related
traits?
3. Is tiredness genetically linked to a systemic proneness to poor
health?
4. Is there a genetic relationship between the personality trait of
neuroticism and tiredness?
With regard to questions 2 and 3, it is important to remember
that a positive answer may constitute more than the obvious
conclusion that the presence of an illness phenotype is inevitably
accompanied by tiredness. Our analyses of UK Biobank data capture
genetic predisposition to illness rather than its actual presence; we
will address this in our polygenic prediction sensitivity analysis.
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The aim of the present study, then, is to understand further the
genetic contribution to self-reported tiredness and/or low energy.
We conducted a genome-wide association analysis, in the UK
Biobank sample, of a response to a single item question: ‘Over the
past two weeks, how often have you felt tired or had little energy?’
On the basis of the foregoing literature overview, we also
investigated pleiotropy with physical- and mental health-related
traits, and we specifically investigated pleiotropy with factors
associated with allostatic load as a first step towards answering
question three above. The current study design, using 4100 000
UK Biobank participants, directly addresses the main limitation
from the previous studies by substantially increasing the sample
size. In addition, we complement this with SNP-based heritability
estimates of tiredness, sex- and age-stratified analysis, and an
examination of the genetic overlap of tiredness with many health-
related traits.
MATERIALS AND METHODS
Study design and participants
UK Biobank is a large resource for identifying determinants of human
diseases in middle-aged and older individuals (http://www.ukbiobank.ac.
uk).43 A total of 502 655 community-dwelling individuals aged between 37
and 73 years were recruited in the United Kingdom between 2006 and
2010. Baseline assessment included cognitive testing, personality self-
report, and physical and mental health measures. For the present study,
genome-wide genotyping data were available for 112 151 participants
(58 914 females and 53 237 males) after quality control (see below). They
were aged from 40 to 73 years (mean= 56.9 years, s.d. = 7.9). UK Biobank
received ethical approval from the Research Ethics Committee (REC
reference for UK Biobank is 11/NW/0382). This study has been completed
under UK Biobank application 10279. Figure 1 shows the study flow for the
present report.
Procedures
Tiredness. Participants were asked the question, ‘Over the past two
weeks, how often have you felt tired or had little energy?’ Possible answers
were: ‘Not at all/Several days/More than half the days/Nearly every day/Do
not know/Prefer not to answer’. This question was asked as part of the
Mental Health Questionnaire, which consists of items from the Patient
Health Questionnaire.44 Participants answering with ‘Do not know’ or
‘Prefer not to answer’ were excluded, resulting in a four-category variable
for tiredness ranging from ‘Not at all’ to ‘Nearly every day’. We will refer to
this question in the rest of the paper as ‘tiredness’, but we ask the reader to
bear in mind the question as it was asked, that is, its referring to tiredness
and/or low energy.
Genotyping and quality control. The interim release of UK Biobank
included genotype data for 152 729 individuals, of whom 49 979 were
genotyped using the UK BiLEVE array and 102 750 using the UK Biobank
axiom array. These arrays have over 95% content in common. Details of the
array design, genotyping procedures and quality control details have been
published elsewhere.45,46
Imputation. An imputed data set was made available as part of the UK
Biobank interim data release. The 1000 Genomes phase 3 and UK10K
haplotype reference panels were merged and the genotype data imputed
to this merged reference panel. Further details can be found at the
following URL: http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id = 157020.
Autosomal variants with a minor allele frequency ⩽ 0.1% and an
imputation quality score of o0.1 were excluded from further analysis
(N~ 17.3M SNPs).
Curation of summary results from GWAS consortia on health-related
variables. Published summary results from international GWAS consortia
were gathered to derive genetic correlations using the linkage disequili-
brium (LD) score regression method and perform polygenic profile score
analysis between the UK Biobank tiredness variable and the genetic
predisposition to multiple health-related traits. Details of the health-related
variables, the consortia’s websites, key references for each consortium and
number of subjects included in each consortium’s GWAS are given in
Supplementary Table 1.
Statistical analysis
Phenotypic correlations. Spearman’s rank correlation coefficients were
calculated between responses to the tiredness question, grip strength,
forced expiratory volume in 1 s, height, BMI, self-rated health, verbal-
numerical reasoning and neuroticism, all of which were measured
phenotypes in UK Biobank. Details on measurements of these phenotypes
can be found in the Supplementary Material.
Genetic association analysis. A total of 111 749 individuals answered the
tiredness question and had genotypic information. After visual inspection
of the distribution of the UK Biobank tiredness variable no exclusions were
made. Prior to analysis, tiredness was adjusted for age, sex, assessment
centre, genotyping batch and array, and 10 principal components for
population stratification. Genotype–phenotype association analyses were
conducted using SNPTEST v2.5.1 (ref. 47) and can be found at the foll-
owing URL: https://mathgen.stats.ox.ac.uk/genetics_software/snptest/
snptest.html#introduction. An additive model was specified using the
‘frequentist 1’ option. Genotype uncertainty was accounted for by
analysing genotype dosages.
Genetic association analyses were also performed on the following UK
Biobank phenotypes to perform further analyses: self-rated health,48 grip
strength, forced expiratory volume in 1 s, neuroticism,49 verbal-numerical
reasoning.50 We specifically examined whether any variants associated
with tiredness were also associated with grip strength, self-rated health
and neuroticism because we judged these to provide some coverage of
physical and mental resilience in UK Biobank.
Estimation of SNP-based heritability. To estimate the proportion of
variance explained by all common SNPs in tiredness, univariate GCTA-
GREML analysis was performed.51 This analysis included only unrelated
individuals, using a relatedness cutoff of 0.025 in the generation of the
genetic relationship matrix.
Gene-based association analysis. Gene-based associations were derived
using MAGMA,52 using the summary GWAS statistics for tiredness. SNPs
were assigned to 18 062 genes using the National Center for Biotechnol-
ogy Information build 37.3. The gene boundary was defined as the start
and stop site of each gene. To account for LD between the SNPs used, the
European panel of the 1000 Genomes data (phase 1, release 3) was used. A
Bonferroni correction was used to control for 18 062 tests (α= 0.05/18 062;
Po2.768× 10− 6).
All recruited participants 
(N = 502 655) 
Interim data release 
(N = 152 729) 
Quality control (QC) 
(N = 112 151) 
Answered tiredness 
question + QC 
(N = 108 976) 
Exclusions based on:
- non-British ancestry  
- high missingness 
- relatedness 
- QC failure in UK 
BiLEVE 
Figure 1. Flow diagram of participant selection.
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Partitioned heritability. The summary statistics from the GWAS on
tiredness was partitioned into functional categories using the same data
processing pipeline as Finucane et al.;53 more details on this method can
be found in the Supplementary Materials.
Shared genetic aetiology: LD score regression and polygenic profiling.
Genetic associations between tiredness and health-related variables from
GWAS consortia were computed using two methods, LD score regression
and polygenic profile score analysis. Each provides a different metric to
infer the existence of loci contributing to pairs of traits. LD score regression
was used to derive genetic correlations between two traits; this tests the
degree to which the polygenic architecture of one trait overlaps with that
of other traits. Polygenic profile score analysis was used to test the extent
to which individual differences in the tiredness phenotype in UK Biobank
could be predicted by polygenic profile scores predictive of the health-
related traits from other GWAS consortia. Both of these methods are
dependent each on trait being polygenic in nature, that is, where a large
number of variants of small effect contribute towards phenotypic
variation.54,55 Bivariate LD score regression was performed between
tiredness and 29 health-related traits. Polygenic profile score analysis
was performed on 26 of the 29 health-related traits, as this method
requires independent samples to provide the summary GWAS information
from which the polygenic profile score is computed.
Bivariate LD score regression: This was used to quantify the extent of
genetic overlap between tiredness in UK Biobank and 29 health-related
traits.55,56 This technique examines the correlational structure of the SNPs
found across the genome. In the present study, LD score regression was
used to derive genetic correlations between tiredness and health-related
traits using the GWAS results of 25 large GWAS consortia and four UK
Biobank phenotypes. The data processing pipeline devised by Bulik-
Sullivan et al.55 was followed. To ensure that the genetic correlation for the
Alzheimer’s disease phenotype was not driven by a single locus or biased
the fit of the regression model, a 500-kb region centred on the APOE locus
was removed and this phenotype was re-run. This additional model is
referred to in the tables and figures as ‘Alzheimer’s disease (500 kb)’.
Polygenic profile scores: The UK Biobank genotyping data were
recoded from numeric (1,2) allele coding to standard ACGT coding using a
bespoke programme developed by one of the present authors (DCML).46
Polygenic profile scores were created for 25 health-related traits in all
genotyped participants using PRSice.57 Prior to creating the scores, SNPs
with a minor allele frequency o0.01 were removed and clumping was
used to obtain SNPs in linkage equilibrium with an r2o0.25 within a
200 bp window. Five polygenic profile scores were created for each trait
including SNPs according to their significance of association with the
relevant trait at P-value thresholds of Po0.01, Po0.05, Po0.1, Po0.5,
and all SNPs.
Regression models were used to examine the association between the
polygenic profile scores and tiredness in UK Biobank, adjusting for age at
measurement, sex, genotyping batch and array, assessment centre, and
the first 10 principal components for population stratification. All
associations were corrected for multiple testing using the false discovery
rate (FDR) method.58 Sensitivity analyses were performed to test whether
the results were confounded by individual’s neuroticism levels, their self-
rated health scores or a diagnosis of major depressive disorder. This was
done by adjusting the models for the neuroticism and self-rated health
scores. Individuals with a probable diagnosis of major depressive disorder
were excluded from the sensitivity analysis, based on the diagnostic
method formulated by Smith et al.59 Further details can be found in the
Supplementary Material. To examine whether any association between
polygenic profile score for type 2 diabetes and tiredness was confounded
by having had a diagnosis of type 2 diabetes, all individuals with a self-
reported doctor’s diagnosis of type 2 diabetes were excluded from that
specific sensitivity analysis (Supplementary Material). Multivariate regres-
sion was performed using all FDR significant polygenic profile scores and
earlier described covariates.
Comparison of gene-based analysis results within UK Biobank. Gene-based
associations for tiredness were compared with gene-based results for other
UK Biobank health-related traits that, in the present report’s results,
showed a statistically significant genetic correlation with tiredness, using
previously described methods.52
Age- and sex-stratified analysis. On the basis of the age and sex distribu-
tion for tiredness (Supplementary Figure 1), further analyses examining
potential age and sex effects were performed. The sample was split by sex,
as well as the following three age groups for each sex: 40 to o50 years, 50
to o60 years and 60 to o70 years, one male aged 470 years was
excluded from these analyses. The analysis included heritability estimates
for the eight different groups, genome-wide association analysis, and
genetic correlations with BMI and waist–hip ratio, as these summary data
were available separately for males and females. All models were adjusted
for age (sex-stratified analyses), sex (age-stratified analysis) and the
previously mentioned covariates (assessment centre, genotyping batch
and array, and 10 principal components for population stratification).




A total of 108 976 individuals from UK Biobank with genotypic
data answered the question ‘Over the past two weeks, how often
have you felt tired or had little energy?’, referred to hereinafter as
‘tiredness’. There were 51 416 individuals who answered ‘not at
all’, 44 208 individuals responded ‘several days’, 6404 individuals
answered ‘more than half the days’ and 6948 individuals
responded ‘nearly every day’. Correlations indicated that indivi-
duals who reported feeling more tired tended to have lower grip
strength, lower lung function, poorer self-rated health, lower
scores for verbal-numerical reasoning and shorter stature
(Table 1). Correlations indicated that individuals who reported
feeling more tired tended to have a higher BMI and higher
neuroticism scores (Table 1). Absolute effect sizes ranged from
very small to moderate (Supplementary Figures 2a–f). The mean
scores and distribution for each of these variables at each level of
tiredness are shown in Supplementary Figure 2 and
Supplementary Table 2.
Genome-wide association study
There was one genome-wide significant SNP (Affymetrix id
1:64178756_C_T; P= 1.36 × 10 − 11) on chromosome 1 (Figure 2).
This SNP is not in a gene and does not have an rs id. It has both a
low minor allele frequency (0.001) and a low imputation quality
score (0.43). It is not in a peak with other SNPs. Therefore, this
result should be treated with caution. Two suggestive peaks were
identified on chromosomes 1 and 17, with the lowest P-values of
5.88 × 10− 8 (rs142592148; an intronic SNP in SLC44A5) and
6.86 × 10− 8 (rs7219015; an intronic SNP in PAFAH1B1) for each
peak, respectively. The peak on chromosome 1 contains three
genes (CRYZ, TYW3 and SLC44A5). The peak on chromosome 17
contains one gene (PAFAH1B1). The CRY/TYW3 locus has previously
been associated with circulating resistin levels, a hormone
associated with insulin resistance, inflammation, and risk of type
2 diabetes and cardiovascular disease.60 SLC44A5 encodes a solute
carrier protein and is important for metabolism of lipids and
Table 1. Spearman phenotypic correlations between tiredness
(responses to the question, ‘Over the past two weeks, how often have
you felt tired or had little energy?’) and physical and mental health
Tiredness
Self-rated health (N= 108 648) − 0.35
Grip strength (N= 108 573) − 0.12
Forced expiratory function in 1 s (N= 101 823) − 0.08
Height (N= 108 796) − 0.09
BMI (N= 108 681) 0.10
Verbal-numerical reasoning (N= 35 101) − 0.04
Neuroticism (N= 105 456) 0.39
Abbreviation: BMI, body mass index. All correlations had Po0.001.
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lipoproteins, and has been associated with birth weight in cattle.61
PAFAH1B1 encodes a subunit of an enzyme that has important
roles in brain development and spermatogenesis. Mutations in
this gene cause the neurological disorder lissencephaly.62
SNP-based heritability estimate
Using GCTA-GREML common SNPs were found to explain 8.4%
(s.e. 0.6%) of the phenotypic variation of tiredness as measured
in UK Biobank.
Gene-based association analysis
Gene-based association analysis identified five genes, DRD2,
PRRC2C, C3orf84, ANO10 and ASXL3, that attained genome-wide
Figure 2. (a) Manhattan and (b) Q–Q plot of P-values of the SNP-based association analysis of tiredness (responses to the question, ‘Over
the past two weeks, how often have you felt tired or had little energy?’). The red line on the Manhattan plot indicates the threshold for
genome-wide significance (Po5 × 10− 8); the grey line on the Manhattan plot indicates the threshold for suggestive significance (Po1 10− 5).
SNP, single-nucleotide polymorphism.
Table 2. The genome-wide significant genes from the UK Biobank
tiredness phenotype and the significance values for the same genes
using the neuroticism, SRH and grip phenotypes, also in the UK
Biobank sample
CHR Gene Tiredness P SRH P Grip P Neuroticism P
11 DRD2 2.94 × 10− 7 0.012 0.156 9.69 × 10− 9
1 PRRC2C 1.43 × 10− 6 0.002 0.314 0.020
3 C3orf84 1.45 × 10− 6 7.38 × 10− 5 0.001 0.016
3 ANO10 1.52 × 10− 6 0.058 0.728 0.001
18 ASXL3 2.67 × 10− 6 1.03− 6 0.052 1.36 × 10− 5
Abbreviations: grip, grip strength; SRH, self-rated health. Unmodified
P-values are shown for all phenotypes.
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significance for tiredness (Table 2 and Supplementary Table 3)
following correction for multiple comparisons. DRD2 encodes a
dopamine receptor and has previously been associated with
psychiatric illnesses.63 Alternative splicing of PRRC2C has been
associated with lung cancer.64 Mutations in ANO10 cause
cerebellar ataxias.65 ASXL3 encodes a polycomb protein and
mutations in this gene are associated with intellectual disability,
feeding problems and distinctive facial features.66
In addition, each of these genes was also nominally significant
in a GWAS of neuroticism, with DRD2 being genome-wide
significant in both phenotypes.49 A comparison with a UK Biobank
GWAS of self-rated health22 showed that four of the five genes
(DRD2, PRRC2C, C3orf84 and ASXL3) were significant across
phenotypes. Grip strength showed less overlap, with only
C3orf84 being nominally associated with grip strength. Of the
five genes examined here, C3orf84 was associated with each of
these four phenotypes. Whereas the genetic correlations between
these traits (see below) are likely to encompass multiple genic and
non-genic regions, as well as unique points of overlap between
pairs of phenotypes, the variants found in the C3orf84 represent a
point of the genome where the genetic architecture of these four
traits converges.
Partitioned heritability
From the full baseline model using 52 annotations, only
evolutionarily conserved regions were found to be enriched for
tiredness (Supplementary Figure 3). This annotation contained
only 2.6% of the SNPs from the summary statistics, but they
collectively explained 40% of the heritability of tiredness
(s.e. = 11%, enrichment metric = 15.34, s.e. = 4.05, P= 0.0004). By
clustering the histone marks into tissue-specific categories, we
found significant enrichment for variants found in the central
nervous system (Supplementary Figure 4). This category contained
15% of the SNPs and explained 45% of the heritability (s.e. = 8%,
enrichment metric = 3.02, s.e. = 0.54, P= 0.0002).
Genetic correlations between tiredness and physical and mental
health traits
LD score regression was used to test whether genetic variants
associated with health-related traits also contribute towards
tiredness in UK Biobank. Table 3 and Figure 3 show these genetic
correlations. Positive significant (FDR corrected) genetic correla-
tions were found between tiredness and BMI (rg = 0.20), C-reactive
protein (rg = 0.17 = 0.02), HbA1c (rg = 0.25), obesity (rg = 0.21),
smoking status (rg = 0.20), triglycerides (rg = 0.13), type 2 diabetes
(rg = 0.18), waist–hip ratio (rg = 0.28), attention deficit hyperactivity
disorder (rg = 0.27), bipolar disorder (rg = 0.14), major depressive
disorder (rg = 0.59), neuroticism (rg = 0.62) and schizophrenia
(rg = 0.25). Negative significant (FDR corrected) genetic correla-
tions were found between high-density lipoprotein (HDL)
cholesterol (rg =− 0.11), forced expiratory volume in 1 s (rg =
− 0.12), grip strength (rg =− 0.16), longevity (rg =− 0.39), self-rated
health (rg =− 0.78) and verbal-numerical reasoning (rg =− 0.14).
These genetic correlations suggest that there are common genetic
associations between tiredness and multiple physical- and mental
health-related traits. Supplementary Table 8 shows the genetic
correlations between traits associated with the concept of
allostatic load (blood pressure, BMI, cholesterol, C-reactive protein,
HbA1c, obesity, triglycerides and waist–hip ratio), indicating
genetic overlap between these traits.
Polygenic prediction
The full results including all five thresholds can be found in
Supplementary Table 4, as well as the number of SNPs included for
the five thresholds in each trait. Table 4 shows the results for the
polygenic profile scores analyses, using the most predictive
threshold for each trait. Higher polygenic profile scores for 10
physical health traits predicted increased tiredness (significant
standardised β’s between 0.008 and 0.026) in UK Biobank: BMI,
low-density lipoprotein (LDL) cholesterol, coronary artery disease,
C-reactive protein, HbA1c, obesity, smoking status, triglycerides,
type 2 diabetes and waist–hip ratio. Higher polygenic profile scores
for HDL cholesterol and height predicted lower tiredness (significant
standardised β’s between β=− 0.016 and β=− 0.008, respectively).
Of the mental health traits, higher polygenic profile scores for
bipolar disorder, neuroticism, major depressive disorder and
schizophrenia were associated with increased tiredness (standar-
dised β’s between 0.008 and 0.028). Polygenic profile scores for
childhood cognitive ability showed a negative association with
tiredness (β=− 0.011).
Sensitivity analysis showed that, when controlling for neuroti-
cism, the associations between tiredness and polygenic profile
scores for BMI, obesity, type 2 diabetes, cholesterol (HDL and LDL),
C-reactive protein, HbA1c, triglycerides, waist–hip ratio, childhood
Table 3. Genetic correlations between tiredness documented in the














− 0.0698 0.0478 0.1444
BMI 0.2024 0.0322 3.18× 10−10
Cholesterol: HDL − 0.1087 0.0373 0.0036




C-reactive protein 0.0165 0.054 0.0021
Grip strengtha − 0.1596 0.0482 0.0009
HbA1c 0.2536 0.0857 0.0031
Height − 0.0201 0.0297 0.4980
Longevity − 0.3943 0.1096 0.0003
Forced expiratory
volume 1sa
− 0.1181 0.0538 0.0281
Obesity 0.2063 0.0381 6.31× 10−8
Rheumatoid arthritis − 0.0181 0.0674 0.7885
Self-rated healtha − 0.7780 0.0349 7.30×10−110
Smoking status 0.2009 0.0603 0.0009
Triglycerides 0.1324 0.0332 6.62× 10−5
Type 2 diabetes 0.1784 0.0689 0.0097
Waist–hip ratio 0.2834 0.0417 1.09× 10−11
Mental
health
ADHD 0.2694 0.1116 0.0158




Anorexia nervosa 0.0192 0.0492 0.6967
Autism 0.0129 0.0695 0.8522
Bipolar disorder 0.1382 0.0605 0.0223
Childhood cognitive
ability
− 0.1528 0.0891 0.0864
Major depressive
disorder
0.5902 0.1015 6.03× 10−9
Neuroticism 0.6150 0.038 7.34× 10−59
Schizophrenia 0.2490 0.0386 1.14× 10−10
Verbal-numerical
reasoninga
− 0.1379 0.0596 0.0206
Abbreviations: ADHD, attention deficit hyperactivity disorder; BMI, body
mass index; FDR, false discovery rate; GWAS, genome-wide association study;
HDL, high-density lipoprotein; LDL, low-density lipoprotein. Statistically
significant P-values (after false discovery rate correction; threshold:
P= 0.0281) are shown in bold. aGWAS based on UK Biobank data.
GWAS of self-reported tiredness
V Deary et al
6
Molecular Psychiatry (2017), 1 – 12
214
cognitive ability and schizophrenia remained significant (after FDR
correction), indicating that these associations are not wholly
confounded by scores for neuroticism. Similar analyses controlling
for self-rated health indicated that the following associations with
tiredness are not wholly confounded by self-rated health: bipolar
disorder, neuroticism, major depressive disorder and schizophre-
nia. Supplementary Table 5 shows the adjusted results and the
percentage of attenuation in standardised β’s for the models.
When excluding individuals with a probable diagnosis of major
depressive disorder (N= 7364) from all individuals with sufficient
information about their mental health to make a probable
depression diagnosis (full model, N= 31 523), the associations
between tiredness and eight polygenic profile scores remained
significant (after FDR correction), compared to nine in the full
model, the association between type 2 diabetes and tiredness
became non-significant after excluding individuals with probable
diagnosis of major depressive disorder (Supplementary Table 6).
When excluding individuals with a type 2 diabetes diagnosis
(N= 725), the association between tiredness and the polygenic risk
score for diabetes remained significant, indicating that this
association is independent of self-reported morbidity for that
disorder.
A multivariate regression model including 17 significant
polygenic profile scores (BMI, HDL cholesterol, LDL cholesterol,
coronary artery disease, C-reactive protein, HbA1c, height, obesity,
smoking status, triglycerides, type 2 diabetes, waist–hip ratio,
bipolar disorder, childhood cognitive ability, major depressive
disorder, neuroticism and schizophrenia) showed that polygenic
profile scores for the following traits contributed independently to
the association with tiredness: BMI, HDL cholesterol, triglycerides,
waist–hip ratio, childhood cognitive ability, major depressive
disorder, neuroticism and schizophrenia. The scores together
accounted for 0.25% of the variance in tiredness (Supplementary
Table 7).
Age- and sex-stratified analysis
GCTA-GREML analysis was used to test for possible differences in
the heritability estimates for tiredness in different age/sex groups.
The proportion of variance in tiredness explained by all common
genetic variants using GCTA-GREML was 9.4% (s.e. = 1%,
N= 57 165) in females and 8.2% (s.e. = 1%, N= 51 811) in males.
Figure 4 shows heritability estimates for the three age groups in
men and women (40 to o50, 50 to o60 years, and 60 to o70
years). The greatest differences can be seen between males aged
40 and 50 years (h2 = 19.8%, s.e. = 6%, N= 10 798) and males aged
60–70 years (h2 = 3.8%, s.e. = 2%, N= 24 467). Genome-wide
association analysis indicated no significant sex differences
between males and females, but did show some significant age
differences in males (Supplementary Figures 5). Genetic correla-
tions between BMI and tiredness were not significantly different
for males (rg = 0.15, s.e. = 0.06, 95% confidence interval (CI) = 0.04–
0.26, P= 0.0074) and females (rg = 0.26, s.e. = 0.05, 95% CI = 0.16–
0.36, P= 4.25 × 10− 7), as the confidence intervals were over-
lapping. Also, no significant differences in the genetic correlations
were found between waist–hip ratio and tiredness for males
(rg = 0.30, s.e. = 0.08, 95% CI = 0.14–0.45, P= 0.0003) and females
(rg = 0.271, s.e. = 0.06, 95% CI = 0.15–0.40, P= 2.2 × 10
− 5), with
overlapping confidence intervals.
Figure 3. Barplot of genetic correlations (s.e.) calculated using LD regression between tiredness in UK Biobank and mental and physical health
measures from GWAS consortia. *Po0.0281. ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GWAS, genome-wide
association study; HDL, high-density lipoprotein; LD, linkage disequilibrium; LDL, low-density lipoprotein.
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DISCUSSION
In the present study, shared genetic aetiology was identified
between tiredness and longevity, grip strength, multiple meta-
bolic indicators, smoking status, neuroticism, childhood cognitive
ability, depression and schizophrenia. These analyses, combining
data from the UK Biobank and many GWAS consortia, provide
the first estimate of the overlap in the genetic variants
contributing to the heritability of tiredness and these physical
and mental health-related traits and disorders. Tiredness demon-
strated a significant SNP-based heritability of 8.4%.
In answer to our first research question—is there a direct
genetic contribution to self-reported tiredness per se?—we found
that, whereas there was no large influence on tiredness from
common genetic variants, five genes attained genome-wide
significance for tiredness: DRD2, PRRC2C, ANO10, ASXL3 and
C3orf84. The latter is an uncharacterised protein representing a
point of genetic convergence between tiredness, neuroticism, grip
strength and self-rated health. DRD2, PRRC2C, ANO10 and ASXL3
have previously been associated with psychiatric illnesses,18 lung
cancer,19 cerebellar ataxias20 and intellectual disability,21 respec-
tively. The three genes within the suggestive peak on chromo-
some 1 (CRYZ, TYW3 and SLC44A5) have previously been
associated with insulin resistance, inflammation, risk of type 2
diabetes, metabolism of lipids and lipoproteins, and cardiovas-
cular disease.15,16 These genes are consistent with the identifica-
tion of regions associated with both tiredness and metabolic
irregularities, and perhaps more broadly with ‘metabolic syn-
drome’ and ‘allostatic load’. PAFAH1B, within a suggestive peak on
chromosome 17 has important roles in brain development.17 This
is consistent with the identification of regions associated with
both tiredness and cognitive traits, and the finding of significant
enrichment for variants found in the central nervous system.
Evolutionarily conserved regions were found to be enriched for
association with tiredness, consistent with findings for other
quantitative traits including disease status,53 suggesting that these
are important loci where common additive SNPs cluster to
produce phenotypic variation in many traits, as explored in more
detail in the paper by Hill et al.67 The range of factors—affective,
cognitive, behavioural and physical—that are genetically asso-
ciated with tiredness is in itself remarkable, and confirms the
observation of Landmark-Høyvik et al.,34 quoted in the introduc-
tion, that the related construct of fatigue is aetiologically
Table 4. Associations between polygenic profile scores of health-related traits created from GWAS consortia summary data, and the UK Biobank
tiredness phenotype controlling for age, sex, assessment centre, genotyping batch, and array and 10 principal components for population structure
Trait category Trait Threshold β P
Physical health Blood pressure: diastolic 0.1 − 0.0028 0.3619
Blood pressure: systolic 0.1 − 0.0025 0.4077
BMI 1 0.0280 4.90× 10−20a
Cholesterol: HDL 0.5 − 0.0163 8.49× 10−8a
Cholesterol: LDL 0.5 0.0081 0.0077a
Coronary artery disease 0.5 0.0084 0.0061
C-reactive protein 1 0.0130 2.10× 10−5a
Forced expiratory volume 1 s 0.01 − 0.0059 0.0529
Longevity 0.05 − 0.0067 0.0297
HbA1c 1 0.0090 0.0033a
Height 1 − 0.0077 0.0154
Obesity 1 0.0236 1.20× 10−14a
Rheumatoid arthritis 0.1 − 0.0016 0.5926
Smoking status 0.5 0.0086 0.0071
Triglycerides 0.5 0.0209 1.06× 10−11a
Type 2 diabetes 1 0.0120 0.0002a,b
Waist–hip ratio 1 0.0258 7.85× 10−17a
Mental health ADHD 1 0.0042 0.1647
Alzheimer’s disease 0.05 − 0.0052 0.0889
Anorexia nervosa 0.5 0.0048 0.1169
Autism 1 − 0.0018 0.5593
Bipolar disorder 0.01 0.0081 0.0076c
Childhood cognitive ability 0.1 − 0.0112 0.0002a
Major depressive disorder 1 0.0185 2.25×10−9c
Neuroticism 0.1 0.0183 2.00×10−9c
Schizophrenia 1 0.0283 2.31× 10−19a,c
Abbreviations: ADHD, attention deficit hyperactivity disorder; BMI, body mass index; FDR, false discovery rate; GWAS, genome-wide association study; HDL,
high-density lipoprotein; LDL, low-density lipoprotein. FDR-corrected statistically significant values (P= 0.0255) are shown in bold. The associations between
the polygenic profile scores with the largest effect size (threshold) and tiredness are presented. Threshold is the P-value threshold with the largest effect size.
aResults remain significant after controlling for neuroticism scores. bResults remain significant after excluding individuals with type 2 diabetes (β= 0.0105,
P= 0.00076). cResults remain significant after controlling for self-rated health.
Figure 4. Age- and sex-stratified heritability estimates with s.e.’s for
tiredness. SNP, single-nucleotide polymorphism.
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heterogeneous and multifactorial. No overlap has been found with
genes (GRIK2, NPAS2) identified in previous GWAS of fatigue;39,40
however, the sample size of these studies was too small to have
enough power to detect statistically significant differences. The
present study did not show significant associations for candidate
genes previously identified.34
The results of the present study add to the body of evidence
that tiredness has a genetic underpinning.35,36,38 This study
estimated the SNP-based heritability of self-reported tiredness at
8.4%, and also examined age- and sex-specific heritability. No
differences were found between males and females, but the
results suggested a higher heritability in males aged between 40
and 50 years, compared to males between 60 and 70 years.
Previous twin studies have shown inconsistent results regarding
the sex-specific heritability. One study reported a higher
heritability for prolonged fatigue (fatigue for more than one
month) in males,36 whereas another reported a higher heritability
for ‘interfering’ fatigue (fatigue for 45 days) in females.35 One
study reported no sex differences in the heritability of chronic
fatigue.36 In summary, the answer to our first question is that,
whereas tiredness is, as expected, largely causally heterogeneous,
there may be a small but significant, direct genetic contribution to
tiredness proneness.
In answer to question two—is tiredness genetically linked to
proneness to health-related traits?—we can answer in the
affirmative. The range of factors—affective, cognitive, behavioural
and physical—that are genetically associated with tiredness is in
itself remarkable, and confirms the observation of Landmark-
Høyvik et al,34 quoted in the introduction, that the related
construct of fatigue is aetiologically heterogeneous and multi-
factorial. This may seem a relatively trivial finding whether we
assume that it simply reflects the sum of genetic factors that are
primarily associated with other more specific phenotypes, which
cause tiredness in one way or another. However, it is important to
recall that the biobank data capture illness propensity rather than
actual morbidity. In our sensitivity analysis, we controlled for the
presence of type 2 diabetes and found that the genetic link
between type 2 diabetes and tiredness remained significant. This
would indicate that, for this health marker at least, tiredness and
illness proneness are genetically related irrespective of the
presence of morbidity. Similarly, the genetic association between
tiredness and longevity would argue for a non-trivial link between
self-reported tiredness and a more general tendency to poor
health.
This takes us into the territory of question three—is tiredness
genetically linked to a systemic proneness to poor health? To
begin to answer this, we examined the genetic associations
between tiredness and putative markers of allostatic load.
Tiredness showed significant shared heritability with a range of
factors associated with the metabolic syndrome68 including
cholesterol, triglycerides, HbA1c, waist–hip ratio, BMI, obesity
and type 2 diabetes. Several of these factors are biomarkers of
allostatic load.61,62 The concept of allostatic load has been used in
the context of both physical and mental ill health, including the
symptom of fatigue. Conceptually, allostatic load represents the
cumulative, physiological ‘wear and tear’ of a prolonged response
to a stressor. Allostatic load has been shown to be a reliably-
measurable multi-variate construct,69,70 with first-order factors
comprising cardiovascular, immune, metabolic, anthropometric
and neuroendocrine markers.29 It is hypothesised that, in response
to threats to homeostasis, the body’s self-regulatory mechanisms,
such as the sympathetic–adrenal medullary axis and the
hypothalamic pituitary adrenal axis, have the potential to ‘over-
compensate and eventually collapse upon themselves’,29 with
consequences for morbidity and mortality.
In our current analysis, we included metabolic (cholesterol,
HbA1c and triglycerides), anthropometric (waist–hip ratio, BMI and
obesity) and cardiovascular/respiratory (diastolic and systolic
blood pressure, and forced expiratory volume) markers of
allostatic load. The results showed significant shared genetic
aetiology, as measured by both LD score regression and polygenic
profile score analysis, between tiredness and most of the
metabolic and anthropometric markers, though not the cardio-
vascular/respiratory markers. This raises the possibility that the
genetic overlap between tiredness and these physiological factors
may be due to a biological propensity to an over-compensatory
physiological stress response. This suggestion will require further
investigation, because a more parsimonious explanation of these
links would be that there is a genetic link between tiredness and
multiple, separate genetic determinants of poor physical health.
However, the substantial genetic correlations between these traits,
and between these traits and tiredness provide some evidence
that the allostatic load concept does have coherence at the
genetic level.
Fourth, to answer the question on the genetic associations
between tiredness and the personality trait of neuroticism, which
is the tendency to experience negative affective states, these were
indeed strongly correlated, both phenotypically and genetically.
This may represent a separate route to fatigue, a predominately
affective one, and/or it may overlap with the physiological factors
described above. A recent paper by Gale et al.,49 also using this UK
Biobank sample, supports that the physiological and affective
dimensions of poor health overlap in neuroticism. That paper
showed that polygenic profile scores for several physical and
mental health traits—BMI, coronary artery disease, smoking status,
bipolar disorder, borderline personality, major depressive disorder,
negative affect and schizophrenia—significantly predicted neuro-
ticism. In the present study, when tiredness polygenic profile score
analyses were adjusted for neuroticism, the associations between
tiredness and mental health disorders (bar schizophrenia) were
largely attenuated, whereas most of the metabolic and anthro-
pometric associations remained significant. This suggests that it is
the propensity to neuroticism, rather than the specific propensity
to these disorders, that accounts or mediates the tiredness
associated with mood disorders. Watson and Pennebaker,71
discussing competing models of how negative affectivity is
related to self-reported physical and emotional well-being, found
that it is associated as much with the former as with the latter, and
that negative affectivity might better be conceptualised as a
general tendency to experience both somatic and emotional
distress. This concept of a general tendency to what they termed
somatopsychic distress could explain the pleiotropy observed in
the present study between neuroticism and tiredness.
That neuroticism may also be a distinct route to fatigue is
supported by the fact that when the polygenic profile score
analysis is adjusted for self-rated health, all associations between
polygenic profile scores for physical health and tiredness are
attenuated to the point of non-significance, whereas the relation-
ship between tiredness, and polygenic profiles for neuroticism,
major depressive disorder and bipolar disorder remain significant.
This is consistent with the study of Gale et al.,49 investigating
shared genetic aetiology between neuroticism and physical and
mental health, where there were more and stronger genetic
associations between neuroticism and mental health than
between neuroticism and physical health. If we take self-rated
health to be a marker, to some extent, of actual physical health
(and the study by Harris et al.48 would indicate that it is), then this
would suggest that when physical health is adjusted for, polygenic
profile scores for neuroticism and its associated negative affective
states, continue to make a unique contribution to tiredness.
These proposed affective and physiological routes to fatigue
may not be mutually exclusive. The allostatic load model, and the
multifactorial models of fatigue described in the introduction,
postulate that individual differences in personality, cognition and
behavioural responses to stress, and socio-cultural factors, affect
the physiological stress response. An increased propensity to
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experience distress, as captured in the concept of neuroticism,
would imply that there is increasing propensity to over-respond to
stressors and thus to physiological dysregulation. In the study by
Gale et al.,49 the only significant result between neuroticism and
physical disease state was a significant association with the
polygenic risk score for coronary artery disease, which is
suggestive of an overlap of affective and cardiovascular stress
responses. This multifactorial understanding of fatigue would also
allow us to incorporate childhood cognitive ability (reduced ability
to problem solve), smoking status (at least one study has found
smoking and allostatic load interaction effects29) and grip strength
(reduced overall system integrity/vigour) into a more general
model that is suggestive of shared genetic variance between
stress proneness (neuroticism, reduced cognitive ability and
reduced vigour), the physiological response to stress (biomarkers),
behavioural responses (smoking), self-reported tiredness, disease
and mortality.72 However, as with our discussion of allostatic load,
these links are suggestive not conclusive, and will require further
empirical and theoretical investigation.
The large sample size of the present study is a strength of this
study, providing powerful and robust tests of shared genetic
aetiology between tiredness, and physical and mental health. A
second strength is that all genetic samples were processed on the
same platform at the same location. The use of summary data
from many international GWAS consortia provided foundations for
a comprehensive examination of shared genetic aetiology
between tiredness and a wide range of health-related phenotypes.
The study has some limitations. The amount of variance
explained by the polygenic profile score analysis was small, which
would be expected as not all SNPs are genotyped. The SNPs that
were genotyped do not necessarily accurately tag the causal
genetic variants. All analyses were restricted to individuals of
white British ancestry, because the sample does not have enough
power to generalise results for individuals with different back-
grounds. Also, the sample consisted of middle- and older-aged
adults, thus limiting its generalisability to the adult population as a
whole. However, as mentioned in the introduction, there are no
clear age-related differences in levels of self-reported fatigue. This
could be taken as an indication that the phenomenon is fairly
stable across the adult life course, at least at the level of
phenotype. Whether the genetic determinants are different in
younger adults is a topic for future research.
A further limitation of the present study is the fact that tiredness
was measured by self-report; that is, that we were looking for
objective correlates of a subjective construct. However, as
Wessely73 observed, an objective measure of fatigue is ‘an
unattainable holy grail’. Almost all the studies cited in the
introduction have used subjective self-reports. The self-report
measures used vary widely, with there being several validated
fatigue measures, and many of the reported studies use either
double- or single-item questionnaires and/or single item visual
analogue scales. This in itself may account for some of the
inconsistency in fatigue research, though the demographic studies
cited at the beginning of this article, using a wide variety of
measures from single questions7 to a well-validated fatigue
questionnaire,2 produced similar findings. However, our findings
of genetic associations of fatigue will need replication with better
validated multi-item measures.
Perhaps a more serious concern is the one signalled in the
introduction: that fatigue is too causally heterogeneous a trait to
meaningfully study at the genetic level. To address this, it is worth
situating this research in the context of other recent and ongoing
fatigue research, such as the recently announced National Institute
of Health Mechanisms of Fatigue programme. The latter, while
acknowledging that fatigue ‘is a common co-morbid condition in
a multitude of disease conditions’, is attempting to define whether
‘molecular, cellular or imaging signatures of fatigue can be
defined’.42 Like the psychosocial and biological fatigue research
cited in our introduction, this work is predicated on the notion
that, whereas fatigue shows up as a response to many physical
and psychosocial stressors, its determinants may be shared across
conditions. As such, we should distinguish between the effective
cause of fatigue (the illness/stressors that set it going), and the
material and formal causes (the bodily and psychosocial processes
that produce and maintain the phenomenon).74 Whereas the
effective causes might be various, the material and formal causes
are likely to be more limited and shared across individuals and
precipitating conditions. Even if this is not the case, we judge that
the present study has gone some way to specifying the nature of
the heterogeneity of tiredness at the genetic level, and that there
are several non-trivial insights that will require further investiga-
tion, specifically: the links between tiredness and illness proneness
as distinct from actual morbidity; the genetic coherence of the
allostatic load concept and its contribution to tiredness; and the
nature of the shared genetic and phenotypic links between
tiredness and the personality trait of neuroticism. In terms of the
genetic contributions to this complex phenomenon, the current
study is probably best seen as the first attempt to use a large and
relatively well-powered GWAS to identify these areas for future
research.
Summary
Being genetically predisposed to a range of mental and physical
health complaints also predisposes individuals to report that they
are more tired or lacking in energy. This study confirms that self-
reported tiredness is a partly heritable, heterogeneous and
complex phenomenon that is phenotypically and genetically
associated with affective, cognitive, personality, health and
physiological processes. This study also served as a first step in
testing some genetic hypotheses from the allostatic load model,
finding suggestive links between tiredness and three genes on
chromosome one associated with allostatic processes and
considerable genetic overlap between tiredness and allostatic
markers. We can foresee more tests of these links as more
genome-wide genotyping data become available.
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The study in Section 7.2 by V. Deary et al. (2017) showed genetic contributions to self-
reported tiredness/low energy, a measure related to negative emotions, as well as extensive 
shared genetic aetiology between self-reported tiredness and the physical and mental health 
variables studied here. The genetic overlap was particularly strong with neuroticism, major 
depressive disorder, and self-rated health. Taken together with the work presented in Chapter 
6, these results support the idea that self-reported variables related to negative emotions, such 
as neuroticism and tiredness, capture the concept of general somato-psychic distress (Watson 
& Pennebaker, 1989), and that this is linked to poorer general health. The next Chapter will 
provide a general discussion of the work presented in this thesis. 
 
Following online publication of this paper, the authors noticed a mistake in Table 3 and Figure 
3, and in Table 4. The genetic correlation between tiredness and C-reactive protein was 
displayed as 0.0165, but the correct genetic correlation is 0.1650. The thresholds for major 
depressive disorder and neuroticism are incorrect in Table 4. The threshold for major 
depressive disorder is 0.1, and for neuroticism the threshold is 1, as displayed in the corrected 





8.1. General findings 
The present Thesis examined the extent to which the phenotypic associations between 
cognitive ability and health, and between negative emotions and health are due to shared 
genetic influences. This was assessed in the large UK Biobank cohort using linkage 
disequilibrium score regression (LDSR) and polygenic risk analysis (PRS) analysis, and other 
molecular genetic techniques. This final Chapter discusses the findings in this thesis in light 
of the two main objectives, considers both methodological and sample limitations, and will 
finish by discussing implications for future research.  
 
8.1.1. Cognitive ability 
The first objective of this thesis was to examine the shared genetic aetiology between cognitive 
ability and mental and physical health. The results in Chapter 4 provide evidence for genetic 
overlap between different measures of cognitive ability and a range of health outcomes. Using 
LDSR and PRS analysis, both verbal-numerical reasoning and college degree attainment were 
positively associated with autism, intracranial volume, childhood cognitive ability, and 
educational attainment, and negatively with ischaemic stroke, Alzheimer’s disease and body 
mass index (BMI). A negative association was found between schizophrenia and all cognitive 
phenotypes, except college degree attainment, which showed a positive association. College 
degree attainment was positively associated with bipolar disorder, infant head circumference, 
and height. A negative association was reported between college degree attainment and 
coronary artery disease.  
 
One of the previously described underlying mechanisms for the association between cognitive 
ability and health was the theory of bodily system integrity (Section 1.2.4). This theory 
223
proposes that better cognitive ability could be a marker for a latent trait of a well-functioning 
body. Both biological and mediated pleiotropy provide support for this theory. The association 
between cognitive ability and health could be caused by genetic variants that have an effect on 
both cognitive ability and health outcomes, i.e. biological pleiotropy. In the case of mediated 
pleiotropy, it is possible that genetic variants associated with better cognitive ability causes 
better lifestyle, higher education, and better socio-economic status, which are all associated 
with better health outcomes. This would be a more sensible idea when taking into account the 
association between educational attainment and health, as one would never expect to find 
genes directly related to educational attainment as this is not a biological trait.  
 
These associations were all in the expected direction, with poor health being associated with 
lower cognitive ability, except the association between college degree attainment and 
schizophrenia and autism, which indicated that higher genetic risk for schizophrenia and 
autism is associated with higher chance of college degree attainment. The association between 
educational attainment and schizophrenia is supported by a study that showed a small positive 
genetic correlation between the two (Okbay et al., 2016b). The study by Okbay et al. (2016b) 
used the same GWAS summary data for schizophrenia, based on the Schizophrenia Working 
Group of the Psychiatric Genomics Consortium (2014), but educational attainment was based 
on years of education and measured in an independent sample. Further evidence supporting 
the positive genetic association of educational attainment with schizophrenia, as well as with 
autism, has been reported by Warrier, Bethlehem, Geschwind, and Baron-Cohen (2016). They 
reported significant enrichment of educational attainment genes in both schizophrenia and 
autism co-expression modules. The authors suggest that genes for educational attainment 
possibly interact with schizophrenia and autism genes in different ways, for example at 
transcriptome level, and the interactions could potentially lead to both cognitive deficits and 
cognitive talents in schizophrenia and autism. However, conclusions about directions of effect 
cannot be made from these findings.  
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Bansal et al. (2017) showed the clinical diagnosis of schizophrenia likely consist of two 
disease subtypes with different genetic aetiologies, one more similar to bipolar disorder and 
high cognitive ability, and the other resembling a cognitive disorder. These results support the 
positive genetic association between educational attainment and both schizophrenia and 
autism, as reported in Section 4.2. Positive selection of autism risk alleles has been reported 
by Polimanti and Gelernter (2017), and these alleles were enriched for biological processes 
related to neural development. Based on these findings the authors suggest that autism risk 
alleles could positively affect behavioural traits related to brain development, which could lead 
to better cognitive ability in carriers of the autism risk alleles. 
 
Limited evidence was found for shared genetic aetiology between reaction time, memory and 
health outcomes. Reaction time was negatively associated with major depressive disorder 
(MDD), while memory showed a negative association with bipolar disorder and a positive 
association with BMI. The SNP-based heritability estimates for both reaction time and 
memory in UK Biobank are 11% and 5%, respectively (G. Davies et al., 2016b), indicating 
that only a small proportion of the variance in test scores can be explained by genetic 
influences. It is therefore unsurprising to find limited evidence for a shared genetic aetiology 
of these two phenotypes and health outcomes, due to both tests being very short and the 
memory test having a poor reliability, which will be discussed in more detail in Section 8.2.2. 
 
Using a bidirectional Mendelian randomization approach, we next examined potential causal 
association between cognitive ability and health. Specifically, we examined if educational 
attainment, a proxy phenotype for cognitive ability, causally influences physical health, or if 
physical health outcomes causally influence cognitive ability (Section 4.3). No evidence for a 
causal association in either direction was found. 
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Two recent studies tested for causal effects of educational attainment on health outcomes (N. 
M. Davies, Dickson, Davey Smith, van den Berg, & Windmeijer, 2016; Tillmann et al., 2017). 
N. M. Davies et al. (2016) used the raising of the school leaving age from 15 to 16 years in 
September 1972 as a natural experiment to test for causal effects of staying in school in UK 
Biobank. A genome-wide genetic risk score for educational attainment was created to estimate 
the effects of attending school on health outcomes. The results showed that remaining in 
school past the age of 15 years is associated with reduced risk of diabetes, stroke, heart attack, 
and mortality, lower BMI and systolic blood pressure, and increased grip strength and income. 
No sensitivity analyses, such as Mendelian randomization Egger regression, have been 
performed on these results; it is therefore possible that these results are biased by pleiotropic 
effects of the genetic variants. Tillmann et al. (2017) used a two-sample MR analysis to assess 
the causal effects of educational attainment on coronary artery disease and cardiovascular risk 
factors. A two-sample MR analysis uses GWAS summary results from two independent 
consortia and thereby increases statistical power. The results reported by Tillmann et al. (2017) 
showed that a 1 SD increase in educational attainment (3.6 years) was associated with a 33% 
decrease in risk for coronary artery disease, as well as decreased risk for cardiovascular risk 
factors such as smoking, BMI, and blood lipids. Sensitivity analyses indicated that the results 
were not biased by pleiotropic effects. While our study did not indicate causal associations 
between cognitive ability, or educational attainment, and health, two more recent studies did 
show a causal relationship, where more time spent in school decreases risk for disease. 
 
The introduction of the Trail making test (TMT) during the web-based assessment in UK 
Biobank provided the opportunity to compare the genetic architecture of the TMT measure 
with the genetic architecture of other cognitive measures. TMT is an important 
neuropsychological test for executive functioning and it is widely used in clinical settings to 
test for performance deficits in for example mental health disorders. Multivariate behavioural 
genetic studies have shown that a common genetic factor underlies the correlational structure 
226
between cognitive measures (T. Lee et al., 2012; Vasilopoulos et al., 2012). T. Lee et al. (2012) 
also identified a genetic correlation between TMT and general cognitive ability of 0.48 in a 
behavioural genetics study of 472 twins. These previous findings support the molecular 
genetic findings as discussed in Chapter 5, showing substantial genetic overlap between TMT 
and general cognitive ability and processing speed. In Chapter 4, we identified shared genetic 
aetiology between measures of cognitive ability in UK Biobank and health outcomes. While 
all three cognitive measures, verbal-numerical reasoning, reaction time, and memory, were 
bespoke non-standardized test, the reaction time and memory test had particularly problematic 
psychometric properties (Lyall et al., 2016). While the study in Chapter 5 did not directly test 
for a genetic association between TMT and health, the genetic overlap between the 
standardized TMT measure and verbal-numerical reasoning in UK Biobank, as well as the 
overlap with general cognitive ability and processing speed, might aid in the understanding of 
the complex relations between cognitive ability and health outcomes. 
 
To answer the first key question of this thesis, using different molecular genetic techniques, 
shared genetic aetiology was identified between cognitive ability and mental and physical 
health. Mendelian randomization analyses did not identify causal associations between 
cognitive ability and physical health. The next Section of this Discussion will summarize the 
findings of Chapter 6 and 7. 
 
8.1.2. Negative emotions 
The second objective of this thesis was to examine the shared genetic aetiology between 
negative emotions and physical and mental health. For this thesis, both the personality trait of 
neuroticism and fatigue (assessed using a question about tiredness and low energy) were used 
as measures of negative emotions. As reported in Chapter 6, both LDSR and PRS analysis 
showed positive genetic associations between neuroticism and anorexia nervosa, MDD, and 
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schizophrenia. PRS analysis alone identified that higher PRS for bipolar disorder, borderline 
personality disorder, anxiety, coronary artery disease, and smoking were associated with 
higher neuroticism scores. Higher PRS for BMI was associated with lower neuroticism scores, 
while based on the phenotypic association one would expect a higher PRS for BMI to predict 
lower neuroticism scores. Krapohl et al. (2016) did not find a significant association between 
polygenic risk for BMI and neuroticism, in a sample of 3152 individuals, but the direction of 
effect was negative, similar to the study in Chapter 4. No significant genetic correlation was 
found using LDSR in either UK Biobank or the Genetic of Personality Consortium in the 
current study. Okbay et al. (2016a) also did not identify a significant genetic correlation 
between neuroticism and BMI. This could indicate that the negative association between BMI 
polygenic risk and neuroticism is a false positive. Overall, the genetic associations between 
neuroticism and mental health traits provide further evidence for the idea that personality and 
mental health are related to each other. 
 
When examining fatigue, using self-reported tiredness/low energy, the previously identified 
positive genetic association between neuroticism and MDD and schizophrenia were also 
identified between tiredness and MDD and schizophrenia, as shown in Chapter 7. Using LDSR 
and PRS analysis, further positive genetic associations were found between tiredness and BMI, 
C-reactive protein, HbA1C, obesity, smoking, triglycerides, type 2 diabetes, waist-hip ratio, 
bipolar disorder, and neuroticism. A negative association was found between tiredness and 
HDL cholesterol. LDSR alone identified negative genetic correlations between tiredness and 
longevity, grip strength, self-rated health, forced expiratory volume in 1, and verbal-numerical 
reasoning. The correlation with the last four phenotypes could not be analysed using PRS 




One of the theories to explain the associations between negative emotions and health, suggests 
that negative emotions correlate with subjective health complaints, rather than actual physical 
health disorders. This is often referred to as ‘the symptom perception’ hypothesis (Costa & 
McCrae, 1987; Watson & Pennebaker, 1989). The phenotypic associations between negative 
emotions and self-rated health, as reported in the current thesis and by Harris et al. (2016a) 
showed that a higher level of negative emotions was correlated with lower self-rated health, 
which would support the symptoms perception hypothesis, as self-rated health is a subjective 
measure of one’s health. Self-rated health, however, does actually capture genetic 
contributions to mental and physical health disorders (Harris et al., 2016a). Combined with the 
results reported in this thesis—i.e., a shared genetic aetiology between negative emotions and 
health—these findings support an association between negative emotions and physical health 
disorders, instead of only subjective health complaints. This suggest that the symptom 
perception hypothesis does not fully explain the association between neuroticism and health. 
 
As previously discussed in the discussion of Chapter 7, neuroticism and tiredness showed a 
phenotypic correlation of 0.39 and a genetic correlation of 0.62. Both showed a shared genetic 
aetiology with mental health disorders such as major depressive disorder and schizophrenia. 
This suggests that the genetic influences on both neuroticism and tiredness are due in part to 
common processes. These findings, therefore, provide support for the idea that negative 
emotions are a measure of somatopsychic distress, as suggested by Watson and Pennebaker 
(1989). 
 
To answer the second key question of this thesis, using different molecular genetic techniques, 
some shared genetic aetiology was identified between negative emotions and mental and 
physical health. The two measures of negative emotions, the personality trait of neuroticism 
and self-reported tiredness, were strongly associated on both a phenotypic and genetic level. 
The next Section of this Chapter will discuss the potential limitations of findings in this Thesis. 
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8.2. Limitations  
Study specific limitations have been discussed in each of the corresponding Chapters, this 




Several methodological limitations should be considered in this Thesis. Firstly, as briefly 
discussed in Section 5.2.4, heritability estimates based on genotype data are generally lower 
than heritability estimates based on twin and family studies. SNP based heritability estimates 
are based on LD between genotyped variants and low LD between genotyped and causal 
variants might lead to lower heritability estimates. Heritability estimates based on twin and 
family studies are based on identity-by-descent (IBD), which refers to alleles that have been 
inherited from a common ancestor. Regions of IBD between pairs of individuals will share all 
genetic variants except de novo mutations (Powell, Visscher, & Goddard, 2010). Twin and 
family studies are therefore likely to capture more of the genetic contributions to a trait. Hill 
et al. (2017) have shown that the difference in heritability estimates for general cognitive 
ability between the two methods is due causal variants being in low LD with genotyped SNPs, 
by using a family design. For neuroticism, the authors did not identify the cause of the 
differences between the twin and SNP-based heritability estimates, which supports the idea 
that non-additive genetic components play a major role in the aetiology of neuroticism. 
 
Secondly, PRS are limited by the strength of the association in the original GWAS. Several of 
PRS used in this Thesis (brain phenotypes, stroke) are based on relatively small samples and 
are therefore potentially limited in statistical power to accurately predict the outcome 
(Dudbridge, 2013). It is also important to note that sample overlap between UK Biobank and 
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some of the GWAS consortia might have led to an overestimation of the associations. Where 
possible, we have excluded overlapping participants, for example 174 individuals from 
GS:SFHS are also part of UK Biobank; these individuals were excluded from GS:SFHS prior 
to any analysis that involved PRS based on UK Biobank data. For most of the data used for 
PRS, it was impossible to quantify the exact overlap, but we expect this to be minimal. 
 
Finally, all studies in this Thesis were based on individuals of White British ancestry, and the 
results are therefore not generalizable to other populations. The majority of GWAS have been 
performed in European populations due to the wide availability of reference panels based on 
European ancestry, such as the 1000 Genomes Project (The 1000 Genomes Project 
Consortium, 2010) and the International HapMap Project (The International HapMap 3 
Consortium, 2010; The International HapMap Consortium, 2007), and the availability of large 
European ancestry cohorts. As mentioned in Section 1.3.2.4, the LD structure differs between 
ethnic populations, the efficiency of reference panels based on European ancestry is therefore 
less efficient in other populations. While there are imputation reference panels available for 
other populations, for example from the International HapMap Project, the number of cohorts 
with non-European ancestry is limited. The full UK Biobank sample consists of 94% of 
individuals with a White background (UK Biobank, 2015b), the other populations consisted 
of relatively small subgroups, it was therefore not possible to have performed GWAS on other 
populations in order to replicate our findings in different populations, due to a lack of power. 
A recent study showed that PRS based on a GWAS of European ancestry individuals did not 
perform well in individuals of African ancestry (Ware et al., 2017); in individuals of European 
ancestry PRS were associated with the trait of interest in 80% of the cases, while in individuals 
of African ancestry these PRS were only associated with the trait of interest in 5% of the cases, 
based on an α of 0.001. 
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8.2.2. UK Biobank 
One of the main limitations of UK Biobank is the use of bespoke cognitive tests. As previously 
shown by Lyall et al. (2016), the measures of reaction time and memory have particularly poor 
psychometric qualities. The measure of reaction time in UK Biobank consisted of four trials, 
whereas measures of reaction time generally include at least 20 to 40 trials (I. J. Deary et al., 
2001; Der & Deary, 2006). The memory tested consisted of two versions, one using a 2x3 grid 
and one using a 3x4 grid. As shown in Figure 3-8, the 2x3 grid displays a ceiling effect, with 
nearly three quarters of the sample making no errors in identifying the three matching pairs. 
The 3x4 grid does not show such a clear ceiling effect but has a very poor test retest reliability 
of 0.15 over a period of two to seven years. These psychometric limitations potentially explain 
the lack of results for these measures. When comparing the measures in UK Biobank with 
standardized well validated cognitive measures in the LBC1936, educational attainment PRS 
explain 3% of the variance in general cognitive ability in LBC1936, while educational 
attainment PRS in UK Biobank only explain 1% of the variance in the test most similar to 
general cognitive ability, verbal-numerical reasoning (G. Davies et al., 2016b). 
 
Secondly, the UK Biobank sample is oversampled for older individuals with higher 
educational attainment and a better socio-economic status, compared to the general population 
in the United Kingdom. UK Biobank has a lower proportion of individuals aged 40 to 55 years, 
and a higher proportion of individuals aged 55 years and older compared to the 2011 Census 
data, as shown in Figure 3-2. When comparing the Townsend deprivation index, there were 
fewer individuals from the very deprived areas and more from the very high SES areas. It is 
important to note that the Townsend deprivation index was based on the 2001 Census data, as 
the Townsend deprivation index is not yet available for the 2011 Census. Individuals in UK 
Biobank are 1.6 times more likely to have a degree compared to the 2011 Census data. 
Generally, population, family, or twin studies include individuals with higher average 
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cognitive abilities than the general population. This could potentially lead to inflated 
heritability estimates (Turkheimer, Haley, Waldron, D'Onofrio, & Gottesman, 2003), because 
these cohorts do not sample the whole distribution of cognitive ability. It also means that the 
results reported in this Thesis are not fully generalizable to the general population. 
 
Disease status was ascertained during the touchscreen questionnaire based on self-report; all 
participants were asked if a doctor ever told them they had a certain diagnosis. If the participant 
answered affirmative or that they did not know, a trained nurse followed up during a verbal 
interview to confirm possible diagnoses. This could be problematic, particularly in the case of 
diabetes mellitus. The touchscreen questionnaire only asked if participants were diagnosed 
with diabetes in general; during the verbal interview participants could be specific about the 
type of diabetes they were diagnosed with (for example, type 1, type 2, gestational, or diabetes 
insipidus). Participants were also asked when they were diagnosed with diabetes, and when 
they started insulin treatment. In practice, this means that there are different ways to compute 
diabetes case control status. The sensitivity analysis in Chapter 7 used a conservative approach 
and only included individuals who answered that they were diagnosed with diabetes in the 
touchscreen interview and confirmed that it was type 2 diabetes in the verbal interview (n = 
725). For the analysis in Section 4.3, we adopted a less conservative approach, as described in 
Section 4.3.2.2, based on Yaghootkar et al. (2016), which lead to 3764 cases of type 2 diabetes. 
It is therefore possible that we underestimated the number of cases and the effect of type 2 
diabetes on our results in Chapter 7. UK Biobank have recently updated their data showcase 
and included algorithmically defined cases of myocardial infarction and stroke, based on a 
combination of self-report data and hospital records. It would be useful to have similar case-
control ascertainment for other diseases, such as type 2 diabetes. 
 
While UK Biobank certainly has several important limitations, one should not forget the 
strengths of this sample. It is currently the largest single sample population study including 
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over 500,000 individuals, with an interim release of genetic data for 150,000 individuals. All 
individuals in UK Biobank have been tested using the same measures and heterogeneity in 
sample composition, cognitive measurement and genetic testing, as can be found in large 
consortia cohorts will be therefore be minimal. 
 
8.3. Future research  
Future studies should focus on replicating the results reported in this Thesis, in particular 
between negative emotions and health, as many of these associations have not been reported 
previously. In order to better understand the underlying mechanisms of these associations, it 
is important to untangle causal phenotypic pathways and identify biological pathways. 
 
The availability of the full release of UK Biobank genetic data, in the second quarter of 2017, 
will provide an opportunity to further identify causal pathways between cognitive ability, 
negative emotions and health. This release will also improve the predictive value of PRS; the 
large sample of 500,000 individuals could be split in to two, where one part could be used for 
GWAS of a trait of interest, and the other part could be used as the prediction sample. This 
would be particularly useful for traits that do not have publicly available GWAS summary 
statistics. The verbal-numerical reasoning test and the trail making test, are at the moment 
likely the most well validated cognitive measures in UK Biobank. Because both have been 
added at a later stage during assessment, only a subset of the whole sample completed these 
tests. The release of the full data will increase the sample size for these tests from ~36,000 to 
~185,000 individuals for verbal-numerical reasoning and from ~23,000 to ~ 120,000 for the 
Trail making test. The findings reported in Chapter 4 and Chapter 5 could be used to address 
the overlap between executive function and health outcomes using this larger sample, to 
further disentangle the complex web of associations between cognitive ability and health. This 
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full release will also provide the opportunity to use longitudinal data to better examine the 
causal associations between cognitive ability, negative emotions and health.  
 
Based on the limitations discussed in the previous section, improvement of the cognitive 
measures in UK Biobank would be of great value. Dementia’s Platform UK is currently 
working on a new set of enhanced cognitive measures, which will be added to UK Biobank in 
due course and will include measures of verbal declarative memory, subjective memory, 
executive function, vocabulary, and non-verbal reasoning (Fawns-Ritchie, 2016). While it 
would be preferred to have extensive cognitive testing such as in LBC1936, this would not be 
feasible for a large cohort as UK Biobank, due to the associated costs and time it would take 
to test all participants.  
 
The availability of molecular genetic methods has changed rapidly in the past three years and 
has not stopped changing. This means that newer and better techniques can be used on the 
same data, for example to examine causal pathways, which will improve power to detect 
associations. Whereas the current Thesis has focussed on the release of genetic data in UK 
Biobank, imaging data has also been released. UK Biobank is planning to release imaging data 
for 100,000 individuals in the future, currently data for about 11,000 individuals is available. 
This provides the exciting opportunity to link brain imaging with genetics data, which will be 
especially useful in the case of cognitive ability, a trait highly linked to brain function. 
 
As indicated by the results in this Thesis, genetic variants explain part of the association 
between cognitive ability and health, and between negative emotions and health. To improve 
the predictive value of these associations, future studies could combine genetic information 
with biomarkers, environmental risk factors, and brain imaging data. This could move the field 
towards precision medicine and will help develop new diagnostics and therapeutics, especially 
in the case of mental health traits. 
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The studies in this Thesis made use of a wide range of PRS. In future research, PRS could be 
used to identify individuals at high risk for disease in both clinical trials and prevention studies. 
Increasing the accuracy of identifying high risk individuals in clinical trials using PRS will 
likely lead to a better chance of success. On the other hand, PRS can be used to identify 
individuals at the other end of the PRS distribution, to identify controls at very low risk of 
disease. In the case of prevention studies, identifying individuals at different risk levels for 
disease could be used to tailor interventions according to risk, especially when combining 
genetic risk with environmental risk factors.  
 
The findings presented in this Thesis could provide a first step in further disentangling 
biological causal pathways between cognitive ability, negative emotions, and health. A better 
understanding of the shared genetic aetiology between these traits could help policymakers to 
link changes in cognitive ability or negative emotions to harmful biological changes in the 
body, which in future will aid to better understand and address health inequalities. On the other 
hand, better understanding of causal pathways between cognitive ability, negative emotions, 
and health could potentially provide new drug targets or inform on new purposes for known 
drug targets. 
 
8.4. Final summary 
The main focus of this thesis was to investigate the potential shared genetic aetiology between 
cognitive ability and health, and between the tendency to experience negative emotions and 
health. Additionally, we tested how the important neuropsychological Trail making test was 
associated with other measures of cognitive ability. We identified extensive genetic overlap 
between verbal-numerical reasoning, educational attainment and mental and physical health 
traits, and made a start to untangle to causal pathways between cognitive ability and health. 
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The trail making test showed strong genetic overlap with measures of general cognitive ability 
and processing speed. Negative emotions, measured by neuroticism and self-reported 
tiredness/low energy, also showed genetic overlap with health outcomes. Neuroticism was 
mainly associated with mental health, while self-reported tiredness showed genetic overlap 
with both mental and physical health. Taken together, the results in the present Thesis provides 
further evidence for, and better understanding of, associations between cognitive ability and 
health, and between negative emotions and health. Progress in these research areas will help 
us better understand the causes of disease, but will also potentially help preventing disease in 
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Supplementary Table 1 
For each health-related phenotype for which we use genome-wide association study summary data, here 
are some key example references showing its relation to prior cognitive function (left-hand column) and 
its possible effects on later cognitive function (right-hand column). (-) indicates a negative association 
with cognitive function, while (+) indicates a positive association with cognitive function. 
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Link to prior cognitive function Phenotype Effect on cognitive function 
 Vascular-metabolic diseases  
Lawlor et al. (2008). (-) Coronary Artery Disease Kovacic et al. (2012) (-) 
Eggermont et al (2012) (-) 
Lawlor et al. (2008) (-) 
Rajan et al. (2014) (-) 
Stroke: Ischaemic Brainin et al. (2015) (-) 
Lawlor et al. (2008) (-) 
Rajan et al. (2014) (-) 
Stroke: Cardioembolic Brainin et al. (2015) (-) 
Lawlor et al. (2008) (-) 
Rajan et al. (2014) (-) 
Stroke: Large Vessel Disease Brainin et al. (2015) (-) 
Lawlor et al. (2008) (-) 
Rajan et al. (2014) (-) 
Stroke: Small Vessel Disease Brainin et al. (2015) (-) 
Mõttus et al. (2013) (-) Type 2 Diabetes Rawlings et al. (2014) (-) 
 Neuropsychiatric disorders  
N/A ADHD Frazier et al. (2004) (-) 
Whalley et al. (2000) (-) Alzheimer's Disease N/A 
N/A Autism Fombonne et al. (2005) (-) 
Gale et al. (2013) (+) Bipolar Disorder Gildengers et al. (2009) (-) 
Gale et al. (2008) (-) Major Depressive Disorder Wilson et al. (2014) (-) 
Dickson et al. (2012) (-) Schizophrenia Hedman et al. (2013) (-) 
 Brain measures  
Aribisala et al. (2014) (+) Hippocampal Volume van Petten et al. (2004) 
Royle et al. (2013) (+) Intracranial Volume Pietschnig et al. (2014) (+) 
 
N/A Infant Head Circumference Gale et al. (2003) (+) 
 Physical and physiological measures  
Starr et al. (2004) (-) Blood Pressure: Diastolic Taylor et al. (2013) (+/-) 
Novak & Hajjar (2010) (+/-) 
Starr et al. (2004) (-) Blood Pressure: Systolic Gottesman et al. (2014) (-) 
Novak & Hajjar (2010) (+/-) 
Belsky et al. (2013) (-) BMI Dahl et al. (2010) (-) 
No reference found. Height Russ et al. (2014) (+) 
Calvin et al. (2011) (+) Longevity N/A 
Richards et al. (2005) (+) Forced Expiratory Volume in 1s Emery et al. (2012) (+) 
 Life-course Cognitive traits and proxies  
N/A Childhood cognitive ability Deary et al. (2013) (+) 
Strenze (2007) (+) College degree Clouston et al. (2012) (+) 
Strenze (2007) (+) Years of Education Banks & Mazzonna (2012) (+) 
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Descriptions of Cognitive Phenotypes  
 
Reaction Time Test 
Reaction Time (RT) was measured in all participants using a computer-based ‘Snap’ game, conceptually 
similar to some ‘Go/No-Go’ reaction time tasks. Two cards with simple symbols (e.g. a square or equals 
sign), were presented to participants on a computer screen. Participants were instructed to push an 
adjacent button box as quickly as possible, using their dominant hand, if the two cards had identical 
symbols. After completing four practice trials, participants completed eight experimental trials, of which 
four included identical pairs; these four required a button to be pressed. Each participant’s RT score 
was calculated as the mean time (in ms) to push the button for the four trials in which the stimuli were 
identical. Owing to a positively-skewed distribution, the reaction time data were log-transformed before 
analysis. One participant with an outlying reaction time score (1905 ms, which is over 11 standard 
deviations above the mean RT) had their data removed from the analysis. The Cronbach alpha 
coefficient, which provides an internal consistency type of reliability, for the five trials was 0.85. The 
UK Biobank Field IDs used in this test were 401, 402, 403, and 404. There is a linear decline in mean 
performance (with longer reaction times found) between age 40 and 70 years (Supplementary Figure 1, 
below). 
 
Memory (Pairs Matching) Test 
Memory was measured using a computerised ‘pairs matching’ game. There were two rounds of the 
game. In the first round, three pairs of cards with matching simple symbols, arranged randomly in a 
grid, were presented to participants on a computer screen for three seconds. The cards were then ‘turned’ 
face down. The participants were instructed to select, from recall and in the fewest number of attempts, 
the pairs of cards that had matching symbols. Pairs were identified by the participant’s touching 
identical cards on the screen consecutively. There was no time limit and the participants could make as 
many attempts as they needed to find all the pairs. The second round included six pairs of cards, shown 
for five seconds. Only the results from this second, more challenging round of the memory test were 
used in this study. The memory test score in the present study is the total number of errors made during 
this task until the six pairs of identical cards were touched consecutively. Twenty-nine participants who 
made more than 30 errors on the task had their number of errors set to 30 (this was not performed for 
the GWAS analysis, therefore this does not apply to the LD regression analysis). The UK Biobank field 
ID for the variable used here (number of errors in the second round) was 399. There is a linear decline 
in mean performance (more errors) between age 40 and 70 years (Supplementary Figure 1, below). 
 
Verbal-numerical Reasoning Test  
This test is named ‘fluid intelligence’ in UK Biobank. This verbal-numerical reasoning test comprised 
thirteen questions presented serially on a computer screen. There were six verbal items. There were 
seven numerical items, involving sequence recognition and arithmetic. Participants were required to 
answer all the items within two minutes. All were multiple-choice. An example verbal item is: “Age is 
to years as height is to?” (answer options were, “Long/Deep/Top/Metres/Tall/Do not know/Prefer not 
to answer”). An example numerical item is: “150…137…125…114…104… what comes next?” 
(answer options were, “96/95/94/93/92/Do not know/Prefer not to answer”). The total score out of 
thirteen was recorded and used for the present study. The Cronbach alpha coefficient for the thirteen 
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items was 0.62. The UK Biobank Field IDs (variable names) used in this test, with each one 
corresponding to each of the 13 items, were 4935, 4946, 4957, 4968, 4979, 4990, 5001, 5012, 5556, 
5699, 5779, 5790, and 5866. The scores on this test show stable mean values between age 40 and 60 
years, and linear decline in mean scores between age 60 and 70 years (Supplementary Figure 1, below). 
Therefore, this test does not, across the whole age range, show the characteristic age-related decline 
expected from ‘fluid’ cognitive functions—the name the test has in UK Biobank—and so we refer to 
the test by its content, which is verbal-numerical reasoning. The cross-sectional age-related pattern of 
this test is similar to that shown by vocabulary tests, which are used to assess crystallised cognitive 
ability (Salthouse TA, Localizing age-related individual differences in a hierarchical structure. 
Intelligence; 32, 541-561, Figure 3). 
 
Educational Attainment 
As part of the sociodemographic questionnaire in the study, participants were asked, “Which of the 
following qualifications do you have? (You can select more than one)”. Possible answers were: 
“College or University Degree/A levels or AS levels or equivalent/O levels or GCSE or 
equivalent/CSEs or equivalent/NVQ or HND or HNC or equivalent/Other professional qualifications 
e.g. nursing, teaching/None of the above/Prefer not to answer”. For the present study, a binary 
education variable was created to indicate whether or not a participant had a college or university-
level degree. This educational attainment variable was used in this study as what has been named and 
validated as a ‘proxy phenotype’ for cognitive function (Rietveld CA, Esko T, Davies G, et al. 
Common genetic variants associated with cognitive performance identified using the proxy-
phenotype method. Proc Natl Acad Sci 2014; 111: 13790-13794). 
 
 
Supplementary Figure 1. Age trends in standardized mean scores for the 
three cognitive abilities (Memory, Reaction Time, and Verbal-Numerical 
Reasoning) in the full sample (left) and the participants with genotyping 
data available (right). Error bars represent +/- one standard error of the 
mean. Valid sample sizes are shown for each individual test. Memory and 
Reaction Time tests had scores reversed so that lower scores indicate 
poorer performance for all three tests. For the ‘Full Sample’ figure, six 
participants aged under 40 years and seven participants aged over 70 years 
were removed. For the ‘Genotyped Participants Only’ figure, one participant 
aged over 70 years was removed. 
 
Genotyping and Quality Control 
Genotyping was performed on 33 batches of ~4700 samples by Affymetrix, who also performed initial 
quality control of the genotyping data. Further details are available of the sample processing specific to 
the UK Biobank project (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155583) and the Axiom array 
(http://media.affymetrix.com/support/downloads/manuals/axiom_2_assay_auto_workflow_user_guide
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.pdf). Prior to the release of the UK Biobank genetic data a stringent QC protocol was applied, and 
performed at the Wellcome Trust Centre for Human Genetics (WTCHG); details of this process can be 
found at the following URL (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580). Prior to the 
analyses described in the main report, further quality control measures were applied by the present 
authors. Individuals were removed based on missingness, relatedness (KING estimated kinship co-
efficient > 0.0442), gender mismatch, non-British ancestry (principal component analysis identified 
probable Caucasians within those individuals that were self-identified as British), and QC failure in the 
UK Bileve study. A sample of 112 151 individuals remained for further analyses. A minor allele 
frequency of maf < 1% filter was applied and only autosomal variants were used in this study (N = 705 
516).  
 
Genome-wide association analyses (GWAS) in the UK Biobank sample 
An imputed dataset, including >70 million variants, was made available in which the UK Biobank 
interim release was imputed to a reference set which combined the UK10K haplotype and 1000 
Genomes Phase 3 reference panels. Further details can be found at the following URL: 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020. Genome-wide association analyses were 
performed on the imputed dataset using SNPTest v2.5.1 (Marchini J, Howie B, Myers S, et al. A new 
multipoint method for genome-wide association studies via imputation of genotypes. Nat Genet 2007; 
39: 906-913; SNPTEST v.2.5.1 can be found at the following URL: 
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html#introduction). An additive model 
was specified using the "frequentist 1" option. To account for genotype uncertainty we analysed the 
expected genotyped counts (dosages). Adjustments for age, sex, genotyping batch, genotyping array, 
assessment centre and 10 principal components were included. Prior to use in LD regression analyses 
the association results were filtered based on minor allele frequency (<0.1%) and imputation quality 
(<0.1). 
 
Sources of genetic results from genome-wide association consortia 
CARDIoGRAM 
Coronary artery disease data have been contributed by CARDIoGRAMplusC4D investigators.  
 
CHARGE-Aging and Longevity 
Longevity data have been provided by the CHARGE-Aging and Longevity consortium. Longevity was 
defined as reaching age 90 years or older. Genotyped participants who died between the ages of 55 and 
80 years were used as the control group. There were 6036 participants who achieved longevity and 3757 
participants in the control group across participating studies in the discovery meta-analysis. 
 
Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, Lunetta KL, Sebastiani P, Smith JA, Smith AV, 
Tanaka T, Yu L, Arnold AM, Aspelund T, Benjamin EJ, De Jager PL, Eirkisdottir G, Evans DA, Garcia 
ME, Hofman A, Kaplan RC, Kardia SL, Kiel DP, Oostra BA, Orwoll ES, Parimi N, Psaty BM, 
Rivadeneira F, Rotter JI, Seshadri S, Singleton A, Tiemeier H, Uitterlinden AG, Zhao W, Bandinelli S, 
Bennett DA, Ferrucci L, Gudnason V, Harris TB, Karasik D, Launer LJ, Perls TT, Slagboom PE, Tranah 
GJ, Weir DR, Newman AB, van Duijn CM and Murabito JM. GWAS of Longevity in CHARGE 
Consortium Confirms APOE and FOXO3 Candidacy. J Gerontol A Biol Sci Med Sci. 2015;70:110-
8. 
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Type 2 diabetes data were obtained from the DIAGRAM consortium. 
 
International Consortium of Blood Pressure (ICBP) 
Blood pressure data were provided by ICBP. 
 
Early Growth Genetics Consortium (EGG)  




Brain imaging data were obtained from the ENIGMA consortium.  
 
GIANT  
Height and BMI data were obtained from the GIANT consortium. 
 
International Genomics of Alzheimer’s Project (IGAP) 
Alzheimer’s disease data were obtained from (IGAP) 
Material and methods 
International Genomics of Alzheimer's Project (IGAP) is a large two-stage study based upon genome-
wide association studies (GWAS) on individuals of European ancestry. In stage 1, IGAP used genotyped 
and imputed data on 7 055 881 single nucleotide polymorphisms (SNPs) to meta-analyse four 
previously-published GWAS datasets consisting of 17 008 Alzheimer's disease cases and 37 154 
controls (The European Alzheimer's disease Initiative – EADI the Alzheimer Disease Genetics 
Consortium – ADGC The Cohorts for Heart and Aging Research in Genomic Epidemiology consortium 
– CHARGE The Genetic and Environmental Risk in AD consortium – GERAD). In stage 2, 11 632 
SNPs were genotyped and tested for association in an independent set of 8572 Alzheimer's disease cases 
and 11 312 controls. Finally, a meta-analysis was performed combining results from stages 1 & 2. 
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Ischaemic stroke data were obtained from the METASTROKE consortium. The METASTROKE 
consortium is supported by NINDS (NS017950). We thank all study participants, volunteers, and study 
personnel that made this consortium possible. The METASTROKE study consists of combined data 
from 15 GWAS of IS (12 389 cases vs 62 004 controls). We used TOAST criteria17 to classify IS as 
large artery stroke (LAS) (2167 cases/49 159 controls from 11 studies), cardioembolic stroke (CE) 
(2365 cases/ 56,140 controls from 13 studies), and small vessel disease (SVD) (1894 cases/51 976 
controls from 12 studies). METASTROKE studies consisted of independently performed genome-wide 
single nucleotide polymorphism (SNP) genotyping using standard technologies and imputation to 
HapMap release 21 or 22 CEU phased genotype18 or 1000 Genome 
reference panels. Investigators contributed summary statistical data from association analyses using 
frequentist additive models for metaanalysis after application of appropriate quality control measures. 
Polygenic scores reveal combined effects of multiple nonsignificant variants derived from a derivation 
sample and tested in an 
independent replication sample. We derived polygenic scores for multiple p value cutoffs (0.5, 0.25, 
0.1, 0.05, 0.01, 0.001, and 0.0001) in derivation samples. 
 
Psychiatric Genetics Consortium  
Schizophrenia, bipolar disorder, major depressive disorder, ADHD and autism data were obtained 
from the Psychiatric Genetics Consortium. 
 
Social Science Genetic Association Consortium 
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Years of education, college degree and childhood cognitive ability data were obtained from the Social 
Science Genetic Association Consortium. 
 
SpiroMeta/CHARGE-Pulmonary  
Lung function data were obtained from the SpiroMeta and CHARGE-Pulmonary consortia.
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Supplementary Table 2 
Sources of genetic results from genome-wide association consortia. 
Pheno
type 











Schunkert et al. Nat Genet 2011; 43: 333-
338. PMID: 21378990 









Traylor et al. Lancet Neurol 2012; 11: 
951-962. PMID: 23041239 










Traylor et al. Lancet Neurol 2012; 11: 











Traylor et al. Lancet Neurol 2012; 11: 











Traylor et al. Lancet Neurol 2012; 11: 










Morris et al. Nat Genet 2012; 44: 981-
990. PMID: 22885922 










Cross-Disorder Group of the Psychiatric 
Genomics Consortium. Lancet 2013; 381: 
1371-1379. PMID: 23453885 
1947 trio cases 
1947 trio 
pseudocontrol













Lambert et al. Nat Genet 2013; 45: 1452-
1458. PMID: 24162737 










Cross-Disorder Group of the Psychiatric 
Genomics Consortium. Nat Genet 2013: 














Psychiatric GWAS Consortium Bipolar 
Disorder Working Group. Nat Genet 















Major Depressive Disorder Working 
Group of the Psychiatric GWAS 
Consortium. Mol Psychiatr 2013; 18: 













Schizophrenia Working Group of the 
Psychiatric Genomics Consortium. 
Nature 2014; 511: 421-427. PMID: 
25056061 









































Consortium of Blood 
Pressure (ICBP) 
 
Ehret et al. (2011) Nature 478, 










Wood et al. Nat Genet 2014; 11: 










Taal et al. Nat Genet 2012; 15: 
532-538. PMID: 22504419  
10 
768 
Longevity CHARGE-Aging and 
Longevity  
 
Broer et al. J Gerontol A Biol Sci 
















Soler Artigas et al. Nature 







Consortium of Blood 
Pressure (ICBP) 
 
Ehret et al. Nature 2011; 478: 103-










Benyamin et al. Mol Psychiatr 









Rietveld et al. Science 2013; 314: 
1467-1471. PMID: 23722424  
95 
427 





Rietveld et al. Science 2013; 314: 




LD regression genetic correlation procedure 
The patterns of LD found across the genome enable genetic correlations between traits to be derived. 
This is due to two reasons. Firstly, the level of association a SNP shows in a GWAS is a product of both 
its own contribution toward a phenotype and those that are in LD with it ( Yang J, Weedon MN, Purcell 
S, et al. Genomic inflation factors under polygenic inheritance. Eur J Hum Genet 2011;19: 807-812). 
Additionally, SNPs in regions of high LD tag a greater proportion of the genome than SNPs in regions 
of low LD. These two facts mean that, assuming a polygenic architecture, SNPs in regions of high LD 
will have greater association statistics than SNPs found in regions of low LD. The effect of this is that 
GWAS association test statistics can be predicted using LD (Bulik-Sullivan B, Finucane HK, Anttila V 
et al. An atlas of genetic correlations across human diseases and traits. bioRxiv 2015; doi: 
http://dx.doi.org/10.1101/014498). This logic can also be extended to a bivariate design, where LD can 
be used to predict the product of pairs of test statistics for each locus across GWAS datasets (Bulik-
Sullivan B, Loh PR, Finucane H, et al. LD score regression distinguishes confounding from polygenicity 
in genome-wide association studies. Nat Genet 2015; 47: 291-295). 
 
We followed the protocol of the above studies by Bulik-Sullivan et al., where data sets demonstrating 
a heritability Z-score (h2z ) > 4 and a mean χ2 statistic of > 1.02 were included. All traits, except small 
vessel disease exceeded these thresholds. This threshold was implemented in order to establish that each 
GWAS data set had evidence of a clear polygenic signal. Where it was included in the summary 
statistics provided, a MAF of > 0.01 was used as a cut off. To control for imputation quality, only those 
SNPs found in the HapMap3 with 1000 Genomes EUR with a MAF > 0.05 were included 
(integrated_phase1_v3.20101123). Next, indels and structural variants were removed along with strand-
ambiguous SNPs. Finally, genome-wide significant SNPs were removed, as were SNPs with very large 
effect sizes (χ2 > 80), as the presence of outliers can increase the standard error in a regression model. 
LD scores and weights for use with the GWAS of European ancestry were downloaded from the Broad 
institute (http://www.broadinstitute.org/~bulik/eur_ldscores/). An unconstrained intercept was used in 
the regression model as it was not possible to quantify the degree of sample overlap between the traits 
used here.  
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Polygenic profiling procedure 
The genetic data files (.map and .ped files) supplied from Biota (the UK Biobank online repository) 
were unsuitable for use in the polygenic profile analyses as the .ped allele coding used a 1, 2 numeric 
allele encode rather than the standard ACGT encode format. In order to enable the analysis, the .ped 
files were recoded to the standard encode format. To achieve this, a bespoke programme was developed 
to create new files using a lookup-substitution method. A fast-in-memory lookup string hash table was 
created to hold the SNP-ID, along with the allele identifiers for the SNP. A simple loop then performed 
serialised lookups based on string position, to create an associated string with the correct ACGT encode. 
This was then appended to the six mandatory data fields extracted from initial string. In order to 
maximise performance and enable timely completion of the lookup-substitution, these loops were run 
in parallel threads in a standard multiprocessor environment. 
 
Sensitivity analysis 
To test whether FDR significant associations between polygenic risk for coronary artery disease, and 
Verbal-numerical reasoning and educational attainment were confounded by individuals diagnosed with 
cardiovascular disease, 2779 individuals who had had a heart attack and 2521 individuals with angina 
were removed from the regression analysis. Similarly 5800 individuals with diabetes (type 1 or type 2) 
were removed from the regression investigating an association between polygenic risk for type 2 
diabetes and educational attainment. Finally, 26 912 individuals with hypertension were removed from 
the regression analysis investigating the association between polygenic risk for systolic blood pressure 
and educational attainment. 
 
Supplementary Table 3 
Number of SNPs included at each threshold for the polygenic profile scores. 
 
 
Threshold Number of SNPs 









































































 Infant Head Circumference 0.01 2031 
  0.05 9004 
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  0.1 16994 
  0.5 73859 
  1 127665 


















































Supplementary Table 4a  
Associations between polygenic profiles of health-related traits, and verbal-numerical reasoning 
controlling for age, sex, assessment centre, genotyping batch and array, and ten principal components 
for population structure. Statistically significant values (P<0.0188) are shown in bold. 
Cognitive/education phenotypes are scored such that higher scores indicate better performance. 
Trait 
category 
Trait Verbal-Numerical Reasoning 






0.01 −0.017 0.0052 0.0003 0.0009 
0.05 −0.012 0.0052 0.0002 0.0188 
0.1 −0.011 0.0052 0.0001 0.0393 
0.5 −0.019 0.0052 0.0004 0.0002 
1 −0.018 0.0052 0.0003 0.0005 
Stroke: 
Ischaemic 
0.01 −0.010 0.0053 0.0001 0.0474 
0.05 −0.014 0.0053 0.0002 0.0068 
0.1 −0.006 0.0053 3.47×10−5 0.2604 
0.5 −0.007 0.0053 4.42×10−5 0.2041 
1 −0.003 0.0053 1.02×10−5 0.5428 
Stroke: 
Cardioembolic 
0.01 0.005 0.0052 2.45×10−5 0.3444 
0.05 0.000 0.0052 8.40×10−8 0.9558 
0.1 −0.005 0.0052 2.06×10−5 0.3858 
0.5 −0.008 0.0052 0.0001 0.1092 
1 −0.009 0.0052 0.0001 0.0937 
Stroke: Large 
Vessel Disease 
0.01 −0.013 0.0053 0.0002 0.0155 
0.05 −0.004 0.0053 1.28×10−5 0.4948 
0.1 −0.007 0.0053 4.24×10−5 0.2134 
0.5 −0.002 0.0052 4.11×10−6 0.6986 
1 −0.010 0.0052 0.0001 0.0629 
Stroke: Small 
Vessel Disease 
0.01 −0.005 0.0052 2.99×10−5 0.2962 
0.05 −0.012 0.0053 0.0001 0.0250 
0.1 −0.007 0.0053 4.34×10−5 0.2085 
0.5 0.001 0.0052 8.21×10−7 0.8626 
1 0.001 0.0052 1.26×10−6 0.8300 
Type 2 Diabetes 0.01 −0.002 0.0053 5.84×10−6 0.6446 
0.05 −0.001 0.0053 1.63×10−6 0.8073 
0.1 −0.004 0.0053 1.60×10−5 0.4442 
0.5 −0.006 0.0054 2.98×10−5 0.2969 




ADHD 0.01 −0.002 0.0052 5.74×10−6 0.6474 
0.05 −0.001 0.0052 3.12×10−7 0.9150 
0.1 −0.004 0.0052 1.67×10−5 0.4354 
0.5 −0.007 0.0052 0.0001 0.1597 
1 −0.008 0.0052 0.0001 0.1054 
Alzheimer's 
Disease 
0.01 −0.014 0.0052 0.0002 0.0061 
0.05 −0.023 0.0053 0.0005 1.27×10−5 
0.1 −0.023 0.0053 0.0005 1.34×10−5 
0.5 −0.021 0.0053 0.0004 0.0001 
1 −0.022 0.0053 0.0005 3.97×10−5 




0.05 0.016 0.0052 0.0002 0.0028 
0.1 0.019 0.0052 0.0003 0.0004 
0.5 0.022 0.0052 0.0005 1.92×10−5 
1 0.023 0.0052 0.0005 1.43×10−5 
Bipolar 
Disorder 
0.01 −0.006 0.0052 3.34×10−5 0.2695 
0.05 −0.003 0.0053 7.87×10−6 0.5920 
0.1 −0.003 0.0053 1.01×10−5 0.5433 
0.5 −0.004 0.0053 1.24×10−5 0.5006 




0.01 −0.008 0.0053 0.0001 0.1455 
0.05 −0.008 0.0053 0.0001 0.1366 
0.1 −0.014 0.0053 0.0002 0.0071 
0.5 −0.018 0.0053 0.0003 0.0005 
1 −0.020 0.0053 0.0004 0.0002 
Schizophrenia 0.01 −0.055 0.0053 0.0030 2.04×10−25 
0.05 −0.062 0.0053 0.0038 7.73×10−32 
0.1 −0.062 0.0053 0.0037 3.22×10−31 
0.5 −0.062 0.0054 0.0037 2.59×10−31 





0.01 0.005 0.0052 2.34×10−5 0.3552 
0.05 0.000 0.0052 1.05×10−8 0.9844 
0.1 −0.002 0.0052 4.24×10−6 0.6943 
0.5 0.002 0.0052 2.78×10−6 0.7500 
1 −0.001 0.0052 3.26×10−7 0.9132 
Intracranial 
Volume 
0.01 0.013 0.0053 0.0002 0.0113 
0.05 0.009 0.0053 0.0001 0.0895 
0.1 0.013 0.0053 0.0002 0.0140 
0.5 0.016 0.0054 0.0003 0.0021 
1 0.016 0.0054 0.0003 0.0023 
Infant Head 
Circumference 
0.01 0.019 0.0052 0.0003 0.0004 
0.05 0.019 0.0053 0.0003 0.0004 
0.1 0.020 0.0053 0.0004 0.0002 
0.5 0.024 0.0053 0.0005 8.53×10−6 






0.01 0.001 0.0052 1.53×10−6 0.8132 
0.05 0.004 0.0052 1.22×10−5 0.5044 
0.1 0.000 0.0053 6.52×10−8 0.9611 
0.5 0.003 0.0053 7.91×10−6 0.5911 
1 0.003 0.0053 9.49×10−6 0.5563 
 Blood Pressure: 
Systolic 
0.01 0.008 0.0052 0.0001 0.1138 
0.05 0.008 0.0052 0.0001 0.1324 
0.1 0.013 0.0052 0.0002 0.0116 
0.5 0.007 0.0053 0.0001 0.1582 
1 0.008 0.0053 0.0001 0.1211 
 BMI 0.01 −0.022 0.0052 0.0005 2.92×10−5 
 
 
0.05 −0.024 0.0052 0.0006 3.44×10−6 
 
 




0.5 −0.027 0.0052 0.0007 3.34×10−7 
 
 
1 −0.026 0.0052 0.0007 8.52×10−7 
 Height 0.01 0.017 0.0053 0.0003 0.0011 
0.05 0.019 0.0053 0.0004 0.0003 
0.1 0.019 0.0054 0.0003 0.0004 
0.5 0.021 0.0054 0.0004 0.0001 
1 0.021 0.0054 0.0004 0.0001 
 Longevity 0.01 0.004 0.0053 1.87×10−5 0.4091 
0.05 0.000 0.0053 4.62×10−8 0.9673 
0.1 0.000 0.0052 7.30×10−8 0.9588 
0.5 0.000 0.0052 1.31×10−7 0.9449 
1 0.000 0.0052 1.98×10−8 0.9786 
 Forced 
Expiratory 
Volume in 1s 
(FEV1) 
0.01 0.000 0.0052 2.08×10−7 0.9306 
0.05 0.007 0.0052 0.0001 0.1604 
0.1 0.007 0.0052 4.38×10−5 0.2064 
0.5 0.012 0.0052 0.0001 0.0220 








0.01 0.031 0.0052 0.0010 3.12×10−9 
0.05 0.052 0.0052 0.0027 2.55×10−23 
0.1 0.063 0.0052 0.0040 1.45×10−33 
0.5 0.077 0.0052 0.0059 1.70×10−48 
1 0.079 0.0052 0.0062 3.49×10−51 
College degree 0.01 0.069 0.0052 0.0048 3.92×10−40 
0.05 0.085 0.0052 0.0071 1.05×10−58 
0.1 0.095 0.0052 0.0089 5.93×10−73 
0.5 0.102 0.0052 0.0102 3.19×10−83 
1 0.101 0.0052 0.0101 2.56×10−82 
Years of 
Education 
0.01 0.077 0.0052 0.0058 1.88×10−48 
0.05 0.090 0.0052 0.0080 2.26×10−65 
0.1 0.096 0.0052 0.0091 7.36×10−75 
0.5 0.105 0.0053 0.0109 6.20×10−89 
1 0.106 0.0053 0.0109 2.96×10−89 
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Supplementary Table 4b 
Associations between polygenic profiles of health related traits and Reaction Time (log transformed) 
controlling for age, sex, assessment centre, genotyping batch and array, and ten principal components 
for population structure. Statistically significant values (P<0.0188) are shown in bold. 
Cognitive/education phenotypes are scored such that higher scores indicate better performance. 
Trait 
category 
Trait Reaction Time 
Threshol
d 






0.01 3.24×10−5 0.0005 3.03×10−8 0.9508 
0.05 2.80×10−4 0.0005 2.27×10−6 0.5939 
0.1 0.001 0.0005 2.33×10−5 0.0875 
0.5 0.001 0.0005 1.37×10−5 0.1894 
1 0.001 0.0005 1.83×10−5 0.1301 
Stroke: 
Ischaemic 
0.01 −0.001 0.0005 2.46×10−5 0.0791 
0.05 −3.00×10−4 0.0005 2.53×10−6 0.5735 
0.1 2.52×10−4 0.0005 1.76×10−6 0.6385 
0.5 −3.68×10−5 0.0005 3.73×10−8 0.9455 
1 −1.53×10−4 0.0005 6.58×10−7 0.7740 
Stroke: 
Cardioembolic 
0.01 0.001 0.0005 2.42×10−5 0.0817 
0.05 0.001 0.0005 1.47×10−5 0.1746 
0.1 0.001 0.0005 7.98×10−6 0.3175 
0.5 1.74×10−4 0.0005 8.71×10−7 0.7412 
1 −2.32×10−5 0.0005 1.55×10−8 0.9648 
Stroke: Large 
Vessel Disease 
0.01 5.86×10−5 0.0005 9.86×10−8 0.9115 
0.05 2.26×10−4 0.0005 1.44×10−6 0.6714 
0.1 −1.54×10−4 0.0005 6.66×10−7 0.7726 
0.5 4.45×10−6 0.0005 5.72×10−10 0.9932 
1 −2.03×10−4 0.0005 1.19×10−6 0.6991 
Stroke: Small 
Vessel Disease 
0.01 −3.12×10−4 0.0005 2.82×10−6 0.5525 
0.05 1.05×10−4 0.0005 3.16×10−7 0.8424 
0.1 −1.45×10−4 0.0005 6.04×10−7 0.7832 
0.5 −4.53×10−4 0.0005 5.94×10−6 0.3882 
1 −0.001 0.0005 7.93×10−6 0.3188 
Type 2 
Diabetes 
0.01 −4.33×10−4 0.0005 5.36×10−6 0.4124 
0.05 −3.10×10−4 0.0005 2.71×10−6 0.5602 
0.1 −4.50×10−4 0.0005 5.70×10−6 0.3982 
0.5 −3.65×10−5 0.0005 3.67×10−8 0.9459 




ADHD 0.01 −2.71×10−4 0.0005 2.13×10−6 0.6053 
0.05 6.76×10−5 0.0005 1.32×10−7 0.8976 
0.1 4.14×10−5 0.0005 4.97×10−8 0.9371 
0.5 −0.001 0.0005 8.45×10−6 0.3036 
1 −0.001 0.0005 1.06×10−5 0.2485  
Alzheimer's 
Disease 
0.01 −4.31×10−4 0.0005 5.38×10−6 0.4116  
0.05 −0.001 0.0005 2.04×10−5 0.1096  
0.1 −2.30×10−4 0.0005 1.53×10−6 0.6619  
0.5 −0.001 0.0005 3.02×10−5 0.0516  
1 −0.001 0.0005 2.64×10−5 0.0692 
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Autism 0.01 0.001 0.0005 1.78×10−5 0.1348 
0.05 0.001 0.0005 1.24×10−5 0.2124 
0.1 0.001 0.0005 1.95×10−5 0.1176 
0.5 0.001 0.0005 1.01×10−5 0.2612 
1 0.001 0.0005 1.01×10−5 0.2605  
Bipolar 
Disorder 
0.01 −0.002 0.0005 9.08×10−5 0.0007 
0.05 −0.002 0.0005 7.79×10−5 0.0018 
0.1 −0.002 0.0005 8.68×10−5 0.0010 
0.5 −0.002 0.0005 8.54×10−5 0.0011 




0.01 −0.001 0.0005 2.95×10−5 0.0544 
0.05 −0.002 0.0005 7.22×10−5 0.0026 
0.1 −0.002 0.0005 9.61×10−5 0.0005 
0.5 −0.002 0.0005 8.30×10−5 0.0013 
1 −0.002 0.0005 6.50×10−5 0.0043  
Schizophrenia 0.01 −0.005 0.0005 0.0007 4.24×10−22 
0.05 −0.005 0.0005 0.0008 1.03×10−23 
0.1 −0.006 0.0005 0.0009 1.88×10−25 
0.5 −0.005 0.0005 0.0008 7.56×10−24 





0.01 0.001 0.0005 8.02×10−6 0.3163 
0.05 0.001 0.0005 1.47×10−5 0.1744 
0.1 0.001 0.0005 1.68×10−5 0.1465 
0.5 0.001 0.0005 1.99×10−5 0.1144 
1 0.001 0.0005 1.98×10−5 0.1156 
Intracranial 
Volume 
0.01 0.001 0.0005 7.56×10−6 0.3306 
0.05 3.57×10−4 0.0005 3.60×10−
6 
0.5020 
0.1 3.32×10−4 0.0005 3.08×10−6 0.5346 
0.5 3.29×10−4 0.0005 2.97×10−6 0.5418 
1 3.21×10−4 0.0005 2.83×10−6 0.5514 
Infant Head 
Circumference 
0.01 −0.001 0.0005 3.16×10−5 0.0468 
0.05 −3.01×10−4 0.0005 2.60×10−6 0.5683 
0.1 −1.06×10−4 0.0005 3.20×10−7 0.8413 
0.5 −1.92×10−4 0.0005 1.05×10−6 0.7174 







0.01 0.001 0.0005 1.14×10−5 0.2325 
0.05 1.59×10−4 0.0005 7.28×10−7 0.7627 
0.1 3.45×10−4 0.0005 3.43×10−6 0.5120 
0.5 4.50×10−4 0.0005 5.82×10−6 0.3931 




0.01 −1.73×10−4 0.0005 8.68×10−7 0.7416 
0.05 −2.58×10−4 0.0005 1.92×10−6 0.6241 
0.1 −4.81×10−4 0.0005 6.66×10−6 0.3609 
0.5 −4.97×10−4 0.0005 7.09×10−6 0.3460 
1 −3.88×10−4 0.0005 4.32×10−6 0.4619 
BMI 0.01 3.96×10−4 0.0005 4.54×10−6 0.4507 
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0.05 1.99×10−5 0.0005 1.15×10−8 0.9697 
0.1 −4.02×10−5 0.0005 4.67×10−8 0.9390 
0.5 −2.47×10−5 0.0005 1.76×10−8 0.9626 
1 1.79×10−5 0.0005 9.25×10−9 0.9728 
Height 0.01 3.64×10−4 0.0005 3.75×10−6 0.4933 
0.05 2.82×10−4 0.0005 2.21×10−6 0.5985 
0.1 4.06×10−4 0.0005 4.54×10−6 0.4508 
0.5 4.46×10−4 0.0005 5.34×10−6 0.4135 
1 4.07×10−4 0.0005 4.43×10−6 0.4562 
Longevity 0.01 2.47×10−5 0.0005 1.75×10−8 0.9627 
0.05 3.23×10−4 0.0005 2.96×10−6 0.5426 
0.1 1.21×10−4 0.0005 4.25×10−7 0.8176 
0.5 2.30×10−4 0.0005 1.52×10−6 0.6623 
1 1.84×10−4 0.0005 9.73×10−7 0.7270 
Forced 
Expiratory 
Volume in 1s 
(FEV1) 
0.01 −4.27×10−4 0.0005 5.28×10−6 0.4162 
0.05 −0.001 0.0005 1.83×10−5 0.1302 
0.1 −0.001 0.0005 1.05×10−5 0.2505 
0.5 −2.14×10−4 0.0005 1.33×10−6 0.6836 








0.01 0.001 0.0005 1.57×10−5 0.1613 
0.05 0.002 0.0005 8.41×10−5 0.0012 
0.1 0.002 0.0005 9.30×10−5 0.0006 
0.5 0.002 0.0005 0.0001 0.0002 
1 0.002 0.0005 8.94×10−5 0.0008 
College 
Degree 
0.01 0.001 0.0005 1.60×10−5 0.1573 
0.05 0.001 0.0005 4.61×10−5 0.0163 
0.1 0.001 0.0005 3.97×10−5 0.0257 
0.5 0.001 0.0005 4.90×10−5 0.0133 
1 0.001 0.0005 4.42×10−5 0.0186 
Years of 
Education 
0.01 0.001 0.0005 2.26×10−5 0.0927 
0.05 0.001 0.0005 2.15×10−5 0.1008 
0.1 0.001 0.0005 4.67×10−5 0.0156 
0.5 0.001 0.0005 2.71×10−5 0.0654 
1 0.001 0.0005 2.92×10−5 0.0558 
  
286
Supplementary Table 4c 
Associations between polygenic profiles of health related traits, and memory controlling for age, sex, 
assessment centre, genotyping batch and array, and ten principal components for population structure. 
Statistically significant values (P<0.0188) are shown in bold. Cognitive/education phenotypes are 










0.01 -0.004 0.003 1.27×10−5 0.2265 
0.05 -0.002 0.003 6.08×10−6 0.4036 
0.1 0.000 0.003 2.25×10−7 0.8725 
0.5 0.000 0.003 1.14×10−7 0.9091 
1 0.001 0.003 3.17×10−7 0.8487 
Stroke: 
Ischaemic 
0.01 −0.002 0.0030 3.64×10−6 0.5184 
0.05 −0.001 0.0030 1.04×10−7 0.9128 
0.1 −0.0005 0.0030 4.03×10−8 0.9458 
0.5 −0.004 0.0030 1.60×10−5 0.1759 




0.01 0.004 0.0030 1.62×10−5 0.1721 
0.05 −0.001 0.0030 6.57×10−7 0.7836 
0.1 −0.003 0.0030 1.14×10−5 0.2535 
0.5 0.004 0.0030 1.65×10−5 0.1691 




0.01 −0.006 0.0030 3.04×10−5 0.0619 
0.05 −0.006 0.0030 3.02×10−5 0.0628 
0.1 −0.008 0.0030 6.69×10−5 0.0056 
0.5 0.0001 0.0030 1.64×10−8 0.9654 




0.01 −0.004 0.0030 1.91×10−5 0.1388 
0.05 −0.004 0.0030 1.42×10−5 0.2025 
0.1 −0.002 0.0030 5.97×10−6 0.4080 
0.5 −0.004 0.0030 1.50×10−5 0.1899 
1 −0.003 0.0030 1.15×10−5 0.2512 
Type 2 
Diabetes 
0.01 0.0003 0.0030 9.07×10−8 0.9187 
0.05 0.002 0.0030 5.23×10−6 0.4387 
0.1 0.0005 0.0030 2.85×10−7 0.8566 
0.5 0.003 0.0030 8.41×10−6 0.3260 




ADHD 0.01 0.0001 0.0030 9.36×10−10 0.9917 
0.05 −0.001 0.0030 4.39×10−7 0.8224 
0.1 0.001 0.0030 8.42×10−7 0.7560 
0.5 0.001 0.0030 1.77×10−6 0.6520 
1 0.001 0.0030 2.85×10−7 0.8566 
Alzheimer's 
Disease 
0.01 −0.009 0.0030 7.56×10−5 0.0032 
0.05 −0.009 0.0030 7.47×10−5 0.0034 
0.1 −0.011 0.0030 0.000129 0.0001 
0.5 −0.010 0.0030 9.31×10−5 0.0011 
1 −0.009 0.0030 8.87×10−5 0.0014 
Autism 0.01 0.001 0.0030 1.50×10−6 0.6784 
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0.05 0.001 0.0030 3.29×10−7 0.8459 
0.1 0.002 0.0030 5.23×10−6 0.4385 
0.5 −0.001 0.0030 2.89×10−6 0.5647 
1 −0.001 0.0030 3.50×10−6 0.5262 
Bipolar 
Disorder 
0.01 −0.012 0.0030 1.45×10−4 4.49×10−5 
0.05 −0.015 0.0030 2.11×10−4 8.77×10−7 
0.1 −0.015 0.0030 2.25×10−4 3.68×10−7 
0.5 −0.017 0.0030 2.66×10−4 3.21×10−8 




0.01 −0.007 0.0030 5.17×10−5 0.0149 
0.05 −0.006 0.0030 3.91×10−5 0.0342 
0.1 −0.010 0.0030 0.0001 0.0007 
0.5 −0.013 0.0030 0.000174 7.77×10−6 
1 −0.014 0.0030 0.000198 1.91×10−6 
Schizophrenia 0.01 −0.035 0.0030 1.18×10−3 2.73×10−31 
0.05 −0.039 0.0030 1.48×10−3 7.62×10−39 
0.1 −0.039 0.0030 1.49×10−3 4.49×10−39 
0.5 −0.038 0.0030 1.35×10−3 1.65×10−35 





0.01 −0.003 0.0030 7.21×10−6 0.3629 
0.05 −0.003 0.0030 1.07×10−5 0.2674 
0.1 −0.005 0.0030 2.59×10−5 0.0848 
0.5 −0.003 0.0030 6.33×10−6 0.3940 
1 −0.003 0.0030 9.46×10−6 0.2975 
Intracranial 
Volume 
0.01 0.0001 0.0030 1.33×10−8 0.9689 
0.05 0.0005 0.0030 2.09×10−7 0.8768 
0.1 0.004 0.0030 1.60×10−5 0.1749 
0.5 0.005 0.0030 2.55×10−5 0.0872 




0.01 0.002 0.0030 4.94×10−6 0.4514 
0.05 0.001 0.0030 1.65×10−6 0.6639 
0.1 0.005 0.0030 2.70×10−5 0.0782 
0.5 0.003 0.0030 7.25×10−6 0.3616 







0.01 0.002 0.0030 3.37×10−6 0.5342 
0.05 −0.001 0.0030 4.65×10−7 0.8173 
0.1 0.001 0.0030 1.22×10−6 0.7082 
0.5 −0.001 0.0030 2.10×10−6 0.6232 




0.01 −0.002 0.0030 5.00×10−6 0.4488 
0.05 −0.003 0.0030 8.80×10−6 0.3149 
0.1 −0.002 0.0030 3.04×10−6 0.5551 
0.5 −0.003 0.0030 8.72×10−6 0.3172 
1 −0.002 0.0030 5.24×10−6 0.4383  
BMI 0.01 0.008 0.0030 6.75×10−5 0.0054   
0.05 0.013 0.0030 0.00016 1.85×10−5   
0.1 0.016 0.0030 0.000253 7.31×10−8 
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0.5 0.014 0.0030 0.000191 2.76×10−6   
1 0.014 0.0030 0.00019 3.05×10−6  
Height 0.01 0.003 0.0030 7.37×10−6 0.3579 
0.05 0.001 0.0030 1.71×10−6 0.6581 
0.1 0.001 0.0030 1.92×10−6 0.6390 
0.5 0.001 0.0031 1.51×10−6 0.6772 
1 0.001 0.0031 7.45×10−7 0.7700  
Longevity 0.01 0.004 0.0030 1.77×10−5 0.1538 
0.05 0.003 0.0030 1.17×10−5 0.2473 
0.1 0.005 0.0030 2.25×10−5 0.1078 
0.5 0.005 0.0030 2.70×10−5 0.0783 
1 0.006 0.0030 3.39×10−5 0.0484  
Forced 
Expiratory 
Volume in 1s 
(FEV1) 
0.01 −0.005 0.0030 2.29×10−5 0.1048 
0.05 −0.005 0.0030 2.55×10−5 0.0870 
0.1 −0.004 0.0030 2.00×10−5 0.1302 
0.5 −0.005 0.0030 2.44×10−5 0.0945 








0.01 0.004 0.0030 1.51×10−5 0.1884 
0.05 0.006 0.0030 3.23×10−5 0.0541 
0.1 0.008 0.0030 5.61×10−5 0.0112 
0.5 0.014 0.0030 0.0001 4.25×10−6 
1 0.014 0.0030 0.0002 1.65×10−6 
College 
degree 
0.01 0.0005 0.0030 2.78×10−7 0.8583 
0.05 −0.002 0.0030 4.55×10−6 0.4698 
0.1 −0.002 0.0030 4.57×10−6 0.4688 
0.5 0.001 0.0030 1.61×10−6 0.6669 
1 0.002 0.0030 2.63×10−6 0.5826 
Years of 
Education 
0.01 −0.0003 0.0030 7.68×10−8 0.9252 
0.05 −0.004 0.0030 1.75×10−5 0.1563 
0.1 −0.004 0.0030 1.21×10−5 0.2377 
0.5 −0.002 0.0030 5.43×10−6 0.4299 
1 −0.002 0.0030 2.28×10−6 0.6089 
289
Supplementary Table 4d 
Associations between polygenic profiles of health related traits, and college controlling for age, sex, 
assessment centre, genotyping batch and array, and ten principal components for population structure. 
Statistically significant values (P<0.0188) are shown in bold. Cognitive/education phenotypes are 
scored such that higher scores indicate better performance. 
Trait 
category 
Trait Educational Attainment 
Threshol
d 






0.01 −0.020 0.0066 0.0001 0.0020 
0.05 −0.026 0.0066 0.0002 0.0001 
0.1 −0.033 0.0066 0.0003 8.09×10−7 
0.5 −0.047 0.0066 0.0006 8.32×10−13 
1 −0.047 0.0066 0.0006 7.92×10−13 
Stroke: 
Ischaemic 
0.01 −0.013 0.0066 4.64×10−5 0.0539 
0.05 −0.020 0.0067 0.0001 0.0032 
0.1 −0.016 0.0067 0.0001 0.0171 
0.5 −0.020 0.0068 0.0001 0.0026 




0.01 −0.0001 0.0066 6.41×10−9 0.9819 
0.05 −0.001 0.0066 1.43×10−7 0.9148 
0.1 0.001 0.0066 2.76×10−7 0.8817 
0.5 −0.003 0.0066 1.94×10−6 0.6931 




0.01 −0.023 0.0066 0.0002 0.0005 
0.05 −0.025 0.0067 0.0002 0.0001 
0.1 −0.031 0.0067 0.0003 5.31×10−6 
0.5 0.008 0.0066 1.70×10−5 0.2438 




0.01 −0.024 0.0066 0.0002 0.0003 
0.05 −0.030 0.0066 0.0003 5.89×10−6 
0.1 −0.034 0.0066 0.0003 2.96×10−7 
0.5 0.000 0.0066 3.41×10−8 0.9583 
1 0.002 0.0066 1.15×10−6 0.7615 
Type 2 
Diabetes 
0.01 −0.023 0.0066 0.0001 0.0006 
0.05 −0.021 0.0067 0.0001 0.0020 
0.1 −0.025 0.0067 0.0002 0.0002 
0.5 −0.025 0.0067 0.0002 0.0002 




ADHD 0.01 −0.010 0.0066 2.73×10−5 0.1391 
0.05 −0.016 0.0066 0.0001 0.0138 
0.1 −0.022 0.0066 0.0001 0.0007 
0.5 −0.025 0.0066 0.0002 0.0001 
1 −0.027 0.0066 0.0002 4.68×10−5  
Alzheimer's 
Disease 
0.01 −0.013 0.0066 4.51×10−5 0.0572 
0.05 −0.034 0.0066 0.0003 2.53×10−7 
0.1 −0.038 0.0066 0.0004 7.00×10−9 
0.5 −0.046 0.0066 0.0006 2.52×10−12 
1 −0.046 0.0066 0.0006 2.33×10−12 
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Autism 0.01 0.046 0.0066 0.0006 4.09×10−12 
0.05 0.061 0.0066 0.0011 1.68×10−20 
0.1 0.060 0.0066 0.0010 1.42×10−19 
0.5 0.068 0.0066 0.0013 5.00×10−25 
1 0.067 0.0066 0.0013 2.88×10−24  
Bipolar 
Disorder 
0.01 0.032 0.0066 0.0003 9.40×10−7 
0.05 0.046 0.0066 0.0006 3.80×10−12 
0.1 0.050 0.0066 0.0007 3.41×10−14 
0.5 0.057 0.0067 0.0009 1.35×10−17 




0.01 0.004 0.0066 4.03×10−6 0.5700 
0.05 0.003 0.0066 2.61×10−6 0.6475 
0.1 0.003 0.0067 2.22×10−6 0.6731 
0.5 −0.006 0.0067 1.14×10−5 0.3400 
1 −0.009 0.0067 2.14×10−5 0.1905  
Schizophrenia 0.01 0.022 0.0066 0.0001 0.0008 
0.05 0.025 0.0067 0.0002 0.0002 
0.1 0.024 0.0067 0.0002 0.0004 
0.5 0.022 0.0068 0.0001 0.0012 





0.01 −0.007 0.0066 1.27×10−5 0.3132 
0.05 −0.001 0.0066 6.01×10−7 0.8262 
0.1 0.005 0.0066 6.29×10−6 0.4778 
0.5 0.007 0.0066 1.40×10−5 0.2887 
1 0.005 0.0066 8.49×10−6 0.4095 
Intracranial 
Volume 
0.01 0.031 0.0066 2.81×10−4 2.08×10−6 
0.05 0.034 0.0067 0.0003 4.30×10−7 
0.1 0.039 0.0067 0.0004 7.92×10−9 
0.5 0.041 0.0068 0.0005 8.86×10−10 




0.01 0.035 0.0066 0.0003 1.64×10−7 
0.05 0.038 0.0066 0.0004 6.43×10−9 
0.1 0.050 0.0066 0.0007 4.01×10−14 
0.5 0.049 0.0067 0.0007 1.37×10−13 







0.01 0.004 0.0066 5.75×10−6 0.4971 
0.05 0.020 0.0066 0.0001 0.0022 
0.1 0.022 0.0066 0.0001 0.0011 
0.5 0.020 0.0066 0.0001 0.0028 




0.01 0.017 0.0066 0.0001 0.0095 
0.05 0.032 0.0066 0.0003 8.25×10−7 
0.1 0.035 0.0066 0.0004 7.61×10−8 
0.5 0.027 0.0066 0.0002 4.66×10−5 
1 0.027 0.0066 0.0002 4.35×10−5 
BMI 0.01 −0.065 0.0066 0.0012 3.15×10−23 
0.05 −0.074 0.0066 0.0016 2.80×10−29 
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0.1 −0.081 0.0066 0.0019 7.97×10−35 
0.5 −0.093 0.0066 0.0025 6.40×10−45 
1 −0.093 0.0066 0.0025 1.07×10−44 
Height 0.01 0.054 0.0067 0.0008 8.35×10−16 
0.05 0.062 0.0067 0.0011 3.00×10−20 
0.1 0.066 0.0068 0.0012 9.82×10−23 
0.5 0.069 0.0069 0.0013 4.84×10−24 
1 0.070 0.0069 0.0013 2.95×10−24 
Longevity 0.01 NA NA NA NA 
0.05 NA NA NA NA 
0.1 NA NA NA NA 
0.5 NA NA NA NA 
1 NA NA NA NA 
Forced 
Expiratory 
Volume in 1s 
(FEV1) 
0.01 NA NA NA NA 
0.05 NA NA NA NA 
0.1 NA NA NA NA 
0.5 NA NA NA NA 








0.01 0.062 0.0066 0.0011 5.29×10−21 
0.05 0.095 0.0066 0.0026 1.67×10−46 
0.1 0.106 0.0066 0.0032 4.17×10−58 
0.5 0.120 0.0066 0.0041 9.28×10−74 
1 0.122 0.0066 0.0042 3.92×10−75 
College 
degree 
0.01 0.205 0.0067 0.0118 1.47×10−206 
0.05 0.251 0.0067 0.0175 1.60×10−303 
0.1 0.265 0.0068 0.0194 0 
0.5 0.280 0.0068 0.0216 0 
1 0.279 0.0068 0.0214 0 
Years of 
Education 
0.01 0.210 0.0067 0.0124 1.56×10−216 
0.05 0.244 0.0067 0.0167 5.61×10−289 
0.1 0.265 0.0068 0.0195 0 
0.5 0.283 0.0068 0.0220 0 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 2. Supplementary material to Section 4.3 
 
Supplementary Materials for: 
 
Cognitive ability and physical health: a Mendelian randomization study 
Saskia P Hagenaars, Catharine R Gale, Ian J Deary and Sarah E Harris 
 
Contents 
Supplementary Figure 1: Educational attainment and verbal-numerical reasoning in UK 
Biobank 
Supplementary Table 1: Power calculations 
Supplementary Table 2: Observational associations between educational attainment and 
health outcomes. 
 
Supplementary Table 3a-f: Summary of the SNPs used for instrumental variants previously 




Supplementary figure 1. Educational attainment categories and mean scores for verbal-numerical 































































































































































































































































































































































































































































































































































































































Supplementary Table 2. Observational associations between educational attainment and health 
outcomes.  
Educational attainment – health 
outcomes (7 vs 10 years) 
Educational attainment – 
health outcomes (7 vs 13 
years)  
Beta 95% CI p Beta 95% CI p 


























































Supplementary Table 3a-f. Summary of the SNPs used for instrumental variants previously 
identified as associated with exposure at genome wide significance. 
 




1 Brion, M.-J. A., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian 
randomization studies. International Journal of Epidemiology 42, 1497-1501, doi:10.1093/ije/dyt179 
(2013)
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Appendix 3. Supplementary material to Section 5.2 
 
Supplementary material  
Hagenaars et al. Genetic contributions to trail making test performance in UK Biobank. 
 
Supplementary Methods 
 Cognitive measures in Generation Scotland and LBC1936 
 Adjusting heritability for reliability of measures 
Supplementary Tables and Figures 
Supplementary Figure 1: Trail making test in UK Biobank 
Supplementary Figure 2: Age-sex distributions for trail making test in UK Biobank. 
Supplementary Table 1: Gene-based results conducted on trail making test. 
Supplementary Table 2: Adjusted heritability estimates 
Supplementary Table 3:  Complete polygenic profile score associations with trail making using 
all five thresholds in UK Biobank, GS and LBC1936. 
Supplementary Figure 3: Manhattan plots for meta-analysis of trail making in UK Biobank and 
CHARGE. 
Supplementary Figure 4: Age distribution for trail making measures and verbal-numerical 




Cognitive measures  
Generation Scotland (GS) 
All participants in GS were invited to complete a short battery of well-validated cognitive tests, personal 
and family medical history details were taken during a clinical interview. The four cognitive tests were 
the Mill Hill Vocabulary test (combined Junior and Senior synonyms)1, Logical Memory in the 
Wechsler Memory Scale III (WMS-III, the sum of immediate and delayed recall for one paragraph)2, 
the phonemic Verbal Fluency test (using letters C, F, and L)3 and Digit Symbol-Coding from the 
Wechsler Adult Intelligence Scale III (WAIS-III)4.  
 
Lothian Birth Cohort 1936 (LBC1936) 
The MHT test scores were converted to a scale with a mean of 100 and SD = 15 for each sample, as 
described elsewhere5. The following cognitive functions were derived from the cognitive test battery: 
trail making test Part B, fluid cognitive function, verbal cognitive function, memory, processing speed. 
Fluid cognitive function, the first unrotated component of a principal component analysis (PCA), was 
derived using the WMS-III Digit Span Backwards and WAIS-III Matrix Reasoning, Letter-Number 
Sequencing, Block Design, Symbol Search and Digit Symbol. Verbal cognitive function was assessed 
by the National Adult Reading Test (NART) 6. Memory was derived via PCA using WMS-III Logical 
Memory I total recall score, Logical Memory II Delayed total recall score, Spatial Span Forward, Spatial 
Span Backward, Verbal Paired Associates I, Verbal Paired Associates II recall total score, and WAIS-
III Letter-Number Sequencing and Digit Span Backwards. Processing speed was derived via PCA using 
Choice Reaction Time Mean, Simple Reaction Time mean, Digit Symbol, Inspection Time and Symbol 
Search in LBC1936 7, 8. The change in cognitive function between childhood and old age was calculated 
using a linear regression model that summarizes the relation between the MHT test scores at age 11 and 
age 70. In this model, the residual values reflect the observed deviation of the MHT test scores at age 
70 based on the MHT test scores predicted at age 11, representing an estimate for change in cognitive 
function. 
 
Adjusting heritability estimates for reliability 
It is likely that the difference score exhibits lower reliability than parts A or B alone 9. We therefore 
adjusted all three heritability estimates for the purposes of comparing the relative impact of phenotypic 
reliability invariance (across Trails A, Trails B and Trails B-A). While reliability data are currently 
unavailable for the TMT in UK Biobank, we used data from a large test-retest reliability study (the 
connections test from Salthouse et al. 10, n = 207), from which we used the reported reliability indices 
(which they obtained by the Spearman-Brown formula) in analogous test components to Trails A 
(‘numbers’, r = 0.88) and Trails B (‘letters and numbers’, r = 0.81) to derive an estimate of the reliability 
of the contrast score (i.e. B-A) according to Crocker & Aligna 9, Webb et al. 11, 
rDD =  
0.5(rXX +  rYY) −  rXY
1 −  rXY
 , 
where rXX and rYY are the reliabilities of the Trails components, and  rXY is their correlation. This gives 
a reliability estimate of the Trails B-A of 0.58. These reliability estimates were then used to illustrate 
the impact that a lower reliability of the contrast score might have on GCTA estimates, such that 




where the adjusted heritability estimate (h2′) of a phenotype (X) is derived by dividing the heritability 
(h2) by the square root of the product of phenotype and genotype reliability estimates (rXX and rYY, 
respectively; after Spearman 12, 13). The measure of relatedness (based on the gene array markers) is 
assumed to be 1 as this is constant across the three TMT measures. Standard errors are derived using 



















































































































Supplementary Table 1a-c. Gene based analysis conducted on trail making measures using common 
variants (MAF >0.01). MAGMA; bold indicates genome wide significance alpha = (0.05/ 18062) CHR, 
chromosome; NSNPS, indicates the number of SNPs found within the start and stop sites.  
 
(See Supplementary Tables at following URL: 
http://biorxiv.org/content/early/2017/01/25/103119.figures-only)  
 
Supplementary Table 2. GCTA heritability estimates for the trail making tests indices in UK Biobank, 
before and after adjusting for differences in phenotype reliability.  
 TMT A  TMT B TMT B-A 
h2 0.079 (0.025)  0.224 (0.026) 0.176 (0.025) 
h2′ 0.084 (0.027)  0.249 (0.029) 0.231 (0.033) 
Note. Heritability with standard errors are reported before (h2) and after (h2′) correction for estimated 
differences in test component reliabilities (see Supplementary Methods). TMT A, trail making part A; 
TMT B, trail making part B; TMT B-A, trail making part B minus trail making part A. 
 
Supplementary Table 3a-c. Complete polygenic profile score associations with trail making using all 
five thresholds in UK Biobank, Generation Scotland and the Lothian Birth Cohort 1936. 
 
(See Supplementary Tables at following URL: 
http://biorxiv.org/content/early/2017/01/25/103119.figures-only)  
 
Supplementary Figure 3. Manhattan plot of P-values of the SNP-based association analysis of meta-
analysis between UK Biobank and CHARGE for Trail Making Part A and Trail Making Part B. The red 
line indicates the threshold for genome-wide significance (P < 5 × 10-8); the grey line indicates the 





Supplementary Figure 4. Age distribution with standard error bars for trail making measures and 
verbal-numerical reasoning in UK Biobank. TMT A, Trail Making Part A; TMT B, Trail Making Part 
B; TMT B-A, Trail Making Part B – Part A. 
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Genotyping and Quality Control 
Genotyping was performed on 33 batches of ~4700 samples by Affymetrix, who also performed 
initial quality control of the genotyping data. Further details are available of the sample processing 
specific to the UK Biobank project (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155583) and the 
Axiom array 
(http://media.affymetrix.com/support/downloads/manuals/axiom_2_assay_auto_workflow_user_guide
.pdf). Prior to the release of the UK Biobank genetic data a stringent QC protocol was applied, and 
performed at the Wellcome Trust Centre for Human Genetics (WTCHG); details of this process can 
be found at the following URL (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580).  
Prior to the analyses described in the main report, further quality control measures were applied by the 
present authors. Individuals were removed based on missingness, relatedness (KING estimated 
kinship co-efficient > 0·0442), gender mismatch, non-British ancestry (principal component analysis 
identified probable Caucasians within those individuals that were self-identified as British), and QC 
failure in the UK BiLEVE study. A sample of 112 151 individuals remained for further analyses. A 
minor allele frequency of maf < 1% filter was applied and only autosomal variants were used in this 
study (N = 705 516). 
 
Genome-wide association analyses (GWAS) in the UK Biobank sample 
An imputed dataset, including >70 million variants, was made available in which the UK Biobank 
interim release was imputed to a reference set which combined the UK10K haplotype and 1000 
Genomes Phase 3 reference panels. Further details can be found at the following URL: 
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=157020.  A genome-wide association analysis of 
neuroticism was performed on the imputed dataset using SNPTest v2.5.1 (Marchini J, Howie B, 
Myers S, et al. A new multipoint method for genome-wide association studies via imputation of 
genotypes. Nat Genet 2007; 39: 906-913; SNPTEST v.2.5.1 can be found at the following URL: 
https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html#introduction). An additive 
model was specified using the "frequentist 1" option. To account for genotype uncertainty we 
analysed the expected genotyped counts (dosages). Adjustments for age, sex, genotyping batch, 
genotyping array, assessment centre and 10 principal components were included. Prior to use in LD 
regression analyses the association results were filtered based on minor allele frequency (<0·1%) and 
imputation quality (<0·1). 
 
LD regression genetic correlation procedure 
Where available in the summary statistics provided, a MAF threshold of > 0·01 was applied. To 
control for imputation quality, only those SNPs found in the HapMap3 with 1000 Genomes EUR with 
a MAF > 0·05 were included (integrated_phase1_v3.20101123). Next, indels and structural variants 
were removed along with strand-ambiguous SNPs. Finally, genome-wide significant SNPs were 
removed, as were SNPs with very large effect sizes (χ2 > 80), as the presence of outliers can increase 
the standard error in a regression model. LD scores and weights for use with the GWAS of European 
ancestry were downloaded from the Broad institute 
(http://www.broadinstitute.org/~bulik/eur_ldscores/). Data sets demonstrating a heritability Z-score 
(h2z ) > 4 and a mean χ2 statistic of > 1.02 were included. All traits, except negative affect and 
borderline personality, exceeded these thresholds. An unconstrained intercept was used in the 
regression model as it was not possible to quantify the degree of sample overlap between the genome-
wide association analyses used here.  
 
Polygenic profiling procedure 
The genetic data files (.map and .ped files) supplied from Biota (the UK Biobank online repository) 
were unsuitable for use in the polygenic profile analyses as the .ped allele coding used a 1, 2 numeric 
allele encode rather than the standard ACGT encode format. In order to enable the analysis, the .ped 
files were recoded to the standard encode format. To achieve this, a bespoke programme was 
developed to create new files using a lookup-substitution method. A fast-in-memory lookup string 
hash table was created to hold the SNP-ID, along with the allele identifiers for the SNP. A simple loop 
then performed serialised lookups based on string position, to create an associated string with the 
correct ACGT encode. This was then appended to the six mandatory data fields extracted from initial 
string. In order to maximise performance and enable timely completion of the lookup-substitution, 
these loops were run in parallel threads in a standard multiprocessor environment. 
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Sources of genetic results from genome-wide association consortia 
CARDIoGRAM 
Coronary artery disease data have been contributed by CARDIoGRAMplusC4D investigators.  
 
CHARGE-Aging and Longevity 
Longevity data have been provided by the CHARGE-Aging and Longevity consortium. Longevity 
was defined as reaching age 90 years or older. Genotyped participants who died between the ages of 
55 and 80 years were used as the control group. There were 6036 participants who achieved longevity 
and 3757 participants in the control group across participating studies in the discovery meta-analysis. 
 
Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, Lunetta KL, Sebastiani P, Smith JA, Smith AV, 
Tanaka T, Yu L, Arnold AM, Aspelund T, Benjamin EJ, De Jager PL, Eirkisdottir G, Evans DA, 
Garcia ME, Hofman A, Kaplan RC, Kardia SL, Kiel DP, Oostra BA, Orwoll ES, Parimi N, Psaty BM, 
Rivadeneira F, Rotter JI, Seshadri S, Singleton A, Tiemeier H, Uitterlinden AG, Zhao W, Bandinelli 
S, Bennett DA, Ferrucci L, Gudnason V, Harris TB, Karasik D, Launer LJ, Perls TT, Slagboom PE, 
Tranah GJ, Weir DR, Newman AB, van Duijn CM and Murabito JM. GWAS of Longevity in 
CHARGE Consortium Confirms APOE and FOXO3 Candidacy. J Gerontol A Biol Sci Med Sci. 
2015;70:110-8. 
Acknowledgments 
The CHARGE Aging and Longevity working group analysis of the longevity phenotype was funded 




Type 2 diabetes data were obtained from the DIAGRAM consortium. 
 
International Consortium of Blood Pressure (ICBP) 
Blood pressure data were provided by ICBP. 
 
GIANT  
BMI data was obtained from the GIANT consortium. 
 
International Genomics of Alzheimer’s Project (IGAP) 
Alzheimer’s disease data were obtained from (IGAP) 
Material and methods 
International Genomics of Alzheimer's Project (IGAP) is a large two-stage study based upon genome-
wide association studies (GWAS) on individuals of European ancestry. In stage 1, IGAP used 
genotyped and imputed data on 7 055 881 single nucleotide polymorphisms (SNPs) to meta-analyse 
four previously-published GWAS datasets consisting of 17 008 Alzheimer's disease cases and 37 154 
controls (The European Alzheimer's disease Initiative – EADI the Alzheimer Disease Genetics 
Consortium – ADGC The Cohorts for Heart and Aging Research in Genomic Epidemiology 
consortium – CHARGE The Genetic and Environmental Risk in AD consortium – GERAD). In stage 
2, 11 632 SNPs were genotyped and tested for association in an independent set of 8572 Alzheimer's 
disease cases and 11 312 controls. Finally, a meta-analysis was performed combining results from 
stages 1 & 2. 
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Supplementary Table 1 
Sources of genetic results from genome-wide association consortia. 
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Supplementary Table 2 
Associations between polygenic profiles of health related traits, and neuroticism controlling for age, 
sex, assessment centre, genotyping batch and array, and ten principal components for population 
structure. Statistically significant values (after False Discovery Rate correction, P < 0.0065) are shown 






Threshold β SE R2 p 
Mental 
health 
ADHD 0.01 -0.00287 0.002994 8.26×10-6 0.337012 
0.05 0.004543 0.002994 2.06×10-5 0.129231 
0.1 0.002974 0.002994 8.84×10-6 0.32062 
0.5 0.003187 0.002996 1.01×10-5 0.287361 
1 0.00351 0.002996 1.23×10-5 0.241329 
Alzheimer's Disease 0.01 -0.00139 0.002997 1.92×10-6 0.643781 
0.05 -0.00647 0.003002 4.16×10-5 0.031179 
0.1 -0.00523 0.003004 2.72×10-5 0.081515 
0.5 -0.00022 0.003008 4.70×10-8 0.942228 
1 0.000818 0.003008 6.63×10-7 0.785614 
Anorexia Nervosa 0.01 0.004731 0.002995 2.24×10-5 0.114197 
0.05 0.003593 0.002995 1.29×10-5 0.230219 
0.1 0.005362 0.002996 2.87×10-5 0.073496 
0.5 0.000139 0.003001 1.93×10-8 0.963021 
1 -0.00112 0.00301 1.23×10-6 0.710872 
Bipolar Disorder 0.01 0.012695 0.003 0.00016 2.33×10-5 
0.05 0.015862 0.00301 0.000249 1.37×10-7 
0.1 0.017013 0.003016 0.000285 1.70×10-8 
0.5 0.017078 0.003028 0.000285 1.71×10-8 
1 0.016886 0.003029 0.000278 2.50×10-8 
Borderline Personality 0.01 0.012467 0.002995 0.000155 3.15×10-5 
0.05 0.011175 0.002996 0.000125 0.000192 
0.1 0.01116 0.002997 0.000124 0.000196 
0.5 0.014967 0.002999 0.000223 6.02×10-7 
1 0.015028 0.002999 0.000225 5.43×10-7 
 Major Depressive Disorder 0.01 0.017178 0.003003 0.000293 1.07×10-8 
0.05 0.024092 0.003021 0.000569 1.54×10-15 
0.1 0.028489 0.00303 0.000791 5.51×10-21 
0.5 0.034745 0.003051 0.001161 4.92×10-30 
1 0.035716 0.003051 0.001226 1.23×10-31 
Negative affect (anxiety) 0.01 0.004815 0.002994 2.32×10-5 0.107844 
0.05 0.004631 0.002994 2.14×10-5 0.121922 
0.1 0.004652 0.002995 2.16×10-5 0.120399 
0.5 0.008842 0.002997 7.80×10-5 0.003171 
1 0.009487 0.002997 8.98×10-5 0.001546 
Neuroticism (GPC) 0.01 0.026405 0.003 0.0007 1.38×10-18 
0.05 0.033051 0.002995 0.001097 2.66×10-28 
0.1 0.037028 0.002995 0.001376 4.30×10-35 
0.5 0.043349 0.002994 0.001885 1.77×10-47 
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1 0.043267 0.002994 0.001877 2.71×10-47 
Schizophrenia 0.01 0.029828 0.00302 0.000873 5.32×10-23 
0.05 0.034372 0.003046 0.001139 1.66×10-29 
0.1 0.035914 0.003058 0.001234 7.88×10-32 
0.5 0.033529 0.003084 0.001058 1.63×10-27 
1 0.033817 0.003086 0.001075 6.23×10-28 
Physical 
health 
Blood Pressure: Diastolic 0.01 0.003944 0.002995 1.55×10-5 0.187925 
0.05 -0.0033 0.002998 1.08×10-5 0.271665 
0.1 -0.00471 0.003002 2.20×10-5 0.116712 
0.5 -0.00294 0.003004 8.60×10-6 0.327081 
1 -0.00258 0.003003 6.60×10-6 0.39054 
 Blood Pressure: Systolic 0.01 -0.00157 0.002996 2.45×10-6 0.601327 
0.05 -0.00159 0.002999 2.51×10-6 0.596891 
0.1 -0.00046 0.003 2.12×10-7 0.877804 
0.5 0.000151 0.003005 2.26×10-8 0.959928 
1 -0.00124 0.003005 1.52×10-6 0.68005 
 BMI 0.01 -0.00949 0.002995 9.00×10-5 0.001529 
0.05 -0.00857 0.002996 7.33×10-5 0.004219 
0.1 -0.00816 0.002997 6.64×10-5 0.006459 
0.5 -0.0049 0.003 2.39×10-5 0.102193 
1 -0.00508 0.003 2.57×10-5 0.090145 
 Coronary Artery Disease 0.01 0.005668 0.002994 3.21×10-5 0.058318 
0.05 0.009317 0.002995 8.67×10-5 0.001866 
0.1 0.010949 0.002995 0.00012 0.000257 
0.5 0.010614 0.002996 0.000112 0.000396 
1 0.010072 0.002996 0.000101 0.000776 
 Longevity 0.01 -0.00181 0.003014 3.24×10-6 0.547298 
0.05 -0.00511 0.003028 2.55×10-5 0.091694 
0.1 -0.00093 0.002996 8.72×10-7 0.755097 
0.5 -0.00261 0.003001 6.78×10-6 0.38437 
1 -0.00217 0.003001 4.68×10-6 0.470043 
 Rheumatoid Arthritis 0.01 0.000553 0.002998 -5.10E-05 0.853539 
0.05 -0.00065 0.003001 -5.09E-05 0.829678 
0.1 -0.00013 0.003005 -5.13E-05 0.964768 
0.5 -0.00066 0.00302 -5.09E-05 0.826638 
1 -0.00058 0.003022 -5.10E-05 0.846755 
 Smoking Status 0.01 0.003084 0.00304 -4.21E-05 0.310425 
0.05 0.014977 0.003084 0.00016 1.20×10-6 
0.1 0.014199 0.003108 0.000136 4.91×10-6 
0.5 0.016294 0.003158 0.000187 2.48×10-7 
1 0.01561 0.003164 0.000167 8.11×10-7 
 Type 2 Diabetes 0.01 -0.00313 0.003014 9.67×10-6 0.298869 




Type 2 Diabetes 0.1 -0.00228 0.003041 5.03×10-6 0.453812 
  0.5 0.000433 0.003069 1.78×10-7 0.887774 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 5. Supplementary material to Section 7.2 
Deary and Hagenaars et al. Genetic contributions to self-reported tiredness 
 
 Supplementary Materials for: 
 




1. Supplementary Methods 
Phenotypic measures 
Sources of genetic results from genome-wide association consortia 
Stratified linkage disequilibrium score regression 
Sensitivity analysis 
2. Supplementary Tables and Figures 
Supplementary Table 1: Details of the sources of genetic results from genome-wide 
association studies (GWAS) consortia. 
Supplementary Figure 1. Age- and sex distribution of standardized tiredness scores 
Supplementary Table 2: Frequency table for tiredness and self-rated health 
Supplementary Figure 2a-f: Distributions of different phenotypic measures at each level 
of tiredness. 
Supplementary Table 3: Genome-wide significant gene-based hits 
Supplementary Figure 3: Enrichment analysis for tiredness using functional categories 
Supplementary Figure 4: Enrichment analysis for tiredness using cell specific functional 
categories. 
Supplementary Table 4: Complete polygenic profile score associations with tiredness 
using all five thresholds. 
Supplementary Table 5. Polygenic profile score associations with tiredness using all five 
thresholds adjusted for self-rated health and neuroticism. 
Supplementary Table 6. Polygenic profile score associations with tiredness using all five 
thresholds adjusted for major depressive disorder. 
Supplementary Table 7. Multivariate model with all significant polygenic profile scores 
predicting tiredness. 
Supplementary Table 8. Genetic correlations between allostatic load traits 
Supplementary Figure 5: Miami and QQ plot for tiredness split by sex 
Supplementary Figure 6: Manhattan plot of the difference in effect size between males 
and females. 
Supplementary Figure 7: Miami and QQ plot for tiredness split by men aged 40-50 years 
and men aged 60-70 years. 
Supplementary Figure 8: Manhattan plot of the difference in effect size between by men 






Right and left hand grip strength were measures using a Jamar J00105 hydraulic hand dynamometer. A 
dominant grip strength measure was computed based on handedness. 
 
Forced expiratory volume in 1s 
Forced expiratory volume in one second was measured using a Vitalograph Pneumotrac 6800. Each 
participant was asked to record two to five blows, lasting for a minimum of six seconds, within a period 
of six minutes. The reproducibility of the first two blows was compared and if there was less than 5% 
difference in forced volume vital capacity and forced expiratory volume in one second, a third blow 
was not required. 
 
Height 
Standing height was measured in cm using a Seca 202 device. 
 
BMI 
BMI values in kg/m2 were constructed from height and weight measures. 
 
Self-rated health 
Participants were asked the question, “In general how would you rate your overall health?”. Possible 
answers were “Excellent/Good/Fair/Poor/Do not know/Prefer not to answer”. We created a four-
category SRH variable indexing how each participant rated their health ranging from “excellent” to 
“poor”; excluding those that responded with “do not know” or “prefer not to answer”. A higher score 
for SRH indicates a better health rating (Harris et al., 2015). 
 
Verbal-numerical reasoning 
Verbal-numerical reasoning was measured by a thirteen item-test with a time limit of two minutes, 
completed by 36 035 individuals. Six items were verbal and seven numerical. An example of a verbal 
question is ‘Bud is to flower as child is to?’ (Possible answers: ‘Grow/Develop/Improve/Adult/Old/Do 
not know/Prefer not to answer’). An example of a numerical question is ‘If sixty is more than half of 
seventy-five, multiply twenty-three by three. If not subtract 15 from eighty-five. Is the answer?’ 
(Possible answers: ‘68/69/70/71/72/Do not know/Prefer not to answer’). The verbal-numerical 
reasoning score was the total score out of thirteen (Hagenaars et al., 2016).  
 
Neuroticism  
Participants completed 12 questions of the Eysenck Personality Questionnaire-Revised Short Form 
(EPQ-R Short Form) neuroticism scale (Deary & Bedford, 2011; Eysenck, Eysenck, & Barrett, 1985). 
Neuroticism refers to the relatively stable personality trait that assesses individual differences in the 
tendency to experience negative emotions. A summary score was derived to obtain a measure of 
neuroticism (Gale et al., In Press).  
 
Sources of genetic results from genome-wide association consortia 
CARDIoGRAM 
Coronary artery disease data have been contributed by CARDIoGRAMplusC4D investigators.  
CHARGE-Aging and Longevity 
Longevity data have been provided by the CHARGE-Aging and Longevity consortium. Longevity was 
defined as reaching age 90 years or older. Genotyped participants who died between the ages of 55 and 
80 years were used as the control group. There were 6036 participants who achieved longevity and 3757 
participants in the control group across participating studies in the discovery meta-analysis. 
Broer L, Buchman AS, Deelen J, Evans DS, Faul JD, Lunetta KL, Sebastiani P, Smith JA, Smith AV, 
Tanaka T, Yu L, Arnold AM, Aspelund T, Benjamin EJ, De Jager PL, Eirkisdottir G, Evans DA, Garcia 
ME, Hofman A, Kaplan RC, Kardia SL, Kiel DP, Oostra BA, Orwoll ES, Parimi N, Psaty BM, 
Rivadeneira F, Rotter JI, Seshadri S, Singleton A, Tiemeier H, Uitterlinden AG, Zhao W, Bandinelli S, 
Bennett DA, Ferrucci L, Gudnason V, Harris TB, Karasik D, Launer LJ, Perls TT, Slagboom PE, Tranah 
GJ, Weir DR, Newman AB, van Duijn CM and Murabito JM. GWAS of Longevity in CHARGE 




The CHARGE Aging and Longevity working group analysis of the longevity phenotype was funded 
through the individual contributing studies. The working group thanks all study participants and study 
staff. 
CHARGE-Inflammation Working Group 
C-reactive protein data have been provided by the CHARGE-Inflammation Working Group.  
Abbas Dehghan, Josée Dupuis, Maja Barbalic, Joshua C. Bis, Gudny Eiriksdottir, Chen Lu, Niina 
Pellikka, Henri Wallaschofski, Johannes Kettunen, Peter Henneman, Jens Baumert, David P. 
Strachan, Christian Fuchsberger, Veronique Vitart, James F. Wilson, Guillaume Paré, Silvia Naitza, 
Megan E. Rudock, Ida Surakka, Eco J.C. de Geus, Behrooz Z. Alizadeh, Jack Guralnik, Alan 
Shuldiner, Toshiko Tanaka, Robert Y.L. Zee, Renate B. Schnabel, Vijay Nambi, Maryam Kavousi, 
Samuli Ripatti, Matthias Nauck, Nicholas L. Smith, Albert V. Smith, Jouko Sundvall, Paul Scheet, 
Yongmei Liu, Aimo Ruokonen, Lynda M. Rose, Martin G. Larson, Ron C. Hoogeveen, Nelson B. 
Freimer, Alexander Teumer, Russell P. Tracy, Lenore J. Launer, Julie E. Buring, Jennifer F. 
Yamamoto, Aaron R. Folsom, Eric J.G. Sijbrands, James Pankow, Paul Elliott, John F. Keaney, Wei 
Sun, Antti-Pekka Sarin, João D. Fontes, Sunita Badola, Brad C. Astor, Albert Hofman, Anneli Pouta, 
Karl Werdan, Karin H. Greiser, Oliver Kuss, Henriette E. Meyer zu Schwabedissen, Joachim Thiery, 
Yalda Jamshidi, Ilja M. Nolte, Nicole Soranzo, Timothy D. Spector, Henry Völzke, Alexander N. 
Parker, Thor Aspelund, David Bates, Lauren Young, Kim Tsui, David S. Siscovick, Xiuqing Guo, 
Jerome I. Rotter, Manuela Uda, David Schlessinger, Igor Rudan, Andrew A. Hicks, Brenda W. 
Penninx, Barbara Thorand, Christian Gieger, Joe Coresh, Gonneke Willemsen, Tamara B. Harris, 
Andre G. Uitterlinden, Marjo-Riitta Järvelin, Kenneth Rice, Dörte Radke, Veikko Salomaa, Ko 
Willems van Dijk, Eric Boerwinkle, Ramachandran S. Vasan, Luigi Ferrucci, Quince D. Gibson, 
Stefania Bandinelli, Harold Snieder, Dorret I. Boomsma, Xiangjun Xiao, Harry Campbell, Caroline 
Hayward, Peter P. Pramstaller, Cornelia M. van Duijn, Leena Peltonen, Bruce M. Psaty, Vilmundur 
Gudnason, Paul M. Ridker, Georg Homuth, Wolfgang Koenig, Christie M. Ballantyne, Jacqueline 
C.M. Witteman, Emelia J. Benjamin, Markus Perola and Daniel I. Chasman. Meta-Analysis of 
Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive 
Protein Levels. Circulation 2011: 123: 731-738.  
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Therefore, all polygenic profile analysis were rerun in individuals with sufficient information to make 
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Supplementary Figure 1. Age- and sex distribution of standardized tiredness scores 
 
Supplementary Table 2. Frequency table for tiredness and self-rated health 
  Self-rated health 
  excellent good fair poor 
Tiredness 
not at all 12556 32258 6105 428 
several days 4857 25633 11665 1921 
more than half the days 316 2814 2531 695 
nearly every day 215 2000 2710 1944 
 





Supplementary Figure 2b. Barplot showing the distribution of lung function for each category of 
tiredness, 13 individuals with values above 7.5 litres/second have been excluded.  
 
Supplementary Figure 2c. Barplot showing the distribution of verbal-numerical reasoning for each 
category of tiredness 
 
335
Supplementary Figure 2d. Barplot showing the distribution of height for each category of tiredness. 
 
Supplementary Figure 2e Barplot showing the distribution of BMI for each category of tiredness. 
336
 
Supplementary Figure 2f. Barplot showing the distribution of neuroticism for each category of 
tiredness. 
 
Supplementary Table 3. Gene based analysis conducted on tiredness using MAGMA. Genome-wide 
significant gene-based hits (P<2.8 x 10-6) are shown in bold. NSNPS is the number of SNPs in the 
gene; Effect Size is the number of independent SNPs in the gene. 




Supplementary Table 4. Associations between polygenic profiles of health related traits, and tiredness 
controlling for age, sex, assessment centre, genotyping batch and array, and ten principal components 
for population structure. Statistically significant values (P < 0.0255) are shown in bold.  




Supplementary Table 5. Associations between polygenic profiles of health-related traits created from 
GWAS consortia summary data, and the UK Biobank tiredness phenotype controlling for age, sex, 
assessment centre, genotyping batch and array and 10 principal components for population structure. 
SRH models are adjusted for self-rated health; N models are adjusted for neuroticism. 




Supplementary Table 6. Associations between polygenic profiles of health-related traits created from 
GWAS consortia summary data, and the UK Biobank tiredness phenotype controlling for age, sex, 
assessment centre, genotyping batch and array and 10 principal components for population structure in 
a subset of individuals who have sufficient data for MDD diagnosis. 


































































































































































































Supplementary Figure 4 
Enrichment analysis for tiredness using the 10 cell specific functional categories. The enrichment 
statistic is the proportion of heritability found in each functional group divided by the proportion of 
SNPs in each group (Pr(h2)/Pr(SNPs). The dashed line indicates no enrichment found when 
Pr(h2)/Pr(SNPs) = 1. Statistical significance is indicated by asterisk at P = 0.000202877. 
 
Supplementary Table 7. Multivariate model predicting tiredness, including all significant polygenic 
profile scores together with covariates (age, sex, assessment centre, genotyping batch and array, and ten 
genetic principal components for population structure; covariate values not shown here). Adjusted R2 
values refer to the polygenic profile scores only (excluding variance explained by the covariates). 
Statistically significant p-values (after FDR correction; threshold: P < 0.0243 are shown in bold. 
 All Traits Adjusted R2 = 0.25%  
Traits β P 
BMI 0.0164 0.0001 
Cholesterol: HDL -0.0079 0.0169 
Cholesterol: LDL 0.0025 0.4304 
Coronary artery disease 0.0045 0.1437 
C-reactive protein 0.0032 0.3114 
HbA1c 0.0060 0.0537 
Height -0.0015 0.6512 
Obesity 0.0057 0.1773 
Smoking status 0.0062 0.0527 
Triglycerides 0.0097 0.0043 
Type 2 diabetes 0.0051 0.1085 
Waist-hip ratio 0.0111 0.0011 
Bipolar disorder 0.0020 0.5131 
Childhood cognitive ability -0.0073 0.0182 
Major depressive disorder 0.0140 8.67×10-6 
Neuroticism 0.0145 1.92×10-6 
Schizophrenia 0.0254 2.25×10-15 
 
Supplementary Table 8. Genetic correlations between allostatic load variables. Statistically significant 
P-values (after false discovery rate correction; threshold: P = 0.0273) are shown in bold. 





Supplementary Figure 5. A) Miami of P-values of the SNP-based association analysis of tiredness 
(responses to the question, “Over the past two weeks, how often have you felt tired or had little 
energy?”). The red line indicates the threshold for genome-wide significance (P<5 x 10-8) and the 
threshold for suggestive significance (P<1 x 10-5), the upper half shows the results for females and the 




Supplementary Figure 6. Manhattan plot of the difference in effect size between males and females. 
 
Supplementary Figure 7. A) Miami of P-values of the SNP-based association analysis of tiredness 
(responses to the question, “Over the past two weeks, how often have you felt tired or had little 
energy?”). The red line indicates the threshold for genome-wide significance (P<5 x 10-8) and the 
threshold for suggestive significance (P<1 x 10-5), the upper half shows the results for females and the 
bottom half shows the results for males. (B) Q-Q plot; red for males aged 40-50 years and blue for males 





Supplementary Figure 8. Manhattan plot of the difference in effect size between males aged 40-50 
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